<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19523877</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.</ArticleTitle><Pagination><StartPage>619</StartPage><EndPage>627</EndPage><MedlinePgn>619-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(09)70139-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in patients with subjective cognitive impairment (SCI) and non-amnestic mild cognitive impairment (naMCI) is unknown. AD is characterised by decreased CSF concentrations of Abeta(42) and increased concentrations of tau. We investigated the prevalence of a CSF AD profile in patients with SCI, naMCI, or aMCI and the association of this profile with cognitive outcome in each group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with SCI, naMCI, aMCI, and neurologically healthy controls were recruited from 20 memory clinics across Europe, between January, 2003, and June, 2005, into this prospective cohort study. A CSF AD profile was defined as an abnormal ratio of Abeta(42):tau. Patients were assessed annually up to 3 years. Outcome measures were changes in memory, overall cognition, mini-mental state examination (MMSE) score, daily function, and progression to AD-type dementia.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The CSF AD profile was more common in patients with SCI (31 of 60 [52%]), naMCI (25 of 37 [68%]), and aMCI (56 of 71 [79%]) than in healthy controls (28 of 89 [31%]). The profile was associated with cognitive decline in patients with naMCI (memory, MMSE, and daily function) and in patients with aMCI (MMSE and daily function). In patients with aMCI, a CSF AD profile was predictive of AD-type dementia (OR 26.8, 95% CI 1.6-456.4).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">AD is a common cause of SCI, naMCI, and aMCI and is associated with cognitive decline in patients with naMCI or aMCI. Patients with SCI might be in the early stages of AD, and cognitive decline might become apparent only after longer follow-up.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">European Commission; Ana Aslan International Foundation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, 6200 MD Maastricht, Netherlands. pj.visser@np.unimaas.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Knol</LastName><ForeName>Dirk L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wahlund</LastName><ForeName>Lars-Olof</ForeName><Initials>LO</Initials></Author><Author ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Minthon</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Asa K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>B&#xfc;rger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pirttila</LastName><ForeName>Tuula</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rikkert</LastName><ForeName>Marcel Olde</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Spiru</LastName><ForeName>Luiza</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2009 Jul;8(7):595-6. doi: 10.1016/S1474-4422(09)70145-0.</RefSource><PMID Version="1">19523878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(09)70139-5</ArticleId><ArticleId IdType="pii">S1474-4422(09)70139-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19527190</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1657</StartPage><EndPage>1664</EndPage><MedlinePgn>1657-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656560903044982</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This paper reviews the pharmacology and chemical efficacy of an A beta-lowering agent, semagacestat (LY450139).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A review of the published literature pertaining to semagacestat was obtained using several electronic search engines; unpublished data on file at Eli Lilly and Co. were used as supplementary material.</AbstractText><AbstractText Label="RESULTS/CONCLUSIONS" NlmCategory="CONCLUSIONS">Semagacestat treatment lowers plasma, cerebrospinal fluid and brain A beta in a dose-dependent manner in animals and plasma and cerebrospinal fluid A beta in humans, compared with placebo-treated patients. On the basis of extant data, semagacestat seems to be well tolerated, with most adverse events related to its actions on inhibition of peripheral Notch cleavage. Thus far, clinical efficacy has not been detectable because of the short duration of the current trials. Phase III trials with 21 months of active treatment are currently underway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henley</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer's Team, DC 6161, Indianapolis, IN 46285-6161, USA. henleyda@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010829" MajorTopicYN="N">Physiological Phenomena</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>43</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19527190</ArticleId><ArticleId IdType="doi">10.1517/14656560903044982</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19539742</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6815</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Experimental gerontology</Title><ISOAbbreviation>Exp Gerontol</ISOAbbreviation></Journal><ArticleTitle>Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).</ArticleTitle><Pagination><StartPage>579</StartPage><EndPage>585</EndPage><MedlinePgn>579-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exger.2009.06.003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's Disease Neuroimaging Initiatives ("ADNI") aim to validate neuroimaging and biochemical markers of Alzheimer's disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We measured CSF beta-amyloid 42 (CSF Abeta42), total tau-protein (t-tau), phosphorylated tau-proteins (P-tau181, P-tau231), plasma beta-amyloid 40 and 42 (Abeta40/Abeta42). Immediate fresh shipment was compared to freezing and later shipment on dry ice.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSF T-tau (fresh samples) was increased in AD versus controls (p=0.049), CSF Abeta42 (frozen samples) was decreased in MCI and AD (p=0.02), as well as plasma Abeta40 (fresh and frozen samples) in AD (p=0.049 and p=0.016). Pooled values of neurochemical parameters and ratios thereof were different between centres (p&lt;0.005). Analysis of frozen samples yielded higher diagnostic accuracy than immediate fresh shipment with 100% (fresh: 100%) correctly classified in control subjects, 100% (78%) in MCI, 91% (91%) in AD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of frozen rather than fresh samples renders higher diagnostic accuracy within a multicentre context. We confirmed the feasibility of a multicentre AD biomarker programme for future clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buerger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilian University Munich, Munich, Germany. katharina.buerger@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Uspenskaya</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Geroldi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Johannsen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rossini</LastName><ForeName>Paolo Maria</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Wahlund</LastName><ForeName>Lars-Olof</ForeName><Initials>LO</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Gerontol</MedlineTA><NlmUniqueID>0047061</NlmUniqueID><ISSNLinking>0531-5565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="Y">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19539742</ArticleId><ArticleId IdType="doi">10.1016/j.exger.2009.06.003</ArticleId><ArticleId IdType="pii">S0531-5565(09)00116-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19553436</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>25</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>7957</StartPage><EndPage>7965</EndPage><MedlinePgn>7957-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1339-09.2009</ELocationID><Abstract><AbstractText>Shown to lower amyloid deposits and improve cognition in APP transgenic mouse models, immunotherapy appears to be a promising approach for the treatment of Alzheimer's disease (AD). Due to limitations in available animal models, however, it has been unclear whether targeting amyloid is sufficient to reduce the other pathological hallmarks of AD-namely, accumulation of pathological, nonmutated tau and neuronal loss. We have now developed two transgenic mouse models (APPSw/NOS2(-/-) and APPSwDI/NOS2(-/-)) that more closely model AD. These mice show amyloid pathology, hyperphosphorylated and aggregated normal mouse tau, significant neuron loss, and cognitive deficits. A beta(1-42) or KLH vaccinations were started in these animals at 12 months, when disease progression and cognitive decline are well underway, and continued for 4 months. Vaccinated APPSwDI/NOS2(-/-) mice, which have predominantly vascular amyloid pathology, showed a 30% decrease in brain A beta and a 35-45% reduction in hyperphosphorylated tau. Neuron loss and cognitive deficits were partially reduced. In APPSw/NOS2(-/-) vaccinated mice, brain A beta was reduced by 65-85% and hyperphosphorylated tau by 50-60%. Furthermore, neurons were completely protected, and memory deficits were fully reversed. Microhemorrhage was observed in all vaccinated APPSw/NOS2(-/-) mice and remains a significant adverse event associated with immunotherapy. Nevertheless, by providing evidence that reducing amyloid pathology also reduces nonmutant tau pathology and blocks neuron loss, these data support the development of amyloid-lowering therapies for disease-modifying treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. donna.wilcock@duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharkholonarehe</LastName><ForeName>Nastaran</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Judianne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vitek</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Colton</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG030942</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS55118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030942</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS055118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023582">Alzheimer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496317">Nos2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2010 Jan 20;30(3):1197-8</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023582" MajorTopicYN="N">Alzheimer Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016233" MajorTopicYN="N">Immunotherapy, Active</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19553436</ArticleId><ArticleId IdType="mid">NIHMS197894</ArticleId><ArticleId IdType="pmc">PMC2871319</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1339-09.2009</ArticleId><ArticleId IdType="pii">29/25/7957</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642910</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain. 2008;131:3299&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton C, Wilt S, Gilbert D, Chernyshev O, Snell J, Dubois-Dalcq M. Species differences in the generation of reactive oxygen species by microglia. Mol Chem Neuropathol. 1996;28:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8871937</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:12867&#x2013;12872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550768</ArticleId><ArticleId IdType="pubmed">16908860</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis. 2008;15:571&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667339</ArticleId><ArticleId IdType="pubmed">19096157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15:505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483061</ArticleId><ArticleId IdType="pubmed">12663680</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem. 2004;279:20296&#x2013;20306.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gayar S, Th&#xfc;ring-Nahler H, Pfeilschifter J, R&#xf6;llinghoff M, Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J Immunol. 2003;171:4561&#x2013;4568.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukutani Y, Kobayashi K, Nakamura I, Watanabe K, Isaki K, Cairns NJ. Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. Neurosci Lett. 1995;200:57&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8584267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci U S A. 2001;98:8638&#x2013;8643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37488</ArticleId><ArticleId IdType="pubmed">11438703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gittins R, Harrison PJ. Neuronal density, size and shape in the human anterior cingulate cortex: a comparison of Nissl and NeuN staining. Brain Res Bull. 2004;63:155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130705</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Grundke-Iqbal I. Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol Psychiatry. 1997;2:178&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152977</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I. Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol Neurobiol. 1994;9:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888088</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongen-R&#xea;lo AL, Feldon J. Specific neuronal protein: a new tool for histological evaluation of excitotoxic lesions. Physiol Behav. 2002;76:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12126979</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Koeppen AH. The history of iron in the brain. J Neurol Sci. 1995;134(Suppl):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8847538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH, Reed BR, Mungas D, Weiner MW, Chui HC. Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry. 2002;72:217&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737728</ArticleId><ArticleId IdType="pubmed">11796772</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A. 1995;92:10688&#x2013;10692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40677</ArticleId><ArticleId IdType="pubmed">7479866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731&#x2013;2738.</Citation><ArticleIdList><ArticleId IdType="pubmed">14978070</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L, Ajmone-Cat MA, De Berardinis MA, De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Brain Res Rev. 2005;48:251&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri MH, Saini K, Li H, Crameri A, Lipp HP, Wolfer DP, Nitsch RM. Intact spatial memory in mice with seizure-induced partial loss of hippocampal pyramidal neurons. Neurobiol Dis. 2003;12:174&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742738</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003a;24:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003b;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D. Immunotherapy reduces vascular amyloid-&#x3b2; in PDAPP mice. J Neurosci. 2008;28:6787&#x2013;6793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670967</ArticleId><ArticleId IdType="pubmed">18596154</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol. 2004;188:52&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15191802</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-&#x3b2; in CNS of Tg-SwDI transgenic mice. J Neurosci. 2007;27:13376&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673094</ArticleId><ArticleId IdType="pubmed">18057195</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg JB, Misukonis MA, Shami PJ, Mason SN, Sauls DL, Dittman WA, Wood ER, Smith GK, McDonald B, Bachus KE, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood. 1995;86:1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15:555&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615484</ArticleId><ArticleId IdType="pubmed">19096156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004a;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004b;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857306</ArticleId><ArticleId IdType="pubmed">17137722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci. 2008;28:1537&#x2013;1545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621082</ArticleId><ArticleId IdType="pubmed">18272675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19553447</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>25</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>8075</StartPage><EndPage>8086</EndPage><MedlinePgn>8075-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0864-09.2009</ELocationID><Abstract><AbstractText>Memory loss, synaptic dysfunction, and accumulation of amyloid beta-peptides (A beta) are major hallmarks of Alzheimer's disease (AD). Downregulation of the nitric oxide/cGMP/cGMP-dependent protein kinase/c-AMP responsive element-binding protein (CREB) cascade has been linked to the synaptic deficits after A beta elevation. Here, we report that the phosphodiesterase 5 inhibitor (PDE5) sildenafil (Viagra), a molecule that enhances phosphorylation of CREB, a molecule involved in memory, through elevation of cGMP levels, is beneficial against the AD phenotype in a mouse model of amyloid deposition. We demonstrate that the inhibitor produces an immediate and long-lasting amelioration of synaptic function, CREB phosphorylation, and memory. This effect is also associated with a long-lasting reduction of A beta levels. Given that side effects of PDE5 inhibitors are widely known and do not preclude their administration to a senile population, these drugs have potential for the treatment of AD and other diseases associated with elevated A beta levels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puzzo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staniszewski</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Shi Xian</ForeName><Initials>SX</Initials></Author><Author ValidYN="Y"><LastName>Privitera</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leznik</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shumin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Palmeri</LastName><ForeName>Agostino</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Donald W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG027468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG027468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013450">Sulfones</NameOfSubstance></Chemical><Chemical><RegistryNumber>BW9B0ZE037</RegistryNumber><NameOfSubstance UI="D000068677">Sildenafil Citrate</NameOfSubstance></Chemical><Chemical><RegistryNumber>H2D2X058MU</RegistryNumber><NameOfSubstance UI="D006152">Cyclic GMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003214" MajorTopicYN="N">Conditioning, Classical</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006152" MajorTopicYN="N">Cyclic GMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058986" MajorTopicYN="Y">Phosphodiesterase 5 Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068677" MajorTopicYN="N">Sildenafil Citrate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013037" MajorTopicYN="N">Spatial Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19553447</ArticleId><ArticleId IdType="pmc">PMC6666028</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0864-09.2009</ArticleId><ArticleId IdType="pii">29/25/8075</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreasen N, Sj&#xf6;gren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry. 2003;4:147&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">14608585</ArticleId></ArticleIdList></Reference><Reference><Citation>Baratti CM, Boccia MM. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav Pharmacol. 1999;10:731&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10780288</ArticleId></ArticleIdList></Reference><Reference><Citation>Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord. 2002;14:156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218259</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglioli E, Andr&#xe9;s ME, Rose DW, Chenoweth JG, Rosenfeld MG, Anderson ME, Mandel G. REST repression of neuronal genes requires components of the hSWI.SNF complex. J Biol Chem. 2002;277:41038&#x2013;41045.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GR. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology. 2007;32:505&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525416</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698365</ArticleId></ArticleIdList></Reference><Reference><Citation>Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102:1661&#x2013;1666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547836</ArticleId><ArticleId IdType="pubmed">15668387</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Weinberg B, Dawson H. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:12867&#x2013;12872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550768</ArticleId><ArticleId IdType="pubmed">16908860</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">12166544</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Kirilovsky J, Hyafil F, Labaudini&#xe8;re R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1&#x2032;,5&#x2032;:1,6]pyrido[3,4-b]indole-1,3(2H)-dio ne analogues. J Med Chem. 2003a;46:4525&#x2013;4532.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521414</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudini&#xe8;re R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1&#x2032;,2&#x2032;:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem. 2003b;46:4533&#x2013;4542.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521415</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond DM, Park CR, Heman KL, Rose GM. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus. 1999;9:542&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560925</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Food and Drug Administration. Washington, DC: 1998. Viagra tablets (sildenafil citrate). Review and evaluation of pharmacology and toxicology data. Report from the Division of Cardio-renal Drug Products (HFD-10). Center for Drug Evaluation and Research; pp. 121&#x2013;122.</Citation></Reference><Reference><Citation>Francis IY, F&#xe0; M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8962655</ArticleId><ArticleId IdType="pubmed">19625751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, Capobianco L, Selvetella G, Lembo G. Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem. 2004;279:48135&#x2013;48142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest. 2004;114:1624&#x2013;1634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529285</ArticleId><ArticleId IdType="pubmed">15578094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923396</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and &#x3b2;-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22:2246&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758281</ArticleId><ArticleId IdType="pubmed">11896164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. Vascular factors in Alzheimer's disease. Int Psychogeriatr. 2003;15(Suppl 1):47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16191216</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil Z, Poliviou H, Maynard CJ, Beyreuther K, Masters CL, Li QX. Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Abeta protein. J Alzheimers Dis. 2002;4:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">12515898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci. 1999;19:10250&#x2013;10261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782403</ArticleId><ArticleId IdType="pubmed">10575022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunyak VV, Burgess R, Prefontaine GG, Nelson C, Sze SH, Chenoweth J, Schwartz P, Pevzner PA, Glass C, Mandel G, Rosenfeld MG. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science. 2002;298:1747&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399542</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol. 1995;10:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">7599445</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992;17:139&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">1356551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology. 1990;101:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190256</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier F, Leys D. Blood pressure and Alzheimer's disease. Rev Neurol. 1998;154:743&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894287</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci. 1992;106:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590953</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JM, Hellermann A, Hellermann G, Sutton ET. Aging enhances vascular dysfunction induced by the Alzheimer's peptide beta-amyloid. Neurol Res. 2004;26:305&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15142324</ArticleId></ArticleIdList></Reference><Reference><Citation>Prickaerts J, de Vente J, Honig W, Steinbusch HW, Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol. 2002a;436:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11834250</ArticleId></ArticleIdList></Reference><Reference><Citation>Prickaerts J, van Staveren WC, Sik A, Markerink-van Ittersum M, Niew&#xf6;hner U, van der Staay FJ, Blokland A, de Vente J. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience. 2002b;113:351&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127092</ArticleId></ArticleIdList></Reference><Reference><Citation>Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, Blokland A. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int. 2004;45:915&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312986</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-&#x3b2; peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci. 2005;25:6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N. Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J Sex Med. 2006;3:173&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409234</ArticleId></ArticleIdList></Reference><Reference><Citation>Randt CT, Judge ME, Bonnet KA, Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol Biochem Behav. 1982;17:677&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">6294676</ArticleId></ArticleIdList></Reference><Reference><Citation>Saenz de Tejada I, Angulo J, Cuevas P, Fern&#xe1;ndez A, Moncada I, Allona A, Lled&#xf3; E, K&#xf6;rschen HG, Niew&#xf6;hner U, Haning H, Pages E, Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001;13:282&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11890515</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk F, Morris RG. Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp Brain Res. 1985;58:11&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3987843</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci. 1998;21:127&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530494</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CC, Stanyer L, Betteridge DJ. Soluble beta-amyloid (A beta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed. Neurosci Lett. 2004;367:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308313</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA. The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res. 2005;46:494&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604523</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhara T, Magran&#xe9; J, Rosen K, Christensen R, Kim HS, Zheng B, McPhie DL, Walsh K, Querfurth H. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging. 2003;24:437&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600720</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrett NK, Bell AS, Brown D, Ellis P. Sildenafil (Viagra&#x2122;), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett. 1996;6:1819&#x2013;1824.</Citation></Reference><Reference><Citation>Thatcher GR, Bennett BM, Dringenberg HC, Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis. 2004;6:S75&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665418</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 2004;55:801&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov. 2003;2:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">12669026</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BM. Cellular memory and the histone code. Cell. 2002;111:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12419240</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol. 2003;467:566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">14624489</ArticleId></ArticleIdList></Reference><Reference><Citation>van Staveren WC, Steinbusch HW, Markerink-van Ittersum M, Behrends S, de Vente J. Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. Eur J Neurosci. 2004;19:2155&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090042</ArticleId></ArticleIdList></Reference><Reference><Citation>Villiger JW, Dunn AJ. Phosphodiesterase inhibitors facilitate memory for passive avoidance conditioning. Behavioral and neural biology. 1981;31:354&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">6164361</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A. 2002;99:13217&#x2013;13221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci. 2005;46:3060&#x2013;3066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1343468</ArticleId><ArticleId IdType="pubmed">16123402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19555648</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake.</ArticleTitle><Pagination><StartPage>788</StartPage><EndPage>801</EndPage><MedlinePgn>788-801</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.05.012</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), the impairment of declarative memory coincides with the accumulation of extracellular amyloid-beta protein (Abeta) and intraneuronal tau aggregates. Dementia severity correlates with decreased synapse density in hippocampus and cortex. Although numerous studies show that soluble Abeta oligomers inhibit hippocampal long-term potentiation, their role in long-term synaptic depression (LTD) remains unclear. Here, we report that soluble Abeta oligomers from several sources (synthetic, cell culture, human brain extracts) facilitated electrically evoked LTD in the CA1 region. Abeta-enhanced LTD was mediated by mGluR or NMDAR activity. Both forms of LTD were prevented by an extracellular glutamate scavenger system. Abeta-facilitated LTD was mimicked by the glutamate reuptake inhibitor TBOA, including a shared dependence on extracellular calcium levels and activation of PP2B and GSK-3 signaling. In accord, synaptic glutamate uptake was significantly decreased by soluble Abeta. We conclude that soluble Abeta oligomers perturb synaptic plasticity by altering glutamate recycling at the synapse and promoting synapse depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shepardson</LastName><ForeName>Nina E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018756">GABA Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>15662-33-6</RegistryNumber><NameOfSubstance UI="D012433">Ryanodine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>40709-69-1</RegistryNumber><NameOfSubstance UI="C017069">bicuculline methiodide</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y37615DVKC</RegistryNumber><NameOfSubstance UI="D001640">Bicuculline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001640" MajorTopicYN="N">Bicuculline</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018756" MajorTopicYN="N">GABA Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012433" MajorTopicYN="N">Ryanodine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19555648</ArticleId><ArticleId IdType="mid">NIHMS119910</ArticleId><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.05.012</ArticleId><ArticleId IdType="pii">S0896-6273(09)00387-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anwyl R. Induction and expression mechanisms of postsynaptic NMDA receptor-independent homosynaptic long-term depression. Prog Neurobiol. 2006;78:17&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423442</ArticleId></ArticleIdList></Reference><Reference><Citation>Asztely F, Erdemli G, Kullmann DM. Extrasynaptic glutamate spillover in the hippocampus: dependence on temperature and the role of active glutamate uptake. Neuron. 1997;18:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastrikova N, Gardner GA, Reece JM, Jeromin A, Dudek SM. Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc Natl Acad Sci U S A. 2008;105:3123&#x2013;3127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268595</ArticleId><ArticleId IdType="pubmed">18287055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat Neurosci. 2000;3:1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036267</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell SL, Hablitz JJ. Glutamate transporters regulate excitability in local networks in rat neocortex. Neuroscience. 2004;127:625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">15283962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci U S A. 2006;103:3410&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413872</ArticleId><ArticleId IdType="pubmed">16492745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem. 2002;77:354&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991763</ArticleId></ArticleIdList></Reference><Reference><Citation>Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008;33:18&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17728696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowburn RF, Wiehager B, Trief E, Li-Li M, Sundstr&#xf6;m E. Effects of beta-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res. 1997;22:1437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9357007</ArticleId></ArticleIdList></Reference><Reference><Citation>Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65:1&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369436</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S, Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging. 2009;30:241&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001;21:4125&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762764</ArticleId><ArticleId IdType="pubmed">11404397</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewer C, Rauen T. Electrogenic glutamate transporters in the CNS: molecular mechanism, pre-steady-state kinetics, and their impact on synaptic signaling. J Membr Biol. 2005;203:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2389879</ArticleId><ArticleId IdType="pubmed">15834685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu QB, Zhao JX, Fei J, Schwarz W. Modulation of Na(+), K(+) pumping and neurotransmitter uptake by beta-amyloid. Neuroscience. 2004;126:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15145073</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkany T, Abrah&#xe1;m I, Timmerman W, Laskay G, T&#xf3;th B, Sasv&#xe1;ri M, K&#xf3;nya C, Sebens JB, Korf J, Nyakas C, Zar&#xe1;ndi M, So&#xf3;s K, Penke B, Luiten PG. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci. 2000;12:2735&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971616</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris ME, Wang Y, Pedigo NW, Jr, Hensley K, Butterfield DA, Carney JM. Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem. 1996;67:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegaya Y, Matsuura S, Ueno S, Baba A, Yamada MK, Nishiyama N, Matsuki N. Beta-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J Biol Chem. 2002;277:32180&#x2013;32186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12070161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Gr&#xfc;nblatt E. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. 2007;11:97&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp N, Bashir ZI. Long-term depression: a cascade of induction and expression mechanisms. Prog Neurobiol. 2001;65:339&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci. 2001;21:1327&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762223</ArticleId><ArticleId IdType="pubmed">11160403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Dunah AW, Wang YT, Sheng M. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron. 2005;46:745&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15924861</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Mol Neurobiol. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, et al. Molecular diversity of the NMDA receptor channel. Nature. 1992;358:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">1377365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Tian X, Hartley DM, Feig LA. Distinct roles for Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and Ras-GRF2 in the induction of long-term potentiation and long-term depression. J Neurosci. 2006;26:1721&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793631</ArticleId><ArticleId IdType="pubmed">16467520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science. 2004;304:1021&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">15143284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Maki R, Robinson MB, Dichter MA. The glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylate depresses excitatory synaptic transmission via a presynaptic mechanism in cultured hippocampal neurons. J Neurosci. 1994;14:6754&#x2013;6762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577273</ArticleId><ArticleId IdType="pubmed">7965076</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol. 1996;40:759&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature. 2004;429:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158816</ArticleId><ArticleId IdType="pubmed">15190253</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Min MY, Rusakov DA, Kullmann DM. Activation of AMPA, kainate, and metabotropic receptors at hippocampal mossy fiber synapses: role of glutamate diffusion. Neuron. 1998;21:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768842</ArticleId></ArticleIdList></Reference><Reference><Citation>Moln&#xe1;r Z, So&#xf3;s K, Lengyel I, Penke B, Szegedi V, Budai D. Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. Neuroreport. 2004;15:1649&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232300</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishita W, Lu W, Smith GB, Nicoll RA, Bear MF, Malenka RC. Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression. Neuropharmacology. 2007;52:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron. 2004;44:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M, Hoppe J, Santin K, Frozza R, Zamin LL, Sim&#xe3;o F, Horn AP, Salbego C. Beta-amyloid peptide toxicity in organotypic hippocampal slice culture involves Akt/PKB, GSK-3beta and PTEN. Neurochem Int. 2007;50:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018242</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Shea SD, Smith IM, McCabe OM, Cronin MM, Walsh DM, O'Connor WT. Intracerebroventricular administration of amyloid b-protein oligomers selectively increases dorsal hippocampal dialysate glutamate levels in the awake rat. Sensors. 2008;8:7428&#x2013;7437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787453</ArticleId><ArticleId IdType="pubmed">27873937</ArticleId></ArticleIdList></Reference><Reference><Citation>Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM, Arancio O, Yan SD, Domenici L. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci. 2008;28:3521&#x2013;3530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670592</ArticleId><ArticleId IdType="pubmed">18367618</ArticleId></ArticleIdList></Reference><Reference><Citation>Overstreet LS, Pasternak JF, Colley PA, Slater NT, Trommer BL. Metabotropic glutamate receptor mediated long-term depression in developing hippocampus. Neuropharmacology. 1997;36:831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225311</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53:703&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">17329210</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995;270:9564&#x2013;9570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara N, Singh R, Deptula D, Chou JC, Schwartz MB, LeWitt PA. Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry. 1992;149:251&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734749</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 2003;968:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarantis M, Ballerini L, Miller B, Silver RA, Edwards M, Attwell D. Glutamate uptake from the synaptic cleft does not shape the decay of the non-NMDA component of the synaptic current. Neuron. 1993 Sep;11(3):541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691104</ArticleId></ArticleIdList></Reference><Reference><Citation>Scimemi A, Fine A, Kullmann DM, Rusakov DA. NR2B-containing receptors mediate cross talk among hippocampal synapses. J Neurosci. 2004;24:4767&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3379686</ArticleId><ArticleId IdType="pubmed">15152037</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson N, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Soluble Amyloid &#x3b2;-Protein Dimers Isolated Directly from Alzheimer Disease Patients Potently Impair Synaptic Plasticity and Memory. Nat Medicine. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovar KR, Westbrook GL. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci. 1999;19:4180&#x2013;4188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782704</ArticleId><ArticleId IdType="pubmed">10234045</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282:33305&#x2013;33312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J Neurochem. 1997;68:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978734</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 2005;25:2455&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725159</ArticleId><ArticleId IdType="pubmed">15758153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci. 2004a;24:6049&#x2013;6056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729673</ArticleId><ArticleId IdType="pubmed">15240796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004b;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Anwyl R, Rowan MJ. beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport. 1995;6:2409&#x2013;2413.</Citation><ArticleIdList><ArticleId IdType="pubmed">8747164</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CH, Huang CC, Hsu KS. Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. J Neurosci. 2005;25:4288&#x2013;4293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725105</ArticleId><ArticleId IdType="pubmed">15858055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron. 2004;44:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19571734</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer disease.</ArticleTitle><Pagination><StartPage>28</StartPage><EndPage>36</EndPage><MedlinePgn>28-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e3181a785c9</ELocationID><Abstract><AbstractText>The posteromedial cortices and other regions of the "default network" are particularly vulnerable to the pathology of Alzheimer disease (AD). In this study, we performed functional magnetic resonance imaging (fMRI) to investigate whether the presence of apolipoprotein E (APOE) epsilon allele and degree of memory impairment were associated with the dysfunction of these brain regions. Seventy-five elderly subjects ranging from cognitively normal to mild AD, divided into epsilon carriers and noncarriers, underwent fMRI during a memory-encoding task. Across all subjects, posteromedial and ventral anterior cingulate cortices (key components of the default network) as well as right middle and inferior prefrontal regions demonstrated reduced task-induced deactivation in the epsilon carriers relative to noncarriers. Even among cognitively normal subjects, epsilon carriers demonstrated reduced posteromedial deactivation compared with the noncarriers in the same regions which demonstrated failure of deactivation in AD patients. Greater failure of posteromedial deactivation was related to worse memory performance (delayed recall) across all subjects and within the range of cognitively normal subjects. In summary, the posteromedial cortical fMRI response pattern is modulated both by the presence of APOE epsilon and episodic memory capability. Altered fMRI activity of the posteromedial areas of the brain default network may be an early indicator of risk for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pihlajam&#xe4;ki</LastName><ForeName>Maija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, MA, USA. Maija.Pihlajamaki@uku.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O' Keefe</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-NS02189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS002189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012150" MajorTopicYN="N">Polymorphism, Restriction Fragment Length</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19571734</ArticleId><ArticleId IdType="mid">NIHMS117958</ArticleId><ArticleId IdType="pmc">PMC2837131</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e3181a785c9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, et al. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Wang L, Krishnan S, et al. Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging. Radiology. 2007;245:224&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">17885190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, Muhlau M, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Dougherty JH, Jr, Hubner KF, et al. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2008;4:265&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631977</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen A, Tervo S, Grau-Olivares M, et al. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage. 2007;37:1122&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683950</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008;70:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734138</ArticleId><ArticleId IdType="pubmed">17898323</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc Brain Metab Rev. 1991;3:297&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">1772739</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Fryer TD, Smielewski P, et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953266</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9 1:173&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447441</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA, Hyman BT, et al. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry. 2007;64:1443&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581771</ArticleId><ArticleId IdType="pubmed">18056553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Bates JF, Cocchiarella AJ, et al. Encoding novel face-name associations: a functional MRI study. Hum Brain Mapp. 2001;14:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871827</ArticleId><ArticleId IdType="pubmed">11559958</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in FMRI. Neuroimage. 2003;20:1052&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568475</ArticleId></ArticleIdList></Reference><Reference><Citation>Worsley KJ, Evans AC, Marrett S, et al. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992;12:900&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">1400644</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson J, Lind J, Larsson A, et al. Altered deactivation in individuals with genetic risk for Alzheimer's disease. Neuropsychologia. 2008;46:1679&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">18346764</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 1995;66:583&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">7644022</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci. 2005;8:977&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">16047022</ArticleId></ArticleIdList></Reference><Reference><Citation>Manelli AM, Bulfinch LC, Sullivan PM, et al. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging. 2007;28:1139&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752940</ArticleId><ArticleId IdType="pubmed">16837105</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. Neuroimage. 2004;23:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Celone K, Depeau K, et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008;105:2181&#x2013;2186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538895</ArticleId><ArticleId IdType="pubmed">18238903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Amaral DG. Macaque monkey retrosplenial cortex: III. Cortical efferents. J Comp Neurol. 2007;502:810&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">17436282</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, Blaizot X, Kondoh Y, et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain. 1999;122:1519&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley KM, O'Sullivan VT, Soper ND, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain. 2002;125:1772&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135968</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon BJ, Buckner RL. Functional-anatomic correlates of memory retrieval that suggest nontraditional processing roles for multiple distinct regions within posterior parietal cortex. J Neurosci. 2004;24:10084&#x2013;10092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730171</ArticleId><ArticleId IdType="pubmed">15537877</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging. 2006;27:1604&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SD, Houston WS, Jak AJ, et al. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging. 2007;28:238&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705815</ArticleId><ArticleId IdType="pubmed">16434125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarahn E, Rakitin B, Abela D, et al. Age-related changes in brain activation during a delayed item recognition task. Neurobiol Aging. 2007;28:784&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621168</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci. 2006;26:6069&#x2013;6076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, McLaren DG, Ries ML, et al. The influence of parental history of Alzheimer's disease and apolipoprotein E {varepsilon}4 on the BOLD signal during recognition memory. Brain. 2008 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724919</ArticleId><ArticleId IdType="pubmed">18829694</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark CE, Squire LR. When zero is not zero: the problem of ambiguous baseline conditions in fMRI. Proc Natl Acad Sci U S A. 2001;98:12760&#x2013;12766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60127</ArticleId><ArticleId IdType="pubmed">11592989</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcom AM, Fletcher PC. Does the brain have a baseline? Why we should be resisting a rest. Neuroimage. 2007;37:1073&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681817</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci. 2003;4:863&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595398</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005;234:851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851934</ArticleId><ArticleId IdType="pubmed">15734937</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckhaus C, Flub MO, Wittsack HJ, et al. Detection of changed regional cerebral blood flow in mild cognitive impairment and early Alzheimer's dementia by perfusion-weighted magnetic resonance imaging. Neuroimage. 2008;40:495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18207425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19581601</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>29</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.</ArticleTitle><Pagination><StartPage>12145</StartPage><EndPage>12150</EndPage><MedlinePgn>12145-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0904866106</ELocationID><Abstract><AbstractText>A number of distinct beta-amyloid (Abeta) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Abeta-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Abeta and amyloidogenic non-Abeta species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of Abeta and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Abeta1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Abeta, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Abeta toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Abeta the monkeys developed high titers not only against Abeta peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Abeta antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Britschgi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olin</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Johns</LastName><ForeName>H T</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Takeda-Uchimura</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>LeMieux</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Rufibach</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rajadas</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tomooka</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Jutel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Leszek</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Yesavage</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Ghiso</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG030539</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020603</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030539</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20603</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19581601</ArticleId><ArticleId IdType="pmc">PMC2715538</ArticleId><ArticleId IdType="doi">10.1073/pnas.0904866106</ArticleId><ArticleId IdType="pii">0904866106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid &#x3b2; protein in Alzheimer's disease. J Biol Chem. 1992;267:17082&#x2013;17086.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512246</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, et al. Relative abundance of Alzheimer A &#x3b2; amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, et al. Dominant and differential deposition of distinct &#x3b2;-amyloid peptide species, A &#x3b2; N3(pE), in senile plaques. Neuron. 1995;14:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, et al. Full-length amyloid-&#x3b2; (1-42(43)) and amino-terminally modified and truncated amyloid-&#x3b2; 42(43) deposit in diffuse plaques. Am J Pathol. 1996;149:1823&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865366</ArticleId><ArticleId IdType="pubmed">8952519</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini A, et al. &#x3b2;-Amyloid is different in normal aging and in Alzheimer disease. J Biol Chem. 2005;280:34186&#x2013;34192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103127</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadarajan S, et al. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A &#x3b2;(1-42) and A &#x3b2;(25-35) J Am Chem Soc. 2001;123:5625&#x2013;5631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403592</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, et al. Neurotoxic, redox-competent Alzheimer's &#x3b2;-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003;278:42959&#x2013;42965.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925530</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-&#x3b2;. Biochemistry. 2004;43:560&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717612</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C, et al. Pyroglutamate-modified amyloid &#x3b2;-peptides&#x2013;A&#x3b2;N3(pE)&#x2013;strongly affect cultured neuron and astrocyte survival. J Neurochem. 2002;82:1480&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Anti-A&#x3b2;42- and anti-A&#x3b2;40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, et al. &#x3b2;-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, et al. Long-term effects of A&#x3b2;42 immunisation in Alzheimer's disease: Follow-up of a randomized, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, et al. Antibodies against &#x3b2;-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, et al. Epitope and isotype specificities of antibodies to &#x3b2;-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, et al. Novel A&#x3b2; peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation. 2005 doi: 10.1186/1742-2094-2-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-28</ArticleId><ArticleId IdType="pmc">PMC1326209</ArticleId><ArticleId IdType="pubmed">16332263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamikonyan G, et al. Anti-A&#x3b2;1 11 antibody binds to different &#x3b2;-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem. 2007;282:22376&#x2013;22386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435219</ArticleId><ArticleId IdType="pubmed">17545160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaskin F, et al. Human antibodies reactive with &#x3b2;-amyloid protein in Alzheimer's disease. J Exp Med. 1993;177:1181&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190957</ArticleId><ArticleId IdType="pubmed">8459212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. Autoantibodies to amyloid-&#x3b2; in Alzheimer's disease. Ann Neurol. 2001;49:808&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A, et al. Autoantibodies to amyloid &#x3b2;-peptide (A&#x3b2;) are increased in Alzheimer's disease patients and A&#x3b2; antibodies can enhance A&#x3b2; neurotoxicity: Implications for disease pathogenesis and vaccine development. Neuromol Med. 2003;3:29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665674</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, et al. Autoantibodies to redox-modified oligomeric A&#x3b2; are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem. 2005;280:17458&#x2013;17463.</Citation><ArticleIdList><ArticleId IdType="pubmed">15728175</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel AW, et al. Immune complexes of auto-antibodies against A&#x3b2; 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol Psychiatry. 2007;12:601&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">17279093</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid &#x3b2; peptide. Autoimmun Rev. 2008;7:415&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustaw KA, et al. Antigen-antibody dissociation in Alzheimer disease: A novel approach to diagnosis. J Neurochem. 2008;106:1350&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575068</ArticleId><ArticleId IdType="pubmed">18485104</ArticleId></ArticleIdList></Reference><Reference><Citation>Weksler ME, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086704</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, et al. Reduced levels of amyloid &#x3b2;-peptide antibody in Alzheimer's disease. Neurology. 2001;57:801&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">11552007</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin NR, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008 doi: 10.1016/j.neurobiolaging.2007.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.12.021</ArticleId><ArticleId IdType="pubmed">18294736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana FJ, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA. 2008;105:18889&#x2013;18894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596207</ArticleId><ArticleId IdType="pubmed">19028871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiller T, et al. Autoreactivity in human IgG+ memory B cells. Immunity. 2007;26:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839941</ArticleId><ArticleId IdType="pubmed">17306569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19058756</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 1999;399:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, et al. A decamer duplication in the 3&#x2032; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA. 2000;97:4920&#x2013;4925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature. 2002;418:291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Quist A, et al. Amyloid ion channels: A common structural link for protein-misfolding disease. Proc Natl Acad Sci USA. 2005;102:10427&#x2013;10432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180768</ArticleId><ArticleId IdType="pubmed">16020533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, et al. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-A&#x3b2; antibodies. BMC Neurosci. 2007 doi: 10.1186/1471-2202-8-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-8-22</ArticleId><ArticleId IdType="pmc">PMC1845169</ArticleId><ArticleId IdType="pubmed">17374155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, et al. Alzheimer's disease a&#x3b2; vaccine reduces central nervous system a&#x3b2; levels in a nonhuman primate, the Caribbean vervet. Am J Pathol. 2004;165:283&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618542</ArticleId><ArticleId IdType="pubmed">15215183</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Tolan DR, Selkoe DJ. Homology of the amyloid &#x3b2; protein precursor in monkey and human supports a primate model for &#x3b2; amyloidosis in Alzheimer's disease. Am J Pathol. 1991;138:1423&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886384</ArticleId><ArticleId IdType="pubmed">1905108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn JH, et al. Reduced serum level of antibodies against amyloid &#x3b2; peptide is associated with aging in Tg2576 mice. Biochem Biophys Res Commun. 2007;361:800&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678618</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-&#x3b2; peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruden MA, et al. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to A&#x3b2;(25-35) oligomers, S100b, and neurotransmitters. J Neuroimmunol. 2007;186:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17477976</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Insights into the mechanisms of action of anti-A&#x3b2; antibodies in Alzheimer's disease mouse models. FASEB J. 2006;20:2576&#x2013;2578.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Schreurs BG. Trace amounts of copper in water induce &#x3b2;-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA. 2003;100:11065&#x2013;11069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196927</ArticleId><ArticleId IdType="pubmed">12920183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, et al. Systemic catabolism of Alzheimer's A&#x3b2;40 and A&#x3b2;42. J Biol Chem. 2004;279:45897&#x2013;45908.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322125</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, et al. Peripheral clearance of amyloid &#x3b2; peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, et al. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, et al. Therapeutically effective antibodies against amyloid-&#x3b2; peptide target amyloid-&#x3b2; residues 4&#x2013;10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, et al. Isolation, chemical characterization, and quantitation of A &#x3b2;3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun. 1997;237:188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9266855</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) Biochemistry. 2006;45:12393&#x2013;12399.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">4172688</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland RP, et al. Antibodies to potato virus Y bind the amyloid-&#x3b2; peptide: Immunohistochemical and NMR studies. J Biol Chem. 2008;283:22550&#x2013;22556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504870</ArticleId><ArticleId IdType="pubmed">18505725</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonham N, Barker I. Strain specific recombinant antibodies to potato virus Y potyvirus. J Virol Methods. 1998;74:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson WH, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002;8:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116&#x2013;5121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33173</ArticleId><ArticleId IdType="pubmed">11309499</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863&#x2013;14868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24541</ArticleId><ArticleId IdType="pubmed">9843981</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha AJ. Java Treeview: Extensible visualization of microarray data. Bioinformatics. 2004;20:3246&#x2013;3248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15180930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B. 2005;67:301&#x2013;320.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19581723</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.</ArticleTitle><Pagination><StartPage>681</StartPage><EndPage>697</EndPage><MedlinePgn>681-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2009-1071</ELocationID><Abstract><AbstractText>Recent epidemiologic studies suggest that caffeine may be protective against Alzheimer's disease (AD). Supportive of this premise, our previous studies have shown that moderate caffeine administration protects/restores cognitive function and suppresses brain amyloid-beta (Abeta) production in AD transgenic mice. In the present study, we report that acute caffeine administration to both young adult and aged AD transgenic mice rapidly reduces Abeta levels in both brain interstitial fluid and plasma without affecting Abeta elimination. Long-term oral caffeine treatment to aged AD mice provided not only sustained reductions in plasma Abeta, but also decreases in both soluble and deposited Abeta in hippocampus and cortex. Irrespective of caffeine treatment, plasma Abeta levels did not correlate with brain Abeta levels or with cognitive performance in individual aged AD mice. Although higher plasma caffeine levels were strongly associated with lower plasma Abeta1-40 levels in aged AD mice, plasma caffeine levels were also not linked to cognitive performance. Plasma caffeine and theophylline levels were tightly correlated, both being associated with reduced inflammatory cytokine levels in hippocampus. Our conclusion is two-fold: first, that both plasma and brain Abeta levels are reduced by acute or chronic caffeine administration in several AD transgenic lines and ages, indicating a therapeutic value of caffeine against AD; and second, that plasma Abeta levels are not an accurate index of brain Abeta levels/deposition or cognitive performance in aged AD mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Byrd Alzheimer's Center &amp; Research Institute, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Verges</LastName><ForeName>Deborah K</ForeName><Initials>DK</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mamcarz</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chi</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Arendash</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical><Chemical><RegistryNumber>C137DTR5RG</RegistryNumber><NameOfSubstance UI="D013806">Theophylline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Alzheimers Dis. 2009 Nov;18(3):727</RefSource><Note>Wang, Lilly [corrected to Wang, Li].</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013806" MajorTopicYN="N">Theophylline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19581723</ArticleId><ArticleId IdType="mid">NIHMS495451</ArticleId><ArticleId IdType="pmc">PMC3746074</ArticleId><ArticleId IdType="doi">10.3233/JAD-2009-1071</ArticleId><ArticleId IdType="pii">31013676523UM704</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61:857&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138593</ArticleId><ArticleId IdType="pubmed">15095008</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly J. Caffeine analogs: biomedical impact. Cell Mol Life Sci. 2007;64:2153&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138448</ArticleId><ArticleId IdType="pubmed">17514358</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredholm B, B&#xe4;ttig K, Holm&#xe9;n J, Nehlig A, Zvartau E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049999</ArticleId></ArticleIdList></Reference><Reference><Citation>Higdon J, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46:101&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Carri&#xe8;re I, de Mendonca A, Portet F, Dartigues J, Rouaud O, Barberger-Gateau P, Ancelin M. The neuroprotective effects of caffeine: a prospective population study (the Three City Study) Neurology. 2007;69:536&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">17679672</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gelder B, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007;61:226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16929246</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia L, de Mendon&#xe7;a A. Does caffeine intake protect from Alzheimer&#x2019;s disease? Eur J Neurol. 2002;9:377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">12099922</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso A, Lippa C, Mossey J. Caffeine: Neuroprotective Functions in Cognition and Alzheimer""s Disease. Am J Alzheimers Dis Other Demen. 2008 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846190</ArticleId><ArticleId IdType="pubmed">19230121</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash G, Schleif W, Rezai-Zadeh K, Jackson E, Zacharia L, Cracchiolo J, Shippy D, Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience. 2006;142:941&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">16938404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam. 2003;20:1&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Garcia E, van Dam R, Li T, Rodriguez-Artalejo F, Hu F. The relationship of coffee consumption with mortality. Ann Intern Med. 2008;148:904&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3958951</ArticleId><ArticleId IdType="pubmed">18559841</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash G, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tan J, Citron B, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain A&#x3b2; levels in aged Alzheimer&#x2019;s mice. 2008. Submitted for publication.</Citation><ArticleIdList><ArticleId IdType="pubmed">19581722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R, Munsell L, Morris J, Swarm R, Yarasheski K, Holtzman D. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, May P, O'Dell M, Taylor J, Parsadanian M, Cramer J, Audia J, Nissen J, Bales K, Paul S, DeMattos R, Holtzman D. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, Kang J, Lee J, Stewart F, Verges D, Silverio L, Bu G, Mennerick S, Holtzman D. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethell D, Shippy D, Cao C, Cracchiolo J, Runfeldt M, Blake B, Arendash G. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis. 2006;23:351&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16733088</ArticleId></ArticleIdList></Reference><Reference><Citation>Cracchiolo J, Mori T, Nazian S, Tan J, Potter H, Arendash G. Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem. 2007;88:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2083653</ArticleId><ArticleId IdType="pubmed">17714960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, Shimoda T, Kamanaka Y, Tateishi N, Asano T. Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther. 2006;318:571&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell R, Mullan M. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci. 2002;5:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrigan L, Kelly J, Connor T. Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol. 2004;4:1409&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, Yamada K, Finn M, Sloviter S, Bales K, May P, Schoepp D, Paul S, Mennerick S, Holtzman D. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash G, Gordon M, Diamond D, Austin L, Hatcher J, Jantzen P, DiCarlo G, Wilcock D, Morgan D. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 2001;20:737&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788052</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash G, King D, Gordon M, Morgan D, Hatcher J, Hope C, Diamond D. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 2001;891:42&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164808</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighty R, Nilsson L, Potter H, Costa D, Low M, Bales K, Paul S, Arendash G. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res. 2004;153:107&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219712</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash G, Jensen M, Salem N, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience. 2007;149:286&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppo E, Arias H. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37:289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla K, Curran G, Holasek S, Gilles E, Wengenack T, Poduslo J. Pharmacokinetic analysis of the blood-brain barrier transport of 125I&#x2013;amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005;313:1370&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15743932</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T. A&#x3b2; Metabolism and Alzheimer&#x2019;s Disease (Landes Bioscience) 2003</Citation></Reference><Reference><Citation>Siemers E, Quinn J, Kaye J, Farlow M, Porsteinsson A, Tariot P, Zoulnouni P, Galvin J, Holtzman D, Knopman D, Satterwhite J, Gonzales C, Dean R, May P. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505324</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R, Bales K, Cummins D, Paul S, Holtzman D. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910111</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman S, Raju S, Hyman B, Frosch M, Irizarry M. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol. 2007;66:264&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A, LaRossa G, Spinner M, Klunk W, Mathis C, DeKosky S, Morris J, Holtzman D. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oijen M, Hofman A, Soares H, Koudstaal P, Breteler M. Plasma Abeta(1&#x2013;40) and Abeta(1&#x2013;42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Blennow K. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2008 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman L, Galasko D, Jutel M, Karydas A, Kaye J, Leszek J, Miller B, Minthon L, Quinn J, Rabinovici G, Robinson W, Sabbagh M, So Y, Sparks D, Tabaton M, Tinklenberg J, Yesavage J, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson B, Georgiev V, Kuosmanen T, Fredholm B. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur J Neurosci. 1996;8:2447&#x2013;2458.</Citation><ArticleIdList><ArticleId IdType="pubmed">8996794</ArticleId></ArticleIdList></Reference><Reference><Citation>Azam S, Hadi N, Khan N, Hadi S. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit. 2003;9:BR325&#x2013;BR330.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Gawryluk J, Wagener J, Ghribi O, Geiger J. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation. 2008;5:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2330033</ArticleId><ArticleId IdType="pubmed">18387175</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Igna O, Fett P, Gomes M, Souza D, Cunha R, Lara D. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25&#x2013;35)-induced cognitive deficits in mice. Exp Neurol. 2007;203:241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">17007839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha G, Canas P, Melo C, Hockemeyer J, M&#xfc;ller C, Oliveira C, Cunha R. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol. 2008;210:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19605829</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>361</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Disclosure of APOE genotype for risk of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>254</EndPage><MedlinePgn>245-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa0809578</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The apolipoprotein E (APOE) genotype provides information on the risk of Alzheimer's disease, but the genotyping of patients and their family members has been discouraged. We examined the effect of genotype disclosure in a prospective, randomized, controlled trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We randomly assigned 162 asymptomatic adults who had a parent with Alzheimer's disease to receive the results of their own APOE genotyping (disclosure group) or not to receive such results (nondisclosure group). We measured symptoms of anxiety, depression, and test-related distress 6 weeks, 6 months, and 1 year after disclosure or nondisclosure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences between the two groups in changes in time-averaged measures of anxiety (4.5 in the disclosure group and 4.4 in the nondisclosure group, P=0.84), depression (8.8 and 8.7, respectively; P=0.98), or test-related distress (6.9 and 7.5, respectively; P=0.61). Secondary comparisons between the nondisclosure group and a disclosure subgroup of subjects carrying the APOE epsilon4 allele (which is associated with increased risk) also revealed no significant differences. However, the epsilon4-negative subgroup had a significantly lower level of test-related distress than did the epsilon4-positive subgroup (P=0.01). Subjects with clinically meaningful changes in psychological outcomes were distributed evenly among the nondisclosure group and the epsilon4-positive and epsilon4-negative subgroups. Baseline scores for anxiety and depression were strongly associated with post-disclosure scores of these measures (P&lt;0.001 for both comparisons).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The disclosure of APOE genotyping results to adult children of patients with Alzheimer's disease did not result in significant short-term psychological risks. Test-related distress was reduced among those who learned that they were APOE epsilon4-negative. Persons with high levels of emotional distress before undergoing genetic testing were more likely to have emotional difficulties after disclosure. (ClinicalTrials.gov number, NCT00571025.)</AbstractText><CopyrightInformation>2009 Massachusetts Medical Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA 02118, USA. rcgreen@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>J Scott</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Tamsen</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Eckert</LastName><ForeName>Susan LaRusse</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Butson</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sadovnick</LastName><ForeName>A Dessa</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Quaid</LastName><ForeName>Kimberly A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Clara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cook-Deegan</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><CollectiveName>REVEAL Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00571025</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000533</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-HG003391</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00533</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG003391</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG/AG02213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG09029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2009 Jul 16;361(3):298-9. doi: 10.1056/NEJMe0903449.</RefSource><PMID Version="1">19605835</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2009 Nov 17;151(10):JC5-9. doi: 10.7326/0003-4819-151-10-200911170-02009.</RefSource><PMID Version="1">19920267</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2010 Jan 14;362(2):181-2; author reply 182. doi: 10.1056/NEJMc096300.</RefSource><PMID Version="1">20071713</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014342" MajorTopicYN="Y">Truth Disclosure</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Annas</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatt</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biesecker</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fasaye</LastName><ForeName>G-A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hiraki</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juengst</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linnenbringer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marteau</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeister</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Post</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravdin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reilly</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roter</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royal</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Topol</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhlmann</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19605829</ArticleId><ArticleId IdType="mid">NIHMS133885</ArticleId><ArticleId IdType="pmc">PMC2778270</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0809578</ArticleId><ArticleId IdType="pii">361/3/245</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolfberg AJ. Genes on the Web &#x2014; direct-to-consumer marketing of genetic testing. N Engl J Med. 2006;355:543&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899772</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle &#x2014; will we get our wish? N Engl J Med. 2008;358:105&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184955</ArticleId></ArticleIdList></Reference><Reference><Citation>Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299:1353&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18349097</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA. 1995;274:1627&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7474250</ArticleId></ArticleIdList></Reference><Reference><Citation>Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA. 1997;277:832&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052715</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell LM, Koenig BA, Greely HT, Raffin TA. Genetic testing and Alzheimer disease: has the time come? Nat Med. 1998;4:757&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662356</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin NR, Tanzi R, Breitner J, et al. Apolipoprotein E genotyping in Alzheimer's disease. Lancet. 1996;347:1091&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, Barber M, Brown TM, et al. Who seeks genetic susceptibility testing for Alzheimer's disease: findings from a multisite, randomized clinical trial. Genet Med. 2004;6:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15266207</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA. Beck Depression Inventory. Psychological Corporation; New York: 1987.</Citation></Reference><Reference><Citation>Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3204199</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: A self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385&#x2013;401.</Citation></Reference><Reference><Citation>Santor DA, Zuroff DC, Ramsay JO, Cervantes P, Palacios J. Examining scale discriminability in the BDI and CES-D as a function of depressive severity. Psychol Assess. 1995;7:131&#x2013;9.</Citation></Reference><Reference><Citation>Vernon SW, Gritz ER, Peterson SK, et al. Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. Health Psychol. 1997;16:73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman D, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996;275:1885&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8648868</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz M, Wilner N, Alvarez MA. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">472086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberg NJ, Weiss DS, Horowitz MJ. Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol. 1982;50:407&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7096742</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne K, Nicholls S, McAllister M, Macleod R, Donnai D, Davies LM. Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health. 2008;11:497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">18489673</ArticleId></ArticleIdList></Reference><Reference><Citation>DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J. Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? J Med Genet. 1998;35:745&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1051427</ArticleId><ArticleId IdType="pubmed">9733033</ArticleId></ArticleIdList></Reference><Reference><Citation>Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a study of emotional impact. J Med Genet. 2001;38:519&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1734924</ArticleId><ArticleId IdType="pubmed">11483640</ArticleId></ArticleIdList></Reference><Reference><Citation>Thewes B, Meiser B, Hickie IB. Psycho-metric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology. 2001;10:459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11747058</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiser B, Butow P, Friedlander M, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer. 2002;38:2025&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12376208</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002;20:514&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786581</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol. 2004;61:875&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15210524</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiser B, Collins V, Warren R, et al. Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet. 2004;66:502&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15521977</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist. 2000;40:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10750312</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test. 2003;7:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12820701</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupples LA, Farrer L, Sadovnick D, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004;6:192&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15266206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36&#x2013;9. [Erratum, BMJ 1996;313:550.]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2351444</ArticleId><ArticleId IdType="pubmed">8664772</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Rosnick CB, Fratiglioni L, B&#xe4;ckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004;19:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584785</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17226738</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JS, LaRusse SA, Katzen H, et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:86&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794385</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann PJ, Hammitt JK, Mueller C, et al. Public attitudes about genetic testing for Alzheimer's disease. Health Aff (Millwood) 2001;20(5):252&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">11558711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chase GA, Geller G, Havstad SL, Holtzman NA, Bassett SS. Physicians' propensity to offer genetic testing for Alzheimer's disease: results from a survey. Genet Med. 2002;4:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172396</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature. 2003;422:835&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12695777</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian-Reynier C, Welkenhuysen M, Hagoel L, Decruyenaere M, Hopwood P. Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet. 2003;11:725&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512961</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury MJ, McCabe LL, McCabe ERB. Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12510043</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga SB, Khoury MJ, Burke W. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet. 2003;34:347&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923535</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA. 2007;298:1682&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925520</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19605830</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>361</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.</ArticleTitle><Pagination><StartPage>255</StartPage><EndPage>263</EndPage><MedlinePgn>255-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa0809437</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The APOE epsilon4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE epsilon4 allele, those who are heterozygous for the allele, and noncarriers is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE epsilon4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE epsilon4 allele, using a mixed model for longitudinal change with age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed 815 subjects: 317 APOE epsilon4 carriers (79 who were homozygous for the APOE epsilon4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P&lt;0.001) and were followed for a longer period (5.3 vs. 4.7 years, P=0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P=0.03), with a possible allele-dose effect (P=0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Age-related memory decline in APOE epsilon4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.</AbstractText><CopyrightInformation>2009 Massachusetts Medical Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dueck</LastName><ForeName>Amylou C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Ahern</LastName><ForeName>Geoffrey L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Leslie C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Rapcsak</LastName><ForeName>Steven Z</ForeName><Initials>SZ</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jiong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Bryan K</ForeName><Initials>BK</Initials></Author><Author ValidYN="Y"><LastName>Locke</LastName><ForeName>Dona E C</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Charlene Hoffman</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2009 Nov 12;361(20):1996; author reply 1996-7. doi: 10.1056/NEJMc091640.</RefSource><PMID Version="1">19907049</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2009 Nov 12;361(20):1996; author reply 1996-7.</RefSource><PMID Version="1">19916243</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19605830</ArticleId><ArticleId IdType="mid">NIHMS182704</ArticleId><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0809437</ArticleId><ArticleId IdType="pii">361/3/255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull. 1996;120:272&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831298</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaeghen P, Cerella J. Aging, executive control, and attention: a review of meta-analyses. Neurosci Behav Rev. 2002;26:849&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470697</ArticleId></ArticleIdList></Reference><Reference><Citation>Treitz FH, Heyder K, Daum I. Differential course of executive control changes during normal aging. Aging, Neuropsychology, and Cognition. 2007;14:370&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">17612814</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Bell L. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer&#x2019;s disease and rate of cognitive decline. Neurology. 2006;67:441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894105</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Blacker D, Moss MB, Tanzi R, McArdle JJ. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology. 2007;21:158&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">17402816</ArticleId></ArticleIdList></Reference><Reference><Citation>Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, Kaye JA. Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc. 2008;14:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">18282317</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Memory aging 18 to 80. Alzeimer Dis Assoc Disord. 2003;17:162&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512830</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke D, Mackay DG. Memory, language, and ageing. Phil Trans R Soc Lond B. 1997;352:1845&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692140</ArticleId><ArticleId IdType="pubmed">9460069</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of AD in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-McLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apolipoprotein E allele &#x3b5;4 with late onset familial and sporadic Alzheimer&#x2019;s disease. Neurol. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter LC, Caselli RJ, Johnson SC, Reiman E, Osborne D. Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer&#x2019;s disease. Neurobiol Aging. 2003 Nov;24(7):947&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928055</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004 Jun 8;62(11):1990&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184602</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64(9):1306&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846270</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Archives of Neurology. 2008;65:1231&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">18779428</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA. Age-related memory decline. Arch Neurol. 2001;58:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255438</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG. Memory function in normal aging. Neurol. 1992;42:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">1736173</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurol. 1999;52:1392&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20(suppl 3):S109&#x2013;S123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the mini-mental satae examination by age and education level. JAMA. 1993;269:2386&#x2013;2391.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th edition Oxford University Press; New York: 2004.</Citation></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition, Revised American Psychiatric Association; Washington DC: 1987.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer&#x2019;s disease. Neurol. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition American Psychiatric Association; Washington D.C.: 1994.</Citation></Reference><Reference><Citation>Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ, Malec JF. Mayo&#x2019;s Older Americans Normative Studies: age- and IQ- adjusted norms for the Auditory Verbal Learning Test and the Visual Spatial Learning Test. The Clinical Neuropsychologist. 2005;19:464&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">16120537</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L&#x2019;examen clinique en psychologie. Presses Universitaires; Paris: 1964.</Citation></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. John Wiley &amp; Sons, Inc.; Hoboken: 2004. (Section 15.4)</Citation></Reference><Reference><Citation>Ware JH, Dockery DW, Louis TA, XU X, Ferris BG, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiology. 1990;132:685&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">2403109</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-&#x3b2; burden in cognitively normal people homozygous for the apolipoprotein E &#x3b5;4 allele. (manuscript under review)</Citation></Reference><Reference><Citation>Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer&#x2019;s disease-related neurofibrillary changes. Exp Neurol. 1998;153:152&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743577</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol. 2000;157:2093&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885772</ArticleId><ArticleId IdType="pubmed">11106581</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal HA, Dickson D, Sliwinski M, Masur D, Blau A, Lipton RB. Associations of status and change measures of neuropsychological function with pathologic changes in elderly, originally nondemented subjects. Arch Neurol. 1996;53:82&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">8599564</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Helisalmi S, Mannermaa A, Soininen H. Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Ann NY Acad Sci. 2000;903:244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818513</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden DA. Healthy aging and dementia: findings from the nun study. Ann Intern Med. 2003;139:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12965975</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Resnick SM, Troncoso JC, An Y, O&#x2019;Brien R, Zonderman AB. Impact of Alzheimer&#x2019;s pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76:1194&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739810</ArticleId><ArticleId IdType="pubmed">16107349</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Mann D, Richard F, et al. IsAlzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2005;76:928&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739723</ArticleId><ArticleId IdType="pubmed">15965197</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsburgh K, McCarron MO, White F, et al. The role of apolipoprotein E in Alzheimer&#x2019;s disease, acute brain injury, and cerebrovascular disease: Evidence of common mechanisms and utility of animal models. Neurobiol Aging. 2000;21:245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867209</ArticleId></ArticleIdList></Reference><Reference><Citation>Olichney JM, Sabbagh MN, Hofstetter CR, et al. The impact of apolipoprotein E4 on cause of death in Alzheimer&#x2019;s disease. Neurology. 1997;49:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222173</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction detected at autopsy. Stroke. 2005;36:954&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Zandi PP, Lyketsos CG, et al. Apolipoprotein E genotype and mortality: findings from the Cache County Study. J Am Geriatr Soc. 2005;53:935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane KA, Gao S, Hui SL, Murrell JR, Hall KS, Hendrie HC. Apolipoprotein E and mortality in African-Americans and Yoruba. J Alzheimers Dis. 2003;5:383&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212028</ArticleId><ArticleId IdType="pubmed">14646029</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van Deerlin V, Yuan W, Bird TD. Early-onset Alzheimer disease families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol. 2006;63:1307&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16966510</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden DA. Healthy aging and dementia: findings from the nun study. Ann Intern Med. 2003;139:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12965975</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley LJ, Starr JM, Athawes R, Hunter D, Pattie A, Deary IJ. Childhood mental ability and dementia. Neurology. 2000;55:1455&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094097</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurn B, Deary IJ, Starr JM. Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia. Neurology. 2008;71:1051&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">18579804</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Hentz JG, Osborne D, et al. Apolipoprotein E and intellectual achievement. J Am Ger Soc. 2002;50:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12028246</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Hentz JG, Osborne D, Alexander GE, Boeve BF. A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes. Sleep. 2002;25:447&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071547</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Hentz JG, Osborne D, Alexander GE. A distinctive interaction between chronic anxiety and problem solving in asymptomatic APOE e4 homozygotes. J Neuropsychiatry Clin Neurosci. 2004;16:320&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19608551</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>20</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity.</ArticleTitle><Pagination><StartPage>3987</StartPage><EndPage>3996</EndPage><MedlinePgn>3987-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddp323</ELocationID><Abstract><AbstractText>ADAM10, a member of a disintegrin and metalloprotease family, is an alpha-secretase capable of anti-amyloidogenic proteolysis of the amyloid precursor protein. Here, we present evidence for genetic association of ADAM10 with Alzheimer's disease (AD) as well as two rare potentially disease-associated non-synonymous mutations, Q170H and R181G, in the ADAM10 prodomain. These mutations were found in 11 of 16 affected individuals (average onset age 69.5 years) from seven late-onset AD families. Each mutation was also found in one unaffected subject implying incomplete penetrance. Functionally, both mutations significantly attenuated alpha-secretase activity of ADAM10 (&gt;70% decrease), and elevated Abeta levels (1.5-3.5-fold) in cell-based studies. In summary, we provide the first evidence of ADAM10 as a candidate AD susceptibility gene, and report two potentially pathogenic mutations with incomplete penetrance for late-onset familial AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minji</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jaehong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Mimy H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Mullin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hooli</LastName><ForeName>Basavaraj</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tesco</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>K David</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH60009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19608551</ArticleId><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddp323</ArticleId><ArticleId IdType="pii">ddp323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saitoh T., Sundsmo M., Roch J.M., Kimura N., Cole G., Schubert D., Oltersdorf T., Schenk D.B. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell. 1989;58:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">2475254</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K., Sopher B.L., Rydel R.E., Begley J.G., Pham D.G., Martin G.M., Fox M., Mattson M.P. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 1996;67:1882&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H., Dodart J.C., Mathis C., Little S., Clemens J., Paul S.M., Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl Acad. Sci. USA. 1998;95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P., Guo Z.H., Geiger J.D. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J. Neurochem. 1999;73:532&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428048</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl Acad. Sci. USA. 1992;89:10075&#x2013;10078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50280</ArticleId><ArticleId IdType="pubmed">1359534</ArticleId></ArticleIdList></Reference><Reference><Citation>Checler F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 1995;65:1431&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7561836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills J., Reiner P.B. Mitogen-activated protein kinase is involved in N-methyl-D-aspartate receptor regulation of amyloid precursor protein cleavage. Neuroscience. 1999;94:1333&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">10625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso G.L., Gandy S.E., Buxbaum J.D., Ramabhadran T.V., Greengard P. Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Natl Acad. Sci. USA. 1992;89:3055&#x2013;3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48802</ArticleId><ArticleId IdType="pubmed">1557413</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J.D., Koo E.H., Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl Acad. Sci. USA. 1993;90:9195&#x2013;9198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47529</ArticleId><ArticleId IdType="pubmed">8415676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabuzda D., Busciglio J., Yankner B.A. Inhibition of beta-amyloid production by activation of protein kinase C. J. Neurochem. 1993;61:2326&#x2013;2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8245986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung A.Y., Haass C., Nitsch R.M., Qiu W.Q., Citron M., Wurtman R.J., Growdon J.H., Selkoe D.J. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. 1993;268:22959&#x2013;22962.</Citation><ArticleIdList><ArticleId IdType="pubmed">8226807</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen J.S., Spruyt M.A., Brown A.M., Sahasrabudhe S.R., Blume A.J., Vitek M.P., Muenkel H.A., Sonnenberg-Reines J. The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. J. Biol. Chem. 1994;269:8376&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pubmed">8132561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S., Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie. 1994;76:300&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7819339</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson T.M., Parkin E.T., Turner A.J., Hooper N.M. ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 2003;74:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D., de Strooper B., Serneels L., Craessaerts K., Herreman A., Annaert W., Umans L., Lubke T., Lena Illert A., von Figura K., et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 2002;11:2615&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354787</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 1998;273:27765&#x2013;27767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlos-Suarez A., Fernandez-Larrea J., Reddy P., Baselga J., Arribas J. Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing. J. Biol. Chem. 1998;273:24955&#x2013;24962.</Citation><ArticleIdList><ArticleId IdType="pubmed">9733803</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp G., Cai H., Brodie T.A., Higashyama S., Manova K., Ludwig T., Blobel C.P. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 2002;22:1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134708</ArticleId><ArticleId IdType="pubmed">11839819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Perez E., Zhang Y., Frank S.J., Creemers J., Seidah N., Checler F. Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10. J. Neurochem. 2001;76:1532&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11238737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl Acad. Sci. USA. 1999;96:3922&#x2013;3927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22396</ArticleId><ArticleId IdType="pubmed">10097139</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker M., Noe M.C., Carty T.J., Goodyer C.G., LeBlanc A.C. Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons. J. Neurochem. 2002;83:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472889</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlos-Suarez A., Ruiz-Paz S., Baselga J., Arribas J. Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J. Biol. Chem. 2001;276:48510&#x2013;48517.</Citation><ArticleIdList><ArticleId IdType="pubmed">11600492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahrenholz F., Postina R. Alpha-secretase activation&#x2014;an approach to Alzheimer's disease therapy. Neurodegener. Dis. 2006;3:255&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047365</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcinkiewicz M., Seidah N.G. Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J. Neurochem. 2000;75:2133&#x2013;2143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032903</ArticleId></ArticleIdList></Reference><Reference><Citation>Colciaghi F., Borroni B., Pastorino L., Marcello E., Zimmermann M., Cattabeni F., Padovani A., Di Luca M. &#x3b1;-secretase ADAM10 as well as &#x3b1;APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med. 2002;8:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039975</ArticleId><ArticleId IdType="pubmed">12080182</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 2004;113:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003;17:7&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514095</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl Acad. Sci. USA. 1990;87:5578&#x2013;5582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54368</ArticleId><ArticleId IdType="pubmed">2164689</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders A., Gilbert S., Garten W., Postina R., Fahrenholz F. Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 2001;15:1837&#x2013;1839.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 2008;83:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C., Harrell L.E., Perry R.T., Bassett S.S., Chase G., Meyers D., et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997;48:139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Hiltunen M., Parkinson M., Ingelsson M., Lange C., Ramasamy K., Mullin K., Menon R., Sampson A.J., Hsiao M.Y., et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N. Engl. J. Med. 2005;352:884&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">15745979</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe J.S., Jacquart S., Chakraverty S., Wang J., Mayo K., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuss M., Reiss K., Hartmann D. Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr. Alzheimer Res. 2008;5:187&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement A.B., Hanstein R., Schroder A., Nagel H., Endres K., Fahrenholz F., Behl C. Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress. Neuroscience. 2008;152:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276079</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky D.M., Moore D.B., Milla M.E., Doms R.W., Lee V.M. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 2000;275:2568&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Loechel F., Overgaard M.T., Oxvig C., Albrechtsen R., Wewer U.M. Regulation of human ADAM 12 protease by the prodomain. Evidence for a functional cysteine switch. J. Biol. Chem. 1999;274:13427&#x2013;13433.</Citation><ArticleIdList><ArticleId IdType="pubmed">10224107</ArticleId></ArticleIdList></Reference><Reference><Citation>Milla M.E., Leesnitzer M.A., Moss M.L., Clay W.C., Carter H.L., Miller A.B., Su J.L., Lambert M.H., Willard D.H., Sheeley D.M., et al. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE) J. Biol. Chem. 1999;274:30563&#x2013;30570.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521439</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard J.D., Lin F., Milla M.E. Chaperone-like properties of the prodomain of TNFalpha-converting enzyme (TACE) and the functional role of its cysteine switch. Biochem. J. 2005;387:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1135011</ArticleId><ArticleId IdType="pubmed">15581423</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D., Albert M.S., Bassett S.S., Go R.C., Harrell L.E., Folstein M.F. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch. Neurol. 1994;51:1198&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">7986174</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D., Bertram L., Saunders A.J., Moscarillo T.J., Albert M.S., Wiener H., Perry R.T., Collins J.S., Harrell L.E., Go R.C., et al. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum. Mol. Genet. 2003;12:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide B.M., McQueen M.B., Mullin K., Divito J., Hogan M.F., Parkinson M., Hooli B., Lange C., Blacker D., Tanzi R.E., et al. Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics. 2009;10:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841132</ArticleId><ArticleId IdType="pubmed">18830724</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C.P., Noble M.E. Dynamite extended: two new services to simplify protein dynamic analysis. Bioinformatics. 2005;21:3174&#x2013;3175.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher R.A. Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd; 1925.</Citation></Reference><Reference><Citation>Lichtenthaler S.F., Dominguez D.I., Westmeyer G.G., Reiss K., Haass C., Saftig P., De Strooper B., Seed B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1961359</PMID><DateCompleted><Year>1992</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>312</EndPage><MedlinePgn>295-312</MedlinePgn></Pagination><Abstract><AbstractText>Neurofibrillary tangles and senile plaques, together with cells immunoreactive for the Alz-50 antibody (A50-ir cells) or for an antibody against paired helical filaments (PHF-ir cells), and amyloid deposits stained with antibodies against beta-(or A4)-amyloid, have been mapped throughout the ventral forebrains of 25 old people. The cognitive status of each individual was assessed and a "Clinical Dementia Rating" (CDR) assigned, either before death in the Memory and Aging Project of Washington University, or by a postmortem interview, with an appropriate collateral source. The cases studied included 13 nondemented cases (CDR = 0), six very mildly to mildly demented cases (CDR = 0/0.5 to 1) and six more severely demented cases (CDR = 2 to 3). Because even the very mildly demented brains showed substantial pathological change, emphasis was placed on examining the nondemented cases for the earliest changes that could be associated with Alzheimer's disease. Different distributions were found for tangles and plaques. Tangles (and A50-ir and PHF-ir cells) were present in all of the brains examined. In the younger nondemented cases (aged 54 to 63) there were a few affected cells in the anterior olfactory nucleus and the parahippocampal gyrus. In older nondemented cases (aged 73-89) more tangles were found in the same areas, and also in hippocampal field CA1. The very mildly demented cases had many more tangles, but their distribution was similar. Only in the severely demented cases were large numbers of tangles present in the neocortex. In contrast, no plaques (or beta-amyloid immunoreactivity) were found in any of the younger nondemented cases or in four of the eight older nondemented cases. In three older nondemented cases there were a few primitive plaques, which were restricted to localized regions of the neocortex (e.g., a portion of the inferior temporal cortex). In one nondemented case and all of the very mildly to mildly demented cases there were very large numbers of mostly primitive plaques, particularly in the neocortex. With greater severity of dementia there is a shift from primitive to mature plaques. These results were interpreted to imply that the first development of tangles and plaques occurs in different parts of the brain. Tangles appear during aging in the anterior olfactory nucleus, the parahippocampal gyrus and the hippocampus, but are rare in the neocortex except in demented brains. Conversely plaques may develop first in the neocortex. Unlike tangles, plaques are not a consistent feature of aging, at least up to age 80.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>P B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH10104</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG0 3991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG0 5681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId><ArticleId IdType="doi">10.1016/0197-4580(91)90006-6</ArticleId><ArticleId IdType="pii">0197-4580(91)90006-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19615450</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>681</EndPage><MedlinePgn>668-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2009.07.011</ELocationID><Abstract><AbstractText>Tensor-based morphometry (TBM) is a powerful method to map the 3D profile of brain degeneration in Alzheimer's disease (AD) and mild cognitive impairment (MCI). We optimized a TBM-based image analysis method to determine what methodological factors, and which image-derived measures, maximize statistical power to track brain change. 3D maps, tracking rates of structural atrophy over time, were created from 1030 longitudinal brain MRI scans (1-year follow-up) of 104 AD patients (age: 75.7+/-7.2 years; MMSE: 23.3+/-1.8, at baseline), 254 amnestic MCI subjects (75.0+/-7.2 years; 27.0+/-1.8), and 157 healthy elderly subjects (75.9+/-5.1 years; 29.1+/-1.0), as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI). To determine which TBM designs gave greatest statistical power, we compared different linear and nonlinear registration parameters (including different regularization functions), and different numerical summary measures derived from the maps. Detection power was greatly enhanced by summarizing changes in a statistically-defined region-of-interest (ROI) derived from an independent training sample of 22 AD patients. Effect sizes were compared using cumulative distribution function (CDF) plots and false discovery rate methods. In power analyses, the best method required only 48 AD and 88 MCI subjects to give 80% power to detect a 25% reduction in the mean annual change using a two-sided test (at alpha=0.05). This is a drastic sample size reduction relative to using clinical scores as outcome measures (619 AD/6797 MCI for the ADAS-Cog, and 408 AD/796 MCI for the Clinical Dementia Rating sum-of-boxes scores). TBM offers high statistical power to track brain changes in large, multi-site neuroimaging studies and clinical trials of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, Los Angeles, CA 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yanovsky</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Leow</LastName><ForeName>Alex D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Yi-Yu</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>April J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Gutman</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matt A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM05639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM005639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017711" MajorTopicYN="N">Nonlinear Dynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19615450</ArticleId><ArticleId IdType="mid">NIHMS138765</ArticleId><ArticleId IdType="pmc">PMC2971697</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2009.07.011</ArticleId><ArticleId IdType="pii">S1053-8119(09)00771-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aganj I, Sapiro G, Parikshak N, Madsen SK, Thompson PM. Measurement of cortical thickness from MRI by minimum line integrals on soft-classified tissue. Hum Brain Mapp. 2009 Feb 13; electronic publication ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903209</ArticleId><ArticleId IdType="pubmed">19219850</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander DC, Pierpaoli C, Basser PJ, Gee JC. Spatial transformations of diffusion tensor magnetic resonance images. IEEE Trans Med Imaging. 2001;20:1131&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700739</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Chen K, Reiman EM, Aschenbrenner M, Merkley TL, Hanson KD, Dale AM, Bernstein MA, Kornak J, Schuff N, Fox NC, Thompson PM, Weiner MW, Jack CR., Jr Regional gray matter reductions in Alzheimer&#x2019;s dementia and amnestic mild cognitive impairment: preliminary findings from the Alzheimer&#x2019;s Disease Neuroimaging Initiative using voxel-based morphometry. Alzheimer&#x2019;s Association International Conference on the Prevention of Dementia; Washington, DC. 2007.</Citation></Reference><Reference><Citation>Alexander GE, Hanson KD, Chen K, Reiman EM, Bernstein MA, Kornak J, Schuff N, Fox NC, Thompson PM, Weiner MW, Jack CR. Six month MRI gray matter declines in Alzheimer&#x2019;s dementia evaluated by voxel-based morphometry with multivariate network analysis: preliminary findings from the ADNI study. International Conference on Alzheimer&#x2019;s Disease; Chicago. 2008.</Citation></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2014;the methods. NeuroImage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Morphometry. Human Brain Function. 2003 Academic Press.</Citation></Reference><Reference><Citation>Beckett L, Harvey D, Zhang H. ADNI preliminary results, July 2008: comparative and longitudinal results. Presentation to Industry Scientific Advisory Board (ISAB) at International Conference on Alzheimer&#x2019;s Disease (ICAD); Chicago, IL. 2008.</Citation></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;B 57(1):289&#x2013;300.</Citation></Reference><Reference><Citation>Berg L. Clinical dementia rating (CDR) Psychopharmacol Bull. 1988;24:637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyes RG, Gunter JL, Frost C, Janke AL, Yeatman T, Hill DL, Bernstein MA, Thompson PM, Weiner MW, Schuff N, Alexander GE, Killiany RJ, DeCarli C, Jack CR, Fox NC. Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage. 2008;39:1752&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562663</ArticleId><ArticleId IdType="pubmed">18063391</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM. Plaque and tangle imaging and cognition in normal aging and Alzheimer&#x2019;s disease. Neurobiol Aging. 2008 Nov 10; electronic publication ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891885</ArticleId><ArticleId IdType="pubmed">19004525</ArticleId></ArticleIdList></Reference><Reference><Citation>Broit C. Optimal registration of deformed images (PhD thesis) University of Pennsylvania; 1981.</Citation></Reference><Reference><Citation>Brun CC, Lepore N, Pennec X, Chou YY, Lee AD, Barysheva M, de Zubicaray GI, McMahon KL, Wright MJ, Toga AW, Thompson PM. A Lagrangian formulation for statistical fluid registration. In: Karl WC, Rosen B, Brooks D, editors. Proceedings of the Sixth IEEE International Symposium on Biomedical Imaging (ISBI2009); Boston, MA. Piscataway, NJ: IEEE; 2009a. pp. 975&#x2013;978. 2009, to appear.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6291211</ArticleId><ArticleId IdType="pubmed">30555621</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun CC, Lepore N, Pennec X, Chou YY, Lee AD, de Zubicaray GI, McMahon KL, Wright MJ, Toga AW, Thompson PM. Medical Image Computing and Computer Assisted Intervention (MICCAI2009) London, UK: 2009b. 3D registration in the Lagrangian framework&#x2014;application to the genetics of brain shape.</Citation></Reference><Reference><Citation>Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structuralMR images of the brain. IEEE Trans Med Imaging. 1999;18:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael OT, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, Kuller LH, Lopez OL, Aizenstein HJ, Meltzer CC, Liu Y, Toga AW, Becker JT. Mapping ventricular changes related to dementia and mild cognitive impairment in a large community-based cohort. IEEE ISBI. 2006:315&#x2013;318.</Citation></Reference><Reference><Citation>Chen K, Reschke C, Lee W, Napatkamon A, Liu X, Bandy D, Langbaum J, Alexander GE, Foster NL, Koeppe RA, Jagust WJ, Weiner MW, Reiman EM. Cross-sectional and longitudinal analyses of fluorodeoxyglucose positron emission tomography images from the Alzheimer&#x2019;s disease neuroimaging initiative. ADNI Data Presentations Meeting; Seattle, WA. 2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886795</ArticleId><ArticleId IdType="pubmed">19349228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Dutton RA, Hayashi KM, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. NeuroImage. 2007a;34:44&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197835</ArticleId><ArticleId IdType="pubmed">17035049</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Reiss AL, Lee AD, Bellugi U, Galaburda AM, Korenberg JR, Mills DL, Toga AW, Thompson PM. 3D pattern of brain abnormalities in Williams syndrome visualized using tensor-based morphometry. Neuroimage. 2007b;36:1096&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713103</ArticleId><ArticleId IdType="pubmed">17512756</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, de Zubicaray GI, Carmichael OT, Becker JT, Toga AW, Thompson PM. Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer&#x2019;s disease. NeuroImage. 2008;40:615&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720413</ArticleId><ArticleId IdType="pubmed">18222096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment and elderly controls. NeuroImage. 2009a;46:394&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696357</ArticleId><ArticleId IdType="pubmed">19236926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepor&#xe9; N, Avedissian C, Madsen SK, Barysheva M, Hua X, Jack CR, Jr, Weiner MW, Toga AW, Thompson PM and the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Mapping ventricular expansion and its clinical correlates in Alzheimer&#x2019;s disease and mild cognitive impairment using multi-atlas fluid image alignment. SPIE Medical Imaging; Lake Buena Vista, Florida: 2009b. Feb, pp. 7&#x2013;12.</Citation></Reference><Reference><Citation>Chung MK, Worsley KJ, Paus T, Cherif C, Collins DL, Giedd JN, Rapoport JL, Evans AC. A unified statistical approach to deformation-based morphometry. NeuroImage. 2001;14:595&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506533</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003;138:400&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614093</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockrell JR, Folstein MF. Mini-mental state examination (MMSE) Psychopharmacol Bull. 1988;24:689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249771</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson MJ, Ourselin S, Nielsen C, Leung KK, Barnes J, Whitwell JL, Gunter JL, Hill DL, Weiner MW, Jack CR, Jr, Fox NC. Comparison of phantom and registration scaling corrections using the ADNI cohort. Neuroimage. 2009 electronic publication online before print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800076</ArticleId><ArticleId IdType="pubmed">19477282</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126267</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593169</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer&#x2019;s disease. NeuroRx. 2005;2:348&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1064996</ArticleId><ArticleId IdType="pubmed">15897955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarini L, Palm WM, Olofsen H, van der Landen R, van Buchem MA, Reiber JH, Admiraal-Behloul F. Ventricular shape biomarkers for Alzheimer&#x2019;s disease in clinical MR images. Magn Reson Med. 2008;59:260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">18228600</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillard P, Arsigny V, Pennec X, Thompson PM, Ayache N. Extrapolation of sparse tensor fields: application to the modeling of brain variability. Information Processing in Medical Imaging (IPMI); Glenwood Springs, Colorado: 2005. pp. 644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354682</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillard P, Arsigny V, Pennec X, Hayashi KM, Thompson PM, Ayache N. Measuring brain variability by extrapolating sparse tensor fields measured on sulcal lines. NeuroImage. 2007;34:639&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113311</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H. Drug discovery and the prevention of Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:S26&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer&#x2019;s disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358:201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC. Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr. 1998;22:838&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee JC. On matching brain volumes. Pattern Recogn. 1999;32:99&#x2013;111.</Citation></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer&#x2019;s disease. J Alzheimers Dis. 2006;9:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914872</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogtay N, Lu A, Leow AD, Klunder AD, Lee AD, Chavez A, Greenstein D, Giedd JN, Toga AW, Rapoport JL, Thompson PM. Three-dimensional brain growth abnormalities in childhood-onset schizophrenia visualized by using tensor-based morphometry. Proc Natl Acad Sci U S A. 2008;105:15979&#x2013;15984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566993</ArticleId><ArticleId IdType="pubmed">18852461</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Jr, Rubin EH, Morris JC. Absence of cognitive impairment or decline in preclinical Alzheimer&#x2019;s disease. Neurology. 2001;56:361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171902</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenander U, Miller MI. Computational anatomy: an emerging discipline. Q Appl Math LVI. 1998:617&#x2013;694.</Citation></Reference><Reference><Citation>Grundman M, Sencakova D, Jack CR, Jr, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002;19:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212787</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter J, Bernstein M, Borowski B, Felmlee J, Blezek D, Mallozzi R. Validation testing of the MRI calibration phantom for the Alzheimer&#x2019;s Disease Neuroimaging Initiative study. ISMRM 14th Scientific Meeting and Exhibition 2006</Citation></Reference><Reference><Citation>Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, Cotman CW. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology. 2003;61:1673&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694028</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Neurotherapeutics. 2009;6:128&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084261</ArticleId><ArticleId IdType="pubmed">19110204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Hua X, Lee S, Yanovsky I, Leow AD, Gutman B, Dinov ID, Toga AW, Jack CR, Jr, Bernstein MA, Reiman EM, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM. Comparing 3 T and 1.5 T MRI for tracking AD progression with tensor-based morphometry. NeuroImage. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875376</ArticleId><ArticleId IdType="pubmed">19780044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, Jack CR, Jr, Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Thompson PM Alzheimer&#x2019;s Disease Neuroimaging, I. 3D characterization of brain atrophy in Alzheimer&#x2019;s disease and mild cognitive impairment using tensor-based morphometry. NeuroImage. 2008a;41:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556222</ArticleId><ArticleId IdType="pubmed">18378167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer&#x2019;s disease: an MRI study of 676 AD, MCI, and normal subjects. NeuroImage. 2008b;43:458&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197851</ArticleId><ArticleId IdType="pubmed">18691658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Levitt JG, Caplan R, Thompson PM, Toga AW. Detecting brain growth patterns in normal children using tensor-based morphometry. Hum Brain Mapp. 2009;30:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975704</ArticleId><ArticleId IdType="pubmed">18064588</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivinson AJ, Lane R, May PC, Hosford DA, Carrillo MC, Siemers ER. Partnership between academia and industry for drug discovery in Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:80&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631952</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O Brien PC, Cha R, Knopman D, Petersen RC. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003;60:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745302</ArticleId><ArticleId IdType="pubmed">12552040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Gunter JL, O Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, O Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, J LW, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008a;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008b;29:1285&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768818</ArticleId><ArticleId IdType="pubmed">17452062</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Alzheimer 100&#x2014;highlights in the history of Alzheimer research. J Neural Transm. 2006;113:1603&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pubmed">17039299</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J, Fischl B, Dale A. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300968</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow A, Huang SC, Geng A, Becker JT, Davis S, Toga AW, Thompson PM. Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Information Processing in Medical Imaging; Glenwood Springs, Colorado, USA: 2005. pp. 493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Chiang MC, Becker JT, Davis SW, Toga AW, Thompson PM. Realizing unbiased deformation: a theoretical consideration. 9th IEEE Conference on Medical Image Computer and Computer Assisted Intervention (MICCAI), MICCAI2006 Workshop on Mathematical Foundations of Computational Anatomy; Copenhagen, Denmark. 2006a.</Citation></Reference><Reference><Citation>Leow AD, Klunder AD, Jack CR, Jr, Toga AW, Dale AM, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Whitwell JL, Borowski BJ, Fleisher AS, Fox NC, Harvey D, Kornak J, Schuff N, Studholme C, Alexander GE, Weiner MW, Thompson PM. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. NeuroImage. 2006b;31:627&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941663</ArticleId><ArticleId IdType="pubmed">16480900</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Yanovsky I, Chiang MC, Lee AD, Klunder AD, Lu A, Becker JT, Davis SW, Toga AW, Thompson PM. Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration. IEEE Trans Med Imaging. 2007;26:822&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">17679333</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR, Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Borowski B, Shaw LM, Trojanowski JQ, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM. Alzheimer&#x2019;s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. NeuroImage. 2009;45:645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696624</ArticleId><ArticleId IdType="pubmed">19280686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore N, Brun C, Chou YY, Chiang MC, Dutton RA, Hayashi KM, Luders E, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. Generalized tensor-based morphometry of HIV/AIDS using multivariate statistics on deformation tensors. IEEE Trans Med Imaging. 2008;27:129&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832297</ArticleId><ArticleId IdType="pubmed">18270068</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, MacDonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, Narr K, Kabani N, Le Goualher G, Boomsma D, Cannon T, Kawashima R, Mazoyer B. Aprobabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356:1293&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. NeuroImage. 2009;44:1415&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648825</ArticleId><ArticleId IdType="pubmed">19027862</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer&#x2019;s disease mild cognitive impairment, and elderly controls. NeuroImage. 2008;43:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624575</ArticleId><ArticleId IdType="pubmed">18675918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra J, Tu Z, Toga AW, Thompson PM. Machine learning for brain image segmentation. In: Gonzalez F, Romero E, editors. Tutorial Chapter in Textbook: Biomedical Image Analysis and Machine Learning Technologies. 2009a. to appear: 2009.</Citation></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Jr, Schuff N, Weiner MW, Thompson PM. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp 2009b</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733926</ArticleId><ArticleId IdType="pubmed">19172649</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Toga AW, Jack CR, Jr, Schuff N, Weiner MW, Thompson PM. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment, and elderly controls. NeuroImage. 2009c;45:S3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733354</ArticleId><ArticleId IdType="pubmed">19041724</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005a;15:869&#x2013;877. xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2005b;1:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Schuff N, Weiner MW. Evaluation of treatment effects in Alzheimer&#x2019;s and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 2006;19:655&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820857</ArticleId><ArticleId IdType="pubmed">16986115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Paling SM, Williams ED, Barber R, Burton EJ, Crum WR, Fox NC, O Brien JT. The application of serial MRI analysis techniques to the study of cerebral atrophy in late-onset dementia. Med Image Anal. 2004;8:69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14644147</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Aging, mild cognitive impairment, and Alzheimer&#x2019;s disease. Neurol Clin. 2000;18:789&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072261</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG. Memory function in very early Alzheimer&#x2019;s disease. Neurology. 1994;44:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190289</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS. Brain imaging in the evaluation of putative Alzheimer&#x2019;s disease slowing, risk-reducing and prevention therapies. In: Jagust W, D&#x2019;Esposito M, editors. Imaging and the Aging Brain. Oxford University Press; New York: in press.</Citation></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Ayutyanont N, Bandy D, Lee W, Reschke C, Alexander GE, Weiner MW, Koeppe RA, Jagust WJ. Twelve-Month Cerebral Metabolic Declines in Probable Alzheimer&#x2019;s Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer&#x2019;s Disease Neuroimaging Initiative. ICAD; Chicago, Illinois: 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle WR, Li R, Fitzpatrick JM, DonLevy SC, Dawant BM, Price RR. Characterizing changes in MR images with color-coded Jacobians. Magn Reson Imaging. 2004;22:769&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234445</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner B. Fundamentals of Biostatistics. PWS-Kent Publishing Company; Boston: 1990.</Citation></Reference><Reference><Citation>Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849541</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Jr, Weiner MW. MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(Pt 4):1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shattuck DW, Leahy RM. BrainSuite: an automated cortical surface identification tool. Med Image Anal. 2002;6:129&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">12045000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D, Davatzikos C. HAMMER: hierarchical attribute matching mechanism for elastic registration. IEEE Trans Med Imaging. 2002;21:1421&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12575879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity inMRI data. IEEE Trans Med Imaging. 1998;17:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD. A direct approach to false discovery rates. J R Stat Soc. 2002;B 64(Pt. 3):479&#x2013;498.</Citation></Reference><Reference><Citation>Studholme C, Cardenas V, Schuff N, Rosen H, Miller B, Weiner M. Detecting spatially consistent structural differences in Alzheimer&#x2019;s and fronto temporal dementia using deformation morphometry. MICCAI. 2001:41&#x2013;48.</Citation></Reference><Reference><Citation>Studholme C, Cardenas V, Maudsley A, Weiner M. An intensity consistent filtering approach to the analysis of deformation tensor derived maps of brain shape. NeuroImage. 2003;19:1638&#x2013;1649.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948718</ArticleId></ArticleIdList></Reference><Reference><Citation>Studholme C, Drapaca C, Cardenas V. Intensity robust viscous fluid deformation based morphometry using regionally adapted mutual information. Conf Proc IEEE Eng Med Biol Soc. 2005;1:470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">17282218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, van Erp TGM, Thompson PM, Bearden CE, Daley M, Kushan L, Hardt ME, Nuechterlein K, Toga AW, Cannon TD. Elucidating an MRI-based biomarker for psychosis: classification using probabilistic brain atlas and machine learning algorithms. Biological Psychiatry. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192809</ArticleId><ArticleId IdType="pubmed">19729150</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Giedd JN, Woods RP, MacDonald D, Evans AC, Toga AW. Growth patterns in the developing brain detected by using continuum mechanical tensor maps. Nature. 2000;404:190&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">10724172</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer&#x2019;s disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW. Mapping hippocampal and ventricular change in Alzheimer disease. NeuroImage. 2004a;22:1754&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15275931</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, Sowell ER, Gogtay N, Giedd JN, Rapoport JL, de Zubicaray GI, Janke AL, Rose SE, Semple J, Doddrell DM, Wang Y, van Erp TG, Cannon TD, Toga AW. Mapping cortical change in Alzheimer&#x2019;s disease, brain development, and schizophrenia. NeuroImage. 2004b;23(Suppl 1):S2&#x2013;S18.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501091</ArticleId></ArticleIdList></Reference><Reference><Citation>Toga AW. Brain Warping. 1. Academic Press; San Diego: 1999.</Citation></Reference><Reference><Citation>Tosun D, Schuff N, Raptentsetsang S, Truran-Sacrey D, Weiner MW. Regional Rates of Brain Atrophy in Correlation to Cognitive Decline and Biomarker Concentrations. Seattle, WA. ADNI Data Presentations Meeting.2009.</Citation></Reference><Reference><Citation>Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401889</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanovsky I, Chiang MC, Thompson PM, Klunder AD, Becker JT, Davis SW, Toga AW, Leow AD. Quantifying deformation using information theory: the logunbiased nonlinear registration. IEEE Int Symp Biomed Imaging (ISBI) 2007a:13&#x2013;16.</Citation></Reference><Reference><Citation>Yanovsky I, Thompson PM, Osher SJ, Leow AD. Topology preserving logunbiased nonlinear image registration: theory and implementation. IEEE Computer Society Conference on Computer Vision and Pattern Recognition (CVPR) 2007b</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687076</ArticleId><ArticleId IdType="pubmed">29152411</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanovsky I, Thompson P, Osher S, Leow AD. Asymmetric and symmetric unbiased image registration: statistical assessment of performance. IEEE Computer Society Workshop On Mathematical Methods in Biomedical Image Analysis. 2008a;1:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687076</ArticleId><ArticleId IdType="pubmed">29152411</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanovsky I, Thompson PM, Osher SJ, Hua X, Shattuck DW, Toga AW, Leow AD. Validating unbiased registration on longitudinal MRI scans from the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) IEEE International Symposium on Biomedical Imaging (ISBI) 2008b:1091&#x2013;1094.</Citation></Reference><Reference><Citation>Yanovsky I, Leow AD, Lee S, Osher SJ, Thompson PM. Comparing registration methods for mapping brain change using tensor-based morphometry. Medical Image Analysis. 2009 doi: 10.1016/j.media.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2009.06.002</ArticleId><ArticleId IdType="pmc">PMC2773147</ArticleId><ArticleId IdType="pubmed">19631572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Wu T, Bae M, Reiman EM, Alexander GE, Jack CR, Jr, Thompson PM, Chen K. Use of the Support Vector Machine and Sensitivity of an AD-Related Region-of-Interest Gray Matter Classifier in Identifying Amnestic MCI Subjects Who Convert to AD: Preliminary Findings from the AD Neuroimaging Initiative. Chicago. International Conference on Alzheimer&#x2019;s Disease.2008.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19622727</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>31</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation.</ArticleTitle><Pagination><StartPage>12926</StartPage><EndPage>12931</EndPage><MedlinePgn>12926-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0903200106</ELocationID><Abstract><AbstractText>Despite the importance of the aberrant polymerization of Abeta in the early pathogenic cascade of Alzheimer's disease, little is known about the induction of Abeta aggregation in vivo. Here we show that induction of cerebral beta-amyloidosis can be achieved in many different brain areas of APP23 transgenic mice through the injection of dilute Abeta-containing brain extracts. Once the amyloidogenic process has been exogenously induced, the nature of the induced Abeta-deposition is determined by the brain region of the host. Because these observations are reminiscent of a prion-like mechanism, we then investigated whether cerebral beta-amyloidosis also can be induced by peripheral and systemic inoculations or by the intracerebral implantation of stainless steel wires previously coated with minute amounts of Abeta-containing brain extract. Results reveal that oral, intravenous, intraocular, and intranasal inoculations yielded no detectable induction of cerebral beta-amyloidosis in APP23 transgenic mice. In contrast, transmission of cerebral beta-amyloidosis through the Abeta-contaminated steel wires was demonstrated. Notably, plasma sterilization, but not boiling of the wires before implantation, prevented the induction of beta-amyloidosis. Our results suggest that minute amounts of Abeta-containing brain material in direct contact with the CNS can induce cerebral beta-amyloidosis, but that systemic cellular mechanisms of prion uptake and transport to the CNS may not apply to Abeta.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eisele</LastName><ForeName>Yvonne S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, D-72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolmont</LastName><ForeName>Tristan</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Heikenwalder</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>Franziska</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Zheng-Xin</ForeName><Initials>ZX</Initials></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Aguzzi</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19622727</ArticleId><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="doi">10.1073/pnas.0903200106</ArticleId><ArticleId IdType="pii">0903200106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685251</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla J, et al. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell. 2008;134:757&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740631</ArticleId><ArticleId IdType="pubmed">18775309</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, et al. Synthetic mammalian prions. Science. 2004;305:673&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286374</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Sigurdson C, Heikenwalder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol. 2008;3:11&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18233951</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prion Biology and Diseases. 2nd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Lab Press; 2004.</Citation></Reference><Reference><Citation>Legname G, et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci USA. 2006;103:19105&#x2013;19110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748184</ArticleId><ArticleId IdType="pubmed">17142317</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Levine H, 3rd, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci. 2006;29:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725716</ArticleId><ArticleId IdType="pubmed">16806508</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark P, Westermark GT. Review: Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc London B. 2008;363:3701&#x2013;3705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735507</ArticleId><ArticleId IdType="pubmed">18849285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane MD, et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci. 2000;20:3606&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772682</ArticleId><ArticleId IdType="pubmed">10804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-L&#xfc;hmann M, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate: Comparison with transmission of spongiform encephalopathy. Mol Neurobiol. 1994;8:25&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8086126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridley RM, Baker HF, Windle CP, Cummings RM. Very-long-term studies of the seeding of beta-amyloidosis in primates. J Neural Transm. 2006;113:1243&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362635</ArticleId></ArticleIdList></Reference><Reference><Citation>Riek R. Cell biology: Infectious Alzheimer's disease? Nature. 2006;444:429&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">17122841</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L, Levine H, Jucker M. Koch's postulates and infectious proteins. Acta Neuropathol. 2006;112:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544537</ArticleId><ArticleId IdType="pubmed">16703338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat Rev Microbiol. 2006;4:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462753</ArticleId></ArticleIdList></Reference><Reference><Citation>Blattler T, et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature. 1997;389:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernoulli C, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet. 1977;i(8009):478&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">65575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs CJ, Jr, et al. Transmission of Creutzfeldt-Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery. J Neurol Neurosurg Psychiatry. 1994;57:757&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072988</ArticleId><ArticleId IdType="pubmed">8006664</ArticleId></ArticleIdList></Reference><Reference><Citation>Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med. 1999;5:240&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230327</ArticleId><ArticleId IdType="pubmed">10448646</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig E, et al. Transmission of scrapie by steel-surface-bound prions. Mol Med. 2001;7:679&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949999</ArticleId><ArticleId IdType="pubmed">11713367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, et al. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006;2006:re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19002474</ArticleId></ArticleIdList></Reference><Reference><Citation>McKintosh E, Tabrizi SJ, Collinge J. Prion diseases. J Neurovirol. 2003;9:183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707849</ArticleId></ArticleIdList></Reference><Reference><Citation>Belay ED, Schonberger LB. The public health impact of prion diseases. Annu Rev Public Health. 2005;26:191&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760286</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol. 2009;144:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18950452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JD, Collinge J. Update on human prion disease. Biochim Biophys Acta. 2007;1772:598&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">17408929</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Sigurdson CJ. Antiprion immunotherapy: To suppress or to stimulate? Nat Rev Immunol. 2004;4:725&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">15343371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbriccoli M, et al. Neuroinvasion of the 263K scrapie strain after intranasal administration occurs through olfactory-unrelated pathways. Acta Neuropathol. 2009;117:175&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">19107494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartz JC, Kincaid AE, Bessen RA. Rapid prion neuroinvasion following tongue infection. J Virol. 2003;77:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140623</ArticleId><ArticleId IdType="pubmed">12477862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kincaid AE, Bartz JC. The nasal cavity is a route for prion infection in hamsters. J Virol. 2007;81:4482&#x2013;4491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900180</ArticleId><ArticleId IdType="pubmed">17301140</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandner S, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996;379:339&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552188</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandner S, et al. Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proc Natl Acad Sci USA. 1996;93:13148&#x2013;13151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24061</ArticleId><ArticleId IdType="pubmed">8917559</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimazawa M, et al. Reduced retinal function in amyloid precursor protein-overexpressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem. 2008;107:279&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">18691390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49:5136&#x2013;5143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947384</ArticleId><ArticleId IdType="pubmed">18566467</ArticleId></ArticleIdList></Reference><Reference><Citation>Johan K, et al. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA. 1998;95:2558&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19412</ArticleId><ArticleId IdType="pubmed">9482925</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundmark K, Westermark GT, Olsen A, Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci USA. 2005;102:6098&#x2013;6102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087940</ArticleId><ArticleId IdType="pubmed">15829582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X, et al. Induction of AApoAII amyloidosis by various heterogeneous amyloid fibrils. FEBS Lett. 2004;563:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">15063745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan ZX, Stitz L, Heeg P, Pfaff E, Roth K. Infectivity of prion protein bound to stainless steel wires: A model for testing decontamination procedures for transmissible spongiform encephalopathies. Infect Control Hosp Epidemiol. 2004;25:280&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15108723</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19625522</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>29</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>9321</StartPage><EndPage>9329</EndPage><MedlinePgn>9321-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4736-08.2009</ELocationID><Abstract><AbstractText>Downregulation of brain-derived neurotrophic factor (BDNF) in the cortex occurs early in the progression of Alzheimer's disease (AD). Since BDNF plays a critical role in neuronal survival, synaptic plasticity, and memory, BDNF reduction may contribute to synaptic and cellular loss and memory deficits characteristic of AD. In vitro evidence suggests that amyloid-beta (A beta) contributes to BDNF downregulation in AD, but the specific A beta aggregation state responsible for this downregulation in vivo is unknown. In the present study, we examined cortical levels of BDNF mRNA in three different transgenic AD mouse models harboring mutations in APP resulting in A beta overproduction, and in a genetic mouse model of Down syndrome. Two of the three A beta transgenic strains (APP(NLh) and TgCRND8) exhibited significantly decreased cortical BDNF mRNA levels compared with wild-type mice, whereas neither the other strain (APP(swe)/PS-1) nor the Down syndrome mouse model (Ts65Dn) was affected. Only APP(NLh) and TgCRND8 mice expressed high A beta(42)/A beta(40) ratios and larger SDS-stable A beta oligomers (approximately 115 kDa). TgCRND8 mice exhibited downregulation of BDNF transcripts III and IV; transcript IV is also downregulated in AD. Furthermore, in all transgenic mouse strains, there was a correlation between levels of large oligomers, A beta(42)/A beta(40), and severity of BDNF decrease. These data show that the amount and species of A beta vary among transgenic mouse models of AD and are negatively correlated with BDNF levels. These findings also suggest that the effect of A beta on decreased BDNF expression is specific to the aggregation state of A beta and is dependent on large oligomers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Shiyong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario L8N 3Z5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzon</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Marchese</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Beverly M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Mount</LastName><ForeName>Howard T J</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>Mufson</LastName><ForeName>Elliott J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Salehi</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fahnestock</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS043939</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>85042</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">CAMS2275</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19625522</ArticleId><ArticleId IdType="mid">CAMS2275</ArticleId><ArticleId IdType="pmc">PMC3411546</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4736-08.2009</ArticleId><ArticleId IdType="pii">29/29/9321</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007;85:525&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878509</ArticleId><ArticleId IdType="pubmed">17149751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando S, Kobayashi S, Waki H, Kon K, Fukui F, Tadenuma T, Iwamoto M, Takeda Y, Izumiyama N, Watanabe K, Nakamura H. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J Neurosci Res. 2002;70:519&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, Casamenti F. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis. 2006;23:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766197</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol. 2005;76:99&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">16099088</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993;259:514&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">8424174</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH, Lee JP, Park CH, Kim S, Baik TK, Suh YH. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol. 2006;26:4327&#x2013;4338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489099</ArticleId><ArticleId IdType="pubmed">16705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360:672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark RF, Goate AM. Molecular genetics of Alzheimer's disease. Arch Neurol. 1993;50:1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8215975</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res. 1997;49:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9387865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyrks T, Dyrks E, Masters CL, Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 1993;324:231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">8508926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Mar&#xed;n C, Rey MJ, Ribalta T, Goutan E, Blanco R, Tolosa E, Mart&#xed; E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 1999;58:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411343</ArticleId></ArticleIdList></Reference><Reference><Citation>Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, Savage MJ, Annaert WG, De Strooper B, Siman R, Scott RW. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging. 2002;23:335&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959395</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neurochem. 2002;82:1058&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358753</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci. 2007;27:2628&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672502</ArticleId><ArticleId IdType="pubmed">17344400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 1994;263:1618&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med. 1995;1:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867782</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res. 2000;76:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762711</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A. 1996;93:13333&#x2013;13338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24093</ArticleId><ArticleId IdType="pubmed">8917591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol Aging. 1997;18:S27&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330982</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs AM, Senn DB, Yuan M, Shine JP, Yankner BA. Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. J Biol Chem. 2006;281:27916&#x2013;27923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1595535</ArticleId><ArticleId IdType="pubmed">16870617</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Schuman EM. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science. 1996;273:1402&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703078</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kn&#xfc;sel B, Beck KD, Winslow JW, Rosenthal A, Burton LE, Widmer HR, Nikolics K, Hefti F. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci. 1992;12:4391&#x2013;4402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576000</ArticleId><ArticleId IdType="pubmed">1432101</ArticleId></ArticleIdList></Reference><Reference><Citation>Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A. 1995;92:8856&#x2013;8860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41066</ArticleId><ArticleId IdType="pubmed">7568031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt MA, Davies DC, Kidd M, Duff K, Rolph SC, Jennings KH, Howlett DR. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp Neurol. 2001;171:59&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem. 2004;335:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25:273&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowenstein DH, Arsenault L. The effects of growth factors on the survival and differentiation of cultured dentate gyrus neurons. J Neurosci. 1996;16:1759&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578675</ArticleId><ArticleId IdType="pubmed">8774444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron. 2003;39:735&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948441</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 1999;22:295&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202541</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis. 1999;6:231&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448051</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767098</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsis M, Timmusk T, Arenas E, Persson H. Differential usage of multiple brain-derived neurotrophic factor promoters in the rat brain following neuronal activation. Proc Natl Acad Sci U S A. 1993;90:8802&#x2013;8806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47448</ArticleId><ArticleId IdType="pubmed">8415610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res. 2007;4:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron. 1996;16:1137&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8663990</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem. 2005;93:1412&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935057</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 1991;7:695&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">1742020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing and multiple promoters. Genomics. 2007;90:397&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2568880</ArticleId><ArticleId IdType="pubmed">17629449</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a &#x201c;humanized&#x201d; Abeta sequence. J Biol Chem. 1996;271:23380&#x2013;23388.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798542</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11:177&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7550346</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm. 2003;110:1313&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14628195</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:10836&#x2013;10840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol. 2004;165:937&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618605</ArticleId><ArticleId IdType="pubmed">15331417</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 1998;20:727&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581764</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev. 2000;33:199&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11011066</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci. 1998;21:127&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530494</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG. Presenilin-1 P264L knock-in mutation: differential effects on A&#x3b2; production, amyloid deposition, and neuronal vulnerability. J Neurosci. 2000;20:8717&#x2013;8726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773081</ArticleId><ArticleId IdType="pubmed">11102478</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581763</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmusk T, Lendahl U, Funakoshi H, Arenas E, Persson H, Metsis M. Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. J Cell Biol. 1995;128:185&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120326</ArticleId><ArticleId IdType="pubmed">7822414</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Thornton PL, Balazs R, Cotman CW. Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem. 2001;276:17301&#x2013;17306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci. 2004;24:6799&#x2013;6809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729714</ArticleId><ArticleId IdType="pubmed">15282285</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers&#x2014;a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto-Sasaki M, Ozawa H, Saito T, Rosler M, Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 1999;824:300&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. The pathogenesis of Alzheimer's disease. Is amyloid beta-protein the beginning or the end? Ann N Y Acad Sci. 2000;924:26&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19631758</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.</ArticleTitle><Pagination><StartPage>169</StartPage><EndPage>176</EndPage><MedlinePgn>169-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2009.07.025</ELocationID><Abstract><AbstractText>Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) epsilon4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE epsilon4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE epsilon4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Banner Good Samaritan PET Center, 901 East Willetta Street, Phoenix, AZ 85006, USA. eric.reiman@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Reschke</LastName><ForeName>Cole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bandy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH57899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19631758</ArticleId><ArticleId IdType="mid">NIHMS135194</ArticleId><ArticleId IdType="pmc">PMC2888804</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2009.07.025</ArticleId><ArticleId IdType="pii">S1053-8119(09)00797-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer&#x2019;s disease treatment studies. Am J Psychiatry. 2002;159:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonarek M, Barberger-Gateau P, Letenneur L, Deschamps V, Iron A, Dubroca B, Dartigues JF. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology. 2000;19:141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">10705232</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci. 2002;7:a50&#x2013;a59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11900994</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer&#x2019;s disease. J Alzheimers Dis. 2008;13:187&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">18376061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res. 2004;29:1897&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pubmed">15532546</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci. 2005;25:299&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725473</ArticleId><ArticleId IdType="pubmed">15647473</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676946</ArticleId><ArticleId IdType="pubmed">18663180</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994;53:125&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005;64:1531&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883313</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, Van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, Von BK, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer&#x2019;s disease &#x3b2;-amyloid peptides A&#x3b2;42 and A&#x3b2;40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98:5856&#x2013;5861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33303</ArticleId><ArticleId IdType="pubmed">11296263</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999;10:1699&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA. Statin use and the risk of Alzheimer&#x2019;s disease: The MIRAGE Study. Alzheimer&#x2019;s &amp; Dementia. 2005;2:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595865</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery, and Psychiatry. 2009;80:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J neurol neurosurg psychiatry. 1960:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, Bisgaier CL. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res. 1995;36:2541&#x2013;2551.</Citation><ArticleIdList><ArticleId IdType="pubmed">8847480</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242163</ArticleId><ArticleId IdType="pubmed">22115874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998;273:16576&#x2013;16582.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632729</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer&#x2019;s disease. Neuron. 2004;44:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H. The Atorvastatin/Donepezil in Alzheimer&#x2019;s Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008;4:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. BMJ. 2001;322:1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">8419817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczynski B, Jagust W, Chui HC, Reed B. An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology. 2009;72:738&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677543</ArticleId><ArticleId IdType="pubmed">19237703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">6978885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer&#x2019;s disease. Biochim Biophys Acta. 1998;1406:291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630681</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Neuroimage. 2009;45:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886795</ArticleId><ArticleId IdType="pubmed">19349228</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001;57:1447&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11673587</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Higdon R, Kukull WA, Peskind E, Van Valen MK, Tsuang D, van BG, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534246</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Kukull WA, Pekind E, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Differential effect of statins on risk of AD by age, sex and APOE genotype: findings from a community-based prospective cohort study. Alzheimer Dis Assoc Disord. 2006;20:S103&#x2013;S104.</Citation></Reference><Reference><Citation>Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724290</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology. 2005;65:1045&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">16217057</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Cao D, Desmond R, Rahman A, Lah JJ, Levey AI, Zamrini E. Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. Dement Geriatr Cogn Disord. 2008;26:384&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679366</ArticleId><ArticleId IdType="pubmed">18931498</ArticleId></ArticleIdList></Reference><Reference><Citation>Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med. 1995;36:1141&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">2877128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64:1689&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 1995;66:583&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">7644022</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, Nitsch RM, Hock C. A cluster of cholesterol-related genes confers susceptibility for Alzheimer&#x2019;s disease. J Clin Psychiatry. 2005;66:940&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">16013913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874399</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush A, Petanceska S, Gandy S. Atorvastatin-induced activation of Alzheimer&#x2019;s alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem. 2004;90:1005&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">15287907</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener. 2009:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654562</ArticleId><ArticleId IdType="pubmed">19126211</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62:1047&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009757</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer&#x2019;s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964604</ArticleId></ArticleIdList></Reference><Reference><Citation>Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2001;8:890&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592856</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS. Brain imaging in the evaluation of putative Alzheimer&#x2019;s disease slowing, risk-reducing and prevention therapies. In: Jagust WJ, D&#x2019;Esposito M, editors. Imaging and the Aging Brain. Oxford University Press; New York: in press.</Citation></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E &#x3b5;4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102:8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A. Cholesterol-Related Genetic Risk Scores are Associated with Hypometabolism in Alzheimer&#x2019;s-Affected Brain Regions. Neuroimage. 2008;40:1214&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441925</ArticleId><ArticleId IdType="pubmed">18280754</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JBS, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-&#x3b2; burden in cognitively normal people at three levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11843693</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon E, Maquet P, Sadzot B, Degueldre C, Lemaire C, Franck G. Decrease of frontal metabolism demonstrated by positron emission tomography in a population of healthy elderly volunteers. Acta Neurol Belg. 1991;91:288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">1781265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M. Multi-center, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia. 2008;4:T200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240843</ArticleId><ArticleId IdType="pubmed">30480082</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15660968</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">12457784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer&#x2019;s disease. Lancet Neurol. 2005;4:841&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297842</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De SB, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. Neurology. 2007;68:751&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer&#x2019;s disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12474023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer&#x2019;s disease: results of the Alzheimer&#x2019;s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Scheff SW, Hunsaker JC, III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8157129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Schreurs BG. Trace amounts of copper in water induce &#x3b2;&#x2013;amyloid plaques and learning deficits in a rabbit model of Alzheimer&#x2019;s disease. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:11065&#x2013;11069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196927</ArticleId><ArticleId IdType="pubmed">12920183</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2007;64:103&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson&#x2019;s disease. BMC Medicine. 2007;5:1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955446</ArticleId><ArticleId IdType="pubmed">17640385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer&#x2019;s disease. Neuroepidemiology. 2004;23:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19633196</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>32</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>13594</StartPage><EndPage>13599</EndPage><MedlinePgn>13594-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0901402106</ELocationID><Abstract><AbstractText>Neural stem cell (NSC) transplantation represents an unexplored approach for treating neurodegenerative disorders associated with cognitive decline such as Alzheimer disease (AD). Here, we used aged triple transgenic mice (3xTg-AD) that express pathogenic forms of amyloid precursor protein, presenilin, and tau to investigate the effect of neural stem cell transplantation on AD-related neuropathology and cognitive dysfunction. Interestingly, despite widespread and established Ass plaque and neurofibrillary tangle pathology, hippocampal neural stem cell transplantation rescues the spatial learning and memory deficits in aged 3xTg-AD mice. Remarkably, cognitive function is improved without altering Ass or tau pathology. Instead, the mechanism underlying the improved cognition involves a robust enhancement of hippocampal synaptic density, mediated by brain-derived neurotrophic factor (BDNF). Gain-of-function studies show that recombinant BDNF mimics the beneficial effects of NSC transplantation. Furthermore, loss-of-function studies show that depletion of NSC-derived BDNF fails to improve cognition or restore hippocampal synaptic density. Taken together, our findings demonstrate that neural stem cells can ameliorate complex behavioral deficits associated with widespread Alzheimer disease pathology via BDNF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitazawa</LastName><ForeName>Masashi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Martinez-Coria</LastName><ForeName>Hilda</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Castello</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Franz-Josef</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Loring</LastName><ForeName>Jeanne F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Tritia R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG029378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99AR05695</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002633" MajorTopicYN="N">Chemotaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039902" MajorTopicYN="N">Multipotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19633196</ArticleId><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="doi">10.1073/pnas.0901402106</ArticleId><ArticleId IdType="pii">0901402106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ebert AD, Beres AJ, Barber AE, Svendsen CN. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol. 2008;209:213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18061591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, Jones LL, Snyder EY, Tuszynski MH. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol. 2003;181(2):115&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781986</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KI, et al. Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury. Exp Neurol. 2006;199(1):179&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714016</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45(5):675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizumoto H, Mizumoto K, Shatos MA, Klassen H, Young MJ. Retinal transplantation of neural progenitor cells derived from the brain of GFP transgenic mice. Vision Res. 2003;43(16):1699&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">12818339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, et al. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007;27:11925&#x2013;11933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673368</ArticleId><ArticleId IdType="pubmed">17978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JP, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nature Med. 2007;13:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351625</ArticleId></ArticleIdList></Reference><Reference><Citation>Imitola J, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA. 2004;101:18117&#x2013;18122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC536055</ArticleId><ArticleId IdType="pubmed">15608062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16:2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608400</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281:39413&#x2013;39423.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry. 2007;12:656&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442923</ArticleId><ArticleId IdType="pubmed">17264839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamei N, et al. BDNF, NT-3, and NGF released from transplanted neural progenitor cells promote corticospinal axon growth in organotypic cocultures. Spine. 2007;32:1272&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17515814</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, et al. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods. 2005;2(8):599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller FJ, Snyder EY, Loring JF. Gene therapy: Can neural stem cells deliver? Nat Rev Neurosci. 2006;7:75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371952</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006;7:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">16760919</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond DE, Jr, et al. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA. 2007;104(29):12175&#x2013;12180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1896134</ArticleId><ArticleId IdType="pubmed">17586681</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm. 2006;113:1217&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362629</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem. 2005;93:1412&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935057</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci. 2007;27:2628&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672502</ArticleId><ArticleId IdType="pubmed">17344400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1963537</PMID><DateCompleted><Year>1991</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>American journal of medical genetics. Supplement</Title><ISOAbbreviation>Am J Med Genet Suppl</ISOAbbreviation></Journal><ArticleTitle>Ultrastructure of the cells forming amyloid fibers in Alzheimer disease and scrapie.</ArticleTitle><Pagination><StartPage>287</StartPage><EndPage>297</EndPage><MedlinePgn>287-97</MedlinePgn></Pagination><Abstract><AbstractText>Ultrastructural, three-dimensional reconstruction of cells surrounding the amyloid star in classical plaques in Alzheimer disease (AD) and histochemical studies of the cells associated with the deposits of amyloid fibers in scrapie were carried out. These studies showed that in both diseases, the fibers appear within the smooth endoplasmic reticulum (ER) and infoldings of cytoplasmic membranes of microglia/macrophages. Additional information about the site of formation of the amyloid fibers derives from histochemical studies of the localization of nucleoside diphosphatase (NDPase) activity. In normal microglia, this enzyme is associated with smooth ER and cell membranes. In the cells that form amyloid fibers, the NDPase activity is associated with the newly formed amyloid fibers within the distended cisternae of ER and the finger-like cytoplasmic projections. In the center of the amyloid star, the NDPase activity disappears. The presence of NDPase-positive amyloid fibers in the same location, where the enzyme is found in non-amyloid-forming cells, further supports our conclusion that the microglia/macrophages are the source of amyloid deposits. These studies also show that in spite of the differences in the proteins that produce the amyloid fibers in AD and scrapie, in both diseases, the microglia/macrophages play a key role in amyloid formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>New York State Institute for Basic Research in Developmental Disabilities, Staten Island 10314.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorbrodt</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Wegiel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morys</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lossinsky</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P0-1-AGO-4220-06</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P0-1-HD-22634-03</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet Suppl</MedlineTA><NlmUniqueID>8706133</NlmUniqueID><ISSNLinking>1040-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.-</RegistryNumber><NameOfSubstance UI="D017766">Acid Anhydride Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.6</RegistryNumber><NameOfSubstance UI="C023837">nucleoside-diphosphatase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017766" MajorTopicYN="Y">Acid Anhydride Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006651" MajorTopicYN="N">Histocytochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012608" MajorTopicYN="N">Scrapie</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1963537</ArticleId><ArticleId IdType="doi">10.1002/ajmg.1320370757</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19660834</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.</ArticleTitle><Pagination><StartPage>1207</StartPage><EndPage>1218</EndPage><MedlinePgn>1207-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2009.07.002</ELocationID><Abstract><AbstractText>The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.</AbstractText><CopyrightInformation>Copyright &#xa9; 2009 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California-Berkeley, CA 94720-3190, USA. slandau@berkeley.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>Cindee M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Norman L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure statement. There are no potential or actual conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19660834</ArticleId><ArticleId IdType="mid">NIHMS132130</ArticleId><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.002</ArticleId><ArticleId IdType="pii">S0197-4580(09)00227-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002;159:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Eustache F, Viader F, De La Sayette V, Pelerin A, Mezenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase. 2005;11:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804920</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci U S A. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Diggle P, Heagerty P, Liang K-Y, Zeger S. 2 ed. Oxford: Oxford University Press; 2002. Analysis of longitudinal data.</Citation></Reference><Reference><Citation>Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord. 2001;15:174&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">11723368</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouquet M, Desgranges B, Landeau B, Duchesnay E, Mezenge F, de la Sayette V, Viader F, Baron JC, Eustache F, Chetelat G. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936690</ArticleId><ArticleId IdType="pubmed">19477964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould R, Abramson I, Galasko D, Salmon D. Rate of cognitive change in Alzheimer's disease: methodological approaches using random effects models. J Int Neuropsychol Soc. 2001;7:813&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771624</ArticleId></ArticleIdList></Reference><Reference><Citation>Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. Eur J Neurol. 2008;15:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">18803648</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, Jelic V, Almkvist O, Collette F, Alberoni M, Kennedy A, Hasselbalch S, Fazio F, Heiss WD. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord. 1999;10:494&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559566</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol. 2006;59:673&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470518</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008a;29:676&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008b;49:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703818</ArticleId><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, Mack WJ, Kramer JH, Weiner MW, Schuff N, Chui HC. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology. 2005;65:565&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820871</ArticleId><ArticleId IdType="pubmed">16116117</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlik VN, Doody RS, Massman PJ, Chan W. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:367&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">16954693</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Conceptual overview. In: Petersen RC, editor. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York: Oxford University Press; 2003. pp. 1&#x2013;14.</Citation></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40:2311&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pubmed">7238911</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ. Role of cognitive testing in disease modifying AD trials. J Nutr Health Aging. 2006;10:131&#x2013;132. discussion 132&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554947</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466744</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19692615</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>33</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.</ArticleTitle><Pagination><StartPage>10405</StartPage><EndPage>10409</EndPage><MedlinePgn>10405-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2288-09.2009</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder. It is characterized by the invariant accumulation of the beta-amyloid peptide (Abeta), which mediates synapse loss and cognitive impairment in AD. Current therapeutic approaches concentrate on reducing Abeta levels and amyloid plaque load via modifying or inhibiting the generation of Abeta. Based on in vivo two-photon imaging, we present evidence that side effects on the level of dendritic spines may counteract the beneficial potential of these approaches. Two potent gamma-secretase inhibitors (GSIs), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester) and LY450139 (hydroxylvaleryl monobenzocaprolactam), were found to reduce the density of dendritic spines in wild-type mice. In mice deficient for the amyloid precursor protein (APP), both GSIs had no effect on dendritic spine density, demonstrating that gamma-secretase inhibition decreases dendritic spine density via APP. Independent of the effects of gamma-secretase inhibition, we observed a twofold higher density of dendritic spines in the cerebral cortex of adult APP-deficient mice. This observation further supports the notion that APP is involved in the modulation of dendritic spine density--shown here for the first time in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Neuropathology and Prion Research, Ludwig-Maximilians-Universit&#xe4;t, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Burgold</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian K E</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Volbracht</LastName><ForeName>Christiane</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mitteregger</LastName><ForeName>Gerda</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419410">N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19692615</ArticleId><ArticleId IdType="pmc">PMC6665795</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2288-09.2009</ArticleId><ArticleId IdType="pii">29/33/10405</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682361</ArticleId><ArticleId IdType="pubmed">18695053</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Mitteregger G, Kretzschmar H, Herms J. Dendritic pathology in prion disease starts at the synaptic spine. J Neurosci. 2007;27:6224&#x2013;6233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672160</ArticleId><ArticleId IdType="pubmed">17553995</ArticleId></ArticleIdList></Reference><Reference><Citation>Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 2002;3:688&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1084181</ArticleId><ArticleId IdType="pubmed">12101103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitter BD, Czilli DL, Dieckman DK, Bender MH, Nissen JS. Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol Aging. 2004;25:571.</Citation></Reference><Reference><Citation>Grutzendler J, Kasthuri N, Gan WB. Long-term dendritic spine stability in the adult cortex. Nature. 2002;420:812&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490949</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Take five&#x2014;BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Wilbrecht L, Knott GW, Welker E, Svoboda K. Experience-dependent and cell-type-specific spine growth in the neocortex. Nature. 2006;441:979&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16791195</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat AJ, Trachtenberg JT, Wilbrecht L, Shepherd GM, Zhang X, Knott GW, Svoboda K. Transient and persistent dendritic spines in the neocortex in vivo . Neuron. 2005;45:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo . Nat Neurosci. 2006;9:1117&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892056</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh IY, Lindquist WB, Zito K, Nimchinsky EA, Svoboda K. An image analysis algorithm for dendritic spines. Neural Comput. 2002;14:1283&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol. 2004;5:499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and CSF in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther. 2003;305:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12626636</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZW, Stark G, G&#xf6;tz J, R&#xfc;licke T, Gschwind M, Huber G, M&#xfc;ller U, Weissmann C. Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells. Proc Natl Acad Sci U S A. 1996;93:6158&#x2013;6162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39206</ArticleId><ArticleId IdType="pubmed">8650236</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewska AK, Newton JR, Sur M. Remodeling of synaptic structure in sensory cortical areas in vivo . J Neurosci. 2006;26:3021&#x2013;3029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673961</ArticleId><ArticleId IdType="pubmed">16540580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ness DK, Boggs LN, Hepburn DL, Gitter B, Long GG, May PC, Piroozi KS, Schafer KA, Yang Z. Reduced amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging. 2004;25(Suppl 2):238.</Citation></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;26:7212&#x2013;7221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimers-Disease&#x2014;a central role for amyloid. J Neuropathol Exp Neurol. 1994;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature. 2002;420:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490942</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yang G, Kwon E, Gan WB. Long-term sensory deprivation prevents dendritic spine loss in primary somatosensory cortex. Nature. 2005;436:261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16015331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19703562</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>425</StartPage><EndPage>434</EndPage><MedlinePgn>425-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2009.08.007</ELocationID><Abstract><AbstractText>Human genetics link Alzheimer's disease pathogenesis to excessive accumulation of amyloid-beta (Abeta) in brain, but the symptoms do not correlate with senile plaque burden. Since soluble Abeta aggregates can cause synaptic dysfunctions and memory deficits, these species could contribute to neuronal dysfunction and dementia. Here we explored selective targeting of large soluble aggregates, Abeta protofibrils, as a new immunotherapeutic strategy. The highly protofibril-selective monoclonal antibody mAb158 inhibited in vitro fibril formation and protected cells from Abeta protofibril-induced toxicity. When the mAb158 antibody was administered for 4 months to plaque-bearing transgenic mice with both the Arctic and Swedish mutations (tg-ArcSwe), Abeta protofibril levels were lowered while measures of insoluble Abeta were unaffected. In contrast, when treatment began before the appearance of senile plaques, amyloid deposition was prevented and Abeta protofibril levels diminished. Therapeutic intervention with mAb158 was however not proven functionally beneficial, since place learning depended neither on treatment nor transgenicity. Our findings suggest that Abeta protofibrils can be selectively cleared with immunotherapy in an animal model that display highly insoluble Abeta deposits, similar to those of Alzheimer's disease brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Molecular Geriatrics, Uppsala University, Rudbeck Laboratory, Dag Hammarskj&#xf6;lds v&#xe4;g 20, SE-751 85 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumucio</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Hillevi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sehlin</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sundquist</LastName><ForeName>Valentina Screpanti</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>S&#xf6;derberg</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>M&#xf6;ller</LastName><ForeName>Christer</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gellerfors</LastName><ForeName>P&#xe4;r</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Pettersson</LastName><ForeName>Frida Ekholm</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Lars N G</ForeName><Initials>LN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19703562</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2009.08.007</ArticleId><ArticleId IdType="pii">S0969-9961(09)00226-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19710322</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>34</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice.</ArticleTitle><Pagination><StartPage>10706</StartPage><EndPage>10714</EndPage><MedlinePgn>10706-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2637-09.2009</ELocationID><Abstract><AbstractText>Amyloid plaques are primarily composed of extracellular aggregates of amyloid-beta (Abeta) peptide and are a pathological signature of Alzheimer's disease. However, the factors that influence the dynamics of amyloid plaque formation and growth in vivo are largely unknown. Using serial intravital multiphoton microscopy through a thinned-skull cranial window in APP/PS1 transgenic mice, we found that amyloid plaques appear and grow over a period of weeks before reaching a mature size. Growth was more prominent early after initial plaque formation: plaques grew faster in 6-month-old compared with 10-month-old mice. Plaque growth rate was also size-related, as smaller plaques exhibited more rapid growth relative to larger plaques. Alterations in interstitial Abeta concentrations were associated with changes in plaque growth. Parallel studies using multiphoton microscopy and in vivo microdialysis revealed that pharmacological reduction of soluble extracellular Abeta by as little as 20-25% was associated with a dramatic decrease in plaque formation and growth. Furthermore, this small reduction in Abeta synthesis was sufficient to reduce amyloid plaque load in 6-month-old but not 10-month-old mice, suggesting that treatment early in disease pathogenesis may be more effective than later treatment. In contrast to thinned-skull windows, no significant plaque growth was observed under open-skull windows, which demonstrated extensive microglial and astrocytic activation. Together, these findings indicate that individual amyloid plaque growth in vivo occurs over a period of weeks and may be influenced by interstitial Abeta concentration as well as reactive gliosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bero</LastName><ForeName>Adam W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Qingli</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Moo</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS048283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS032636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017785" MajorTopicYN="N">Photons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19710322</ArticleId><ArticleId IdType="mid">NIHMS143912</ArticleId><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2637-09.2009</ArticleId><ArticleId IdType="pii">29/34/10706</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Braakman N, Matysik J, van Duinen SG, Verbeek F, Schliebs R, de Groot HJ, Alia A. Longitudinal assessment of Alzheimer's &#x3b2;-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging. 2006;24:530&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892201</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM. Anti-A&#x3b2; antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005;115:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544607</ArticleId><ArticleId IdType="pubmed">15668737</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/&#x3b2; amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, Hyman BT. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci. 2001;21:858&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762315</ArticleId><ArticleId IdType="pubmed">11157072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-&#x3b2; in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol. 2003;62:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578223</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent &#x3b3;-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Dodwell SA, Meyer-Luehmann M, Hyman BT, Bacskai BJ. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J Neuropathol Exp Neurol. 2006;65:1082&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086105</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, Golde TE, Hyman BT, Bacskai BJ. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the &#x3b3;-secretase inhibitor LY-411575. Mol Neurodegener. 2009;4:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687427</ArticleId><ArticleId IdType="pubmed">19419556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002;173:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, Peachey J, Townend T, Vithlani M, Beher D, Shearman MS, Hutson PH. Determination of guinea-pig cortical &#x3b3;-secretase activity ex vivo following the systemic administration of a &#x3b3;-secretase inhibitor. Neuropharmacology. 2005;48:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y, Tomidokoro Y, Ikeda M, Sasaki A, Kawarabayashi T, Matsubara E, Kanai M, Saido TC, Younkin SG, Shoji M. Type-specific evolution of amyloid plaque and angiopathy in APPsw mice. Neurosci Lett. 2006;395:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993;52:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, Poduslo JF. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci. 2005;25:10041&#x2013;10048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744887</ArticleId><ArticleId IdType="pubmed">16251453</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of A&#x3b2; production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-&#x3b2; via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673&#x2013;10678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging A&#x3b2; plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96:5274&#x2013;5279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323:1211&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an A&#x3b2;-like peptide. J Biol Chem. 2002;277:44754&#x2013;44759.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223485</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, Price DL, Eberhart CG, Wong PC. Moderate reduction of &#x3b3;-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci. 2007;27:10849&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672827</ArticleId><ArticleId IdType="pubmed">17913918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT. Amyloid-&#x3b2; antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879&#x2013;10883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740984</ArticleId><ArticleId IdType="pubmed">14645482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, Staufenbiel M, Jucker M. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni CY, Murphy MP, Golde TE, Carpenter G. &#x3b3;-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294:2179&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679632</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to &#x3b2;-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-&#x3b2; plaques. J Neurosci. 2004;24:4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem. 2000;48:1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata K, Kitamura Y, Yanagisawa D, Morikawa S, Morita M, Inubushi T, Tsuchiya D, Chishiro S, Saeki M, Taniguchi T, Shimohama S, Tooyama I. Microglial transplantation increases amyloid-&#x3b2; clearance in Alzheimer model rats. FEBS Lett. 2007;581:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17240371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience. 2000;101:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the &#x3b3;-secretase inhibitor LY-411,575 inhibits &#x3b2;-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. Adult mouse astrocytes degrade amyloid-&#x3b2; in vitro and in situ. Nat Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HT, Pan F, Yang G, Gan WB. Choice of cranial window type for in vivo imaging affects dendritic spine turnover in the cortex. Nat Neurosci. 2007;10:549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19710325</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>34</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.</ArticleTitle><Pagination><StartPage>10741</StartPage><EndPage>10749</EndPage><MedlinePgn>10741-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1065-09.2009</ELocationID><Abstract><AbstractText>A hallmark feature of Alzheimer's disease pathology is the presence of neurofibrillary tangles (NFTs), which are intracellular aggregates of conformationally abnormal and hyperphosphorylated tau. The presence of NFTs in the forebrain is associated with impairments of cognitive function, supporting a central role for tau in dementia. The significance of the accumulation of NFTs for neuronal and cognitive function is still obscure. It is possible that NFTs disrupt synaptic transmission and plasticity, leading to memory deficits and cognitive malfunction. To elucidate the relationship between the development of tau pathology and synaptic and cognitive functions, we performed behavioral tests and electrophysiological experiments in the htau mouse. Here we report age-dependent cognitive and physiological impairments in htau mice that preceded neurodegeneration. Twelve-month-old htau mice with moderate tau pathology, but not 4-month-old mice with early-stage tau pathology, presented cognitive deficits in an object recognition memory task in which the visual recognition memory of a novel object was disrupted. Moreover, only 12-month-old htau mice exhibit spatial memory deficits, as indicated by the impaired performance in the Morris water maze. In addition, we report that basal synaptic transmission and induction of long-term potentiation with high-frequency stimulation, but not theta burst stimulation, is perturbed in hippocampal CA1 region of old but not young htau mice. Our results suggest that tau pathology may underlie an age-dependent learning impairment through disruption of synaptic function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polydoro</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acker</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Pablo E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048447</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D054641">Dual Specificity Phosphatase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C517033">Dusp2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054641" MajorTopicYN="N">Dual Specificity Phosphatase 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19710325</ArticleId><ArticleId IdType="mid">NIHMS143902</ArticleId><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1065-09.2009</ArticleId><ArticleId IdType="pii">29/34/10741</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, Garcia MF. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 2004;1012:29&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158158</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993;162:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350458</ArticleId><ArticleId IdType="pubmed">4727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988;31:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">3228475</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeli-Azad B, McCarty JH, Feinstein SC. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci. 1994;107:869&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056843</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther RA. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. 1999;450:306&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">10359094</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, Dekosky ST, Asada T. An immunohistochemical study of GABA receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology. 2009;29:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078755</ArticleId><ArticleId IdType="pubmed">19019179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y, Takemura R, Oshima T, Mori H, Ihara Y, Yanagisawa M, Masaki T, Hirokawa N. Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J Cell Biol. 1989;109:1173&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115758</ArticleId><ArticleId IdType="pubmed">2504728</ArticleId></ArticleIdList></Reference><Reference><Citation>Knops J, Kosik KS, Lee G, Pardee JD, Cohen-Gould L, McConlogue L. Overexpression of tau in a nonneuronal cell induces long cellular processes. J Cell Biol. 1991;114:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289897</ArticleId><ArticleId IdType="pubmed">1678391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CW, Lee G, Jay DG. Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons. Cell Motil Cytoskeleton. 1999;43:232&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401579</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA. Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol. 1993;70:1451&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">7904300</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature. 1986;319:774&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">2869411</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Dostrovsky J. The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res. 1971;34:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Kas A, D'Souza I, Zhou Y, Pham Q, Stone M, Olson MV, Schellenberg GD. A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome. 2001;12:700&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">11641718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome. 1997;8:711&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">9321461</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei Y, Teng J, Harada A, Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol. 2000;150:989&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175245</ArticleId><ArticleId IdType="pubmed">10973990</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson AM. Facilitation, augmentation and potentiation at central synapses. Trends Neurosci. 2000;23:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10856940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;87:1327&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ. Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci. 2004;24:5901&#x2013;5908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729235</ArticleId><ArticleId IdType="pubmed">15229237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19717642</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration.</ArticleTitle><Pagination><StartPage>1598</StartPage><EndPage>1609</EndPage><MedlinePgn>1598-609</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2353/ajpath.2009.090462</ELocationID><Abstract><AbstractText>Here, we describe the generation and characterization of a novel tau transgenic mouse model (mTau) that overexpresses wild-type murine tau protein by twofold compared with endogenous levels. Transgenic tau expression was driven by a BAC transgene containing the entire wild-type mouse tau locus, including the endogenous promoter and the regulatory elements associated with the tau gene. The mTau model therefore differs from other tau models in that regulation of the genomic mouse transgene mimics that of the endogenous gene, including normal exon splicing regulation. Biochemical data from the mTau mice demonstrated that modest elevation of mouse tau leads to tau hyperphosphorylation at multiple pathologically relevant epitopes and accumulation of sarkosyl-insoluble tau. The mTau mice show a progressive increase in hyperphosphorylated tau pathology with age up to 15 to 18 months, which is accompanied by gliosis and vacuolization. In contrast, older mice show a decrease in tau pathology levels, which may represent hippocampal neuronal loss occurring in this wild-type model. Collectively, these results describe a novel model of tauopathy that develops pathological changes reminiscent of early stage Alzheimer's disease and other related neurodegenerative diseases, achieved without overexpression of a mutant human tau transgene. This model will provide an important tool for understanding the early events leading to the development of tau pathology and a model for analysis of potential therapeutic targets for sporadic tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Stephanie J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA. adams.stephanie@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Richard J P</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Deture</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Randle</LastName><ForeName>Suzanne J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Innes</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xin Z</ForeName><Initials>XZ</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wen-Lang</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Dugger</LastName><ForeName>Brittany N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Melinda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>McGowan</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG027638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001947" MajorTopicYN="N">Breeding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022202" MajorTopicYN="N">Chromosomes, Artificial, Bacterial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19717642</ArticleId><ArticleId IdType="pmc">PMC2751556</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2009.090462</ArticleId><ArticleId IdType="pii">S0002-9440(10)60671-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A, Brown WM, Kosi KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;31:10626&#x2013;10633.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Pertersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Zehr C, Lewis J. Biologic models of neurodegenerative disorders. Duyckaerts C, Litvan I, editors. New York,: Elsevier,; 2008:pp. 173&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Smith MJ, Goedert M. proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998;437:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Zukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayanandan R, Van Slegtenhorst M, Mack TG, Ko L, Yen SH, Leroy K, Brion JP, Anderton BH, Hutton M, Lovestone S. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 1999;446:228&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis. 2000;7:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783293</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2:1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao QS, Memmott J, Lafyatis R, Stamm S, Screaton G, Andreadis A. Complex regulation of tau exon 10: whose missplicing causes frontotemporal dementia. J Neurochem. 2000;74:490&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">10646499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chohan MO, Haque N, Alonso A, El-Akkad E, Iqbal-Grundke I, Grover A, Iqbal K. Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J Neural Transm. 2005;112:1035&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">15583961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Pangalos M, Geerts H, Wiech H, Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer&#x2019;s disease. FEBS Lett. 1999;451:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10356980</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B. Interactions between prion protein isoforms: the kiss of death? Trends Biochem Sci. 2001;26:235&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11295556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interaction between A&#x3b2; (1-42) and A&#x3b2; (1-40) in Alzheimer&#x2019;s &#x3b2;-amyloid fibril formation in vitro. Biochemistry. 1999;38:15514&#x2013;15521.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The potential for B-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous tau in inducible mouse models of tauopathy. Neurobiol Dis. 2008;28:737&#x2013;7448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image J. Biophoton Int. 2004;11:36&#x2013;42.</Citation></Reference><Reference><Citation>Ghandour MS, Langley OK, Vincendon G, Gombos G, Filippi D, Limozin N, Dalmasso D, Laurent G. Immunochemical and immunohistochemical study of carbonic anhydrase II in adult rat cerebellum: a marker for oligodendrocytes. Neuroscience. 1980;5:559&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">6769072</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Braak E, Braak H, Azidi T, Grundke-Iqbal I. A silver impregnation method for labeling both Alzheimer paired helical filaments and their polypeptides separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Neurobiol Aging. 1991;12:357&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">1720514</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M, Ko LW, Easson C, Yen SH. assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol. 2002;161:1711&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850799</ArticleId><ArticleId IdType="pubmed">12414518</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Biochemical and anatomical redistribution of tau protein in Alzheimer&#x2019;s disease. Am J Pathol. 1993;143:565&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887045</ArticleId><ArticleId IdType="pubmed">8342603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Zehr C, Lewis J, Hutton M, Yen SH, Dickson DW. Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau. J Neurocytol. 2005;34:397&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902761</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Tolnay M, Barmettler R, Chen F, Probst A, Nitsch RM. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci. 2001;13:2131&#x2013;2140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422454</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowsk JQ, Lee VM. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci. 2005;25:9434&#x2013;9443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725712</ArticleId><ArticleId IdType="pubmed">16221853</ArticleId></ArticleIdList></Reference><Reference><Citation>Scallet AC, Ye X. Excitotoxic mechanisms of neurodegeneration in transmissible spongiform encephalopathies. Ann NY Acad Sci. 1997;825:194&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">9369987</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol. 1997;54:1234&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341569</ArticleId></ArticleIdList></Reference><Reference><Citation>Osokine I, Hsu R, Loeb GB, McManus MT. Unintentional miRNA ablation is a risk factor in gene knockout studies: a short report. PLoS Genet. 2008;4:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242815</ArticleId><ArticleId IdType="pubmed">18282110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem. 2002;83:1498&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472903</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ransden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Byman B, Hutton M, Ashe KH. suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, Santacruz K, Guimaraes A, Yue M, Lewis J, Carlson GA, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci. 2008;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Meyers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams DS, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, Baker A, Jonasdottir A, Ingason A, Gudnadottir VG, Desnica N, Hicks A, Gylfason A, Gudbjartsson DF, Jonsdottir GM, Sainz J, Angnarsson K, Birdgisdottir B, Ghosh S, Olafsdottir A, Cazier JB, Kristjansson D, Frigge ML, Thorgeirsson TE, Gulcher JR, Kong A, Stefansson K. A common inversion under selection in Europeans. Nat Genet. 2005;37:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res. 2009;87:440&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739042</ArticleId><ArticleId IdType="pubmed">18798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok JB, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, Buchanan DD, Silburn PA, Schofield PR. haplotypes regulate transcription and are associated with Parkinson&#x2019;s disease. Ann Neurol. 2004;55:329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991810</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St. George-Hyslop P, Munoz DG, Mann DMA, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56:1702&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425937</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, Frasson E, Marchese R, Montagna P, Munoz DG, Pramstaller PP, Zanusso G, Ajmar F, Mandich P. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol. 2000;47:374&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716259</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Andreadis A, Trojanowsk JQ, Dickson D, Kang D, Chen X, Wiederholt WC, Hansen L, Masliah E, Thal U, Katzman R, Xia Y, Saitoh T. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029080</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio EH, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8:711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19748335</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Polyglutamine dances the conformational cha-cha-cha.</ArticleTitle><Pagination><StartPage>1151</StartPage><EndPage>1153</EndPage><MedlinePgn>1151-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2009.08.004</ELocationID><Abstract><AbstractText>While polyglutamine repeats appear in dozens of human proteins, high-resolution structural analysis of these repeats in their native context has eluded researchers. Kim et al. now describe multiple crystal structures and demonstrate that polyglutamine in huntingtin dances through multiple conformations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rutenber</LastName><ForeName>Earl</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Muchowski</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS054753</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016433">News</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Structure. 2009 Sep 9;17(9):1205-12. doi: 10.1016/j.str.2009.08.002.</RefSource><PMID Version="1">19748341</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020449" MajorTopicYN="N">Repetitive Sequences, Amino Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748335</ArticleId><ArticleId IdType="mid">NIHMS171096</ArticleId><ArticleId IdType="pmc">PMC2830152</ArticleId><ArticleId IdType="doi">10.1016/j.str.2009.08.004</ArticleId><ArticleId IdType="pii">S0969-2126(09)00302-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Hum Mol Genet. 2007;16:2600&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya A, Thakur AK, Chellgren VM, Thiagarajan G, Williams AD, Chellgren BW, Creamer TP, Wetzel R. J Mol Biol. 2006;355:524&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16321399</ArticleId></ArticleIdList></Reference><Reference><Citation>Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, Lee SS, Wilkinson A, Yang GS, Yuen MM, et al. BMC Genomics. 2007;8:126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1896166</ArticleId><ArticleId IdType="pubmed">17519034</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell G, Orgel JP, Pahl R, Meredith SC. J Mol Biol. 2007;374:688&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945257</ArticleId></ArticleIdList></Reference><Reference><Citation>Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Proc Natl Acad Sci USA. 2006;103:11045&#x2013;11050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544171</ArticleId><ArticleId IdType="pubmed">16832050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I. Structure. 2009;17(this issue):1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863341</ArticleId><ArticleId IdType="pubmed">19748341</ArticleId></ArticleIdList></Reference><Reference><Citation>Legleiter J, Lotz GP, Miller J, Ko J, Ng C, Williams GL, Finkbeiner S, Patterson PH, Muchowski PJ. J Biol Chem. 2009;284:21647&#x2013;21658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755888</ArticleId><ArticleId IdType="pubmed">19491400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, Urade Y, Goto Y, Naiki H, Toda T. Nat Struct Mol Biol. 2007;14:332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">17369839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuinstra RL, Peterson FC, Kutlesa S, Elgin ES, Kron MA, Volkman BF. Proc Natl Acad Sci USA. 2008;105:5057&#x2013;5062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278211</ArticleId><ArticleId IdType="pubmed">18364395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Nat Struct Mol Biol. 2004;11:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">15543156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19748341</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Secondary structure of Huntingtin amino-terminal region.</ArticleTitle><Pagination><StartPage>1205</StartPage><EndPage>1212</EndPage><MedlinePgn>1205-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2009.08.002</ELocationID><Abstract><AbstractText>Huntington's disease is a genetic neurodegenerative disorder resulting from polyglutamine (polyQ) expansion (&gt;36Q) within the first exon of Huntingtin (Htt) protein. We applied X-ray crystallography to determine the secondary structure of the first exon (EX1) of Htt17Q. The structure of Htt17Q-EX1 consists of an amino-terminal alpha helix, poly17Q region, and polyproline helix formed by the proline-rich region. The poly17Q region adopts multiple conformations in the structure, including alpha helix, random coil, and extended loop. The conformation of the poly17Q region is influenced by the conformation of neighboring protein regions, demonstrating the importance of the native protein context. We propose that the conformational flexibility of the polyQ region observed in our structure is a common characteristic of many amyloidogenic proteins. We further propose that the pathogenic polyQ expansion in the Htt protein increases the length of the random coil, which promotes aggregation and facilitates abnormal interactions with other proteins in cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Mee Whi</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. MeeWhi.Kim@UTSouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chelliah</LastName><ForeName>Yogarany</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sang Woo</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Otwinowski</LastName><ForeName>Zbyszek</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Bezprozvanny</LastName><ForeName>Ilya</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>3IO4</AccessionNumber><AccessionNumber>3IO6</AccessionNumber><AccessionNumber>3IOR</AccessionNumber><AccessionNumber>3IOT</AccessionNumber><AccessionNumber>3IOU</AccessionNumber><AccessionNumber>3IOV</AccessionNumber><AccessionNumber>3IOW</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM053163</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056224</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM053163</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS056224</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>25191-13-3</RegistryNumber><NameOfSubstance UI="C011083">polyproline</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Structure. 2009 Sep 9;17(9):1151-3. doi: 10.1016/j.str.2009.08.004.</RefSource><PMID Version="1">19748335</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748341</ArticleId><ArticleId IdType="mid">NIHMS197163</ArticleId><ArticleId IdType="pmc">PMC2863341</ArticleId><ArticleId IdType="doi">10.1016/j.str.2009.08.002</ArticleId><ArticleId IdType="pii">S0969-2126(09)00299-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altschuler EL, Hud NV, Mazrimas JA, Rupp B. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res. 1997;50:73&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9273890</ArticleId></ArticleIdList></Reference><Reference><Citation>Armen RS, Bernard BM, Day R, Alonso DO, Daggett V. Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases. Proc Natl Acad Sci U S A. 2005;102:13433&#x2013;13438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224618</ArticleId><ArticleId IdType="pubmed">16157882</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet. 2007;16:2600&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Jr., Ross SA, Bjorkman PJ. Inaugural Article: A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A. 2002;99:11634&#x2013;11639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129321</ArticleId><ArticleId IdType="pubmed">12193654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevivino AE, Loll PJ. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc Natl Acad Sci U S A. 2001;98:11955&#x2013;11960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59749</ArticleId><ArticleId IdType="pubmed">11572942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15:89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226745</ArticleId><ArticleId IdType="pubmed">19230774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya A, Thakur AK, Chellgren VM, Thiagarajan G, Williams AD, Chellgren BW, Creamer TP, Wetzel R. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol. 2006;355:524&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16321399</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondelle SE, Forood B, Houghten RA, Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. Biochemistry. 1997;36:8393&#x2013;8400.</Citation><ArticleIdList><ArticleId IdType="pubmed">9204887</ArticleId></ArticleIdList></Reference><Reference><Citation>Center RJ, Kobe B, Wilson KA, Teh T, Howlett GJ, Kemp BE, Poumbourios P. Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein. Protein Sci. 1998;7:1612&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144054</ArticleId><ArticleId IdType="pubmed">9684894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol. 2007;83:228&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2449822</ArticleId><ArticleId IdType="pubmed">17467140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellgren BW, Miller AF, Creamer TP. Evidence for polyproline II helical structure in short polyglutamine tracts. J Mol Biol. 2006;361:362&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854433</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Berthelier V, Yang W, Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol. 2001;311:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469866</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell G, Orgel JP, Pahl R, Meredith SC. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol. 2007;374:688&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Bertolotti A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem. 2006;281:35608&#x2013;35615.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973603</ArticleId></ArticleIdList></Reference><Reference><Citation>Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A. 2006;103:11045&#x2013;11050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544171</ArticleId><ArticleId IdType="pubmed">16832050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser PE, Nguyen JT, Surewicz WK, Kirschner DA. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J. 1991;60:1190&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1260174</ArticleId><ArticleId IdType="pubmed">1760507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2000;1:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley NW, Huang X, Tam S, Spiess C, Frydman J, Pande VS. The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. J Mol Biol. 2009;388:919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677131</ArticleId><ArticleId IdType="pubmed">19361448</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare SD, Ding F, Gwanmesia KN, Dokholyan NV. Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput Biol. 2005;1:230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1193989</ArticleId><ArticleId IdType="pubmed">16158094</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein FA, Pastore A, Masino L, Zeder-Lutz G, Nierengarten H, Oulad-Abdelghani M, Altschuh D, Mandel JL, Trottier Y. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol. 2007;371:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">17560603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathrop RH, Casale M, Tobias DJ, Marsh JL, Thompson LM. Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease. Proc Int Conf Intell Syst Mol Biol. 1998;6:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9783215</ArticleId></ArticleIdList></Reference><Reference><Citation>Legleiter J, Lotz GP, Miller J, Ko J, Ng C, Williams GL, Finkbeiner S, Patterson PH, Muchowski PJ. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem. 2009;284:21647&#x2013;21658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755888</ArticleId><ArticleId IdType="pubmed">19491400</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Huey-Tubman KE, Gao T, Li X, West AP, Jr., Bennett MJ, Bjorkman PJ. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat Struct Mol Biol. 2007;14:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">17450152</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 2004;20:146&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036808</ArticleId></ArticleIdList></Reference><Reference><Citation>Masino L, Kelly G, Leonard K, Trottier Y, Pastore A. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 2002;513:267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">11904162</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor W, Tomchick D, Otwinowski Z. Strategies for macromolecular synchrotron crystallography. Structure. 2000;8:R105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">10801499</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng. 2002;4:155&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, Urade Y, Goto Y, Naiki H, Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol. 2007;14:332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">17369839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen J, Baldwin MA, Cohen FE, Prusiner SB. Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. Biochemistry. 1995;34:4186&#x2013;4192.</Citation><ArticleIdList><ArticleId IdType="pubmed">7703230</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr Opin Struct Biol. 1996;6:848&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994886</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Finch JT, Berriman J, Lesk A. Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A. 2002;99:5591&#x2013;5595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122814</ArticleId><ArticleId IdType="pubmed">11960014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet. 2007;16:61&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002;35:819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet. 2002;18:202&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932021</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer SJ, Dewji NN. Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci U S A. 2006;103:1546&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345708</ArticleId><ArticleId IdType="pubmed">16432204</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet. 2008;17:345&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">17947294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Morishima I, Akagi T, Hashikawa T, Nukina N. Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem. 2001;276:45470&#x2013;45475.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584007</ArticleId></ArticleIdList></Reference><Reference><Citation>Temussi PA, Masino L, Pastore A. From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J. 2003;22:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140729</ArticleId><ArticleId IdType="pubmed">12554637</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, Byeon IJ, Anjum DH, Kodali R, Creamer TP, Conway JF, et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol. 2009;16:380&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706102</ArticleId><ArticleId IdType="pubmed">19270701</ArticleId></ArticleIdList></Reference><Reference><Citation>The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000;10:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121745</ArticleId></ArticleIdList></Reference><Reference><Citation>Truant R, Atwal RS, Desmond C, Munsie L, Tran T. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 2008;275:4252&#x2013;4262.</Citation><ArticleIdList><ArticleId IdType="pubmed">18637947</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto K, Shimizu H, Ishida T, Akiyama Y, Nukina N. Aggregation mechanism of polyglutamine disease revealed using quantum chemical calculations, fragment molecular orbital calculations, molecular dynamics simulations, and binding free energy calculations. Journal of molecular Structure. 2006;778:85&#x2013;95.</Citation></Reference><Reference><Citation>Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta. 2004;1698:131&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitalis A, Wang X, Pappu RV. Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization. J Mol Biol. 2008;384:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847503</ArticleId><ArticleId IdType="pubmed">18824003</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Vitalis A, Wyczalkowski MA, Pappu RV. Characterizing the conformational ensemble of monomeric polyglutamine. Proteins. 2006;63:297&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16299774</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008;31:521&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580745</ArticleId><ArticleId IdType="pubmed">18778858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19752451</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.</ArticleTitle><Pagination><StartPage>847</StartPage><EndPage>853</EndPage><MedlinePgn>847-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181b78448</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Several lines of evidence indicate that a decrease in the CSF concentration of amyloid beta(42) (Abeta(42)) is a potential biomarker for incident Alzheimer disease. In contrast, studies on plasma Abeta(1-40) and Abeta(1-42) peptide levels have yielded contradictory results. Here, we explored the links between incident dementia and plasma Abeta(1-40) and Abeta(1-42) peptide concentrations in the prospective, population-based Three-City (3C) Study. We also assessed the association between plasma concentrations of truncated Abeta (Abeta(n-40) and Abeta(n-42)) and the risk of dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">During a subsequent 4-year follow-up period, 257 individuals presented incident dementia from 8,414 participants, and a subcohort of 1,185 individuals without dementia was drawn as a control cohort. Plasma levels of Abeta(1-40), Abeta(1-42), Abeta(n-40), and Abeta(n-42) were measured using an xMAP-based assay technology. The association between plasma Abeta peptide levels and the risk of dementia was assessed using Cox proportional hazard models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the various Abeta variables analyzed, the Abeta(1-42)/Abeta(1-40) and Abeta(n-42)/Abeta(n-40) ratios presented the strongest association with the risk of dementia: people with a high Abeta(1-42)/Abeta(1-40) or Abeta(n-42)/Abeta(n-40) ratio had a lower risk of developing dementia. These associations were restricted to individuals diagnosed at 2 years of follow-up and the Abeta(n-42)/Abeta(n-40) ratio was mainly associated with the risk of mixed/vascular dementia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Plasma Abeta peptide concentrations and Abeta(1-42)/Abeta(1-40) and Abeta(n-42)/Abeta(n-40) ratios may be useful markers to indicate individuals susceptible to short-term risk of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>J-C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Unit&#xe9; INSERM 744, Institut Pasteur de Lille, BP 245, 1, rue du professeur Calmette, F-59019 Lille c&#xe9;dex, France. jean-charles.lambert@pasteur-lille.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schraen-Maschke</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fievet</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rouaud</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>J-F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alp&#xe9;rovitch</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011933">Reagent Kits, Diagnostic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011933" MajorTopicYN="N">Reagent Kits, Diagnostic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19752451</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181b78448</ArticleId><ArticleId IdType="pii">73/11/847</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19776284</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>38</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.</ArticleTitle><Pagination><StartPage>11982</StartPage><EndPage>11992</EndPage><MedlinePgn>11982-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3158-09.2009</ELocationID><Abstract><AbstractText>Microglia are the brain's tissue macrophages and are found in an activated state surrounding beta-amyloid plaques in the Alzheimer's disease brain. Microglia interact with fibrillar beta-amyloid (fAbeta) through an ensemble of surface receptors composed of the alpha(6)beta(1) integrin, CD36, CD47, and the class A scavenger receptor. These receptors act in concert to initiate intracellular signaling cascades and phenotypic activation of these cells. However, it is unclear how engagement of this receptor complex is linked to the induction of an activated microglial phenotype. We report that the response of microglial cells to fibrillar forms of Abeta requires the participation of Toll-like receptors (TLRs) and the coreceptor CD14. The response of microglia to fAbeta is reliant upon CD14, which act together with TLR4 and TLR2 to bind fAbeta and to activate intracellular signaling. We find that cells lacking these receptors could not initiate a Src-Vav-Rac signaling cascade leading to reactive oxygen species production and phagocytosis. The fAbeta-mediated activation of p38 MAPK also required CD14, TLR4, and TLR2. Inhibition of p38 abrogated fAbeta-induced reactive oxygen species production and attenuated the induction of phagocytosis. Microglia lacking CD14, TLR4, and TLR2 showed no induction of phosphorylated IkappaBalpha following fAbeta. These data indicate these innate immune receptors function as members of the microglial fAbeta receptor complex and identify the signaling mechanisms whereby they contribute to microglial activation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reed-Geaghan</LastName><ForeName>Erin G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Hise</LastName><ForeName>Amy G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG16047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 T32 AG0071</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS057867</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31NS057867</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19776284</ArticleId><ArticleId IdType="mid">NIHMS155908</ArticleId><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3158-09.2009</ArticleId><ArticleId IdType="pii">29/38/11982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aderem A. How to eat something bigger than your head. Cell. 2002;110:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150991</ArticleId></ArticleIdList></Reference><Reference><Citation>Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">10358769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ago T, Nunoi H, Ito T, Sumimoto H. Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47(phox). Triple replacement of serines 303, 304, and 328 with aspartates disrupts the SH3 domain-mediated intramolecular interaction in p47(phox), thereby activating the oxidase. J Biol Chem. 1999;274:33644&#x2013;33653.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ago T, Kuribayashi F, Hiroaki H, Takeya R, Ito T, Kohda D, Sumimoto H. Phosphorylation of p47phox directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. Proc Natl Acad Sci U S A. 2003;100:4474&#x2013;4479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153580</ArticleId><ArticleId IdType="pubmed">12672956</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S. Toll-like receptors and innate immunity. Adv Immunol. 2001;78:1&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11432202</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol. 2000;1:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">11101877</ArticleId></ArticleIdList></Reference><Reference><Citation>Babior BM. NADPH oxidase: an update. Blood. 1999;93:1464&#x2013;1476.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029572</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242:540&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">3140380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742111</ArticleId><ArticleId IdType="pubmed">12684452</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaty CD, Franklin TL, Uehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. Eur J Immunol. 1994;24:1278&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515809</ArticleId></ArticleIdList></Reference><Reference><Citation>Beg AA, Baldwin AS., Jr The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 1993;7:2064&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pubmed">8224838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergendi L, Benes L, Durackov&#xe1; Z, Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sci. 1999;65:1865&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10576429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998;18:1633&#x2013;1641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792636</ArticleId><ArticleId IdType="pubmed">9464988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianca VD, Dusi S, Bianchini E, Dal Pr&#xe0; I, Rossi F. beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem. 1999;274:15493&#x2013;15499.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science. 2004;304:1014&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">15143282</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;27:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">2110186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol. 1995;130:503&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120533</ArticleId><ArticleId IdType="pubmed">7542656</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol. 1995;15:2809&#x2013;2818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230512</ArticleId><ArticleId IdType="pubmed">7739562</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267:1485&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7878466</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 1996;84:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">8601309</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci. 1999;19:928&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782151</ArticleId><ArticleId IdType="pubmed">9920656</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Karlo JC, Kao SC, Landreth GE. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001;21:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762255</ArticleId><ArticleId IdType="pubmed">11160388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D, Chang P, Zhang Q, Reddy PG, Bokoch GM, Greenberg S. Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J Exp Med. 1997;186:1487&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199122</ArticleId><ArticleId IdType="pubmed">9348306</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, Hayem G, Jensen ON, Gougerot-Pocidalo MA, El-Benna J. A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest. 2006;116:2033&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1479423</ArticleId><ArticleId IdType="pubmed">16778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLeo FR, Quinn MT. Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leukoc Biol. 1996;60:677&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8975869</ArticleId></ArticleIdList></Reference><Reference><Citation>El Bekay R, Alba G, Reyes ME, Chac&#xf3;n P, Vega A, Mart&#xed;n-Nieto J, Jim&#xe9;nez J, Ramos E, Oliv&#xe1;n J, Pintado E, Sobrino F. Rac2 GTPase activation by angiotensin II is modulated by Ca2+/calcineurin and mitogen-activated protein kinases in human neutrophils. J Mol Endocrinol. 2007;39:351&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">17975262</ArticleId></ArticleIdList></Reference><Reference><Citation>El Benna J, Faust RP, Johnson JL, Babior BM. Phosphorylation of the respiratory burst oxidase subunit p47phox as determined by two-dimensional phosphopeptide mapping. Phosphorylation by protein kinase C, protein kinase A, and a mitogen-activated protein kinase. J Biol Chem. 1996;271:6374&#x2013;6378.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626435</ArticleId></ArticleIdList></Reference><Reference><Citation>English BK, Ihle JN, Myracle A, Yi T. Hck tyrosine kinase activity modulates tumor necrosis factor production by murine macrophages. J Exp Med. 1993;178:1017&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191180</ArticleId><ArticleId IdType="pubmed">8350043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Walter S, K&#xfc;hl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004;18:203&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox Res. 2004;6:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15658002</ArticleId></ArticleIdList></Reference><Reference><Citation>Finco TS, Beg AA, Baldwin AS., Jr Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. Proc Natl Acad Sci U S A. 1994;91:11884&#x2013;11888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45340</ArticleId><ArticleId IdType="pubmed">7991551</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res. 2007;10:61&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17378753</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Combs CK. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci. 2006;26:4644&#x2013;4648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674057</ArticleId><ArticleId IdType="pubmed">16641245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangloff SC, Hijiya N, Haziot A, Goyert SM. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin Infect Dis. 1999;28:491&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">10194066</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Y, Gulbins E, Altman A, Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci U S A. 1994;91:8602&#x2013;8606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44654</ArticleId><ArticleId IdType="pubmed">8078929</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. 2002;11:257&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12505419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory CD, Devitt A. CD14 and apoptosis. Apoptosis. 1999;4:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14634291</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT. Cutting edge: cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol. 1999;162:6971&#x2013;6975.</Citation><ArticleIdList><ArticleId IdType="pubmed">10358136</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzelmann M, Polk HC, Jr, Miller FN. Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan. Infect Immun. 1998;66:5842&#x2013;5847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC108739</ArticleId><ArticleId IdType="pubmed">9826363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 1999;72:2053&#x2013;2058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi Y, Claus S, Relman DA. Bordetella pertussis filamentous hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18) J Exp Med. 1994;180:1225&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191706</ArticleId><ArticleId IdType="pubmed">7931059</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol. 2008;181:7254&#x2013;7262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701549</ArticleId><ArticleId IdType="pubmed">18981147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Yan EZ, Fan Y, Zong ZH, Qi ZM, Li Z. Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. Acta Pharmacol Sin. 2005;26:943&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16038626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res. 2006;83:711&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440498</ArticleId><ArticleId IdType="pubmed">16541438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging. 2004;25:431&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Ordija CM, Freeman MW. Activation of signaling pathways by putative scavenger receptor class A (SR-A) ligands requires CD14 but not SR-A. Biochem Biophys Res Commun. 2003;310:542&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521944</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar &#x3b2;-amyloid through a &#x3b2;1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong L, Ge BX. MyD88-independent activation of a novel actin-Cdc42/Rac pathway is required for Toll-like receptor-stimulated phagocytosis. Cell Res. 2008;18:745&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">18542102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopec KK, Carroll RT. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J Neurochem. 1998;71:2123&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798938</ArticleId></ArticleIdList></Reference><Reference><Citation>Laroux FS, Romero X, Wetzler L, Engel P, Terhorst C. Cutting edge: MyD88 controls phagocyte NADPH oxidase function and killing of gram-negative bacteria. J Immunol. 2005;175:5596&#x2013;5600.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DJ, Cox D, Li J, Greenberg S. Rac1 and Cdc42 are required for phagocytosis, but not NF-kappaB-dependent gene expression, in macrophages challenged with Pseudomonas aeruginosa. J Biol Chem. 2000;275:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617597</ArticleId></ArticleIdList></Reference><Reference><Citation>Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-Schaeffer W, Fassbender K. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 2009;30:759&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">17905482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain. 2005;128:1778&#x2013;1789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A. 1994;91:12243&#x2013;12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45413</ArticleId><ArticleId IdType="pubmed">7991613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble A&#x3b2; through fluid phase macropinocytosis. J Neurosci. 2009;29:4252&#x2013;4262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034143</ArticleId><ArticleId IdType="pubmed">19339619</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Bamberger ME, Combs CK, Landreth GE. &#x3b2;-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci. 1998;18:4451&#x2013;4460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792680</ArticleId><ArticleId IdType="pubmed">9614222</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Bonaiuto C, Baron P, Otvos L, Jr, Rossi F, Cassatella MA. Priming of monocyte respiratory burst by beta-amyloid fragment (25&#x2013;35) Neurosci Lett. 1996;219:91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8971787</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11905821</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoretti P, Gazzaruso C, Vito CD, Emanuele E, Bianchi M, Coen E, Reino M, Geroldi D. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci Lett. 2006;391:147&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157451</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber A, Hackam DJ. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176:3070&#x2013;3079.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493066</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Osada Y, Sunatani T, Kim IS, Nakanishi Y, Shiratsuchi A. Signalling pathway involving GULP, MAPK, and Rac1 for SR-BI-induced phagocytosis of apoptotic cells. J Biochem. 2009;145:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">19122200</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Kim HY, Jou I, Park SM. GM1 induces p38 and microtubule dependent ramification of rat primary microglia in vitro. Brain Res. 2008;1244:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930716</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett. 1990;119:32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2097581</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer A, B&#xf6;ttcher A, Ors&#xf3; E, Kapinsky M, Nagy P, Bodn&#xe1;r A, Spreitzer I, Liebisch G, Drobnik W, Gempel K, Horn M, Holmer S, Hartung T, Multhoff G, Sch&#xfc;tz G, Schindler H, Ulmer AJ, Heine H, Stelter F, Sch&#xfc;tt C, et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol. 2001;31:3153&#x2013;3164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11745332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pick E. Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using an enzyme immunoassay microplate reader. Methods Enzymol. 1986;132:407&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo H, Jou I, Jung S, Hong S, Joe EH. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport. 1998;9:871&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">9579682</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Li G, Qian X, Liu Y, Wu X, Liu B, Hong JS, Block ML. Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia. 2005;52:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920727</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard KL, Filali M, Pr&#xe9;fontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid &#x3b2;1&#x2013;42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci. 2008;28:5784&#x2013;5793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670789</ArticleId><ArticleId IdType="pubmed">18509040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70:401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">1643658</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol. 1998;63:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">9581795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Jr, Ritchie TC, Hunninghake GW, Zandi E, Engelhardt JF. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem. 2001;276:30188&#x2013;30198.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402028</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci. 2002;22:3376&#x2013;3385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758401</ArticleId><ArticleId IdType="pubmed">11978814</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci. 2009;29:1846&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699573</ArticleId><ArticleId IdType="pubmed">19211891</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendide K, Reiner NE, Lee JS, Bourgoin S, Talal A, Hmama Z. Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: regulation by phosphatidylinositol 3-kinase and cytohesin-1. J Immunol. 2005;174:4210&#x2013;4219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15778383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia. 2007;55:412&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203473</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits HA, de Vos NM, Wat JW, van der Bruggen T, Verhoef J, Nottet HS. Intracellular pathways involved in TNF-alpha and superoxide anion release by Abeta(1-42)-stimulated primary human macrophages. J Neuroimmunol. 2001;115:144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282164</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanov&#xe1; I, Corcoran ML, Horak EM, Wahl LM, Bolen JB, Horak ID. Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn. J Biol Chem. 1993;268:20725&#x2013;20728.</Citation><ArticleIdList><ArticleId IdType="pubmed">7691802</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation. 2004;1:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC509427</ArticleId><ArticleId IdType="pubmed">15285801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumimoto H, Hata K, Mizuki K, Ito T, Kage Y, Sakaki Y, Fukumaki Y, Nakamura M, Takeshige K. Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47phox with p22phox is required for activation of the NADPH oxidase. J Biol Chem. 1996;271:22152&#x2013;22158.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol. 2003;183:394&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Taborda CP, Casadevall A. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity. 2002;16:791&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 2006;129:3006&#x2013;3019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2445613</ArticleId><ArticleId IdType="pubmed">16984903</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, Yue Z, Talloczy Z, Hagemann T, Cho W, Messing A, Sulzer DL, Goldman JE. Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Hum Mol Genet. 2008;17:1540&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902290</ArticleId><ArticleId IdType="pubmed">18276609</ArticleId></ArticleIdList></Reference><Reference><Citation>Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 1995;14:2876&#x2013;2883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398406</ArticleId><ArticleId IdType="pubmed">7796813</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou M, Brandenburg K, Kusumoto S, Fukase K, Mackie A, Seydel U, Triantafilou K. Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J. 2004;381:527&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133861</ArticleId><ArticleId IdType="pubmed">15040785</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006;281:31002&#x2013;31011.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880211</ArticleId></ArticleIdList></Reference><Reference><Citation>Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem. 2008;104:524&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986235</ArticleId></ArticleIdList></Reference><Reference><Citation>Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 1999;401:811&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10548109</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Muiswinkel FL, Raupp SF, de Vos NM, Smits HA, Verhoef J, Eikelenboom P, Nottet HS. The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. J Neuroimmunol. 1999;96:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227431</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oosten M, van Amersfoort ES, van Berkel TJ, Kuiper J. Scavenger receptor-like receptors for the binding of lipopolysaccharide and lipoteichoic acid to liver endothelial and Kupffer cells. J Endotoxin Res. 2001;7:381&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">11753207</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007;20:947&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem. 2006;281:20842&#x2013;20850.</Citation><ArticleIdList><ArticleId IdType="pubmed">16728400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WS, Simon DI, Rosoff PM, Rao NK, Chapman HA. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87) Immunology. 1996;88:90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1456468</ArticleId><ArticleId IdType="pubmed">8707356</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamori T, Inanami O, Nagahata H, Cui Y, Kuwabara M. Roles of p38 MAPK, PKC and PI3-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. FEBS Lett. 2000;467:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SR, Al-Hertani W, Byers D, Bortolussi R. Lipopolysaccharide-binding protein- and CD14-dependent activation of mitogen-activated protein kinase p38 by lipopolysaccharide in human neutrophils is associated with priming of respiratory burst. Infect Immun. 2002;70:4068&#x2013;4074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC128158</ArticleId><ArticleId IdType="pubmed">12117913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuluaga S, Guti&#xe9;rrez-Uzquiza A, Bragado P, Alvarez-Barrientos A, Benito M, Nebreda AR, Porras A. p38alpha MAPK can positively or negatively regulate Rac-1 activity depending on the presence of serum. FEBS Lett. 2007;581:3819&#x2013;3825.</Citation><ArticleIdList><ArticleId IdType="pubmed">17658519</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19778514</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Cortical firing and sleep homeostasis.</ArticleTitle><Pagination><StartPage>865</StartPage><EndPage>878</EndPage><MedlinePgn>865-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.08.024</ELocationID><Abstract><AbstractText>The need to sleep grows with the duration of wakefulness and dissipates with time spent asleep, a process called sleep homeostasis. What are the consequences of staying awake on brain cells, and why is sleep needed? Surprisingly, we do not know whether the firing of cortical neurons is affected by how long an animal has been awake or asleep. Here, we found that after sustained wakefulness cortical neurons fire at higher frequencies in all behavioral states. During early NREM sleep after sustained wakefulness, periods of population activity (ON) are short, frequent, and associated with synchronous firing, while periods of neuronal silence are long and frequent. After sustained sleep, firing rates and synchrony decrease, while the duration of ON periods increases. Changes in firing patterns in NREM sleep correlate with changes in slow-wave activity, a marker of sleep homeostasis. Thus, the systematic increase of firing during wakefulness is counterbalanced by staying asleep.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vyazovskiy</LastName><ForeName>Vladyslav V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Wisconsin-Madison, Madison, WI 53719, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olcese</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Lazimy</LastName><ForeName>Yaniv M</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Faraguna</LastName><ForeName>Ugo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Esser</LastName><ForeName>Steve K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Justin C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Cirelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tononi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP1 OD000579</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH077967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2009 Sep 24;63(6):719-21. doi: 10.1016/j.neuron.2009.09.008.</RefSource><PMID Version="1">19778500</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005583" MajorTopicYN="N">Fourier Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011921" MajorTopicYN="N">Rats, Inbred WKY</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012815" MajorTopicYN="N">Signal Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COI statement: All authors indicated no financial conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19778514</ArticleId><ArticleId IdType="mid">NIHMS173051</ArticleId><ArticleId IdType="pmc">PMC2819325</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.08.024</ArticleId><ArticleId IdType="pii">S0896-6273(09)00637-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Achermann P, Borbely AA. Mathematical models of sleep regulation. Front Biosci. 2003;8:s683&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700054</ArticleId></ArticleIdList></Reference><Reference><Citation>Amzica F, Steriade M. Electrophysiological correlates of sleep delta waves. Electroencephalogr Clin Neurophysiol. 1998;107:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751278</ArticleId></ArticleIdList></Reference><Reference><Citation>Aton SJ, Seibt J, Dumoulin M, Jha SK, Steinmetz N, Coleman T, Naidoo N, Frank MG. Mechanisms of sleep-dependent consolidation of cortical plasticity. Neuron. 2009;61:454&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665998</ArticleId><ArticleId IdType="pubmed">19217381</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21:1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11598490</ArticleId></ArticleIdList></Reference><Reference><Citation>Badawy RA, Curatolo JM, Newton M, Berkovic SF, Macdonell RA. Sleep deprivation increases cortical excitability in epilepsy: syndrome-specific effects. Neurology. 2006;67:1018&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartho P, Hirase H, Monconduit L, Zugaro M, Harris KD, Buzsaki G. Characterization of neocortical principal cells and interneurons by network interactions and extracellular features. J Neurophysiol. 2004;92:600&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazhenov M, Timofeev I, Steriade M, Sejnowski TJ. Model of thalamocortical slow-wave sleep oscillations and transitions to activated States. J Neurosci. 2002;22:8691&#x2013;8704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757797</ArticleId><ArticleId IdType="pubmed">12351744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellina V, Huber R, Rosanova M, Mariotti M, Tononi G, Massimini M. Cortical excitability and sleep homeostasis in humans: a TMS/hd-EEG study. Journal of Sleep Research. 2008;17:39.</Citation></Reference><Reference><Citation>Burns BD, Stean JP, Webb AC. The effects of sleep on neurons in isolated cerebral cortex. Proc R Soc Lond B Biol Sci. 1979;206:281&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">43974</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G, Kaila K, Raichle M. Inhibition and brain work. Neuron. 2007;56:771&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266612</ArticleId><ArticleId IdType="pubmed">18054855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajochen C, Foy R, Dijk DJ. Frontal predominance of a relative increase in sleep delta and theta EEG activity after sleep loss in humans. Sleep Res Online. 1999;2:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11382884</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvet J, Fourment A, Thiefry M. Electrical activity in neocortical projection and association areas during slow wave sleep. Brain Res. 1973;52:173&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">4349541</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908446</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirelli C, Tononi G. Is sleep essential? PLoS Biol. 2008;6:e216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525690</ArticleId><ArticleId IdType="pubmed">18752355</ArticleId></ArticleIdList></Reference><Reference><Citation>Civardi C, Boccagni C, Vicentini R, Bolamperti L, Tarletti R, Varrasi C, Monaco F, Cantello R. Cortical excitability and sleep deprivation: a transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry. 2001;71:809&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737655</ArticleId><ArticleId IdType="pubmed">11723210</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras D, Steriade M. Cellular basis of EEG slow rhythms: a study of dynamic corticothalamic relationships. J Neurosci. 1995;15:604&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578315</ArticleId><ArticleId IdType="pubmed">7823167</ArticleId></ArticleIdList></Reference><Reference><Citation>Czarnecki A, Birtoli B, Ulrich D. Cellular mechanisms of burst firing-mediated long-term depression in rat neocortical pyramidal cells. J Physiol. 2007;578:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075152</ArticleId><ArticleId IdType="pubmed">17082228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadvand L, Stryker MP, Frank MG. Sleep does not enhance the recovery of deprived eye responses in developing visual cortex. Neuroscience. 2006;143:815&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1832163</ArticleId><ArticleId IdType="pubmed">17000056</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash MB, Douglas CL, Vyazovskiy VV, Cirelli C, Tononi G. Long-term homeostasis of extracellular glutamate in the rat cerebral cortex across sleep and waking states. J Neurosci. 2009;29:620&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770705</ArticleId><ArticleId IdType="pubmed">19158289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deboer T, Vansteensel MJ, Detari L, Meijer JH. Sleep states alter activity of suprachiasmatic nucleus neurons. Nat Neurosci. 2003;6:1086&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">12958601</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai NS, Cudmore RH, Nelson SB, Turrigiano GG. Critical periods for experience-dependent synaptic scaling in visual cortex. Nat Neurosci. 2002;5:783&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">12080341</ArticleId></ArticleIdList></Reference><Reference><Citation>Desiraju T. Discharge properties of neurons of the parietal association cortex during states of sleep and wakefulness in the monkey. Brain Res. 1972;47:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4345036</ArticleId></ArticleIdList></Reference><Reference><Citation>Destexhe A, Contreras D, Steriade M. Spatiotemporal analysis of local field potentials and unit discharges in cat cerebral cortex during natural wake and sleep states. J Neurosci. 1999;19:4595&#x2013;4608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782626</ArticleId><ArticleId IdType="pubmed">10341257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijk DJ, Beersma DG, Daan S. EEG power density during nap sleep: reflection of an hourglass measuring the duration of prior wakefulness. J Biol Rhythms. 1987;2:207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">2979661</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragoi G, Harris KD, Buzsaki G. Place representation within hippocampal networks is modified by long-term potentiation. Neuron. 2003;39:843&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948450</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser SK, Hill SL, Tononi G. Sleep homeostasis and cortical synchronization: I. Modeling the effects of synaptic strength on sleep slow waves. Sleep. 2007;30:1617&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276134</ArticleId><ArticleId IdType="pubmed">18246972</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci. 2008;28:4088&#x2013;4095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597531</ArticleId><ArticleId IdType="pubmed">18400908</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank MG, Issa NP, Stryker MP. Sleep enhances plasticity in the developing visual cortex. Neuron. 2001;30:275&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343661</ArticleId></ArticleIdList></Reference><Reference><Citation>Galarreta M, Hestrin S. Frequency-dependent synaptic depression and the balance of excitation and inhibition in the neocortex. Nat Neurosci. 1998;1:587&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil Z, Connors BW, Amitai Y. Differential regulation of neocortical synapses by neuromodulators and activity. Neuron. 1997;19:679&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">9331357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilestro GF, Tononi G, Cirelli C. Widespread changes in synaptic markers as a function of sleep and wakefulness in Drosophila. Science. 2009;324:109&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715914</ArticleId><ArticleId IdType="pubmed">19342593</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider B, Duque A, Hasenstaub AR, McCormick DA. Neocortical network activity in vivo is generated through a dynamic balance of excitation and inhibition. J Neurosci. 2006;26:4535&#x2013;4545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674060</ArticleId><ArticleId IdType="pubmed">16641233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirase H, Leinekugel X, Czurko A, Csicsvari J, Buzsaki G. Firing rates of hippocampal neurons are preserved during subsequent sleep episodes and modified by novel awake experience. Proc Natl Acad Sci U S A. 2001;98:9386&#x2013;9390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55430</ArticleId><ArticleId IdType="pubmed">11470910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson JA, McCarley RW. Cortical unit activity in sleep and waking. Electroencephalogr Clin Neurophysiol. 1971;30:97&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">4100287</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber R, Esser SK, Ferrarelli F, Massimini M, Peterson MJ, Tononi G. TMS-induced cortical potentiation during wakefulness locally increases slow wave activity during sleep. PLoS ONE. 2007a;2:e276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1803030</ArticleId><ArticleId IdType="pubmed">17342210</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber R, Ghilardi MF, Massimini M, Ferrarelli F, Riedner BA, Peterson MJ, Tononi G. Arm immobilization causes cortical plastic changes and locally decreases sleep slow wave activity. Nat Neurosci. 2006;9:1169&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936722</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature. 2004;430:78&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184907</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber R, Tononi G, Cirelli C. Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep. 2007b;30:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">17326538</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomura Y, Sirota A, Ozen S, Montgomery S, Mizuseki K, Henze DA, Buzsaki G. Integration and Segregation of Activity in Entorhinal-Hippocampal Subregions by Neocortical Slow Oscillations. Neuron. 2006;52:871&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">17145507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji D, Wilson MA. Coordinated memory replay in the visual cortex and hippocampus during sleep. Nat Neurosci. 2007;10:100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">17173043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci. 2005;26:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183137</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson MP, Frank LM. Network dynamics underlying the formation of sparse, informative representations in the hippocampus. J Neurosci. 2008;28:14271&#x2013;14281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632980</ArticleId><ArticleId IdType="pubmed">19109508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattler H, Dijk DJ, Borbely AA. Effect of unilateral somatosensory stimulation prior to sleep on the sleep EEG in humans. J Sleep Res. 1994;3:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudrimoti HS, Barnes CA, McNaughton BL. Reactivation of hippocampal cell assemblies: effects of behavioral state, experience, and EEG dynamics. J Neurosci. 1999;19:4090&#x2013;4101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782694</ArticleId><ArticleId IdType="pubmed">10234037</ArticleId></ArticleIdList></Reference><Reference><Citation>Laughlin SB, de Ruyter van Steveninck RR, Anderson JC. The metabolic cost of neural information. Nat Neurosci. 1998;1:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubenov EV, Siapas AG. Decoupling through synchrony in neuronal circuits with propagation delays. Neuron. 2008;58:118&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400168</ArticleId></ArticleIdList></Reference><Reference><Citation>Luczak A, Bartho P, Marguet SL, Buzsaki G, Harris KD. Sequential structure of neocortical spontaneous activity in vivo. Proc Natl Acad Sci U S A. 2007;104:347&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765463</ArticleId><ArticleId IdType="pubmed">17185420</ArticleId></ArticleIdList></Reference><Reference><Citation>Marder E, Thirumalai V. Cellular, synaptic and network effects of neuromodulation. Neural Netw. 2002;15:479&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12371506</ArticleId></ArticleIdList></Reference><Reference><Citation>Massimini M, Huber R, Ferrarelli F, Hill S, Tononi G. The sleep slow oscillation as a traveling wave. J Neurosci. 2004;24:6862&#x2013;6870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729597</ArticleId><ArticleId IdType="pubmed">15295020</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick DA, Connors BW, Lighthall JW, Prince DA. Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J Neurophysiol. 1985;54:782&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">2999347</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol. 2001;63:815&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181977</ArticleId></ArticleIdList></Reference><Reference><Citation>Molle M, Yeshenko O, Marshall L, Sara SJ, Born J. Hippocampal sharp wave-ripples linked to slow oscillations in rat slow-wave sleep. J Neurophysiol. 2006;96:62&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611848</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukovski M, Chauvette S, Timofeev I, Volgushev M. Detection of Active and Silent States in Neocortical Neurons from the Field Potential Signal during Slow-Wave Sleep. Cereb Cortex 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16547348</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata K, Kameda K. The Activity of Single Cortical Neurones of Unrestrained Cats During Sleep and Wakefulness. Arch Ital Biol. 1963;101:306&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">14166963</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda H, Adey WR. Firing of neuron pairs in cat association cortex during sleep and wakefulness. J Neurophysiol. 1970;33:672&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">4318175</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda H, Adey WR. Neuronal activity in the association cortex of the cat during sleep, wakefulness and anesthesia. Brain Res. 1973;54:243&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">4350811</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleksenko AI, Mukhametov LM, Polyakova IG, Supin AY, Kovalzon VM. Unihemispheric sleep deprivation in bottlenose dolphins. J Sleep Res. 1992;1:40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlides C, Winson J. Influences of hippocampal place cell firing in the awake state on the activity of these cells during subsequent sleep episodes. J Neurosci. 1989;9:2907&#x2013;2918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569689</ArticleId><ArticleId IdType="pubmed">2769370</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao Y, Liu ZW, Borok E, Rabenstein RL, Shanabrough M, Lu M, Picciotto MR, Horvath TL, Gao XB. Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons. J Clin Invest. 2007;117:4022&#x2013;4033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2104495</ArticleId><ArticleId IdType="pubmed">18060037</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedner BA, Vyazovskiy VV, Huber R, Massimini M, Esser S, Murphy M, Tononi G. Sleep homeostasis and cortical synchronization: III. A high-density EEG study of sleep slow waves in humans. Sleep. 2007;30:1643&#x2013;1657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276133</ArticleId><ArticleId IdType="pubmed">18246974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan AJ, Veldhuisen RJ, Nagelkerke NJ. Comparative evaluation of sleep deprivation and sedated sleep EEGs as diagnostic aids in epilepsy. Electroencephalogr Clin Neurophysiol. 1982;54:357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6181958</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalise A, Desiato MT, Gigli GL, Romigi A, Tombini M, Marciani MG, Izzi F, Placidi F. Increasing cortical excitability: a possible explanation for the proconvulsant role of sleep deprivation. Sleep. 2006;29:1595&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">17252890</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol GH, Ziburkus J, Huang S, Song L, Kim IT, Takamiya K, Huganir RL, Lee HK, Kirkwood A. Neuromodulators control the polarity of spike-timing-dependent synaptic plasticity. Neuron. 2007;55:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756178</ArticleId><ArticleId IdType="pubmed">17880895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">864466</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Amzica F, Nunez A. Cholinergic and noradrenergic modulation of the slow (approximately 0.3 Hz) oscillation in neocortical cells. J Neurophysiol. 1993a;70:1385&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">8283204</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Contreras D, Curro Dossi R, Nunez A. The slow (&lt; 1 Hz) oscillation in reticular thalamic and thalamocortical neurons: scenario of sleep rhythm generation in interacting thalamic and neocortical networks. J Neurosci. 1993b;13:3284&#x2013;3299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576531</ArticleId><ArticleId IdType="pubmed">8340808</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Nunez A, Amzica F. Intracellular analysis of relations between the slow (&lt; 1 Hz) neocortical oscillation and other sleep rhythms of the electroencephalogram. J Neurosci. 1993c;13:3266&#x2013;3283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576520</ArticleId><ArticleId IdType="pubmed">8340807</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Nunez A, Amzica F. A novel slow (&lt; 1 Hz) oscillation of neocortical neurons in vivo: depolarizing and hyperpolarizing components. J Neurosci. 1993d;13:3252&#x2013;3265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576541</ArticleId><ArticleId IdType="pubmed">8340806</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Timofeev I, Grenier F. Natural waking and sleep states: a view from inside neocortical neurons. J Neurophysiol. 2001;85:1969&#x2013;1985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11353014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobler I, Borbely AA. Sleep EEG in the rat as a function of prior waking. Electroencephalogr Clin Neurophysiol. 1986;64:74&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">2424723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376591</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano GG. Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci. 1999;22:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322495</ArticleId></ArticleIdList></Reference><Reference><Citation>van Welie I, van Hooft JA, Wadman WJ. Homeostatic scaling of neuronal excitability by synaptic modulation of somatic hyperpolarization-activated Ih channels. Proc Natl Acad Sci U S A. 2004;101:5123&#x2013;5128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387384</ArticleId><ArticleId IdType="pubmed">15051886</ArticleId></ArticleIdList></Reference><Reference><Citation>Verzeano M, Negishi K. Neuronal activity in cortical and thalamic networks. J Gen Physiol. 1960;43(6 Suppl):177&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195072</ArticleId><ArticleId IdType="pubmed">13841952</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat Neurosci. 2008a;11:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Tononi G, Tobler I. Cortical metabolic rates as measured by 2-deoxyglucose-uptake are increased after waking and decreased after sleep in mice. Brain Res Bull. 2008b;75:591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386085</ArticleId><ArticleId IdType="pubmed">18355635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Faraguna U, Cirelli C, Tononi G. Triggering slow waves during NREM sleep in the rat by intracortical electrical stimulation: effects of sleep/wake history and background activity. J Neurophysiol. 2009;101:1921&#x2013;1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695630</ArticleId><ArticleId IdType="pubmed">19164101</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Riedner BA, Cirelli C, Tononi G. Sleep homeostasis and cortical synchronization: II. A local field potential study of sleep slow waves in the rat. Sleep. 2007;30:1631&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276140</ArticleId><ArticleId IdType="pubmed">18246973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Ruijgrok G, Deboer T, Tobler I. Running wheel accessibility affects the regional electroencephalogram during sleep in mice. Cereb Cortex. 2006;16:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15901653</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Tobler I. Handedness leads to interhemispheric EEG asymmetry during sleep in the rat. J Neurophysiol. 2008;99:969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">18077659</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth E, Achermann P, Borbely AA. Brain topography of the human sleep EEG: antero-posterior shifts of spectral power. Neuroreport. 1996a;8:123&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051765</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth E, Dijk DJ, Achermann P, Borbely AA. Dynamics of the sleep EEG after an early evening nap: experimental data and simulations. Am J Physiol. 1996b;271:R501&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">8853369</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JC, Rennaker RL, Kipke D. Stability of chronic multichannel neural recordings: Implications for a long-term neural interface. Neurocomputing. 1999;26&#x2013;27:1069&#x2013;1076.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19779148</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>326</Volume><Issue>5955</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.</ArticleTitle><Pagination><StartPage>1005</StartPage><EndPage>1007</EndPage><MedlinePgn>1005-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1180962</ELocationID><Abstract><AbstractText>Amyloid-beta (Abeta) accumulation in the brain extracellular space is a hallmark of Alzheimer's disease. The factors regulating this process are only partly understood. Abeta aggregation is a concentration-dependent process that is likely responsive to changes in brain interstitial fluid (ISF) levels of Abeta. Using in vivo microdialysis in mice, we found that the amount of ISF Abeta correlated with wakefulness. The amount of ISF Abeta also significantly increased during acute sleep deprivation and during orexin infusion, but decreased with infusion of a dual orexin receptor antagonist. Chronic sleep restriction significantly increased, and a dual orexin receptor antagonist decreased, Abeta plaque formation in amyloid precursor protein transgenic mice. Thus, the sleep-wake cycle and orexin may play a role in the pathogenesis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jae-Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Miranda M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Smyth</LastName><ForeName>Liam P</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Fujiki</LastName><ForeName>Nobuhiro</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Nishino</LastName><ForeName>Seiji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH072525</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH072525</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000954">Antigens, Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501103">Cd200r1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064446">Orexin Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068797">Orexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018013">Receptors, Neuropeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9KCW39P2EI</RegistryNumber><NameOfSubstance UI="C519150">almorexant</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000954" MajorTopicYN="N">Antigens, Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="N">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064446" MajorTopicYN="N">Orexin Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068797" MajorTopicYN="N">Orexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018013" MajorTopicYN="N">Receptors, Neuropeptide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="Y">Wakefulness</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19779148</ArticleId><ArticleId IdType="mid">NIHMS159243</ArticleId><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="doi">10.1126/science.1180962</ArticleId><ArticleId IdType="pii">1180962</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Nat Cell Biol. 2004 Nov;6:1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. Neuron. 2003 Mar 27;37:925.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Neuron. 2005 Dec 22;48:913.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Science. 1996;274:99.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Proc Natl Acad Sci U S A. 2007 Jun 19;104:10673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilduff TS, et al. J Neurosci. 2008 Nov 12;28:11814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628168</ArticleId><ArticleId IdType="pubmed">19005045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y, et al. Eur J Neurosci. 2001 Oct;14:1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683899</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyron C, et al. J Neurosci. 1998 Dec 1;18:9996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793310</ArticleId><ArticleId IdType="pubmed">9822755</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ZL, et al. Proc Natl Acad Sci U S A. 2001 Aug 14;98:9965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55561</ArticleId><ArticleId IdType="pubmed">11493714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyazovskiy VV, Cirelli C, Pfister-Genskow M, Faraguna U, Tononi G. Nat Neurosci. 2008 Feb;11:200.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilestro GF, Tononi G, Cirelli C. Science. 2009 Apr 3;324:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715914</ArticleId><ArticleId IdType="pubmed">19342593</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlea JM, Ramanan N, Shaw PJ. Science. 2009 Apr 3;324:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850598</ArticleId><ArticleId IdType="pubmed">19342592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, et al. J Neurosci. 2009 Aug 26;29:10706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon JF, Petit D, Latreille V, Montplaisir J. Curr Pharm Des. 2008;14:3430.</Citation><ArticleIdList><ArticleId IdType="pubmed">19075719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19782030</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4164</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Molecular cell</Title><ISOAbbreviation>Mol Cell</ISOAbbreviation></Journal><ArticleTitle>Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes.</ArticleTitle><Pagination><StartPage>806</StartPage><EndPage>817</EndPage><MedlinePgn>806-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2009.07.021</ELocationID><Abstract><AbstractText>To unravel the roles of LXRs in inflammation and immunity, we examined the function of LXRs in development of IFN-gamma-mediated inflammation using cultured rat brain astrocytes. LXR ligands inhibit neither STAT1 phosphorylation nor STAT1 translocation to the nucleus but, rather, inhibit STAT1 binding to promoters and the expression of IRF1, TNFalpha, and IL-6, downstream effectors of STAT1 action. Immunoprecipitation data revealed that LXRbeta formed a trimer with PIAS1-pSTAT1, whereas LXRalpha formed a trimer with HDAC4-pSTAT1, mediated by direct ligand binding to the LXR proteins. In line with the fact that both PIAS1 and HDAC4 belong to the SUMO E3 ligase family, LXRbeta and LXRalpha were SUMO-conjugated by PIAS1 or HDAC4, respectively, and SUMOylation was blocked by transient transfection of appropriate individual siRNAs, reversing LXR-induced suppression of IRF1 and TNFalpha expression. Together, our data show that SUMOylation is required for the suppression of STAT1-dependent inflammatory responses by LXRs in IFN-gamma-stimulated brain astrocytes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon 442-721, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Myun</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ohn Soon</ForeName><Initials>OS</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chang Seok</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Joo Hong</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Soo Jung</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Joe</LastName><ForeName>Eun-hye</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Jou</LastName><ForeName>Ilo</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell</MedlineTA><NlmUniqueID>9802571</NlmUniqueID><ISSNLinking>1097-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050856">Interferon Regulatory Factor-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605215">Nr1h3 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057093">Orphan Nuclear Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050828">Protein Inhibitors of Activated STAT</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050794">STAT1 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025841">Small Ubiquitin-Related Modifier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494081">Stat1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mol Cell. 2009 Sep 24;35(6):731-2. doi: 10.1016/j.molcel.2009.09.002.</RefSource><PMID Version="1">19782020</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050856" MajorTopicYN="N">Interferon Regulatory Factor-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057093" MajorTopicYN="N">Orphan Nuclear Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050828" MajorTopicYN="N">Protein Inhibitors of Activated STAT</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050794" MajorTopicYN="N">STAT1 Transcription Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025841" MajorTopicYN="N">Small Ubiquitin-Related Modifier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19782030</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2009.07.021</ArticleId><ArticleId IdType="pii">S1097-2765(09)00517-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19786858</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1175</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Anesthesiology</Title><ISOAbbreviation>Anesthesiology</ISOAbbreviation></Journal><ArticleTitle>Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness.</ArticleTitle><Pagination><StartPage>964</StartPage><EndPage>970</EndPage><MedlinePgn>964-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/ALN.0b013e3181bc9719</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persistent postoperative cognitive decline is thought to be a public health problem, but its severity may have been overestimated because of limitations in statistical methodology. This study assessed whether long-term cognitive decline occurred after surgery or illness by using an innovative approach and including participants with early Alzheimer disease to overcome some limitations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort study, three groups were identified from participants tested annually at the Washington University Alzheimer's Disease Research Center in St. Louis, Missouri: those with noncardiac surgery, illness, or neither. This enabled long-term tracking of cognitive function before and after surgery and illness. The effect of surgery and illness on longitudinal cognitive course was analyzed using a general linear mixed effects model. For participants without initial dementia, time to dementia onset was analyzed using sequential Cox proportional hazards regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 575 participants, 214 were nondemented and 361 had very mild or mild dementia at enrollment. Cognitive trajectories did not differ among the three groups (surgery, illness, control), although demented participants declined more markedly than nondemented participants. Of the initially nondemented participants, 23% progressed to a clinical dementia rating greater than zero, but this was not more common after surgery or illness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study did not detect long-term cognitive decline independently attributable to surgery or illness, nor were these events associated with accelerated progression to dementia. The decision to proceed with surgery in elderly people, including those with early Alzheimer disease, may be made without factoring in the specter of persistent cognitive deterioration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avidan</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anesthesiology and Cardiothoracic Intensive Care, Department of Anesthesiology, Washington University in St. Louis, Missouri 63110-1093, USA. avidanm@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Searleman</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Storandt</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vannucci</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Saager</LastName><ForeName>Leif</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Evers</LastName><ForeName>Alex S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesthesiology</MedlineTA><NlmUniqueID>1300217</NlmUniqueID><ISSNLinking>0003-3022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2009 Nov;111(5):931-2. doi: 10.1097/ALN.0b013e3181bc988f.</RefSource><PMID Version="1">19786857</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2010 May;112(5):1280-1; author reply 1283-5. doi: 10.1097/ALN.0b013e3181d690a6.</RefSource><PMID Version="1">20418703</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2010 May;112(5):1281-2; author reply 1283-5. doi: 10.1097/ALN.0b013e3181d690b8.</RefSource><PMID Version="1">20418704</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2010 May;112(5):1282; author reply 1283-5. doi: 10.1097/ALN.0b013e3181d690ca.</RefSource><PMID Version="1">20418705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19786858</ArticleId><ArticleId IdType="mid">NIHMS149521</ArticleId><ArticleId IdType="pmc">PMC2783989</ArticleId><ArticleId IdType="doi">10.1097/ALN.0b013e3181bc9719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, Rabbitt P, Jolles J, Larsen K, Hanning CD, Langeron O, Johnson T, Lauven PM, Kristensen PA, Biedler A, van Beem H, Fraidakis O, Silverstein JH, Beneken JE, Gravenstein JS. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet. 1998;351:857&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9525362</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, Gravenstein JS. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology. 2008;108:18&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">18156878</ArticleId></ArticleIdList></Reference><Reference><Citation>Abildstrom H, Rasmussen LS, Rentowl P, Hanning CD, Rasmussen H, Kristensen PA, Moller JT. Cognitive dysfunction 1-2 years after non-cardiac surgery in the elderly. ISPOCD group. International Study of Post-Operative Cognitive Dysfunction. Acta Anaesthesiol Scand. 2000;44:1246&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11065205</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Russo P, Sharrock NE, Mattis S, Szatrowski TP, Charlson ME. Cognitive effects after epidural vs general anesthesia in older adults. A randomized trial. Jama. 1995;274:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7791257</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz J, Christensen KB, Lund T, Lohse N, Rasmussen LS. Long-term consequences of postoperative cognitive dysfunction. Anesthesiology. 2009;110:548&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225398</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology. 2004;101:703&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329595</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Tanzi RE. Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol. 2006;41:346&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564662</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Culley DJ, Dong Y, Zhang G, Zhang B, Moir RD, Frosch MP, Crosby G, Tanzi RE. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol. 2008;64:618&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612087</ArticleId><ArticleId IdType="pubmed">19006075</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Dong Y, Maeda U, Moir R, Inouye SK, Culley DJ, Crosby G, Tanzi RE. Isoflurane-induced apoptosis: A potential pathogenic link between delirium and dementia. J Gerontol A Biol Sci Med Sci. 2006;61:1300&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17234824</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T, Monk T, Rasmussen LS, Abildstrom H, Houx P, Korttila K, Kuipers HM, Hanning CD, Siersma VD, Kristensen D, Canet J, Ibanaz MT, Moller JT. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology. 2002;96:1351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12170047</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen LS, Larsen K, Houx P, Skovgaard LT, Hanning CD, Moller JT. The assessment of postoperative cognitive function. Acta Anaesthesiol Scand. 2001;45:275&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207462</ArticleId></ArticleIdList></Reference><Reference><Citation>Selnes OA, Pham L, Zeger S, McKhann GM. Defining cognitive change after CABG: Decline versus normal variability. Ann Thorac Surg. 2006;82:388&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16863734</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman S, Stygall J, Hirani S, Shaefi S, Maze M. Postoperative cognitive dysfunction after noncardiac surgery: A systematic review. Anesthesiology. 2007;106:572&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325517</ArticleId></ArticleIdList></Reference><Reference><Citation>Selwood A, Orrell M. Long term cognitive dysfunction in older people after non-cardiac surgery. Bmj. 2004;328:120&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314495</ArticleId><ArticleId IdType="pubmed">14726316</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11172175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearn SJ, Pole R, Wesnes K, Faragher EB, Hooper TL, McCollum CN. Cerebral injury during cardiopulmonary bypass: Emboli impair memory. J Thorac Cardiovasc Surg. 2001;121:1150&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11385383</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroobant N, Van Nooten G, Belleghem Y, Vingerhoets G. Short-term and long-term neurocognitive outcome in on-pump versus off-pump CABG. Eur J Cardiothorac Surg. 2002;22:559&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen LS, Johnson T, Kuipers HM, Kristensen D, Siersma VD, Vila P, Jolles J, Papaioannou A, Abildstrom H, Silverstein JH, Bonal JA, Raeder J, Nielsen IK, Korttila K, Munoz L, Dodds C, Hanning CD, Moller JT. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand. 2003;47:260&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648190</ArticleId></ArticleIdList></Reference><Reference><Citation>Selnes OA, Grega MA, Bailey MM, Pham LD, Zeger SL, Baumgartner WA, McKhann GM. Cognition 6 years after surgical or medical therapy for coronary artery disease. Ann Neurol. 2008;63:581&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481292</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke WJ, Miller JP, Rubin EH, Morris JC, Coben LA, Duchek J, Wittels IG, Berg L. Reliability of the Washington University Clinical Dementia Rating. Arch Neurol. 1988;45:31&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Storandt M, Miller JP, Kinscherf DA, Grant EA, Morris JC, Berg L. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechler D, Stone CP. Wechler Memory Scale Manual. New York: Psychological Corporation; 1973.</Citation></Reference><Reference><Citation>Benton AL. The Revised Visual Retention Test: Clinical and Experimental Applictaions. New York: Psychological Corporation; 1963.</Citation></Reference><Reference><Citation>Wechler D. Wechler Adult Intelligence Scale Manual. New York: Psychological Corporation; 1955.</Citation></Reference><Reference><Citation>Goodglass H, Kaplan E. Boston Naming Test Scoring Booklet. Philadelphia: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Armitage SG. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol Monogr. 1946;60:1&#x2013;48.</Citation></Reference><Reference><Citation>Botwinick J, Storandt M. Speed functions, vocabulary ability, and age. Percept Mot Skills. 1973;36:1123&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">4711963</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurstone LL, Thurstone TG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago: Science Research Associates; 1949.</Citation></Reference><Reference><Citation>Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, Miller JP, Storandt M, Morris JC. The AD8: A brief informant interview to detect dementia. Neurology. 2005;65:559&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006;67:1942&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159098</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzitari M, Pozzi C, Ferrucci L, Chiarantini D, Rinaldi LA, Baccini M, Pini R, Masotti G, Marchionni N, Di Bari M. Subtle neurological abnormalities as risk factors for cognitive and functional decline, cerebrovascular events, and mortality in older community-dwelling adults. Arch Intern Med. 2008;168:1270&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642714</ArticleId><ArticleId IdType="pubmed">18574083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT. Alzheimer's disease and cumulative exposure to anesthesia: A case-control study. J Am Geriatr Soc. 1994;42:198&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini M, Vanacore N, Schiaffini C, Brusa L, Panella M, Talarico G, Bruno G, Meco G, Lenzi GL. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci. 2002;23:11&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111615</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip AG, Brayne C, Matthews FE. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing. 2006;35:154&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16414964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkstra JB, Van Boxtel MP, Houx PJ, Jolles J. An operation under general anesthesia as a risk factor for age-related cognitive decline: results from a large cross-sectional population study. J Am Geriatr Soc. 1998;46:1258&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19787032</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.</ArticleTitle><Pagination><StartPage>e1000157</StartPage><MedlinePgn>e1000157</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1000157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1000157</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cholinesterase inhibitors are commonly used to treat dementia. These drugs enhance the effects of acetylcholine, and reports suggest they may precipitate bradycardia in some patients. We aimed to examine the association between use of cholinesterase inhibitors and hospitalization for bradycardia.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We examined the health care records of more than 1.4 million older adults using a case-time-control design, allowing each individual to serve as his or her own control. Case patients were residents of Ontario, Canada, aged 67 y or older hospitalized for bradycardia between January 1, 2003 and March 31, 2008. Control patients (3:1) were not hospitalized for bradycardia, and were matched to the corresponding case on age, sex, and a disease risk index. All patients had received cholinesterase inhibitor therapy in the 9 mo preceding the index hospitalization. We identified 1,009 community-dwelling older persons hospitalized for bradycardia within 9 mo of using a cholinesterase inhibitor. Of these, 161 cases informed the matched analysis of discordant pairs. Of these, 17 (11%) required a pacemaker during hospitalization, and six (4%) died prior to discharge. After adjusting for temporal changes in drug utilization, hospitalization for bradycardia was associated with recent initiation of a cholinesterase inhibitor (adjusted odds ratio [OR] 2.13, 95% confidence interval [CI] 1.29-3.51). The risk was similar among individuals with pre-existing cardiac disease (adjusted OR 2.25, 95% CI 1.18-4.28) and those receiving negative chronotropic drugs (adjusted OR 2.34, 95% CI 1.16-4.71). We found no such association when we replicated the analysis using proton pump inhibitors as a neutral exposure. Despite hospitalization for bradycardia, more than half of the patients (78 of 138 cases [57%]) who survived to discharge subsequently resumed cholinesterase inhibitor therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among older patients, initiation of cholinesterase inhibitor therapy was associated with a more than doubling of the risk of hospitalization for bradycardia. Resumption of therapy following discharge was common, suggesting that the cardiovascular toxicity of cholinesterase inhibitors is underappreciated by clinicians.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park-Wyllie</LastName><ForeName>Laura Y</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Family and Community Medicine, St. Michael's Hospital, Ontario, Canada. parkwylliel@smh.toronto.on.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamdani</LastName><ForeName>Muhammad M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Sudeep S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Laupacis</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Juurlink</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2010 Aug;13(3):91. doi: 10.1136/ebmh.13.3.91.</RefSource><PMID Version="1">20682831</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001919" MajorTopicYN="N">Bradycardia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>MMM was employed at Pfizer Global Pharmaceuticals from January 2006 to April 2007.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19787032</ArticleId><ArticleId IdType="pmc">PMC2742897</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1000157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qaseem A, Snow V, Cross JT,, Jr, Forciea MA, Hopkins R,, Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">18316755</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease&#x2013;from basic research to bedside. Curr Alzheimer Res. 2004;1:315&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975060</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Romero JM, Ramos-Salado JL. [Symptomatic sinus bradycardia associated with donepezil]. Revista de Neurologia. 1999;28:1070&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">10390778</ArticleId></ArticleIdList></Reference><Reference><Citation>Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J. 2006;23:641&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564171</ArticleId><ArticleId IdType="pubmed">16858101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordier P, Garrigue S, Barold SS, Bressolles N, Lanusse S, et al. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace. 2003;5:429&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">14753643</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby VJ, Kenny RA, McKeith IG. Donepezil and cardiac syncope: a case report. Int J Geriatr Psychiatry. 2004;19:1110&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15497193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc J. Drug interactions with cholinesterase inhibitors: an analysis of the french pharmacovigilance database and a comparison of two national drug formularies. Drug Safety. 2007;30:1063&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973542</ArticleId></ArticleIdList></Reference><Reference><Citation>Roisin T, Van Ermen A, Rogiers A. Cardiac adverse effects with cholinesterase inhibitors. Drug Safety. 2006;29:930.</Citation></Reference><Reference><Citation>Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999;33:812&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10466911</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11:e274&#x2013;e285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordier P, Garrigue S, Lanusse S, Margaine J, Robert F, et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs. 2006;20:411&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">16696580</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol. 2002;42:558&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">12017350</ArticleId></ArticleIdList></Reference><Reference><Citation>Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">15295047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634&#x2013;2643.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073359</ArticleId></ArticleIdList></Reference><Reference><Citation>Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652&#x2013;1658.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672733</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamdani MM, Tu K, van Walraven C, Austin PC, Naylor CD. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ. 2000;162:1421&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1232454</ArticleId><ArticleId IdType="pubmed">10834045</ArticleId></ArticleIdList></Reference><Reference><Citation>Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354:1352&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16510739</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12879144</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">1985444</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclure M, Mittleman MA. Should we use a case-crossover design? Annual Review of Public Health. 2000;21:193&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884952</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnan PT, Wang J. The case-crossover and case-time-control designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2001;10:259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11501340</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S51&#x2013;S59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073755</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S. The case-time-control design: further assumptions and conditions. Epidemiology. 1998;9:441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9647910</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S. The case-time-control design. Epidemiology. 1995;6:248&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">7619931</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology. 1996;7:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8728434</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Institute for Health Information. The International Statistical Classification of Diseases and Related Health Problems - Tenth Revision. Ottawa, Canada: Canadian Institute for Health Information; 2003.</Citation></Reference><Reference><Citation>Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006;163:813&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">16648321</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18:67&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">18562398</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbogast PG, Kaltenbach L, Ding H, Ray WA. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology. 2008;19:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18091000</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">18316756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169:867&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433698</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70:2024&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322263</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. Possible increased mortality in patients with mild cognitive impairment. 2005.  Dear Healthcare Professional Letter:  www.fda.gov/medwatch/SAFETY/2005/reminylDDLmarch.pdf.</Citation></Reference><Reference><Citation>Greenberg HM. Bradycardia at onset of sudden death: potential mechanisms. Ann N Y Acad Sci. 1984;427:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">6378014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19805156</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>40</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Triplet repeat length bias and variation in the human transcriptome.</ArticleTitle><Pagination><StartPage>17095</StartPage><EndPage>17100</EndPage><MedlinePgn>17095-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0907112106</ELocationID><Abstract><AbstractText>Length variation in short tandem repeats (STRs) is an important family of DNA polymorphisms with numerous applications in genetics, medicine, forensics, and evolutionary analysis. Several major diseases have been associated with length variation of trinucleotide (triplet) repeats including Huntington's disease, hereditary ataxias and spinobulbar muscular atrophy. Using the reference human genome, we have catalogued all triplet repeats in genic regions. This data revealed a bias in noncoding DNA repeat lengths. It also enabled a survey of repeat-length polymorphisms (RLPs) in human genomes and a comparison of the rate of polymorphism in humans versus divergence from chimpanzee. For short repeats, this analysis of three human genomes reveals a relatively low RLP rate in exons and, somewhat surprisingly, in introns. All short RLPs observed in multiple genomes are biallelic (at least in this small sample). In contrast, long repeats are highly polymorphic and some long RLPs are multiallelic. For long repeats, the chimpanzee sequence frequently differs from all observed human alleles. This suggests a high expansion/contraction rate in all long repeats. Expansions and contractions are not, however, affected by natural selection discernable from our comparison of human-chimpanzee divergence with human RLPs. Our catalog of human triplet repeats and their surrounding flanking regions can be used to produce a cost-effective whole-genome assay to test individuals. This repeat assay could someday complement SNP arrays for producing tests that assess the risk of an individual to develop a disease, or become part of personalized genomic strategy that provides therapeutic guidance with respect to drug response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molla</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering and Center for Advanced Biotechnology, Boston University, Boston, MA 02215, USA. molla@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delcher</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sunyaev</LastName><ForeName>Shamil</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cantor</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kasif</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33 HG002850</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 LM008748</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54LM008748-02</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 HG002850-02</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030561" MajorTopicYN="N">Databases, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002679" MajorTopicYN="N">Pan troglodytes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018911" MajorTopicYN="N">Trinucleotide Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19805156</ArticleId><ArticleId IdType="pmc">PMC2746125</ArticleId><ArticleId IdType="doi">10.1073/pnas.0907112106</ArticleId><ArticleId IdType="pii">0907112106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science. 2008;322:881&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694957</ArticleId><ArticleId IdType="pubmed">18988837</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen JM, et al. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet. 2007;71(Pt 3):295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">17181545</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007;315:848&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665772</ArticleId><ArticleId IdType="pubmed">17289997</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarroll SA. Extending genome-wide association studies to copy-number variation. Hum Mol Genet. 2008;17(R2):R135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">18852202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kasif S, Weng Z, Cantor CR. Quantitative analysis of single nucleotide polymorphisms within copy number variation. PLoS ONE. 2008;3:e3906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600609</ArticleId><ArticleId IdType="pubmed">19093001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin SM. DNA structures, repeat expansions and human hereditary disorders. Curr Opin Struct Biol. 2006;16:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin SM. Expandable DNA repeats and human disease. Nature. 2007;447:932&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581576</ArticleId></ArticleIdList></Reference><Reference><Citation>Usdin K. The biological effects of simple tandem repeats: Lessons from the repeat expansion diseases. Genome Res. 2008;18:1011&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960014</ArticleId><ArticleId IdType="pubmed">18593815</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman YAN, Rechavi G, Eisenberg E. Trinucleotide repeats are prevalent among cancer-related genes. Trends Genet. 2007;24:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">18054813</ArticleId></ArticleIdList></Reference><Reference><Citation>Penney JB, Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41:689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobczak K, Krzyzosiak WJ. CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J Biol Chem. 2005;280:3898&#x2013;3910.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002;35:819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372277</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JL, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet. 2003;73:682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180695</ArticleId><ArticleId IdType="pubmed">12900792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifi N, Figg WD. Androgen receptor modulation: Lessons learned from beyond the prostate. Cancer Biol Ther. 2007;6:1358&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">17881894</ArticleId></ArticleIdList></Reference><Reference><Citation>Fondon JW, III, Garner HR. Molecular origins of rapid and continuous morphological evolution. Proc Natl Acad Sci USA. 2004;101:18058&#x2013;18063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539791</ArticleId><ArticleId IdType="pubmed">15596718</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy S, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5:e254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964779</ArticleId><ArticleId IdType="pubmed">17803354</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DA, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008;452:872&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">18421352</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson G, Waterman MS. A method for fast database search for all k-nucleotide repeats. Nucleic Acids Res. 1994;22:4828&#x2013;4836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308537</ArticleId><ArticleId IdType="pubmed">7984436</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson G. Tandem repeats finder: A program to analyze DNA sequences. Nucleic Acids Res. 1999;27:573&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC148217</ArticleId><ArticleId IdType="pubmed">9862982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi Sachidanandam, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacolla A, et al. Abundance and length of simple repeats in vertebrate genomes are determined by their structural properties. Genome Res. 2008;18:1545&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556271</ArticleId><ArticleId IdType="pubmed">18687880</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska A, et al. Structures of trinucleotide repeats in human transcripts and their functional implications. Nucleic Acids Res. 2003;31:5463&#x2013;5468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC206467</ArticleId><ArticleId IdType="pubmed">14500808</ArticleId></ArticleIdList></Reference><Reference><Citation>The Chimpanzee Sequencing and Analysis Consortium. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature. 2005;437:69&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136131</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald JH, Kreitman M. Adaptive protein evolution at the Adh locus in Drosophila. Nature. 1991;351:652&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">1904993</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis RL, et al. cDNAs with long CAG trinucleotide repeats from human brain. Hum Genet. 1997;100:114&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Gen. 1998;43:149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">9747025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G SB, Jr, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Gen Biol. 2003;4:3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Heger S, et al. Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis. J Clin Invest. 2007;117:2145&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1906733</ArticleId><ArticleId IdType="pubmed">17627301</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert TJ, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods. 2007;4:903&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934467</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K, et al. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA. 1999;96:10016&#x2013;10020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17834</ArticleId><ArticleId IdType="pubmed">10468554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogurtsov AY, Sunyaev S, Kondrashov AS. Indel-based evolutionary distance and mouse-human divergence. Genome Res. 2004;14:1610&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC509270</ArticleId><ArticleId IdType="pubmed">15289479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum Mol Genet. 2000;9:2009&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">10942430</ArticleId></ArticleIdList></Reference><Reference><Citation>Swayne LA, Braun JE. Aggregate-centered redistribution of proteins by mutant huntingtin. Biochem Biophys Res Commun. 2007;354:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17208201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237011</ArticleId></ArticleIdList></Reference><Reference><Citation>Andken BB, et al. 3&#x2032;-UTR SIRF: A database for identifying clusters of short interspersed repeats in 3&#x2032; untranslated regions. BMC Bioinformatics. 2007;8:274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973087</ArticleId><ArticleId IdType="pubmed">17663765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand Y, Rodriguez A, Benson G. TRDB&#x2013;the Tandem Repeats Database. Nucleic Acids Res. 2007;35:D80&#x2013;D87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1781109</ArticleId><ArticleId IdType="pubmed">17175540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz S, et al. Versatile and open software for comparing large genomes. Genome Biol. 2004;5:R12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395750</ArticleId><ArticleId IdType="pubmed">14759262</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JR, et al. Aggressive assembly of pyrosequencing reads with mates. Bioinformatics. 2008;24:2818&#x2013;2824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639302</ArticleId><ArticleId IdType="pubmed">18952627</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW SB, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protocols. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A. A survey of exact inference for contegency tables. Statitical Science. 1992;7:131&#x2013;153.</Citation></Reference><Reference><Citation>Becker KG BK, Bright TJ, Wang SA. The Genetic Association Database. Nat Genet. 2004;36:431&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15118671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19805234</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>37</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Reelin signaling antagonizes beta-amyloid at the synapse.</ArticleTitle><Pagination><StartPage>15938</StartPage><EndPage>15943</EndPage><MedlinePgn>15938-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0908176106</ELocationID><Abstract><AbstractText>Abnormal processing of the amyloid precursor protein (APP) and beta-amyloid (Abeta) plaque accumulation are defining features of Alzheimer disease (AD), a genetically complex neurodegenerative disease that is characterized by progressive synapse loss and neuronal cell death. Abeta induces synaptic dysfunction in part by altering the endocytosis and trafficking of AMPA and NMDA receptors. Reelin is a neuromodulator that increases glutamatergic neurotransmission by signaling through the postsynaptic ApoE receptors Apoer2 and Vldlr and thereby potently enhances synaptic plasticity. Here we show that Reelin can prevent the suppression of long-term potentiation and NMDA receptors, which is induced by levels of Abeta comparable to those present in an AD-afflicted brain. This reversal is dependent upon the activation of Src family tyrosine kinases. At high concentrations of Abeta peptides, Reelin can no longer overcome the Abeta induced functional suppression and this coincides with a complete blockade of the Reelin-dependent phosphorylation of NR2 subunits. We propose a model in which Abeta, Reelin, and ApoE receptors modulate neurotransmission and thus synaptic stability as opposing regulators of synaptic gain control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durakoglugil</LastName><ForeName>Murat S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Kavalali</LastName><ForeName>Ege T</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091042">Reelin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717127">RELN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717128">Reln protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19805234</ArticleId><ArticleId IdType="pmc">PMC2747222</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908176106</ArticleId><ArticleId IdType="pii">0908176106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000;283:1615&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Synaptic targeting by Alzheimer's-related amyloid &#x3b2; oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid &#x3b2;-protein on hippocampal synaptic plasticity: A potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeber EJ, et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002;277:39944&#x2013;39952.</Citation><ArticleIdList><ArticleId IdType="pubmed">12167620</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Ballif BA, Cooper JA. Regulation of protein tyrosine kinase signaling by substrate degradation during brain development. Mol Cell Biol. 2003;23:9293&#x2013;9302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC309695</ArticleId><ArticleId IdType="pubmed">14645539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballif BA, Arnaud L, Cooper JA. Tyrosine phosphorylation of Disabled-1 is essential for Reelin-stimulated activation of Akt and Src family kinases. Brain Res Mol Brain Res. 2003;117:152&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock HH, Herz J. Reelin activates SRC family tyrosine kinases in neurons. Curr Biol. 2003;13:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526740</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, et al. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron. 2005;47:567&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu S, Zhao LF, Korwek KM, Weeber EJ. Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J Neurosci. 2006;26:12943&#x2013;12955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674964</ArticleId><ArticleId IdType="pubmed">17167084</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97:689&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Reelin modulates NMDA receptor activity in cortical neurons. J Neurosci. 2005;25:8209&#x2013;8216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725528</ArticleId><ArticleId IdType="pubmed">16148228</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7:850&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053810</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Kalia LV. Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci. 2004;5:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034556</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasser V, et al. Receptor clustering is involved in Reelin signaling. Mol Cell Biol. 2004;24:1378&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC321426</ArticleId><ArticleId IdType="pubmed">14729980</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Arcangelo G, et al. Reelin is a ligand for lipoprotein receptors. Neuron. 1999;24:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiesberger T, et al. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999;24:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571241</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SG, et al. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903&#x2013;1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima K, Mikoshiba K, Miyata T, Kudo C, Ogawa M. Disruption of hippocampal development in vivo by CR-50 mAb against reelin. Proc Natl Acad Sci USA. 1997;94:8196&#x2013;8201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21580</ArticleId><ArticleId IdType="pubmed">9223338</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Groc L, et al. NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. J Neurosci. 2007;27:10165&#x2013;10175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672660</ArticleId><ArticleId IdType="pubmed">17881522</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo CG, Sinagra M, Verrier D, Manzoni OJ, Chavis P. Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS One. 2009;4:e5505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675077</ArticleId><ArticleId IdType="pubmed">19430527</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, et al. Increased amyloid &#x3b2;-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: High-avidity binding to &#x3b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommer BL, et al. ApoE isoform-specific effects on LTP: Blockade by oligomeric amyloid-&#x3b2;1&#x2013;42. Neurobiol Dis. 2005;18:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649697</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, et al. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3&#x3b2;. J Biol Chem. 2002;277:49958&#x2013;49964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12376533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19812343</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>40</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Disruption of functional connectivity in clinically normal older adults harboring amyloid burden.</ArticleTitle><Pagination><StartPage>12686</StartPage><EndPage>12694</EndPage><MedlinePgn>12686-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3189-09.2009</ELocationID><Abstract><AbstractText>Amyloid deposition is present in 20-50% of nondemented older adults yet the functional consequences remain unclear. The current study found that amyloid accumulation is correlated with functional disruption of the default network as measured by intrinsic activity correlations. Clinically normal participants (n = 38, aged 60-88 years) were characterized using (11)C-labeled Pittsburgh Compound B positron emission tomography imaging to estimate fibrillar amyloid burden and, separately, underwent functional magnetic resonance imaging (fMRI). The integrity of the default network was estimated by correlating rest-state fMRI time courses extracted from a priori regions including the posterior cingulate, lateral parietal, and medial prefrontal cortices. Clinically normal participants with high amyloid burden displayed significantly reduced functional correlations within the default network relative to participants with low amyloid burden. These reductions were also observed when amyloid burden was treated as a continuous, rather than a dichotomous, measure and when controlling for age and structural atrophy. Whole-brain analyses initiated by seeding the posterior cingulate cortex, a region of high amyloid burden in Alzheimer's disease, revealed significant disruption in the default network including functional disconnection of the hippocampal formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA. hedden@nmr.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Dijk</LastName><ForeName>Koene R A</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG-021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-027435-S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19812343</ArticleId><ArticleId IdType="mid">NIHMS157901</ArticleId><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3189-09.2009</ArticleId><ArticleId IdType="pii">29/40/12686</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2014;the methods. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Birn RM, Diamond JB, Smith MA, Bandettini PA. Separating respiratory-variation-related fluctuations from neuronal-activity-related fluctuations in fMRI. Neuroimage. 2006;31:1536&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632379</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brainard DH. The Psychophysics Toolbox. Spat Vis. 1997;10:433&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">9176952</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Beckmann CF, Arigita EJ, Barkhof F, Scheltens P, Stam CJ, Smith SM, Rombouts SA. Reduced resting-state brain activity in the &#x201c;default network&#x201d; in normal aging. Cereb Cortex. 2008;18:1856&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063564</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2805&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans AJ, Iwai F, Grist TA, Sostman HD, Hedlund LW, Spritzer CE, Negro-Vilar R, Beam CA, Pelc NJ. Magnetic resonance imaging of blood flow with a phase subtraction technique. In vitro and in vivo validation. Invest Radiol. 1993;28:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">8444566</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair DA, Schlaggar BL, Cohen AL, Miezin FM, Dosenbach NU, Wenger KK, Fox MD, Snyder AZ, Raichle ME, Petersen SE. A method for using blocked and event-related fMRI data to study &#x201c;resting state&#x201d; functional connectivity. Neuroimage. 2007;35:396&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563954</ArticleId><ArticleId IdType="pubmed">17239622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol. 2008;65:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: evidence from a partial correlation network analysis. Neuroimage. 2008;42:1178&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">18598773</ArticleId></ArticleIdList></Reference><Reference><Citation>Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage. 2008;43:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">18789389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637553</ArticleId><ArticleId IdType="pubmed">18794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, Kurz A, Drzezga A. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging. 2008 doi: 10.1016/j.neurobiolaging.2008.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.01.016</ArticleId><ArticleId IdType="pubmed">18346821</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol. 1991;13:933&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">1779032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Fr&#xf6;lich L, Sch&#xf6;nknecht P, Ito K, Mielke R, Kalbe E, Z&#xfc;ndorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingshead AB. Two factor index of social position. Mimeo. New Haven, CT: Yale University; 1957.</Citation></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA. Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. Curr Neurol Neurosci Rep. 2006;6:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074285</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn I, Andrews-Hanna JR, Vincent JL, Snyder AZ, Buckner RL. Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493488</ArticleId><ArticleId IdType="pubmed">18385483</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol. 2008;21:683&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637561</ArticleId><ArticleId IdType="pubmed">18989113</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R, Cheng HM, Brady TJ, Rosen BR. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675&#x2013;5679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49355</ArticleId><ArticleId IdType="pubmed">1608978</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2212;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Macey PM, Macey KE, Kumar R, Harper RM. A method for removal of global effects from fMRI time series. Neuroimage. 2004;22:360&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15110027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Disease Neuroimaging Initiative. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugurbil K. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A. 1992;89:5951&#x2013;5955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC402116</ArticleId><ArticleId IdType="pubmed">1631079</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelli DG. The VideoToolbox software for visual psychophysics: transforming numbers into movies. Spat Vis. 1997;10:437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9176953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlajam&#xe4;ki M, DePeau KM, Blacker D, Sperling RA. Impaired medial temporal repetition suppression is related to failure of parietal deactivation in Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:283&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2602949</ArticleId><ArticleId IdType="pubmed">18378553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172:277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2501111</ArticleId><ArticleId IdType="pubmed">18582948</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan JJ, Paolo AM. A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol. 1992;6:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14589637</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. The processing-speed theory of adult age differences in cognition. Psychol Rev. 1996;103:403&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">8759042</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99:4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M. Rey auditory-verbal learning test. Lutz, FL: Psychological Assessment Resources; 1996.</Citation></Reference><Reference><Citation>Sorg C, Riedl V, M&#xfc;hlau M, Calhoun VD, Eichele T, L&#xe4;er L, Drzezga A, F&#xf6;rstl H, Kurz A, Zimmer C, Wohlschl&#xe4;ger AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette P, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreen O, Benton AL. Victoria, BC: University of Victoria Neuropsychology Laboratory; 1977. Neurosensory center comprehensive examination for aphasia (NCCEA)</Citation></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dijk KR, Hedden T, Tu PC, LaViolette P, Sperling RA, Buckner RL. Optimal acquisition parameters for resting state functional connectivity MRI. Soc Neurosci Abstr. 2008;34:885&#x2013;24.</Citation></Reference><Reference><Citation>Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343463</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WAIS-III/WMS-III technical manual: updated. San Antonio, TX: Psychological Corporation; 2002.</Citation></Reference><Reference><Citation>Wise RG, Ide K, Poulin MJ, Tracey I. Resting fluctuations in arterial carbon dioxide induce significant low frequency variations in BOLD signal. Neuroimage. 2004;21:1652&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050588</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt ST, Laird AR, Meyerand ME. Functional neuroimaging correlates of finger-tapping task variations: an ALE meta-analysis. Neuroimage. 2008;42:343&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592684</ArticleId><ArticleId IdType="pubmed">18511305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, Leirer VO. Development and validation of a geriatric depression rating scale: a preliminary report. J Psychiatr Res. 1983;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zar J. Biostatistical analysis. Upper Saddle River, NJ: Prentice-Hall; 1996.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19822780</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Ten-year change in plasma amyloid beta levels and late-life cognitive decline.</ArticleTitle><Pagination><StartPage>1247</StartPage><EndPage>1253</EndPage><MedlinePgn>1247-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2009.207</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Plasma levels of amyloid beta peptide (Abeta) are potential biomarkers of early cognitive impairment and decline and of Alzheimer disease risk.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To relate midlife plasma Abeta measures and 10-year change in plasma Abeta measures since midlife to late-life cognitive decline.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective study of a population-based sample.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic research.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Plasma Abeta40 and Abeta42 levels were measured in 481 Nurses' Health Study participants in late midlife (mean age, 63.6 years) and again 10 years later (mean age, 74.6 years). Cognitive testing also began 10 years after the initial blood draw. Participants completed 3 repeated telephone-based assessments (mean span, 4.1 years). Multivariable linear mixed-effects models were used to estimate relations of midlife plasma Abeta40 to Abeta42 ratios and Abeta42 levels to late-life cognitive decline, as well as relations of 10-year change in Abeta40 to Abeta42 ratios and Abeta42 levels to cognitive decline.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The 3 primary outcomes were the Telephone Interview for Cognitive Status (TICS) findings, a global score averaging the results of all tests (TICS, immediate and delayed verbal recall, category fluency, and attention), and a verbal memory score averaging the results of 4 tests of verbal recall.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher midlife plasma Abeta40 to Abeta42 ratios were associated with worse late-life decline on the global score (P = .04 for trend). Furthermore, increase in Abeta40 to Abeta42 ratios since midlife predicted greater decline in the global score (P = .03 for trend) and in the TICS (P = .02 for trend). There was no association of cognitive decline with midlife plasma Abeta42 levels alone or with change in Abeta42 levels since midlife.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this large community-dwelling sample, higher plasma Abeta40 to Abeta42 ratios in late midlife and increases in Abeta40 to Abeta42 ratios 10 years later were significantly associated with greater decline in global cognition at late life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okereke</LastName><ForeName>Olivia I</ForeName><Initials>OI</Initials><AffiliationInfo><Affiliation>Division of Aging and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Third Floor, Boston, MA 02115, USA. olivia.okereke@channing.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Weiming</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA087969</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA87969</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA49449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG24215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA049449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA049449</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004493" MajorTopicYN="N">Education</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19822780</ArticleId><ArticleId IdType="mid">NIHMS110278</ArticleId><ArticleId IdType="pmc">PMC2761951</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2009.207</ArticleId><ArticleId IdType="pii">66/10/1247</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593169</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol. 2007;64:862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61:1185&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Mehta PD, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 2008;70:1664&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670993</ArticleId><ArticleId IdType="pubmed">18401021</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:14052&#x2013;14057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544577</ArticleId><ArticleId IdType="pubmed">18779561</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundel&#xf6;f J, Giedraitis V, Irizarry MC, et al. Plasma A&#x3b2; and the risk of Alzheimer's disease and dementia in elderly men: a prospective population-based cohort study. Arch Neurol. 2008;65:256&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">18268197</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354&#x2013;362. Erratum in: Arch Neurol 2007;64:1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oijen M, Hofman A, Soares HD, et al. Plasma Abeta(1&#x2212;40) and Abeta(1&#x2212;42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857570</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65:542&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042807</ArticleId><ArticleId IdType="pubmed">18458206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70:596&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914065</ArticleId></ArticleIdList></Reference><Reference><Citation>Okereke OI, Xia W, Irizarry MC, et al. Performance characteristics of plasma amyloid beta 40 and 42 assays. Journal of Alzheimer's Disease. 2009;16:277&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737811</ArticleId><ArticleId IdType="pubmed">19221417</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt J, Spencer M, Folstein MF. The telephone interview for cognitive status. Neuropsych, Neuropsychol, Behav Neurol. 1988;1:111&#x2013;117.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Smith LA, Scherr PA, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci. 1991;57:167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1938160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook N, Manson J, et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med. 2006;166:2462&#x2013;2468.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Ratcliff G, Belle SH, et al. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry. 2001;58:853&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11545668</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Barnes LL, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117364</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care. 1991;29:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">1994148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. Erratum in: Science 2002;297:2209.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Dementia Rating Scale. Psychological Assessment Resources; Odessa, FL: 1983.</Citation></Reference><Reference><Citation>Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002;1:61&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Jacobs D, Andrews H, et al. Cardiovascular risk and memory in non-demented elderly women. Neurobiol Aging. 2008 Sep 19; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900768</ArticleId><ArticleId IdType="pubmed">18805604</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19829371</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>461</Volume><Issue>7266</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>916</StartPage><EndPage>922</EndPage><MedlinePgn>916-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature08538</ELocationID><Abstract><AbstractText>Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG00568125</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32NS007205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19829371</ArticleId><ArticleId IdType="mid">NIHMS169707</ArticleId><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="doi">10.1038/nature08538</ArticleId><ArticleId IdType="pii">nature08538</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A. (Translated by Jarvik, L.a.G., H.). ber eine eignartige Erkrankung der Hirnrinde. (About a peculiar disease of the cerebral cortex.) Alzheimer Dis. Assoc. Disorders. 1987;1:7&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331112</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer&#x2019;s disease. Arch Neurol. 1985;42:1097&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer&#x2019;s disease. Neurology. 1988;38:1682&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D, et al. Prevalence of Alzheimer&#x2019;s disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JS, D J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson NE, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology. 2008;70:828&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046010</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007;68:828&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353470</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun M, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MR, et al. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetami de, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004;47:2228&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15084121</ArticleId></ArticleIdList></Reference><Reference><Citation>Vas A, et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J Neurol Sci. 2008;264:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17727889</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, et al. Microglia, amyloid, and cognition in Alzheimer&#x2019;s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32:412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, et al. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 1990;80:419&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2239154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirvonen J, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85:506&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19129751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer&#x2019;s disease: Insights from functional MRI studies. Neuropsychologia. 2008;46:1624&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760288</ArticleId><ArticleId IdType="pubmed">18206188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirao K, et al. The prediction of rapid conversion to Alzheimer&#x2019;s disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage. 2005;28:1014&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16129627</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci U S A. 2001;98:10966&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, et al. Mild Cognitive Impairment - Can FDG-PET Predict Who is to Rapidly Convert to Alzheimer&#x2019;s Disease. Neurology. 2003;60:1374&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, A N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, L&#xe4;rks&#xe4;ter M, Winblad B, Zetterberg H, Blennow K, L&#xe5;ngstr&#xf6;m B, Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer&#x2019;s disease. Annals of Neurology. 2008;63:621&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain&#x2019;s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Motter R, et al. Reduction of &#x3b2;-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease. Ann. Neurol. 1995;38:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, et al. Cerebrospinal fluid tau/A&#x3b2;42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007;64:343&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, et al. CSF tau/A&#x3b2;42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology. 2007;69:631&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Pirttila T, Patrick B, Barshatzky M, Mehta S. Amyloid &#x3b2; protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11335065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11132093</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford N, et al. Association of low plasma A&#x3b2;42/A&#x3b2;40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer&#x2019;s disease. Ann Neurol. 1999;46:412&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482274</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Targeted proteomics in Alzheimer&#x2019;s disease: focus on amyloid-beta. Expert Rev Proteomics. 2008;5:225&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466053</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M, et al. Detection of tau proteins in normal and Alzheimer&#x2019;s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbant assay. J. Neurochem. 1993;61:1828&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">8228996</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, S.-J T, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer&#x2019;s disease patients. Am J Pathol. 1999;155:863&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866881</ArticleId><ArticleId IdType="pubmed">10487843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer&#x2019;s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998;12:1777&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837868</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon M, et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol Sci. 2007 Nov 14;</Citation><ArticleIdList><ArticleId IdType="pubmed">17994313</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratico D, et al. Increased 8,12-iso-iPF2alpha-VI in Alzheimer&#x2019;s disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000;48:809&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079549</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. No difference in plasma or urinary F2-isoprostanes among patients with Huntington&#x2019;s disease or Alzheimer&#x2019;s disease and controls. Ann Neurol. 2000;48:950.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117557</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer&#x2019;s disease. J Neurosci Res. 2002;70:447&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391605</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham C, Selkoe D, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer&#x2019;s disease. Cell. 1988;52:487&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">3257719</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Schober R, Birkenmeier G. The subunits of alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed alpha2-macroglobulin and interleukin 6 in Alzheimer&#x2019;s disease. Brain Res. 1997;777:223&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9449432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanjani H, et al. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15942322</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky S, et al. Plasma and cerebrospinal fluid &#x3b1;1-antichymotrypsin levels in Alzheimer&#x2019;s disease: Correlation with cognitive impairment. Ann. Neurol. 2003;53:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hye A, et al. Proteome-based plasma biomarkers for Alzheimer&#x2019;s disease. Brain. 2006;129:3042&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer&#x2019;s disease. Proteomics - Clin. Appl. 2007;1:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pubmed">21136637</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer&#x2019;s disease. J Neurol. 2008;255:1712&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19156487</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth MD, et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol Aging. 1994;15:609&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824052</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler DA, et al. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:555&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007;68:1902&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536046</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer&#x2019;s disease and mild cognitive impairment. Neurodegener Dis. 2007;4:406&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934323</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidsson P, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport. 2002;13:611&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">11973456</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis. 2005;7:125&#x2013;33. discussion 173-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851850</ArticleId></ArticleIdList></Reference><Reference><Citation>Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, et al. Alzheimer&#x2019;s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10:13&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726757</ArticleId><ArticleId IdType="pubmed">18813964</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh-Bohmer KA, J S, G J. In: Handbook of Dementing Illnesses. Second Edition Morris JC, Holtzman DM, editors. Taylor &amp; Francis; New York: 2006.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19833321</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.</ArticleTitle><Pagination><StartPage>584</StartPage><EndPage>587</EndPage><MedlinePgn>584-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2009.08.024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Important functional connections within the default mode network (DMN) are disrupted in Alzheimer's disease (AD), likely from amyloid-beta (Abeta) plaque-associated neuronal toxicity. Here, we sought to determine if pathological effects of Abeta amyloid plaques could be seen, even in the absence of a task, by examining functional connectivity in cognitively normal participants with and without preclinical amyloid deposition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants with Alzheimer's disease (AD) (n = 35) were compared with 68 cognitively normal participants who were further subdivided by positron emission tomography (PET) Pittsburgh Compound-B (PIB) imaging into those without evidence of brain amyloid (PIB-) and those with brain amyloid (PIB+) deposition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Resting state functional magnetic resonance imaging (fMRI) demonstrated that, compared with the PIB- group, the PIB+ group differed significantly in functional connectivity of the precuneus to hippocampus, parahippocampus, anterior cingulate, dorsal cingulate, gyrus rectus, superior precuneus, and visual cortex. These differences were in the same regions and in the same direction as differences found in the AD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Thus, before any manifestations of cognitive or behavioral changes, there were differences in resting state connectivity in cognitively normal subjects with brain amyloid deposition, suggesting that early manifestation of Abeta toxicity can be detected using resting state fMRI.</AbstractText><CopyrightInformation>Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheline</LastName><ForeName>Yvette I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. yvette@npg.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marcus E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Suzhi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS006833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG026275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH079510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS06833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24MH079510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19833321</ArticleId><ArticleId IdType="mid">NIHMS156020</ArticleId><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2009.08.024</ArticleId><ArticleId IdType="pii">S0006-3223(09)01032-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raichle M, MacLeod A, Snyder A, Powers W, Gusnard D, Shulman G. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius M, Srivastava G, Reiss A, Menon V. Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Supekar K, Menon V, Rubin D, Musen M, Greicius M. Network analysis of intrinsic functional brain connectivity in Alzheimer&#x2019;s disease. PLoS Comput Biol. 2008;4:e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435273</ArticleId><ArticleId IdType="pubmed">18584043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HY, Wang SJ, Xing J, Liu B, Ma ZL, Yang M, Zhang ZJ, Teng GJ. Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer&#x2019;s disease. Behav Brain Res. 2009;197:103&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786570</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J, Morris J. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. Biochemistry and Molecular Biology of Amyloid beta-Protein and the Mechanism of Alzheimer&#x2019;s Disease. Handb Clin Neurol. 2008;89:245&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631749</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant E, Miller P, Morris J. Rates of progression in mild cognitive impairment and early Alzheimer&#x2019;s disease. Neurology. 2002;59:1034&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370458</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, D&#x2019;Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65:1467&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752218</ArticleId><ArticleId IdType="pubmed">19001165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M, Corbetta M, Snyder A, Vincent J, Raichle M. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. PNAS. 2006;103:10046&#x2013;10051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480402</ArticleId><ArticleId IdType="pubmed">16788060</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen D. A Population-Average, Landmark- and Surface-based (PALS) atlas of the human cerebral cortex. Neuroimage. 2005;28:635&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, LaViolette P, O&#x2019;Keefe K, O&#x2019;Brien J, Rentz D, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Amaral D. Macaque monkey retrosplenial cortex: II. Cortical afferents. J Comp Neurol. 2003;466:48&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14515240</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R, Andrews-Hanna J, Schacter D. The brain&#x2019;s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D, Mintun M. APOE Predicts A&#xe2; but not Tau Alzheimer&#x2019;s Pathology in Cognitively Normal Aging. Ann Neurol. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19833869</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>44</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.</ArticleTitle><Pagination><StartPage>18809</StartPage><EndPage>18814</EndPage><MedlinePgn>18809-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0908767106</ELocationID><Abstract><AbstractText>Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that show considerable clinical and pathologic overlap, with no effective treatments available. Mutations in the RNA binding protein TDP-43 were recently identified in patients with familial amyotrophic lateral sclerosis (ALS), and TDP-43 aggregates are found in both ALS and FTLD-U (FTLD with ubiquitin aggregates), suggesting a common underlying mechanism. We report that mice expressing a mutant form of human TDP-43 develop a progressive and fatal neurodegenerative disease reminiscent of both ALS and FTLD-U. Despite universal transgene expression throughout the nervous system, pathologic aggregates of ubiquitinated proteins accumulate only in specific neuronal populations, including layer 5 pyramidal neurons in frontal cortex, as well as spinal motor neurons, recapitulating the phenomenon of selective vulnerability seen in patients with FTLD-U and ALS. Surprisingly, cytoplasmic TDP-43 aggregates are not present, and hence are not required for TDP-43-induced neurodegeneration. These results indicate that the cellular and molecular substrates for selective vulnerability in FTLD-U and ALS are shared between mice and humans, and suggest that altered DNA/RNA-binding protein function, rather than toxic aggregation, is central to TDP-43-related neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wegorzewska</LastName><ForeName>Iga</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Hope Center for Neurological Diseases, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Shaughn</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS055980</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS055980</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19833869</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pii">0908767106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seeley WW. Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr Opin Neurol. 2008;21:701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909835</ArticleId><ArticleId IdType="pubmed">18989116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy JM, et al. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol. 2007;64:530&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63:535&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoseki A, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008;63:538&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain. 1991;114:775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar Z, Cheung AF. Towards the classification of subpopulations of layer V pyramidal projection neurons. Neurosci Res. 2006;55:105&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16542744</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol. 2007;113:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>Charcot JM, Joffroy A. Deux cas d'atrophie musculaire progressive avec les lesions de la substance grise et faiscaux anterolateraux de la moelle epiniere. Archives de Physiologic Normale et Pathologique. 1869;2:354&#x2013;367. 629&#x2013;649, 744&#x2013;760.</Citation></Reference><Reference><Citation>Baloh RH, Rakowicz W, Gardner R, Pestronk A. Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle Nerve. 2007;36:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299742</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530&#x2013;10534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Expression Of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci USA. 2008;105:3785&#x2013;3789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268791</ArticleId><ArticleId IdType="pubmed">18305152</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, et al. Generation and characterization of human TDP-43 transgenic mice. Society for Neuroscience Abstracts, Annual Meeting Publications. 2008</Citation></Reference><Reference><Citation>Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: Gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement IA, et al. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell. 1998;95:41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778246</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21:9549&#x2013;9560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763041</ArticleId><ArticleId IdType="pubmed">11739566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen M, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell. 2007;26:175&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17466621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19834067</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-2191</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of pathology</Title><ISOAbbreviation>Am J Pathol</ISOAbbreviation></Journal><ArticleTitle>Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.</ArticleTitle><Pagination><StartPage>2099</StartPage><EndPage>2110</EndPage><MedlinePgn>2099-110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2353/ajpath.2009.090159</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is pathologically characterized by accumulation of beta-amyloid (Abeta) protein deposits and/or neurofibrillary tangles in association with progressive cognitive deficits. Although numerous studies have demonstrated a relationship between brain pathology and AD progression, the Alzheimer's pathological hallmarks have not been found in the AD retina. A recent report showed Abeta plaques in the retinas of APPswe/PS1DeltaE9 transgenic mice. We now report the detection of Abeta plaques with increased retinal microvascular deposition of Abeta and neuroinflammation in Tg2576 mouse retinas. The majority of Abeta-immunoreactive plaques were detected from the ganglion cell layer to the inner plexiform layer, and some plaques were observed in the outer nuclear layer, photoreceptor outer segment, and optic nerve. Hyperphosphorylated tau was labeled in the corresponding areas of the Abeta plaques in adjacent sections. Although Abeta vaccinations reduced retinal Abeta deposits, there was a marked increase in retinal microvascular Abeta deposition as well as local neuroinflammation manifested by microglial infiltration and astrogliosis linked with disruption of the retinal organization. These results provide evidence to support further investigation of the use of retinal imaging to diagnose AD and to monitor disease activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bingqian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Irvine School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasool</LastName><ForeName>Suhail</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhikuan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Steven S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Zhiqun</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Pathol</MedlineTA><NlmUniqueID>0370502</NlmUniqueID><ISSNLinking>0002-9440</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Am J Pathol. 2010 Apr;176(4):2055. doi: 10.2353/ajpath.2010.100076.</RefSource><PMID Version="1">20167871</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19834067</ArticleId><ArticleId IdType="pmc">PMC2774073</ArticleId><ArticleId IdType="doi">10.2353/ajpath.2009.090159</ArticleId><ArticleId IdType="pii">S0002-9440(10)60719-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology. 1998;51:690&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748011</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer&#x2019;s disease. J Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Lu T. Amyloid &#x3b2;-protein toxicity and the pathogenesis of Alzheimer&#x2019;s disease. J Biol Chem. 2009:4755&#x2013;4759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643502</ArticleId><ArticleId IdType="pubmed">18957434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Lott IT. Down syndrome and &#x3b2;-amyloid deposition. Curr Opin Neurol. 2004;17:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">15021233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pache M, Smeets CH, Gasio PF, Savaskan E, Flammer J, Wirz-Justice A, Kaiser HJ. Colour vision deficiencies in Alzheimer&#x2019;s disease. Age Ageing. 2003;32:422&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">12851187</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Crutch SJ, Warrington EK. A disorder of colour perception associated with abnormal colour after-images: a defect of the primary visual cortex. J Neurol Neurosurg Psychiatry. 2001;71:515&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763505</ArticleId><ArticleId IdType="pubmed">11561036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshminarayanan V, Lagrave J, Kean ML, Dick M, Shankle R. Vision in dementia: contrast effects. Neurol Res. 1996;18:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8714529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendola JD, Cronin-Golomb A, Corkin S, Growdon JH. Prevalence of visual deficits in Alzheimer&#x2019;s disease. Optom Vis Sci. 1995;72:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">7609938</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker KW, Burdon MA, Shah P. Visual field loss and Alzheimer&#x2019;s disease. Eye. 2002;16:206&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988830</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetewsky SJ, Duffy CJ. Visual loss and getting lost in Alzheimer&#x2019;s disease. Neurology. 1999;52:958&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102412</ArticleId></ArticleIdList></Reference><Reference><Citation>Butter CM, Trobe JD, Foster NL, Berent S. Visual-spatial deficits expalin visual symptoms in Alzheimer&#x2019;s disease. Am J Ophthalmol. 1996;122:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">8659604</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer&#x2019;s disease. Surv Ophthalmol. 1989;34:31&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">2678551</ArticleId></ArticleIdList></Reference><Reference><Citation>Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16518161</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer&#x2019;s disease. Brain Res. 1989;501:364&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">2819446</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer&#x2019;s disease. Neurosci Lett. 2007;420:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17543991</ArticleId></ArticleIdList></Reference><Reference><Citation>Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 2006;67:1852&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">17130422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, Chi T, Hsieh FY. Optic nerve head and nerve fiber layer in Alzheimer&#x2019;s disease. Arch Ophthalmol. 1991;109:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1993028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer&#x2019;s disease. N Engl J Med. 1986;315:485&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">3736630</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, Ransom NL, Tahzib NG, Reitsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">11923249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson GA, Edward DP, Wilensky JT. Ocular amyloidosis and secondary glaucoma. Ophthalmology. 1999;106:1363&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pubmed">10406623</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederikse PH, Ren XO. Lens defects and age-related fiber cell degeneration in a mouse model of increased A&#x3b2;PP gene dosage in Down syndrome. Am J Pathol. 2002;161:1985&#x2013;1990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850926</ArticleId><ArticleId IdType="pubmed">12466113</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Jr, Bush AI. Cytosolic &#x3b2;-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer&#x2019;s disease. Lancet. 2003;361:1258&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699953</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. &#x3b2;-Amyloid deposition and functional impairment in the retina of the APPswe/PS1&#x3b4;E9 transgenic mouse model of Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2009;50:793&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3697019</ArticleId><ArticleId IdType="pubmed">18791173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Tenner AJ. Novel A&#x3b2; peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer&#x2019;s disease. J Neuroinflammation. 2005;2:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326209</ArticleId><ArticleId IdType="pubmed">16332263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006;413:326&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046404</ArticleId></ArticleIdList></Reference><Reference><Citation>Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, Almeida OF. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009;14:95&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17912249</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer&#x2019;s disease. Nature. 1988;331:528&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">2893290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Price DL. Role of the &#x3b2;-amyloid protein in Alzheimer&#x2019;s disease. FASEB J. 1995;9:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7896005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung SS, Gauthier S, Cashman NR. &#x3b2;-Amyloid precursor protein is detectable on monocytes and is increased in Alzheimer&#x2019;s disease. Neurobiol Aging. 1999;20:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588572</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD. Correlation between A&#x3b2;x-40-. A&#x3b2;x-42-, and A&#x3b2;x-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001;58:2025&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735776</ArticleId></ArticleIdList></Reference><Reference><Citation>Viale G, Gambacorta M, Coggi G, Dell&#x2019;Orto P, Milani M, Doglioni C. Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch A Pathol Anat Histopathol. 1991;418:339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">1708927</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarthy PV, Fu M, Huang J. Developmental expression of the glial fibrillary acidic protein (GFAP) gene in the mouse retina. Cell Mol Neurobiol. 1991;11:623&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11567395</ArticleId><ArticleId IdType="pubmed">1723659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998;57:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Akiyama H, Kondo H, Ikeda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-&#x3b2; protein in Alzheimer&#x2019;s disease brain. Stroke. 1997;28:1948&#x2013;1950.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z, Sankar R, Tu W, Shin D, Liu H, Wasterlain CG, Schreiber SS. Immunohistochemical study of p53-associated proteins in rat brain following lithium-pilocarpine status epilepticus. Brain Res. 2002;929:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11852039</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A&#x3b2; deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49:5136&#x2013;5143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947384</ArticleId><ArticleId IdType="pubmed">18566467</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, McGeer PL. Occurrence of the diffuse amyloid &#x3b2;-protein (A&#x3b2;) deposits with numerous A&#x3b2;-containing glial cells in the cerebral cortex of patients with Alzheimer&#x2019;s disease. Glia. 1999;25:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10028915</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T. &#x3b2;-Amyloid deposits in transgenic mice expressing human &#x3b2;-amyloid precursor protein have the same characteristics as those in Alzheimer&#x2019;s disease. Neuroscience. 2001;104:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11377835</ArticleId></ArticleIdList></Reference><Reference><Citation>Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, Maccioni RB. A&#x3b2;PP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis. 2002;4:417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446973</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M. Brain A&#x3b2; amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J Pathol. 2001;194:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">11523060</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. J Neuropathol Exp Neurol. 2001;60:357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Vorbrodt AW, Wegiel J. Amyloid angiopathy and blood-brain barrier changes in Alzheimer&#x2019;s disease. Ann NY Acad Sci. 1997;826:161&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329688</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer&#x2019;s disease pathogenesis. Neurobiol Aging. 2004;25:599&#x2013;602; discussion 603&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral &#x3b2;-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006;16:30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095991</ArticleId><ArticleId IdType="pubmed">16612980</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller NR. Alzheimer&#x2019;s disease, optic neuropathy, and selective ganglion cell damage. Ophthalmology. 1990;97:7&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2314846</ArticleId></ArticleIdList></Reference><Reference><Citation>Keri S, Antal A, Kalman J, Janka Z, Benedek G. Early visual impairment is independent of the visuocognitive and memory disturbances in Alzheimer&#x2019;s disease. Vision Res. 1999;39:2261&#x2013;2265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10343807</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer&#x2019;s disease patients. Clin Neurophysiol. 2001;112:1860&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595144</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH. Mannan-A&#x3b2;28 conjugate prevents A&#x3b2;-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation. 2008;5:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567310</ArticleId><ArticleId IdType="pubmed">18823564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-&#x3b2; vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1857306</ArticleId><ArticleId IdType="pubmed">17137722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208483</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of A&#x3b2; immunization on the vasculature of human Alzheimer&#x2019;s disease brain. Brain. 2008;131:3299&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Ferrara BJ, Dodwell SA, Hickey GA, Hyman BT, Bacskai BJ. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis. 2007;28:286&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193669</ArticleId><ArticleId IdType="pubmed">17822910</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer&#x2019;s disease. Science. 2003;302:834&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593170</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Cudennec C, Faure A, Ly M, Delatour B. One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain Behav. 2008;7(Suppl 1):83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale G, Good M. Impaired visuospatial recognition memory but normal object novelty detection and relative familiarity judgments in adult mice expressing the APPswe Alzheimer&#x2019;s disease mutation. Behav Neurosci. 2005;119:884&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">16187817</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RE, Wong AA. The influence of visual ability on learning and memory performance in 13 strains of mice. Learn Mem. 2007;14:134&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838554</ArticleId><ArticleId IdType="pubmed">17351136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer&#x2019;s disease. Am J Ophthalmol. 1987;104:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">3618708</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer&#x2019;s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">8725900</ArticleId></ArticleIdList></Reference><Reference><Citation>Strenn K, Dal-Bianco P, Weghaupt H, Koch G, Vass C, Gottlob I. Pattern electroretinogram and luminance electroretinogram in Alzheimer&#x2019;s disease. J Neural Transm Suppl. 1991;33:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1753255</ArticleId></ArticleIdList></Reference><Reference><Citation>Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer&#x2019;s disease. Invest Ophthalmol Vis Sci. 2007;48:2285&#x2013;2289.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19838174</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains.</ArticleTitle><Pagination><StartPage>1340</StartPage><EndPage>1346</EndPage><MedlinePgn>1340-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb1978</ELocationID><Abstract><AbstractText>Gamma-secretase, an aspartyl protease that belongs to the iCLiPs (intramembrane cleaving proteases) family, is a multiprotein complex that consists of presenilin (PS), nicastrin (NCT), Aph-1 and Pen-2 (ref. 1). It is responsible for generation of the beta-amyloid peptide (Abeta), the primary component of senile plaques in the brains of patients with Alzheimer's disease. Although the four components are necessary and sufficient for gamma-secretase activity, additional proteins are possibly involved in its regulation. Consequently, we purified proteins associated with the active gamma-secretase complex from reconstituted PS-deficient fibroblasts, using tandem affinity purification (TAP) and identified a series of proteins that transiently interact with the gamma-secretase complex and are probably involved in complex maturation, membrane trafficking and, importantly, the tetraspanin web. Tetraspanins form detergent-resistant microdomains in the cell membrane and regulate cell adhesion, cell signalling and proteolysis. Association of the gamma-secretase complex with tetraspanin-enriched microdomains provides an explanation for the previously documented localization of gamma-secretase to raft-like domains. Thus, these studies suggest that maintenance of the integrity of tetraspanin microdomains contributes to the refinement of proteolytic activity of the gamma-secretase complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Human Genetics, K.U.Leuven, Herestraat 49, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craessaerts</LastName><ForeName>Katleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bammens</LastName><ForeName>Leen</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bentahir</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Borgions</LastName><ForeName>Filip</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Herdewijn</LastName><ForeName>Piet</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Staes</LastName><ForeName>An</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Timmerman</LastName><ForeName>Evy</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vandekerckhove</LastName><ForeName>Jo&#xeb;l</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rubinstein</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Boucheix</LastName><ForeName>Claude</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gevaert</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19838174</ArticleId><ArticleId IdType="doi">10.1038/ncb1978</ArticleId><ArticleId IdType="pii">ncb1978</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trends Genet. 2007 Mar;23(3):140-50</Citation><ArticleIdList><ArticleId IdType="pubmed">17280736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2003 May;5(5):486-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16314869</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2004 Aug 3;43(30):9774-89</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2006 May 15;119(Pt 10):1992-2002</Citation><ArticleIdList><ArticleId IdType="pubmed">16687736</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 15;181(10):7002-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18981120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Mar 16;276(11):7974-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11113129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 Jan 10;415(6868):141-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11805826</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6382-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2006 Jun 1;119(Pt 11):2214-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16684815</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2009 Feb 17;48(6):1183-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19159235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2006 Feb;96(3):732-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Apr 8;398(6727):513-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Jul 18;283(29):20096-105</Citation><ArticleIdList><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2009 May 13;420(2):133-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19426143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Jan 16;284(3):1373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19028695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Dec 3;279(49):51654-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15456764</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2004 Feb;6(2):97-105</Citation><ArticleIdList><ArticleId IdType="pubmed">14743216</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Cell Dev Biol. 2002;18:25-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2002 May 1;11(9):1037-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11978763</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jan 22;391(6665):387-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biochem. 2001;2:10</Citation><ArticleIdList><ArticleId IdType="pubmed">11696247</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jun 21;296(5576):2215-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12077416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Apr 27;440(7088):1208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16641999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2001 Aug;58(9):1189-205</Citation><ArticleIdList><ArticleId IdType="pubmed">11577978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2008 Sep;7(9):747-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18758472</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 May 24;102(21):7499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">15890777</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2003 Jan 6;160(1):113-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2720-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11867728</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2002 Feb;9(1):11-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11848681</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Apr 10;38(1):9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Mar 27;422(6930):438-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19843697</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>47</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures.</ArticleTitle><Pagination><StartPage>19813</StartPage><EndPage>19818</EndPage><MedlinePgn>19813-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0905007106</ELocationID><Abstract><AbstractText>We performed mass-per-length (MPL) measurements and electron cryomicroscopy (cryo-EM) with 3D reconstruction on an Abeta(1-42) amyloid fibril morphology formed under physiological pH conditions. The data show that the examined Abeta(1-42) fibril morphology has only one protofilament, although two protofilaments were observed with a previously studied Abeta(1-40) fibril. The latter fibril was resolved at 8 A resolution showing pairs of beta-sheets at the cores of the two protofilaments making up a fibril. Detailed comparison of the Abeta(1-42) and Abeta(1-40) fibril structures reveals that they share an axial twofold symmetry and a similar protofilament structure. Furthermore, the MPL data indicate that the protofilaments of the examined Abeta(1-40) and Abeta(1-42) fibrils have the same number of Abeta molecules per cross-beta repeat. Based on this data and the previously studied Abeta(1-40) fibril structure, we describe a model for the arrangement of peptides within the Abeta(1-42) fibril.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rosenstiel Basic Medical Sciences Research Center and Howard Hughes Medical Institute, Brandeis University, MS 029, Waltham, MA 02454-9110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachse</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>F&#xe4;ndrich</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grigorieff</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 GM062580</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 P01 GM-62580</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20555-6. doi: 10.1073/pnas.0910978107.</RefSource><PMID Version="1">19955442</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="Y">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19843697</ArticleId><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="doi">10.1073/pnas.0905007106</ArticleId><ArticleId IdType="pii">0905007106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fandrich M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci. 2007;64:2066&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138455</ArticleId><ArticleId IdType="pubmed">17530168</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem. 1992;267:17082&#x2013;17086.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512246</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994;91:8378&#x2013;8382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44609</ArticleId><ArticleId IdType="pubmed">8078890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol. 2007;17:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer's amyloid-beta(1&#x2013;42) fibrils. Proc Natl Acad Sci USA. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Makin OS, Serpell LC. Structures for amyloid fibrils. FEBS J. 2005;272:5950&#x2013;5961.</Citation><ArticleIdList><ArticleId IdType="pubmed">16302960</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandrich M, Meinhardt J, Grigorieff N. Structural polymorphism of Alzheimer Abeta and other amyloid fibrils. Prion. 2009;3:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712605</ArticleId><ArticleId IdType="pubmed">19597329</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury CS, et al. Studies on the in vitro assembly of a beta 1&#x2013;40: Implications for the search for a beta fibril formation inhibitors. J Struct Biol. 2000;130:217&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940227</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Fandrich M. Abeta(1&#x2013;40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol. 2009;386:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760659</ArticleId><ArticleId IdType="pubmed">19038266</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel R, Shivaprasad S, Williams AD. Plasticity of amyloid fibrils. Biochemistry. 2007;46:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526019</ArticleId><ArticleId IdType="pubmed">17198370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, et al. Quaternary structure of a mature amyloid fibril from Alzheimer's Abeta(1&#x2013;40) peptide. J Mol Biol. 2006;362:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, et al. High-resolution electron microscopy of helical specimens: A fresh look at tobacco mosaic virus. J Mol Biol. 2007;371:812&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2025690</ArticleId><ArticleId IdType="pubmed">17585939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse C, Fandrich M, Grigorieff N. Paired beta-sheet structure of an Abeta(1&#x2013;40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci USA. 2008;105:7462&#x2013;7466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396686</ArticleId><ArticleId IdType="pubmed">18483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaya M, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandomeneghi G, Krebs MR, McCammon MG, Fandrich M. FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci. 2004;13:3314&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287307</ArticleId><ArticleId IdType="pubmed">15537750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunde M, et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature. 1997;386:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052786</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez JL, et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 1999;18:815&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171174</ArticleId><ArticleId IdType="pubmed">10022824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tattum MH, et al. Elongated oligomers assemble into mammalian PrP amyloid fibrils. J Mol Biol. 2006;357:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473369</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews BW. Solvent content of protein crystals. J Mol Biol. 1968;33:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">5700707</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Avalos R, King CY, Wall J, Simon M, Caspar DL. Strain-specific morphologies of yeast prion amyloid fibrils. Proc Natl Acad Sci USA. 2005;102:10165&#x2013;10170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177419</ArticleId><ArticleId IdType="pubmed">16006506</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry. 2002;41:15436&#x2013;15450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484785</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury C, Frey P, Olivieri V, Aebi U, Muller SA. Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. J Mol Biol. 2005;352:282&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095615</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova A, et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Torok M, et al. Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem. 2002;277:40810&#x2013;40815.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Interprotofilament interactions between Alzheimer's Abeta1&#x2013;42 peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci USA. 2009;106:4653&#x2013;4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660777</ArticleId><ArticleId IdType="pubmed">19264960</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford SE, Gosal WS, Platt GW. Towards an understanding of the structural molecular mechanism of beta(2)-microglobulin amyloid formation in vitro. Biochim Biophys Acta. 2005;1753:51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16099226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry. 2006;45:5503&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593882</ArticleId><ArticleId IdType="pubmed">16634632</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JT, Xu Y. Amyloid fibril structure modeling using protein threading and molecular dynamics simulations. Methods Enzymol. 2006;412:300&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046665</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson A, Sauer-Eriksson AE, Ohman A. The solvent protection of alzheimer amyloid-beta-(1&#x2013;42) fibrils as determined by solution NMR spectroscopy. J Biol Chem. 2006;281:477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">16215229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall JS, Simon MN. Scanning transmission electron microscopy of DNA-protein complexes. Methods Mol Biol. 2001;148:589&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11357616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke SJ, Baldwin PR, Chiu W. EMAN: Semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999;128:82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J, et al. SPIDER and WEB: Processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol. 1996;116:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol. 2003;142:334&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19847047</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Behavioural neurology</Title><ISOAbbreviation>Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals.</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>91</EndPage><MedlinePgn>77-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/BEN-2009-0231</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common form of dementia in old age, and is characterized by prominent impairment of episodic memory. Recent functional imaging studies in AD have demonstrated alterations in a distributed network of brain regions supporting memory function, including regions of the default mode network. Previous positron emission tomography studies of older individuals at risk for AD have revealed hypometabolism of association cortical regions similar to the metabolic abnormalities seen in AD patients. In recent functional magnetic resonance imaging (fMRI) studies of AD, corresponding brain default mode regions have also been found to demonstrate an abnormal fMRI task-induced deactivation response pattern. That is, the relative decreases in fMRI signal normally observed in the default mode regions in healthy subjects performing a cognitive task are not seen in AD patients, or may even be reversed to a paradoxical activation response. Our recent studies have revealed alterations in the pattern of deactivation also in elderly individuals at risk for AD by virtue of their APOE e4 genotype, or evidence of mild cognitive impairment (MCI). In agreement with recent reports from other groups, these studies demonstrate that the pattern of fMRI task-induced deactivation is progressively disrupted along the continuum from normal aging to MCI and to clinical AD and more impaired in e4 carriers compared to non-carriers. These findings will be discussed in the context of current literature regarding functional imaging of the default network in AD and at-risk populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pihlajam&#xe4;ki</LastName><ForeName>Maija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Maija.Pihlajamaki@uku.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23-NS02189</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG04953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Neurol</MedlineTA><NlmUniqueID>8914585</NlmUniqueID><ISSNLinking>0953-4180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012815" MajorTopicYN="N">Signal Processing, Computer-Assisted</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19847047</ArticleId><ArticleId IdType="pmc">PMC5450588</ArticleId><ArticleId IdType="doi">10.3233/BEN-2009-0231</ArticleId><ArticleId IdType="pii">R6331X54T779523W</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19865478</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals.</ArticleTitle><Pagination><StartPage>e7642</StartPage><MedlinePgn>e7642</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e7642</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0007642</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent findings suggest that Alzheimer's disease (AD) neuropathological features (neuritic plaques and NFTs) are not strongly associated with dementia in extreme old (over 90 years of age) and compel a search for neurobiological indices of dementia in this rapidly growing segment of the elderly population. We sought to characterize transcriptional and protein profiles of dementia in the oldest-old.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Gene and protein expression changes relative to non-demented age-matched controls were assessed by two microarray platforms, qPCR and Western blot in different regions of the brains of oldest-old and younger old persons who died at mild or severe stages of dementia. Our results indicate that: i) consistent with recent neuropathological findings, gene expression changes associated with cognitive impairment in oldest-old persons are distinct from those in cognitively impaired youngest-old persons; ii) transcripts affected in young-old subjects with dementia participate in biological pathways related to synaptic function and neurotransmission while transcripts affected in oldest-old subjects with dementia are associated with immune/inflammatory function; iii) upregulation of immune response genes in cognitively intact oldest-old subjects and their subsequent downregulation in dementia suggests a potential protective role of the brain immune-associated system against dementia in the oldest-old; iv) consistent with gene expression profiles, protein expression of several selected genes associated with the inflammatory/immune system in inferior temporal cortex is significantly increased in cognitively intact oldest-old persons relative to cognitively intact young-old persons, but impaired in cognitively compromised oldest-old persons relative to cognitively intact oldest-old controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that disruption of the robust immune homeostasis that is characteristic of oldest-old individuals who avoided dementia may be directly associated with dementia in the oldest-old and contrast with the synaptic and neurotransmitter system failures that typify dementia in younger old persons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsel</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA. pavel.katsel@mssm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Weilun</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19865478</ArticleId><ArticleId IdType="pmc">PMC2764344</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0007642</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>USCB. National Vital Statistics Report. Centers for Disease Control. 2004;53</Citation></Reference><Reference><Citation>USCB. Population Projections (middle series). US Census Bureau. 2002</Citation></Reference><Reference><Citation>Crystal HA, Davies P. Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J Neurochem. 1982;38:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">6176686</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomassen R, van Schaick HW, Blansjaar BA. Prevalence of dementia over age 100. Neurology. 1998;50:283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology. 1994;44:1593&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">7936280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Verghese J, Sliwinski M, Chen Z, Katz M, et al. Dementia incidence may increase more slowly after age 90 - Results from the Bronx Aging Study. Neurology. 2005;65:882&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186528</ArticleId></ArticleIdList></Reference><Reference><Citation>Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, et al. Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology. 2002;58:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Vignolo P, Duyckaerts C, Beck H, Forette F, et al. A Neuropathological Study of 12 Centenarians - the Incidence of Senile Dementia of the Alzheimer Type Is Not Increased in This Group of Very Old-People. Revue Neurologique. 1986;142:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">3726387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Kildea D. Is Senile Dementia Age-Related Or Aging-Related - Evidence from Metaanalysis of Dementia Prevalence in the Oldest-Old. Lancet. 1995;346:931&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">7564727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberg BS, Kokmen E, Okazaki H. Alzheimers-Disease and Other Dementing Illnesses in A Defined United-States Population - Incidence Rates and Clinical-Features. Annals of Neurology. 1987;22:724&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">3435081</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernicke TF, Reischies FM. Prevalence of Dementia in Old-Age - Clinical Diagnoses in Subjects Aged 95 Years and Older. Neurology. 1994;44:250&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309568</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls TT, Morris JN, Ooi WL, Lipsitz LA. The Relationship Between Age, Gender and Cognitive Performance in the Very Old - the Effect of Selective Survival. Journal of the American Geriatrics Society. 1993;41:1193&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8227893</ArticleId></ArticleIdList></Reference><Reference><Citation>Imhof A, Kovari E, Von Gunten A, Gold G, Rivara CB, et al. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J Neurol Sci. 2007;257:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303173</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999;56:713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369312</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55:1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol. 2008;65:1211&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071251</ArticleId><ArticleId IdType="pubmed">18779425</ArticleId></ArticleIdList></Reference><Reference><Citation>Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociations of Neuropathology with Severity of Dementia in Late-Onset Alzheimer's Disease. Neurology. 2006;66:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401845</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Corrada MM, Kahle-Wrobleski K, Kim RC, Sarsoza F, et al. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging. 2009;30:1125&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295175</ArticleId><ArticleId IdType="pubmed">18006193</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, et al. Age, neuropathology, and dementia. NEJM. 2009;360:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, et al. Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles &#x201c;Do Count&#x201d; When Staging Disease Severity. J Neuropathol Exp Neurol. 2007;66:1136&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Hof PR, Kovari E, Vallet PG, Herrmann FR, et al. Distinct patterns of neuronal loss and Alzheimer's disease lesion distribution in elderly individuals older than 90 years. J Neuropathol Exp Neurol. 1996;55:1210&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">8957444</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Gunten A, Kovari E, Rivara CB, Bouras C, Hof PR, et al. Stereologic analysis of hippocampal Alzheimer's disease pathology in the oldest-old: Evidence for sparing of the entorhinal cortex and CA1 field. Experimental Neurology. 2005;193:198&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817278</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Kovari E, Herrmann FR, Rivara CB, Bailey TL, et al. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. Journal of Neuropathology and Experimental Neurology. 2006;65:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651885</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver MH, Newell K, Brady C, Hedley-White ET, Perls TT. Distinguishing between neurodegenerative disease and disease-free aging: correlating neuropsychological evaluations and neuropathological studies in centenarians. Psychosom Med. 2002;64:493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021423</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y, Yamada M, Suematsu N, Matsushita M, Otomo E. An immunohistochemical study of centenarian brains: a comparison. J Neurol Sci. 1998;157:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9600680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Katsel P, Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging. 2007;30:561&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746014</ArticleId><ArticleId IdType="pubmed">17845826</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol. 2006;19:125&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563070</ArticleId><ArticleId IdType="pubmed">18832152</ArticleId></ArticleIdList></Reference><Reference><Citation>Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P, Mann JJ, Sibille E. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry. 2005;57:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">15737671</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis. 2003;12:97&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett. 2001;298:191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11165439</ArticleId></ArticleIdList></Reference><Reference><Citation>Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 2001;20:683&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788046</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Avignone E, Ulmann L, Levavasseur F, Rassendren F, Audinat E. Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J Neurosci. 2008;28:9133&#x2013;9144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670931</ArticleId><ArticleId IdType="pubmed">18784294</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 2005;16:5061&#x2013;5069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266406</ArticleId><ArticleId IdType="pubmed">16107560</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkai P, Bogerts B, Rozumek M. Limbic Pathology in Schizophrenia: The Entorhinal Region-A Morphometric Study. Biological Psychiatry. 1988;24:515&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">3167140</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls T. Centenarians who avoid dementia. Trends in Neurosciences. 2004;27:633&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15374676</ArticleId></ArticleIdList></Reference><Reference><Citation>Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J, Beach TG, Cotman CW. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging. 2007;28:1821&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198930</ArticleId><ArticleId IdType="pubmed">17052803</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:132&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193789</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P, Rogers J, McGeer E. Neuroimmune Mechanisms in Alzheimer Disease Pathogenesis. Alzheimer Disease and Associated Disorders. 1994;8:149&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">7986484</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Stampfer-Kountchev M, Robatscher P, Verrhuis R, Eikelenboom P, et al. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15268750</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM. Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers. 2006;22:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850819</ArticleId><ArticleId IdType="pubmed">16410654</ArticleId></ArticleIdList></Reference><Reference><Citation>Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000;57:1153&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">10927795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiace LA, Davies P, Dickson DW. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol. 1990;136:1101&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877424</ArticleId><ArticleId IdType="pubmed">1693471</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol. 1990;110:93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698655</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95:10896&#x2013;10901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27992</ArticleId><ArticleId IdType="pubmed">9724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res. 2002;69:418&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">12125082</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Davis CN, Harrison JK. Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists. Curr Alzheimer Res. 2005;2:187&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974917</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zujovic V, Benavides J, Vige X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000;29:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;979:65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850572</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P, Lanier LL, Timonen T, Peltonen L. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25:357&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007;20:947&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982277</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem. 1983;258:785&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">6218163</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol. 2003;70:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568360</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AE, III, Whitehead AS, Harrison RA, Dauphinais A, Bruns GA, et al. Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci U S A. 1986;83:3161&#x2013;3165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323472</ArticleId><ArticleId IdType="pubmed">3458172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheepsunthorn P, Palmer C, Connor JR. Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol. 1998;400:73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S, Anginot A, Vuaillat C, Malaval L, Fodil N, et al. Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol. 2005;166:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602283</ArticleId><ArticleId IdType="pubmed">15632019</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2008;12:762&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401126</ArticleId><ArticleId IdType="pubmed">18363841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia. 2001;36:118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596120</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10217056</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions: A gene ontology study. Schizo Res. 2005;79:157&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">16139990</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizo Res. 2005;77:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">15923110</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Katsel P, Dracheva S, Davis KL. The Human Homolog of QKI Gene Affected in the Severe Dysmyelination &#x201c;Quaking&#x201d; Mouse Phenotype is Downregulated in Multiple Brain Regions in Schizophrenia. Am J Psychiat. 2006;163:1834&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012699</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsel P, Li C, Haroutunian V. Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease? Neurochem Res. 2007;32:845&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17342407</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. Journal of the Neurological Sciences. 1970;11:205&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Che S, Counts SE, Mufson EJ. Single cell gene expression profiling in Alzheimer's disease. NeuroRx. 2006;3:302&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593387</ArticleId><ArticleId IdType="pubmed">16815214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Society Series B (Methodology) 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Dracheva S, McGurk SR, Haroutunian V. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res. 2005;79:868&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">15696539</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhraja V, Spitznagel E, Schaiff WT, Sadovsky Y. Incorporation of gene-specific variability improves expression analysis using high-density DNA microarrays. BMC Biol. 2003;1:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288513</ArticleId><ArticleId IdType="pubmed">14641937</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, Sadovsky Y. A variable fold change threshold determines significance for expression microarrays. FASEB J. 2003;17:321&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19889996</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>44</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>13850</StartPage><EndPage>13859</EndPage><MedlinePgn>13850-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2312-09.2009</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease inherited in a small subset of patients. The SOD1(G93A) transgenic mouse models this subset of patients, and studies of this strain have suggested that endoplasmic reticulum (ER) stress and deficits in ER chaperone function are contributors to ALS pathophysiology. Here, we demonstrate that the reticulon family of proteins is a novel regulator of the ER chaperone protein disulfide isomerase (PDI), and that through PDI, reticulon-4A (Nogo-A) can protect mice against the neurodegeneration that characterizes ALS. We show that overexpressing reticulon protein induces a punctate redistribution of PDI intracellularly, both in vitro and in vivo. Conversely, reduction of endogenous NogoA expression causes a more homogeneous expression pattern in vivo. These effects occur without induction of the unfolded protein response. To examine the effect of PDI redistribution on ALS disease progression, we conducted survival and behavior studies of SOD1(G93A) mice. Deletion of a single copy of the NogoA,B gene accelerates disease onset and progression, while deletion of both copies further worsens disease. We conclude that NogoA contributes to the proper function of the ER resident chaperone PDI, and is protective against ALS-like neurodegeneration. Our results provide a novel intracellular role for reticulon proteins and support the hypothesis that modulation of PDI function is a potential therapeutic approach to ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yvonne S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration, and Repair, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harel</LastName><ForeName>Noam Y</ForeName><Initials>NY</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS033020</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042304</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS056212</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TG 2 T32 GM07205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009185">Myelin Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070798">Nogo Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603201">Rtn4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.3.4.1</RegistryNumber><NameOfSubstance UI="D019704">Protein Disulfide-Isomerases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020297" MajorTopicYN="N">Mice, Congenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009185" MajorTopicYN="N">Myelin Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070798" MajorTopicYN="N">Nogo Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019704" MajorTopicYN="N">Protein Disulfide-Isomerases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19889996</ArticleId><ArticleId IdType="mid">NIHMS163456</ArticleId><ArticleId IdType="pmc">PMC2797811</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2312-09.2009</ArticleId><ArticleId IdType="pii">29/44/13850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, Heiman-Patterson TD. Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130:7&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519671</ArticleId></ArticleIdList></Reference><Reference><Citation>Appenzeller-Herzog C, Ellgaard L. The human PDI family: versatility packed into a single fold. Biochim Biophys Acta. 2008;1783:535&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">18093543</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, Horne MK. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J Biol Chem. 2006;281:30152&#x2013;30165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847061</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, Horne MK. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis. 2008;30:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">18440237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandtlow CE, Schwab ME. NI-35/250/nogo-a: a neurite growth inhibitor restricting structural plasticity and regeneration of nerve fibers in the adult vertebrate CNS. Glia. 2000;29:175&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">10625336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafferty WB, Strittmatter SM. The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J Neurosci. 2006;26:12242&#x2013;12250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848954</ArticleId><ArticleId IdType="pubmed">17122049</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroni P, Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron. 1988;1:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272156</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Gonzalez de Aguilar JL, di Scala F, Rene F, de Tapia M, Pradat PF, Lacomblez L, Seihlan D, Prinjha R, Walsh FS, Meininger V, Loeffler JP. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">12270696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci. 2007;27:9201&#x2013;9219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672214</ArticleId><ArticleId IdType="pubmed">17715356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001;409:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">11201742</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, Gould GC, Liu BP, Strittmatter SM. Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci. 2002a;22:8876&#x2013;8883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757674</ArticleId><ArticleId IdType="pubmed">12388594</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, GrandPr&#xe9; T, Gould G, Wang X, Strittmatter SM. Nogo and the Nogo-66 receptor. Prog Brain Res. 2002b;137:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440378</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert HF. Protein disulfide isomerase. Methods Enzymol. 1998;290:26&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9534149</ArticleId></ArticleIdList></Reference><Reference><Citation>GrandPr&#xe9; T, Strittmatter SM. Nogo: a molecular determinant of axonal growth and regeneration. Neuroscientist. 2001;7:377&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11597097</ArticleId></ArticleIdList></Reference><Reference><Citation>GrandPr&#xe9; T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature. 2000;403:439&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern. 1973;3:610&#x2013;621.</Citation></Reference><Reference><Citation>Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, Byers N, Toman I, Alexander GM. Background and gender effects on survival in the TgN(SOD1&#x2013;G93A)1Gur mouse model of ALS. J Neurol Sci. 2005;236:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, DeGennaro LJ, Cleveland DW, Rothstein JD. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci U S A. 2002;99:1604&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Shibata Y, Zhu PP, Voss C, Rismanchi N, Prinz WA, Rapoport TA, Blackstone C. A class of dynamin-like GTPases involved in the generation of the tubular ER network. Cell. 2009;138:549&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746359</ArticleId><ArticleId IdType="pubmed">19665976</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber AB, Weinmann O, Br&#xf6;samle C, Oertle T, Schwab ME. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci. 2002;22:3553&#x2013;3567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758364</ArticleId><ArticleId IdType="pubmed">11978832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva EV, Ayala V, Jov&#xe9; M, Dalf&#xf3; E, Cacabelos D, Povedano M, Bellmunt MJ, Ferrer I, Pamplona R, Portero-Ot&#xed;n M. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130:3111&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, Dubourg O, Seilhean D, Hauw JJ, Loeffler JP, Meininger V. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol. 2005;57:553&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">15786457</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, Schwab ME, Dupuis L, Loeffler JP. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 2006;7:1162&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1679784</ArticleId><ArticleId IdType="pubmed">17039253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Suzuki H, Aiso S, Matsuoka M. ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol. 2009;39:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19184563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008;7:1013&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">19043451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Li S, GrandPr&#xe9; T, Qiu D, Strittmatter SM. Axon regeneration in young adult mice lacking Nogo-A/B. Neuron. 2003;38:187&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Liu BP, Park JH, Strittmatter SM. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron. 2004;44:439&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15504325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiseleva E, Morozova KN, Voeltz GK, Allen TD, Goldberg MW. Reticulon 4a/NogoA locates to regions of high membrane curvature and may have a role in nuclear envelope growth. J Struct Biol. 2007;160:224&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2048824</ArticleId><ArticleId IdType="pubmed">17889556</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654259</ArticleId><ArticleId IdType="pubmed">18188003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:933&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182156</ArticleId><ArticleId IdType="pubmed">15478096</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol. 2007;18:716&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706143</ArticleId><ArticleId IdType="pubmed">18023214</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto A, Okada Y, Nakamichi M, Nakamura M, Toyama Y, Sobue G, Nagai M, Aoki M, Itoyama Y, Okano H. Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res. 2006;83:119&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16342121</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalak M, Robert Parker JM, Opas M. Ca2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell Calcium. 2002;32:269&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543089</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Ilieva H, Murakami T, Shiote M, Narai H, Ohta Y, Hayashi T, Shoji M, Abe K. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neurol Res. 2007;29:767&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">17672929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007;581:3641&#x2013;3651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040386</ArticleId><ArticleId IdType="pubmed">17481612</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertle T, Schwab ME. Nogo and its paRTNers. Trends Cell Biol. 2003;13:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667756</ArticleId></ArticleIdList></Reference><Reference><Citation>Oertle T, Klinger M, Stuermer CA, Schwab ME. A reticular rhapsody: phylogenic evolution and nomenclature of the RTN/Nogo gene family. FASEB J. 2003;17:1238&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12832288</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver JD, Roderick HL, Llewellyn DH, High S. ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol Biol Cell. 1999;10:2573&#x2013;2582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25489</ArticleId><ArticleId IdType="pubmed">10436013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelham HR. The dynamic organisation of the secretory pathway. Cell Struct Funct. 1996;21:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 1995;92:689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, Christ F, Sansig G, van der Putten H, Schwab ME. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron. 2003;38:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718855</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ. Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J Cell Biol. 2007;177:393&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064823</ArticleId><ArticleId IdType="pubmed">17470639</ArticleId></ArticleIdList></Reference><Reference><Citation>Voeltz GK, Prinz WA, Shibata Y, Rist JM, Rapoport TA. A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell. 2006;124:573&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002;110:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Shi Q, Hu X, Zhou X. Reticulon proteins: emerging players in neurodegenerative diseases. Cell Mol Life Sci. 2006;63:877&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136446</ArticleId><ArticleId IdType="pubmed">16505974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YS, Strittmatter SM. The reticulons: a family of proteins with diverse functions. Genome Biol. 2007;8:234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246256</ArticleId><ArticleId IdType="pubmed">18177508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19897719</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>47</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>20057</StartPage><EndPage>20062</EndPage><MedlinePgn>20057-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0905529106</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta)-containing plaques, neurofibrillary tangles, and neuron and synapse loss. Tangle formation has been reproduced in P301L tau transgenic pR5 mice, whereas APP(sw)PS2(N141I) double-transgenic APP152 mice develop Abeta plaques. Cross-breeding generates triple transgenic ((triple)AD) mice that combine both pathologies in one model. To determine functional consequences of the combined Abeta and tau pathologies, we performed a proteomic analysis followed by functional validation. Specifically, we obtained vesicular preparations from (triple)AD mice, the parental strains, and nontransgenic mice, followed by the quantitative mass-tag labeling proteomic technique iTRAQ and mass spectrometry. Within 1,275 quantified proteins, we found a massive deregulation of 24 proteins, of which one-third were mitochondrial proteins mainly related to complexes I and IV of the oxidative phosphorylation system (OXPHOS). Notably, deregulation of complex I was tau dependent, whereas deregulation of complex IV was Abeta dependent, both at the protein and activity levels. Synergistic effects of Abeta and tau were evident in 8-month-old (triple)AD mice as only they showed a reduction of the mitochondrial membrane potential at this early age. At the age of 12 months, the strongest defects on OXPHOS, synthesis of ATP, and reactive oxygen species were exhibited in the (triple)AD mice, again emphasizing synergistic, age-associated effects of Abeta and tau in perishing mitochondria. Our study establishes a molecular link between Abeta and tau protein in AD pathology in vivo, illustrating the potential of quantitative proteomics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rhein</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric University Clinics, University of Basel, 4025 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiaomin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wiesner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Baysang</LastName><ForeName>Ginette</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Fides</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ozmen</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bluethmann</LastName><ForeName>Horst</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dr&#xf6;se</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Savaskan</LastName><ForeName>Egemen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Czech</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eckert</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="Y">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010085" MajorTopicYN="Y">Oxidative Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19897719</ArticleId><ArticleId IdType="pmc">PMC2774257</ArticleId><ArticleId IdType="doi">10.1073/pnas.0905529106</ArticleId><ArticleId IdType="pii">0905529106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gotz J, et al. Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatry. 2004;9:664&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem. 2005;280:23802&#x2013;23814. Epub 2005 Apr 14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, et al. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics. 2006;6:6566&#x2013;6577.</Citation><ArticleIdList><ArticleId IdType="pubmed">17111439</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards JG, et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003;23:8989&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740398</ArticleId><ArticleId IdType="pubmed">14523101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters N, Ittner LM, Gotz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci. 2008;28:137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">18662339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennanen L, Wolfer DP, Nitsch RM, Gotz J. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav. 2006;5:369&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879631</ArticleId></ArticleIdList></Reference><Reference><Citation>Grueninger F, et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">19781645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugino K, et al. Molecular taxonomy of major neuronal classes in the adult mouse forebrain. Nat Neurosci. 2006;9:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369481</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleardi AM, et al. Gradual alteration of mitochondrial structure and function by beta-amyloids: Importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bionenerg Biomembr. 2005;37:207&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">16167177</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A, et al. Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med. 2008;86:1255&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">18709343</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A, et al. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis. 2008;5:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sompol P, et al. A neuronal model of Alzheimer's disease: An insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience. 2008;153:120&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430183</ArticleId><ArticleId IdType="pubmed">18353561</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira PI, et al. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets. 2008;7:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18289026</ArticleId></ArticleIdList></Reference><Reference><Citation>Su B, et al. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res. 2008;5:525&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780015</ArticleId><ArticleId IdType="pubmed">19075578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA. 2008;105:19318&#x2013;19323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614759</ArticleId><ArticleId IdType="pubmed">19050078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhein V, et al. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol. 2009;29:1063&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11506282</ArticleId><ArticleId IdType="pubmed">19350381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauptmann S, et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30:1574&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295378</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira PI, Santos MS, Oliveira CR. Alzheimer's disease: A lesson from mitochondrial dysfunction. Antioxid Redox Signal. 2007;9:1621&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17678440</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA. 2008;105:15605&#x2013;15610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563070</ArticleId><ArticleId IdType="pubmed">18832152</ArticleId></ArticleIdList></Reference><Reference><Citation>Keil U, et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem. 2004;279:50310&#x2013;50320.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilescu MA, Fendel U, Zwicker K, Kerscher S, Brandt U. Exploring the ubiquinone binding cavity of respiratory complex I. J Biol Chem. 2007;282:29514&#x2013;29520.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. V-ATPase V0 sector subunit a1 in neurons is a target of calmodulin. J Biol Chem. 2008;283:294&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249936</ArticleId><ArticleId IdType="pubmed">17933871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging. 2003;24:1079&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA. 2008;105:15997&#x2013;16002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572931</ArticleId><ArticleId IdType="pubmed">18832465</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:1953&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413647</ArticleId><ArticleId IdType="pubmed">16446437</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Siedlak SL, Richey PL, Mulvihill P, Ghiso J. Tau protein directly interacts with the amyloid beta-protein precursor: Implications for Alzheimer's disease. Nat Med. 1995;1:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA. 2007;104:19067&#x2013;19072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141909</ArticleId><ArticleId IdType="pubmed">18003925</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19906985</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>48</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.</ArticleTitle><Pagination><StartPage>20228</StartPage><EndPage>20233</EndPage><MedlinePgn>20228-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0910757106</ELocationID><Abstract><AbstractText>gamma-Secretase cleaves multiple substrates within the transmembrane domain that include the amyloid precursor protein as well as the Notch family of receptors. These substrates are associated with Alzheimer disease and cancer. Despite extensive investigation of this protease, little is known regarding the regulation of gamma-secretase specificity. To discover selective inhibitors for drug development and for probing the mechanisms of gamma-secretase specificity, we screened chemical libraries and consequently developed a di-coumarin family of inhibitors that preferentially inhibit gamma-secretase-mediated production of Abeta42 over other cleavage activities. These coumarin dimer-based compounds interact with gamma-secretase by binding to an allosteric site. By developing a multiple photo-affinity probe approach, we demonstrate that this allosteric binding causes a conformational change within the active site of gamma-secretase at the S2 and S1 sub-sites that leads to selective inhibition of Abeta42. In conclusion, by using these di-coumarin compounds, we reveal a mechanism by which gamma-secretase specificity is regulated and provide insights into the molecular basis by which familial presenilin mutations may affect the active site and specificity of gamma-secretase. Furthermore, this class of selective inhibitors provides the basis for development of Alzheimer disease therapeutic agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology and Chemistry Program and High Throughput Screening Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Deming</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Djaballah</LastName><ForeName>Hakim</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG20670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5F31NS053218</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR022415</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS053218</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003374">Coumarins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019920">Photoaffinity Labels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019920" MajorTopicYN="N">Photoaffinity Labels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="Y">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19906985</ArticleId><ArticleId IdType="pmc">PMC2787169</ArticleId><ArticleId IdType="doi">10.1073/pnas.0910757106</ArticleId><ArticleId IdType="pii">0910757106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol. 2000;2:428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev. 2000;14:2799&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090127</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959515</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, et al. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. J Neurosci. 2006;26:3845&#x2013;3854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674120</ArticleId><ArticleId IdType="pubmed">16597739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27:686&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer SC, et al. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem. 2008;51:7348&#x2013;7351.</Citation><ArticleIdList><ArticleId IdType="pubmed">19012391</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer WJ, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA. 2003;100:12444&#x2013;12449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218777</ArticleId><ArticleId IdType="pubmed">14523244</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1&#x2013;42/1&#x2013;40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11:545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison T, Churcher I, Beher D. gamma-Secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Devel. 2004;7:709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">15503873</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393:382&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearman MS, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry. 2000;39:8698&#x2013;8704.</Citation><ArticleIdList><ArticleId IdType="pubmed">10913280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin YI, et al. {gamma}-secretase substrate concentration modulates the Abeta42/Abeta40 ratio: Implications for Alzheimer disease. J Biol Chem. 2007;282:23639&#x2013;23644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian G, et al. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem. 2002;277:31499&#x2013;31505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12072428</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol. 2009;385:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967;27:157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">6035483</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G, et al. Stereo-controlled synthesis of novel photoreactive gamma-secretase inhibitors. Bioorg Med Chem Lett. 2009;19:922&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254698</ArticleId><ArticleId IdType="pubmed">19097779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun J, Yin YI, Yang G, Tarassishin L, Li YM. Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors. J Org Chem. 2004;69:7344&#x2013;7347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15471490</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarassishin L, Yin YI, Bassit B, Li YM. Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct. Proc Natl Acad Sci USA. 2004;101:17050&#x2013;17055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535399</ArticleId><ArticleId IdType="pubmed">15563588</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, et al. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005;280:25892&#x2013;25900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993;695:144&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239273</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L, et al. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 {gamma}-secretase complexes. J Biol Chem. 2009;284:2967&#x2013;2977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631949</ArticleId><ArticleId IdType="pubmed">19036728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, et al. Coumarin-based inhibitors of HIV integrase. J Med Chem. 1997;40:242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">9003523</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan KA, et al. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. J Med Chem. 2007;50:6316&#x2013;6325.</Citation><ArticleIdList><ArticleId IdType="pubmed">17999461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou HY, Hong JL, Shu P, Ni YJ, Qin MJ. A new dicoumarin and anticoagulant activity from Viola yedoensis Makino. Fitoterapia. 2009;80:283&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammich S, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem. 2002;277:44754&#x2013;44759.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223485</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Sweeney D, Gandy SE, Sisodia SS. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem. 1996;271:31894&#x2013;31902.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecimovic S, et al. Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol Dis. 2004;17:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19907078</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>3692</StartPage><EndPage>3702</EndPage><MedlinePgn>3692-702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI39716</ELocationID><ELocationID EIdType="pii" ValidYN="Y">39716</ELocationID><Abstract><AbstractText>Ectopic cell cycle events (CCEs) mark vulnerable neuronal populations in human Alzheimer disease (AD) and are observed early in disease progression. In transgenic mouse models of AD, CCEs are found before the onset of beta-amyloid peptide (Abeta) deposition to form senile plaques, a hallmark of AD. Here, we have demonstrated that alterations in brain microglia occur coincidently with the appearance of CCEs in the R1.40 transgenic mouse model of AD. Furthermore, promotion of inflammation with LPS at young ages in R1.40 mice induced the early appearance of neuronal CCEs, whereas treatment with 2 different nonsteroidal antiinflammatory drugs (NSAIDs) blocked neuronal CCEs and alterations in brain microglia without altering amyloid precursor protein (APP) processing and steady-state Abeta levels. In addition, NSAID treatment of older R1.40 animals prevented new neuronal CCEs, although it failed to reverse existing ones. Retrospective human epidemiological studies have identified long-term use of NSAIDs as protective against AD. Prospective clinical trials, however, have failed to demonstrate a similar benefit. Our use of CCEs as an outcome measure offers fresh insight into this discrepancy and provides important information for future clinical trials, as it suggests that NSAID use in human AD may need to be initiated as early as possible to prevent disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varvel</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhaskar</LastName><ForeName>Kiran</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kounnas</LastName><ForeName>Maria Z</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO24494</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>57Y76R9ATQ</RegistryNumber><NameOfSubstance UI="D009288">Naproxen</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009288" MajorTopicYN="N">Naproxen</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19907078</ArticleId><ArticleId IdType="pmc">PMC2786797</ArticleId><ArticleId IdType="doi">10.1172/JCI39716</ArticleId><ArticleId IdType="pii">39716</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. . 2009 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2009;5:234&#x2013;270. doi: 10.1016/j.jalz.2009.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.03.001</ArticleId><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H., et al. Inflammation and Alzheimer&#x2019;s disease. Neurobiol. Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T., et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 2008;28:4283&#x2013;4292. doi: 10.1523/JNEUROSCI.4814-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4814-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M., et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer&#x2019;s disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer&#x2019;s disease and duration of NSAID use. Neurology. 1997;48:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70:1672&#x2013;1677. doi: 10.1212/01.wnl.0000311269.57716.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000311269.57716.63</ArticleId><ArticleId IdType="pmc">PMC2758242</ArticleId><ArticleId IdType="pubmed">18458226</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin B.K., et al. Cognitive function over time in the Alzheimer&#x2019;s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 2008;65:896&#x2013;905. doi: 10.1001/archneur.2008.65.7.nct70006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.2008.65.7.nct70006</ArticleId><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G.P., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging. 2001;22:983&#x2013;991. doi: 10.1016/S0197-4580(01)00299-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00299-8</ArticleId><ArticleId IdType="pubmed">11755007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer&#x2019;s disease. J. Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T., et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007;8:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1948891</ArticleId><ArticleId IdType="pubmed">17650315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S., et al. Modulation of nuclear factor-kappa B activity by indomethacin influences Abeta levels but not Abeta precursor protein metabolism in a model of Alzheimer&#x2019;s disease. Am. J. Pathol. 2004;165:2197&#x2013;2206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618710</ArticleId><ArticleId IdType="pubmed">15579461</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen J., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003;112:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216. doi: 10.1038/35102591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35102591</ArticleId><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T.L., et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453:925&#x2013;929. doi: 10.1038/nature07055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07055</ArticleId><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M., et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 2006;103:443&#x2013;448. doi: 10.1073/pnas.0503839103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0503839103</ArticleId><ArticleId IdType="pmc">PMC1326151</ArticleId><ArticleId IdType="pubmed">16407166</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Rodel L., Gartner U., Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer&#x2019;s disease. Neuroreport. 1996;7:3047&#x2013;3049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A., Harris P.L., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer&#x2019;s disease. Am. J. Pathol. 1997;150:1933&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858317</ArticleId><ArticleId IdType="pubmed">9176387</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer&#x2019;s disease? J. Cell Biol. 1996;132:413&#x2013;425. doi: 10.1083/jcb.132.3.413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.132.3.413</ArticleId><ArticleId IdType="pmc">PMC2120731</ArticleId><ArticleId IdType="pubmed">8636218</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Geldmacher D.S., Herrup K. DNA replication precedes neuronal cell death in Alzheimer&#x2019;s disease. J. Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer&#x2019;s disease. Neurologia. 2000;15:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Varvel N.H., Lamb B.T., Herrup K. Ectopic cell cycle events link human Alzheimer&#x2019;s disease and amyloid precursor protein transgenic mouse models. J. Neurosci. 2006;26:775&#x2013;784. doi: 10.1523/JNEUROSCI.3707-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3707-05.2006</ArticleId><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron. 2008;60:803&#x2013;817. doi: 10.1016/j.neuron.2008.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.015</ArticleId><ArticleId IdType="pmc">PMC2912147</ArticleId><ArticleId IdType="pubmed">19081376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallhoff-Munoz V., Hu L., Chen X., Pautler R.G., Zheng H. Genetic dissection of gamma-secretase-dependent and -independent functions of presenilin in regulating neuronal cell cycle and cell death. J. Neurosci. 2008;28:11421&#x2013;11431. doi: 10.1523/JNEUROSCI.2873-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2873-08.2008</ArticleId><ArticleId IdType="pmc">PMC2615184</ArticleId><ArticleId IdType="pubmed">18971484</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C., et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 2005;25:5446&#x2013;5454. doi: 10.1523/JNEUROSCI.4637-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4637-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb B.T., et al. Altered metabolism of familial Alzheimer&#x2019;s disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 1997;6:1535&#x2013;1541. doi: 10.1093/hmg/6.9.1535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/6.9.1535</ArticleId><ArticleId IdType="pubmed">9285791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb B.T., et al. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 1993;5:22&#x2013;30. doi: 10.1038/ng0993-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0993-22</ArticleId><ArticleId IdType="pubmed">8220418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman E.J., et al. Genetic Background Regulates beta-Amyloid Precursor Protein Processing and beta-Amyloid Deposition in the Mouse. Hum. Mol. Genet. 2003;12:2949&#x2013;2956. doi: 10.1093/hmg/ddg322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg322</ArticleId><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel N.H., et al. Abeta oligomers induce neuronal cell cycle events in Alzheimer&#x2019;s disease. . J. Neurosci. 2008;28:10786&#x2013;10793. doi: 10.1523/JNEUROSCI.2441-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2441-08.2008</ArticleId><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="pubmed">18945886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane L.S., Lamb B.T. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol. Dis. 2001;8:982&#x2013;992. doi: 10.1006/nbdi.2001.0446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0446</ArticleId><ArticleId IdType="pubmed">11741394</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltys Z., et al. Quantitative morphological study of microglial cells in the ischemic rat brain using principal component analysis. J. Neurosci. Methods. 2005;146:50&#x2013;60. doi: 10.1016/j.jneumeth.2005.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2005.01.009</ArticleId><ArticleId IdType="pubmed">15935220</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlowski D., Soltys Z., Janeczko K. Morphological development of microglia in the postnatal rat brain. A quantitative study. Int. J. Dev. Neurosci. 2003;21:445&#x2013;450. doi: 10.1016/j.ijdevneu.2003.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijdevneu.2003.09.001</ArticleId><ArticleId IdType="pubmed">14659995</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltys Z., Ziaja M., Pawlinski R., Setkowicz Z., Janeczko K. Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J. Neurosci. Res. 2001;63:90&#x2013;97. doi: 10.1002/1097-4547(20010101)63:1&lt;90::AID-JNR11&gt;3.0.CO;2-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-4547(20010101)63:1&lt;90::AID-JNR11&gt;3.0.CO;2-9</ArticleId><ArticleId IdType="pubmed">11169618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona A.E., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006;9:917&#x2013;924. doi: 10.1038/nn1715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1715</ArticleId><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun M.A., et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452. doi: 10.1212/01.wnl.0000228230.26044.a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228230.26044.a4</ArticleId><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe C.C., et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725. doi: 10.1212/01.wnl.0000261919.22630.ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000261919.22630.ea</ArticleId><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso J.C., Martin L.J., Dal Forno G., Kawas C.H. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol. Aging. 1996;17:365&#x2013;371. doi: 10.1016/0197-4580(96)00028-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00028-0</ArticleId><ArticleId IdType="pubmed">8725897</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon D.A. Aging and Alzheimer&#x2019;s disease: lessons from the Nun Study. Gerontologist. 1997;37:150&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9127971</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J., Geldmacher D.S., Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer&#x2019;s disease brain. . J. Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Mufson E.J., Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer&#x2019;s disease. J. Neurosci. 2003;23:2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelsins M.C., et al. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer&#x2019;s disease mice. J. Neuroinflammation. 2005;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276812</ArticleId><ArticleId IdType="pubmed">16232318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehranian R., Hasanvan H., Iverfeldt K., Post C., Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci. Lett. 2001;301:54&#x2013;58. doi: 10.1016/S0304-3940(01)01592-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01592-0</ArticleId><ArticleId IdType="pubmed">11239715</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502. doi: 10.1016/j.neuron.2006.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.01.022</ArticleId><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007;13:432&#x2013;438. doi: 10.1038/nm1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1555</ArticleId><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer&#x2019;s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165707</ArticleId><ArticleId IdType="pubmed">12869452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek L.A., et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131:651&#x2013;664. doi: 10.1093/brain/awn008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn008</ArticleId><ArticleId IdType="pmc">PMC2628581</ArticleId><ArticleId IdType="pubmed">18292081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer&#x2019;s disease. J. Neurosci. 2003;23:7504&#x2013;7509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740758</ArticleId><ArticleId IdType="pubmed">12930788</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I., Overmyer M., Helisalmi S., Soininen H. Lower counts of astroglia and activated microglia in patients with Alzheimer&#x2019;s disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimers Dis. 2000;2:37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566383</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005;128:1442&#x2013;1453. doi: 10.1093/brain/awh452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh452</ArticleId><ArticleId IdType="pubmed">15817521</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantzen P.T., et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2002;22:2246&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758281</ArticleId><ArticleId IdType="pubmed">11896164</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen P.S., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819&#x2013;2826. doi: 10.1001/jama.289.21.2819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.21.2819</ArticleId><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Green R.D., Schneider L.S., Hendrix S.B., Zavitz K.H., Swabb E. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer&#x2019;s disease: results from an 18-month multi-center phase 3 trial. Alzheimers Dement. 2008;4(Suppl.):T165.</Citation></Reference><Reference><Citation>Kukar T., et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 2005;11:545&#x2013;550. doi: 10.1038/nm1235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1235</ArticleId><ArticleId IdType="pubmed">15834426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz T.A., Fici G.J., Merchant K.M. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. 2005;312:399&#x2013;406. doi: 10.1124/jpet.104.073965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.104.073965</ArticleId><ArticleId IdType="pubmed">15340006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997;272:3406&#x2013;3410. doi: 10.1074/jbc.272.6.3406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.6.3406</ArticleId><ArticleId IdType="pubmed">9013583</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001;4:233&#x2013;234. doi: 10.1038/85064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85064</ArticleId><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71&#x2013;82. doi: 10.1016/S1074-7613(03)00174-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00174-2</ArticleId><ArticleId IdType="pubmed">12871640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane L.S., Lehman E.J., Hock B.J., Tsuchiya K.D., Lamb B.T. Rapid and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm. Genome. 2002;13:223&#x2013;226. doi: 10.1007/s00335-001-2128-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-001-2128-5</ArticleId><ArticleId IdType="pubmed">11956767</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., et al. Amyloid precursor protein in aged nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 1991;88:1461&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51038</ArticleId><ArticleId IdType="pubmed">1899927</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19914182</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation.</ArticleTitle><Pagination><StartPage>328</StartPage><EndPage>340</EndPage><MedlinePgn>328-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.08.036</ELocationID><Abstract><AbstractText>Senile plaques consisting of beta-amyloid (Abeta) and neurofibrillary tangles composed of hyperphosphorylated tau are major pathological hallmarks of Alzheimer's disease (AD). Elucidation of factors that modulate Abeta generation and tau hyperphosphorylation is crucial for AD intervention. Here, we identify a mouse gene Rps23r1 that originated through retroposition of ribosomal protein S23. We demonstrate that RPS23R1 protein reduces the levels of Abeta and tau phosphorylation by interacting with adenylate cyclases to activate cAMP/PKA and thus inhibit GSK-3 activity. The function of Rps23r1 is demonstrated in cells of various species including human, and in transgenic mice overexpressing RPS23R1. Furthermore, the AD-like pathologies of triple transgenic AD mice were improved and levels of synaptic maker proteins increased after crossing them with Rps23r1 transgenic mice. Our studies reveal a new target/pathway for regulating AD pathologies and uncover a retrogene and its role in regulating protein kinase pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-wu</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shijie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wu-Bo</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaomin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiumei</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Liangwu</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Netzer</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Threadgill</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wiegand</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruishan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Stanley N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Francesca-Fang</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Limin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS054880</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545338">RPS23R1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.11</RegistryNumber><NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.6.1.1</RegistryNumber><NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017868" MajorTopicYN="N">Cyclic AMP-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19914182</ArticleId><ArticleId IdType="mid">NIHMS145508</ArticleId><ArticleId IdType="pmc">PMC3846276</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.08.036</ArticleId><ArticleId IdType="pii">S0896-6273(09)00674-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, Frebourg T, Checler F. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --&gt; Met betaAPP-770 mutation responsible for probable early-onset Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 1999;96:4119&#x2013;4124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22430</ArticleId><ArticleId IdType="pubmed">10097173</ArticleId></ArticleIdList></Reference><Reference><Citation>Babushok DV, Ostertag EM, Kazazian HH., Jr. Current topics in genome evolution: molecular mechanisms of new gene formation. Cell. Mol. Life. Sci. 2007;64:542&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11138463</ArticleId><ArticleId IdType="pubmed">17192808</ArticleId></ArticleIdList></Reference><Reference><Citation>Barelli H, Lebeau A, Vizzavona J, Delaere P, Chevallier N, Drouot C, Marambaud P, Ancolio K, Buxbaum JD, Khorkova O, et al. Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer&#x2019;s disease and cerebral amyloid angiopathy cases. Mol. Med. 1997;3:695&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230230</ArticleId><ArticleId IdType="pubmed">9392006</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. USA. 1994;91:4489&#x2013;4493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43811</ArticleId><ArticleId IdType="pubmed">8183935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Yang DS, Petanceska S, Yang A, Tandon A, Yu G, Rozmahel R, Ghiso J, Nishimura M, Zhang DM, et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J. Biol. Chem. 2000;275:36794&#x2013;36802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10962005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme BACE1. Mol. Neurodegener. 2007;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG. Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. Embo J. 1995;14:4932&#x2013;4938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394596</ArticleId><ArticleId IdType="pubmed">7588622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA. 2000;97:11960&#x2013;11965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17277</ArticleId><ArticleId IdType="pubmed">11035810</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res. 2000;62:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11054815</ArticleId></ArticleIdList></Reference><Reference><Citation>Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001;359:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222116</ArticleId><ArticleId IdType="pubmed">11563964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001;21:2561&#x2013;2570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762523</ArticleId><ArticleId IdType="pubmed">11306609</ArticleId></ArticleIdList></Reference><Reference><Citation>Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2007;26:212&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">17306982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollis GF, Hieter PA, McBride OW, Swan D, Leder P. Processed genes: a dispersed human immunoglobulin gene bearing evidence of RNA-type processing. Nature. 1982;296:321&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori N, Murakawa K, Matoba R, Fukushima A, Okubo K, Matsubara K. A cDNA sequence of human ribosomal protein, homologue of yeast S28. Nucleic Acids Res. 1993;21:4394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC310080</ArticleId><ArticleId IdType="pubmed">8415000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem. 2007;282:22707&#x2013;22720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffs P, Ashburner M. Processed pseudogenes in Drosophila. Proc. Biol. Sci. 1991;244:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">1679549</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res. Mol. Brain Res. 1991;10:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaessmann H, Vinckenbosch N, Long M. RNA-based gene duplication: mechanistic and evolutionary insights. Nat. Rev. Genet. 2009;10:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690669</ArticleId><ArticleId IdType="pubmed">19030023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetsky M, Middelhaufe S, Bank EM, Levin LR, Buck J, Steegborn C. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J. Mol. Biol. 2006;362:623&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662476</ArticleId><ArticleId IdType="pubmed">16934836</ArticleId></ArticleIdList></Reference><Reference><Citation>Karin M, Richards RI. Human metallothionein genes--primary structure of the metallothionein-II gene and a related processed gene. Nature. 1982;299:797&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">7133118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev. 2000;14:2799&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell. 1996;85:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8616888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lih CJ, Wei W, Cohen SN. Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev. 2006;20:2082&#x2013;2095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1536059</ArticleId><ArticleId IdType="pubmed">16847352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P, Li F, Zhang YW, Huang H, Tong G, Farquhar MG, Xu H. Calnuc binds to Alzheimer's beta-amyloid precursor protein and affects its biogenesis. J. Neurochem. 2007;100:1505&#x2013;1514.</Citation><ArticleIdList><ArticleId IdType="pubmed">17348862</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Li L, Cohen SN. Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis. J. Biol. Chem. 2000a;275:31093&#x2013;31098.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906334</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. Mol. Cell. Biol. 1999;19:3696&#x2013;3703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84183</ArticleId><ArticleId IdType="pubmed">10207093</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. J. Biol. Chem. 2000b;275:40195&#x2013;40201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032831</ArticleId></ArticleIdList></Reference><Reference><Citation>Long M, Betran E, Thornton K, Wang W. The origin of new genes: glimpses from the young and old. Nat. Rev. Genet. 2003;4:865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pubmed">14634634</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002;22:373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111750</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathern GW, Bertram EH, 3rd, Babb TL, Pretorius JK, Kuhlman PA, Spradlin S, Mendoza D. In contrast to kindled seizures, the frequency of spontaneous epilepsy in the limbic status model correlates with greater aberrant fascia dentata excitatory and inhibitory axon sprouting, and increased staining for N-methyl-D-aspartate, AMPA and GABA(A) receptors. Neuroscience. 1997;77:1003&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130782</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Devel. 2008;11:533&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18600569</ArticleId></ArticleIdList></Reference><Reference><Citation>Mighell AJ, Smith NR, Robinson PA, Markham AF. Vertebrate pseudogenes. FEBS Lett. 2000;468:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">10692568</ArticleId></ArticleIdList></Reference><Reference><Citation>Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G. Protein kinase A as a biological target in cancer therapy. Expert Opin. Ther. Targets. 2009;13:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19063708</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rost B, Yachdav G, Liu J. The PredictProtein server. Nucleic Acids Res. 2004;32:W321&#x2013;W326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441515</ArticleId><ArticleId IdType="pubmed">15215403</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Yamaguchi H, Noguchi K, Michel G, Ishiguro K, Sato K, Hoshino T, Hoshi M, Imahori K. Amyloid beta peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3 beta in rat hippocampal neurons. Neurosci. Lett. 1995;198:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor SS, Kim C, Cheng CY, Brown SH, Wu J, Kannan N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim. Biophys. Acta. 2008;1784:16&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561045</ArticleId><ArticleId IdType="pubmed">17996741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda S, Nakai S, Nishida Y, Hisajima H, Honjo T. Long terminal repeat-like elements flank a human immunoglobulin epsilon pseudogene that lacks introns. Embo J. 1982;1:1539&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553248</ArticleId><ArticleId IdType="pubmed">6327276</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinckenbosch N, Dupanloup I, Kaessmann H. Evolutionary fate of retroposed gene copies in the human genome. Proc. Natl. Acad. Sci. USA. 2006;103:3220&#x2013;3225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413932</ArticleId><ArticleId IdType="pubmed">16492757</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Zhang YW, Zhang X, Liu R, Zhang X, Hong S, Xia K, Xia J, Zhang Z, Xu H. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. Faseb J. 2006;20:1275&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16645044</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 1998;4:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Sweeney D, Greengard P, Gandy S. Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proc. Natl. Acad. Sci. USA. 1996;93:4081&#x2013;4084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39490</ArticleId><ArticleId IdType="pubmed">8633020</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, Greengard P, Gandy S. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc. Natl. Acad. Sci. USA. 1997;94:3748&#x2013;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>York RD, Molliver DC, Grewal SS, Stenberg PE, McCleskey EW, Stork PJ. Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1. Mol. Cell. Biol. 2000;20:8069&#x2013;8083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86417</ArticleId><ArticleId IdType="pubmed">11027277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 2007;282:10873&#x2013;10880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303576</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Xu H. Molecular and Cellular Mechanisms for Alzheimer's Disease: Understanding APP Metabolism. Curr. Mol. Med. 2007;7:687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">18045146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Carriero N, Gerstein M. Comparative analysis of processed pseudogenes in the mouse and human genomes. Trends Genet. 2004;20:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">14746985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Harrison P, Gerstein M. Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res. 2002;12:1466&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187539</ArticleId><ArticleId IdType="pubmed">12368239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19923278</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>46</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau.</ArticleTitle><Pagination><StartPage>14439</StartPage><EndPage>14450</EndPage><MedlinePgn>14439-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3590-09.2009</ELocationID><Abstract><AbstractText>Alzheimer's disease is characterized by synaptic alterations and neurodegeneration. Histopathological hallmarks represent amyloid plaques composed of amyloid-beta (Abeta) and neurofibrillary tangles containing hyperphosphorylated tau. To determine whether synaptic changes and neurodegeneration share common pathways, we established an ex vivo model using organotypic hippocampal slice cultures from amyloid precursor protein transgenic mice combined with virus-mediated expression of EGFP-tagged tau constructs. Confocal high-resolution imaging, algorithm-based evaluation of spines, and live imaging were used to determine spine changes and neurodegeneration. We report that Abeta but not tau induces spine loss and shifts spine shape from mushroom to stubby through a mechanism involving NMDA receptor (NMDAR), calcineurin, and GSK-3beta activation. In contrast, Abeta alone does not cause neurodegeneration but induces toxicity through phosphorylation of wild-type (wt) tau in an NMDAR-dependent pathway. We show that GSK-3beta levels are elevated in APP transgenic cultures and that inhibiting GSK-3beta activity or use of phosphorylation-blocking tau mutations prevented Abeta-induced toxicity of tau. FTDP-17 tau mutants are differentially affected by Abeta. While R406W tau shows increased toxicity in the presence of Abeta, no change is observed with P301L tau. While blocking NMDAR activity abolishes toxicity of both wt and R406W tau, the inhibition of GSK-3beta only protects against toxicity of wt tau but not of R406W tau induced by Abeta. Tau aggregation does not correlate with toxicity. We propose that Abeta-induced spine pathology and tau-dependent neurodegeneration are mediated by divergent pathways downstream of NMDAR activation and suggest that Abeta affects wt and R406W tau toxicity by different pathways downstream of NMDAR activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tackenberg</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Osnabr&#xfc;ck, D-49076 Osnabr&#xfc;ck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19923278</ArticleId><ArticleId IdType="pmc">PMC6665808</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3590-09.2009</ArticleId><ArticleId IdType="pii">29/46/14439</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol. 2003;184:247&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res. 2006;3:437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol. 2007;17:381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17498943</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Gu Z, Liu W, Yan Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol. 2007;72:40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrengruber MU, Lundstrom K, Schweitzer C, Heuss C, Schlesinger S, G&#xe4;hwiler BH. Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc Natl Acad Sci U S A. 1999;96:7041&#x2013;7046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22049</ArticleId><ArticleId IdType="pubmed">10359835</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidenm&#xfc;ller J, Fath T, Maas T, Pool M, Sontag E, Brandt R. Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J. 2001;357:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222005</ArticleId><ArticleId IdType="pubmed">11463346</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath T, Eidenm&#xfc;ller J, Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci. 2002;22:9733&#x2013;9741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757822</ArticleId><ArticleId IdType="pubmed">12427828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A&#x3b2;. Mol Cell Neurosci. 1997;9:220&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245504</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H, Ishiguro K, Hasegawa M, Yen SH, Chishti MA, Harigaya Y, Abe K, Okamoto K, St George-Hyslop P, Westaway D. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh IY, Lindquist WB, Zito K, Nimchinsky EA, Svoboda K. An image analysis algorithm for dendritic spines. Neural Comput. 2002;14:1283&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YI, Seo M, Kim Y, Kim SY, Kang UG, Kim YS, Juhnn YS. Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J Biol Chem. 2005;280:22044&#x2013;22052.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799972</ArticleId></ArticleIdList></Reference><Reference><Citation>Leschik J, Welzel A, Weissmann C, Eckert A, Brandt R. Inverse and distinct modulation of tau-dependent neurodegeneration by presenilin 1 and amyloid-beta in cultured cortical neurons: evidence that tau phosphorylation is the limiting factor in amyloid-beta-induced cell death. J Neurochem. 2007;101:1303&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">17298384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mitani S, Ihara Y. Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol Dis. 2005;20:372&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D, Bhat R, Sydow A, Mandelkow EM, Berg S, Hellberg S, F&#xe4;lting J, Distel M, K&#xf6;ster RW, Schmid B, Haass C. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest. 2009;119:1382&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673864</ArticleId><ArticleId IdType="pubmed">19363289</ArticleId></ArticleIdList></Reference><Reference><Citation>Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53:703&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">17329210</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Kaiserman-Abramof IR. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. Am J Anat. 1970;17:321&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">4985058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci. 2002;59:1668&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11337454</ArticleId><ArticleId IdType="pubmed">12475178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J Neurosci. 2006;31:6103&#x2013;6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675219</ArticleId><ArticleId IdType="pubmed">16738255</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci. 2006;33:274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16962789</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1999;249:266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653281</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Ghori A, Brandt R. Thin, stubby or mushroom: spine pathology in Alzheimer's disease. Curr Alzheimer Res. 2009;6:261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagrebelsky M, Holz A, Dechant G, Barde YA, Bonhoeffer T, Korte M. The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. J Neurosci. 2005;25:9989&#x2013;9999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725571</ArticleId><ArticleId IdType="pubmed">16251447</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci. 2004;24:4657&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729383</ArticleId><ArticleId IdType="pubmed">15140937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002;115:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19923550</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>24</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.</ArticleTitle><Pagination><StartPage>2061</StartPage><EndPage>2070</EndPage><MedlinePgn>2061-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181c67808</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p &lt; 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, The Warren Alpert Medical School of Brown University, 345 Blackstone Blvd., Providence, RI 02906, USA. SSalloway@Butler.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gilman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>N C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Mulnard</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Barakos</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gregg</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lieberburg</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Bapineuzumab 201 Clinical Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50-AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS15655</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U01AG032438-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 R01 MH58620-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG017761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R43AG033474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG14763</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-UO1-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG026114</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0801306</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RL1AA017536-01</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06036-13</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54RR024350-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS042859</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 R03 AG023916-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1AGO24904</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL091099</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50MH068789</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-R01-AG030457-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5-U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007224-19</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG007370</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 RR020626</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IR21DK062098</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030004-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AF10483</GrantID><Acronym>AF</Acronym><Agency>ACF HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 P3-AG 019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>NC11WKO35D</RegistryNumber><NameOfSubstance UI="C545458">bapineuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2009 Dec 15;73(24):2052-3. doi: 10.1212/WNL.0b013e3181c6784a.</RefSource><PMID Version="1">19923549</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2010 Jun 15;74(24):2026; author reply 2026-7. doi: 10.1212/WNL.0b013e3181e03844.</RefSource><PMID Version="1">20548049</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19923550</ArticleId><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181c67808</ArticleId><ArticleId IdType="pii">WNL.0b013e3181c67808</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28:6787&#x2013;6793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670967</ArticleId><ArticleId IdType="pubmed">18596154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RSK, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008;5:194&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322388</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7396427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 suppl 2:S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, G&#xe9;linas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9 suppl 1:163&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447439</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, &#xc5;gren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid &#x3b2;-amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers K, Wilcock GK, Love S. APOE &#x3b5;4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A&#x3b2; protein. Neuropathol Appl Neurobiol 2003;29:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007;68:1411&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452586</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 2004;62:494&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">14872042</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21:1199&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174901</ArticleId><ArticleId IdType="pubmed">10954269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamy C, Oppenheim C, M&#xe9;der JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 2004;14:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15095552</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomized phase II trial. Lancet Neurol 208;7:483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450517</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirttil&#xe4; T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004;11:734&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann PJ, Araki SS, Areculs A, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurol 2001;57:957&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571317</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005;5:661&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16149870</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19928774</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1520-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>50</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein.</ArticleTitle><Pagination><StartPage>11837</StartPage><EndPage>11839</EndPage><MedlinePgn>11837-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/bi901839d</ELocationID><Abstract><AbstractText>Evidence that certain gamma-secretase modulators (GSMs) target the 99-residue C-terminal domain (C99) of the amyloid precursor protein, a substrate of gamma-secretase, but not the protease complex itself has been presented [Kukar, T. L., et al. (2008) Nature 453, 925-929]. Here, NMR results demonstrate a lack of specific binding of these GSMs to monodisperse C99 in LMPG micelles. In addition, results indicate that C99 was likely to have been aggregated in some of the key experiments of the previous work and that binding of GSMs to these C99 aggregates is also of a nonspecific nature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beel</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee 37232-8725, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schnier</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Hitchcock</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Bagal</LastName><ForeName>Dhanashri</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Charles R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 GM080513</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008320</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C441641">amyloid precursor protein carboxyl-terminal fragment gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19928774</ArticleId><ArticleId IdType="mid">NIHMS161437</ArticleId><ArticleId IdType="pmc">PMC2794937</ArticleId><ArticleId IdType="doi">10.1021/bi901839d</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Wolfe MS. Science. 2001;293:1449&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520976</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Sanders CR. Cell Mol Life Sci. 2008;65:1311&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569971</ArticleId><ArticleId IdType="pubmed">18239854</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. J Biol Chem. 2003;278:31831&#x2013;31837.</Citation><ArticleIdList><ArticleId IdType="pubmed">12805356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT. Nat Med. 2004;10:1065&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448688</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S. J Biol Chem. 2007;282:24504&#x2013;24513.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, Iwatsubo T. J Biol Chem. 2003;278:18664&#x2013;18670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Nyborg AC, Iwata N, Diehl TS, Saido TC, Golde TE, Wolfe MS. Biochemistry. 2006;45:8649&#x2013;8656.</Citation><ArticleIdList><ArticleId IdType="pubmed">16834339</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Fukumori A, Jiang J, Itoh N, Kimura R, Steiner H, Haass C, Tagami S, Takeda M. J Biol Chem. 2006;281:7890&#x2013;7898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE. Nature. 2008;453:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P, Liu Q, Scarborough GA. Anal Biochem. 1998;259:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9606148</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger-Koplin RD, Sorgen PL, Krueger-Koplin ST, Rivera-Torres IO, Cahill SM, Hicks DB, Grinius L, Krulwich TA, Girvin ME. J Biomol NMR. 2004;28:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian C, Vanoye CG, Kang C, Welch RC, Kim HJ, George AL, Jr, Sanders CR. Biochemistry. 2007;46:11459&#x2013;11472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2565491</ArticleId><ArticleId IdType="pubmed">17892302</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, Prestegard JH, Sanders CR. Biochemistry. 2008;47:9428&#x2013;9446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572687</ArticleId><ArticleId IdType="pubmed">18702528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang C, Tian C, Sonnichsen FD, Smith JA, Meiler J, George AL, Jr, Vanoye CG, Kim HJ, Sanders CR. Biochemistry. 2008;47:7999&#x2013;8006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580054</ArticleId><ArticleId IdType="pubmed">18611041</ArticleId></ArticleIdList></Reference><Reference><Citation>Prento P. Biotech Histochem. 2009:1&#x2013;20.</Citation></Reference><Reference><Citation>Inouye H, Kirschner DA. Subcell Biochem. 2005;38:203&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709480</ArticleId></ArticleIdList></Reference><Reference><Citation>Matulis D, Lovrien R. Biophys J. 1998;74:422&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299394</ArticleId><ArticleId IdType="pubmed">9449342</ArticleId></ArticleIdList></Reference><Reference><Citation>McGovern SL, Caselli E, Grigorieff N, Shoichet BK. J Med Chem. 2002;45:1712&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19940172</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>47</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.</ArticleTitle><Pagination><StartPage>14770</StartPage><EndPage>14778</EndPage><MedlinePgn>14770-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3669-09.2009</ELocationID><Abstract><AbstractText>Inverse correlations between amyloid-beta (Abeta) load measured by Pittsburgh Compound-B (PiB) positron emission tomography (PET) and cerebral metabolism using [(18)F]fluoro-2-deoxy-d-glucose (FDG) in Alzheimer's disease (AD) patients, suggest local Abeta-induced metabolic insults. However, this relationship has not been well studied in mild cognitive impairment (MCI) or amyloid-positive controls. Here, we explored associations of Abeta deposition with metabolism via both region-of-interest-based and voxel-based analyses in amyloid-positive control subjects and patients with MCI or AD. Metabolism in parietal and precuneus cortices of AD patients was negatively correlated with PiB retention locally, and more distantly with PiB retention in frontal cortex. In amyloid-positive controls, no clear patterns in correlations were observed. In MCI patients, there were essentially no significant, negative correlations, but there were frequent significant positive correlations between metabolism and PiB retention. Metabolism in anterior cingulate showed positive correlations with PiB in most brain areas in MCI, and metabolism and PiB retention were positively correlated locally in precuneus/parietal cortex. However, there was no significant increase in metabolism in MCI compared to age-matched controls, negating the possibility that Abeta deposition directly caused reactive hypermetabolism. This suggests that, in MCI, higher basal metabolism could either be exacerbating Abeta deposition or increasing the level of Abeta necessary for cognitive impairment sufficient for the clinical diagnosis of AD. Only after extensive Abeta deposition has been present for longer periods of time does Abeta become the driving force for decreased metabolism in clinical AD and, only in more vulnerable brain regions such as parietal and precuneus cortices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Weissfeld</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>Bedda L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Wenzhu</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Nebes</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH001976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG027998</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG001039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000222" MajorTopicYN="N">Adaptation, Physiological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001481" MajorTopicYN="N">Basal Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054022" MajorTopicYN="N">Cerebrum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19940172</ArticleId><ArticleId IdType="mid">NIHMS168077</ArticleId><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3669-09.2009</ArticleId><ArticleId IdType="pii">29/47/14770</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Boller F, Saxton J, McGonigle-Gibson KL. Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex. 1987;23:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53&#x2013;60.</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135&#x2013;140.</Citation></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Pounds SB, Boyett JM, Pei D, Kuo ML, Roussel MF. Statistical significance threshold criteria for analysis of microarray gene expression data. Stat Appl Genet Mol Biol. 2004;3 Article36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704526</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement. 2008;4:S29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631997</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983;7:590&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">6602819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamacher K, Coenen HH, St&#xf6;cklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">3712040</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Fr&#xf6;lich L, Sch&#xf6;nknecht P, Ito K, Mielke R, Kalbe E, Z&#xfc;ndorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80:S160&#x2013;S167.</Citation><ArticleIdList><ArticleId IdType="pubmed">18445746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, L&#xe4;rks&#xe4;ter M, Winblad B, Zetterberg H, Blennow K, L&#xe5;ngstr&#xf6;m B, Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008;63:621&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300284</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, N&#xe5;gren K, Kim BC, Tsui W, de Leon MJ. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008;35:2169&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693402</ArticleId><ArticleId IdType="pubmed">18566819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000;55:1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Kamo H, Harrop R, McGeer EG, Martin WR, Pate BD, Li DK. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36:1569&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">3491344</ArticleId></ArticleIdList></Reference><Reference><Citation>McKiernan KA, Kaufman JN, Kucera-Thompson J, Binder JR. A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging. J Cogn Neurosci. 2003;15:394&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Chu T, Mazziotta JC, Trivedi KH, Thompson PM, Shah A, Cole G, Frautschy SA, Toga AW. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease. Neuroreport. 1999;10:2911&#x2013;2917.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549796</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, Lin MP, Price JC. Comparative evaluation of MR-based partial volume correction schemes for PET. J Nucl Med. 1999;40:2053&#x2013;2065.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616886</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry. 2008;79:630&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin N Am. 2003;13:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024960</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19:541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">7622680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol. 2007;42:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839732</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006;66:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401845</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172:277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2501111</ArticleId><ArticleId IdType="pubmed">18582948</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM. Validity of the Trail-making Tests as an indication of organic brain damage. Percept Mot Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Saxton J, Ratcliff G, Newman A, Belle S, Fried L, Yee J, Kuller L. Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology. 2000;19:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Raichle ME, Petersen SE. Common blood flow changes across visual tasks: II. Decreases in cerebral cortex. J Cogn Neurosci. 1997;9:648&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am. 2005;43:67&#x2013;77. x.</Citation><ArticleIdList><ArticleId IdType="pubmed">15693648</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Zarahn E, Hilton HJ, Flynn J, DeLaPaz R, Rakitin B. Exploring the neural basis of cognitive reserve. J Clin Exp Neuropsychol. 2003;25:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler adult intelligence scale. Ed 3. New York: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994;44:609&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">8164812</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AA, Garcia A, Chestakova A, Kung HF, Houle S. A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-(4&#x2032;-methylaminophenyl)-6-hydroxybenzothiazole ([C-11]-6-OH-BTA-1) J Label Compd Radiopharm. 2004;47:679&#x2013;682.</Citation></Reference><Reference><Citation>Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord. 1999;13:226&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, DeKosky ST, Price JC. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006;33:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16905334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19951690</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>624</StartPage><EndPage>633</EndPage><MedlinePgn>624-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2009.10.003</ELocationID><Abstract><AbstractText>Adult neurogenesis regulates plasticity and function in the hippocampus, which is critical for memory and vulnerable to Alzheimer's disease (AD). Promoting neurogenesis may improve hippocampal function in AD brains. However, how amyloid beta (Abeta), the key AD pathogen, affects the development and function of adult-born neurons remains unknown. Adult-born granule cells (GCs) in human amyloid precursor protein (hAPP) transgenic mice, an AD model, showed greater dendritic length, spine density, and functional responses than did controls early in development, but were impaired morphologically and functionally during later maturation. Early inhibition of GABA(A) receptors to suppress GABAergic signaling or late inhibition of calcineurin to enhance glutamatergic signaling normalized the development of adult-born GCs in hAPP mice with high Abeta levels. Abeta-induced increases in GABAergic neurotransmission or an imbalance between GABAergic and glutamatergic neurotransmission may contribute to impaired neurogenesis in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Binggui</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, University of California, San Francisco, 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halabisky</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guiqiu</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG004342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CO6 RRO18928</GrantID><Acronym>CO</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058787">GABA-A Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.31</RegistryNumber><NameOfSubstance UI="D037342">Pertussis Toxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2009 Dec 4;5(6):573-4. doi: 10.1016/j.stem.2009.11.007.</RefSource><PMID Version="1">19951683</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058787" MajorTopicYN="N">GABA-A Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037342" MajorTopicYN="N">Pertussis Toxin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19951690</ArticleId><ArticleId IdType="mid">NIHMS153598</ArticleId><ArticleId IdType="pmc">PMC2823799</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2009.10.003</ArticleId><ArticleId IdType="pii">S1934-5909(09)00514-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aghajanian GK, Rasmussen K. Intracellular studies in the facial nucleus illustrating a simple new method for obtaining viable motoneurons in adult rat brain slices. Synapse. 1989;3:331&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">2740992</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol. 1965;124:319&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">5861717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat Rev Neurosci. 2002;3:728&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209121</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekhoorn K, Joels M, Lucassen PJ. Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis. 2006;24:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CD, Choi M, Romberg C, Clemenson GD, Jr, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA, Gage FH, et al. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science. 2009;325:210&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997634</ArticleId><ArticleId IdType="pubmed">19590004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem. 2007;88:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2031869</ArticleId><ArticleId IdType="pubmed">17521929</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol. 2006;495:70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432899</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, Kitabatake Y, Liu XB, Yang CH, Jordan JD, Ma DK, et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell. 2007;130:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2002573</ArticleId><ArticleId IdType="pubmed">17825401</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci. 2007;10:411&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322876</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund TF, Buzsaki G. Interneurons of the hippocampus. Hippocampus. 1996;6:347&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">8915675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Qiao S, Lan X, Chi L, Luo C, Lien L, Yan Liu Q, Liu R. Neurogenic responses to amyloid-beta plaques in the brain of Alzheimer's disease-like transgenic (pPDGF-APPSw,Ind) mice. Neurobiol Dis. 2008;29:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2180424</ArticleId><ArticleId IdType="pubmed">17916429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly K, Schinder AF, Wong ST, Poo M. GABA itself promotes the developmental switch of neuronal GABAergic responses from excitation to inhibition. Cell. 2001;105:521&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">11371348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Goh EL, Sailor KA, Kitabatake Y, Ming GL, Song H. GABA regulates synaptic integration of newly generated neurons in the adult brain. Nature. 2006;439:589&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1420640</ArticleId><ArticleId IdType="pubmed">16341203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Sailor KA, Ming GL, Song H. Synaptic integration and plasticity of new neurons in the adult hippocampus. J Physiol. 2008;586:3759&#x2013;3765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538931</ArticleId><ArticleId IdType="pubmed">18499723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040308</ArticleId><ArticleId IdType="pubmed">17521569</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, Mori K, Ikeda T, Itohara S, Kageyama R. Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nat Neurosci. 2008;11:1153&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758458</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A. 2004a;101:13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA. 2004b;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, et al. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S, Iqbal K, Grundke-Iqbal I. Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol. 2008;67:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191920</ArticleId><ArticleId IdType="pubmed">18091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Toledano MA, Shelanski ML. Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind) J Alzheimers Dis. 2007;12:229&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057556</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006;51:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens DF, Kriegstein AR. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci. 2002;3:715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209120</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KJ. The Mouse Brain in Stereotaxic Coordinates. Second edn. Academic Press; 2001.</Citation></Reference><Reference><Citation>Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907793</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxe MD, Battaglia F, Wang JW, Malleret G, David DJ, Monckton JE, Garcia AD, Sofroniew MV, Kandel ER, Santarelli L, et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A. 2006;103:17501&#x2013;17506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1859958</ArticleId><ArticleId IdType="pubmed">17088541</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging. 2003;24:1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Hieber C, Jonas P, Bischofberger J. Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus. Nature. 2004;429:184&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15107864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005a;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder JS, Hong NS, McDonald RJ, Wojtowicz JM. A role for adult neurogenesis in spatial long-term memory. Neuroscience. 2005b;130:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652983</ArticleId></ArticleIdList></Reference><Reference><Citation>Taglialatela G, Hogan D, Zhang WR, Dineley KT. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res. 2009;200:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663011</ArticleId><ArticleId IdType="pubmed">19162087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro A, Sandler VM, Toni N, Zhao C, Gage FH. NMDA-receptor-mediated, cell-specific integration of new neurons in adult dentate gyrus. Nature. 2006a;442:929&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">16906136</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro A, Zhao C, Gage FH. Retrovirus-mediated single-cell gene knockout technique in adult newborn neurons in vivo. Nat Protoc. 2006b;1:3049&#x2013;3055.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tozuka Y, Fukuda S, Namba T, Seki T, Hisatsune T. GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron. 2005;47:803&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157276</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis in the adult hippocampus. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Trouche S, Zerwas M, Rampon C. Hippocampal neurogenesis during normal and pathological aging. Psychoneuroendocrinology. 2007;32 Suppl 1:S26&#x2013;S30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17629417</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, Takashima A. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One. 2008;3:e3029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515633</ArticleId><ArticleId IdType="pubmed">18716656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Teng EM, Summers RG, Jr, Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci. 2006;26:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674324</ArticleId><ArticleId IdType="pubmed">16399667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19996185</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>49</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Subregional neuroanatomical change as a biomarker for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>20954</StartPage><EndPage>20959</EndPage><MedlinePgn>20954-9</MedlinePgn></Pagination><Abstract><AbstractText>Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease (AD), and this leads to a predictable pattern of brain atrophy. In vivo quantification of subregional atrophy, such as changes in cortical thickness or structure volume, could lead to improved diagnosis and better assessment of the neuroprotective effects of a therapy. Toward this end, we have developed a fast and robust method for accurately quantifying cerebral structural changes in several cortical and subcortical regions using serial MRI scans. In 169 healthy controls, 299 subjects with mild cognitive impairment (MCI), and 129 subjects with AD, we measured rates of subregional cerebral volume change for each cohort and performed power calculations to identify regions that would provide the most sensitive outcome measures in clinical trials of disease-modifying agents. Consistent with regional specificity of AD, temporal-lobe cortical regions showed the greatest disease-related changes and significantly outperformed any of the clinical or cognitive measures examined for both AD and MCI. Global measures of change in brain structure, including whole-brain and ventricular volumes, were also elevated in AD and MCI, but were less salient when compared to changes in normal subjects. Therefore, these biomarkers are less powerful for quantifying disease-modifying effects of compounds that target AD pathology. The findings indicate that regional temporal lobe cortical changes would have great utility as outcome measures in clinical trials and may also have utility in clinical practice for aiding early diagnosis of neurodegenerative disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. dominic.holland@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Hagler</LastName><ForeName>Donald J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Fennema-Notestine</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS022343</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 NS022343</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50MH081755</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 MH081755</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS22343</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS056883</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54NS056883</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG22381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6551</RefSource><Note>Fenema-Notestine, Christine [corrected to Fennema-Notestine, Christine]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: A.M.D. is a founder and holds equity in CorTechs Labs, Inc, and also serves on the Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California at San Diego in accordance with its conflict of interest policies.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William Z</ForeName><Initials>WZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheuk</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzloff</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozauer</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zerrate</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Given</LastName><ForeName>Curtis A</ForeName><Initials>CA</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laubinger</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benincasa</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayam-Trouth</LastName><ForeName>Annapurni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendin</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Englert</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stopa</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19996185</ArticleId><ArticleId IdType="pmc">PMC2791580</ArticleId><ArticleId IdType="doi">10.1073/pnas.0906053106</ArticleId><ArticleId IdType="pii">106/49/20954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiya M, Hyman BT, Albert MS, Killiany R. Structural magnetic resonance imaging in established and prodromal Alzheimer disease: A review. Alzheimer Dis Assoc Disord. 2003;17:177&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512832</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci. 2007;1097:114&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413016</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology. 2007;68:828&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology. 1999;52:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9921854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: A volumetric MRI study. Neurology. 1998;51:357&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">9710003</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccardi M, et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol Aging. 2003;24:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493555</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CR, et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer's disease. Neurology. 2009;73:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727145</ArticleId><ArticleId IdType="pubmed">19667321</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy LK, et al. Alzheimer disease: Quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009;251:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663582</ArticleId><ArticleId IdType="pubmed">19201945</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, et al. Measuring atrophy in Alzheimer disease: A serial MRI study over 6 and 12 months. Neurology. 2005;65:119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009896</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, et al. Volumetric MRI and cognitive measures in Alzheimer disease: Comparison of markers of progression. J Neurol. 2008;255:567&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18274807</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58:1188&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, et al. Short-term practice effects in amnestic mild cognitive impairment: Implications for diagnosis and treatment. Int Psychogeriatr. 2008;20:986&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789513</ArticleId><ArticleId IdType="pubmed">18405398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciumas C, Montavont A, Ryvlin P. Magnetic resonance imaging in clinical trials. Curr Opin Neurol. 2008;21:431&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18607203</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002;19:23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212787</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ. Therapeutics and mild cognitive impairment: Current status and future directions. Alzheimer Dis Assoc Disord. 2003;17(Suppl 2):S69&#x2013;S71.</Citation><ArticleIdList><ArticleId IdType="pubmed">12813215</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009;188:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">19234858</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann N Y Acad Sci. 2007;1097:146&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Small SA. Imaging the earliest stages of Alzheimer's disease. Curr Alzheimer Res. 2006;3:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168652</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Prince SE, Wang L, Hellegers C, Doraiswamy PM. Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS ONE. 2007;2:e1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040216</ArticleId><ArticleId IdType="pubmed">17971867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21:813&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">19538824</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson CM, Wallin AK, Levander S, Minthon L. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol. 2009;9:7&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666627</ArticleId><ArticleId IdType="pubmed">19208247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother. 2009;9:591&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402770</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009;6:86&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">19355843</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, van der Meulen M. Pharmacological interventions in primary care: Hopes and illusions. Front Neurol Neurosci. 2009;24:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">19182463</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke AG, Lieb K, Fellgiebel A. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease] Fortschr Neurol Psychiatr. 2009;77:326&#x2013;333. (Translated from German) (in German).</Citation><ArticleIdList><ArticleId IdType="pubmed">19504422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicich J, et al. Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300968</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23(Suppl 1):S69&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501102</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Sereno MI. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: A linear approach. J Cognitive Neurosci. 1993;5:162&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23972151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000;97:11050&#x2013;11055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen GE, Rabbitt RD, Miller MI. Deformable templates using large deformation kinematics. IEEE Trans Image Process. 1996;5:1435&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">18290061</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MI, Christensen GE, Amit Y, Grenander U. Mathematical textbook of deformable neuroanatomies. Proc Natl Acad Sci USA. 1993;90:11944&#x2013;11948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48101</ArticleId><ArticleId IdType="pubmed">8265653</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC. Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr. 1998;22:838&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Andersson JL, Friston KJ. High-dimensional image registration using symmetric priors. Neuroimage. 1999;9:619&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">10334905</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Hagler DJ, Fennema-Notestine C, Dale AM. Longitudinal nonlinear registration and quantitative analysis of change in whole brain and regions of interest. Alzheimers &amp; Dementia: The Journal of the Alzheimer's Association. 2008;4:T288.</Citation></Reference><Reference><Citation>Grandy J. Efficient Computation of Volume of Hexahedral Cells. Livermore, CA: Lawrence Livermore National Laboratory; 1997.</Citation></Reference><Reference><Citation>van der Kouwe AJ, Benner T, Dale AM. Real-time rigid body motion correction and shimming using cloverleaf navigators. Magn Reson Med. 2006;56:1019&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029223</ArticleId></ArticleIdList></Reference><Reference><Citation>White NS, et al. PROMO&#x2013;Real-time prospective motion correction in MRI using image-based tracking. Magn Reson Med. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892665</ArticleId><ArticleId IdType="pubmed">20027635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley-Interscience; 2004. p. 406. Eqn. (15.2)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20005821</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.</ArticleTitle><Pagination><StartPage>632</StartPage><EndPage>644</EndPage><MedlinePgn>632-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.11.013</ELocationID><Abstract><AbstractText>Apolipoprotein E (APOE) is the strongest genetic risk factor for Alzheimer's disease (AD). Previous studies suggest that the effect of apoE on amyloid-beta (A beta) accumulation plays a major role in AD pathogenesis. Therefore, understanding proteins that control apoE metabolism may provide new targets for regulating A beta levels. LDLR, a member of the LDL receptor family, binds to apoE, yet its potential role in AD pathogenesis remains unclear. We hypothesized that LDLR overexpression in the brain would decrease apoE levels, enhance A beta clearance, and decrease A beta deposition. To test our hypothesis, we created several transgenic mice that overexpress LDLR in the brain and found that apoE levels in these mice decreased by 50%-90%. Furthermore, LDLR overexpression dramatically reduced A beta aggregation and enhanced A beta clearance from the brain extracellular space. Plaque-associated neuroinflammatory responses were attenuated in LDLR transgenic mice. These findings suggest that increasing LDLR levels may represent a novel AD treatment strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Developmental Biology, Hope Center for Neurological Disorders, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Basak</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Vi</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS032636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG034004</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034004-01A1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20005821</ArticleId><ArticleId IdType="mid">NIHMS159898</ArticleId><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.11.013</ArticleId><ArticleId IdType="pii">S0896-6273(09)00896-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53:1992&#x2013;1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer&#x2019;s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Hsiao M, McQueen MB, Parkinson M, Mullin K, Blacker D, Tanzi RE. The LDLR locus in Alzheimer&#x2019;s disease: a family-based study and meta-analysis of case-control data. Neurobiol Aging . 2007a;28(18):e11&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16378661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007b;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">3513311</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cam JA, Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener. 2006;1:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1563464</ArticleId><ArticleId IdType="pubmed">16930455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006;27:1632&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236385</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci. 2007;27:13357&#x2013;13365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673397</ArticleId><ArticleId IdType="pubmed">18045930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Huang R, Lanham IS, Cathcart HM, Howard M, Corder EH, Poduslo SE. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer&#x2019;s disease. J Med Genet. 2005;42:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735987</ArticleId><ArticleId IdType="pubmed">15689450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer&#x2019;s disease Beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O&#x2019;Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, O&#x2019;Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2002;99:10843&#x2013;10848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA, Gasperi RD, Fisher EA, Mathews PM, Haroutunian V, Buxbaum JD. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem. 2007;102:1220&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">17472705</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipovic I. Effect of inhibiting N-glycosylation on the stability and binding activity of the low density lipoprotein receptor. J Biol Chem. 1989;264:8815&#x2013;8820.</Citation><ArticleIdList><ArticleId IdType="pubmed">2722801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Demattos RB, McCormick LM, O&#x2019;Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280:25754&#x2013;25759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888448</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. Disease modifying therapy for AD? J Neurochem. 2006;99:689&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17076654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, Bennett DA, Estus S. Genetic association of low density lipoprotein receptor and Alzheimer&#x2019;s disease. Neurobiol Aging. 2005;26:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585340</ArticleId></ArticleIdList></Reference><Reference><Citation>Halford RW, Russell DW. Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer&#x2019;s disease, but does extend lifespan. Proc Natl Acad Sci USA. 2009;106:3502&#x2013;3506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2651246</ArticleId><ArticleId IdType="pubmed">19204288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A hundred years of Alzheimer&#x2019;s disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J. Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol. 2009;20:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848396</ArticleId><ArticleId IdType="pubmed">19433918</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem. 2002;71:405&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">12045102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann SL, Russell DW, Brown MS, Goldstein JL, Hammer RE. Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. Science. 1988;239:1277&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">3344433</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2000a;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann Neurol. 2000b;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 Inhibits Amyloid Deposition In Vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Krul ES, Tikkanen MJ, Schonfeld G. Heterogeneity of apolipoprotein E epitope expression on human lipoproteins: importance for apolipoprotein E function. J Lipid Res. 1988;29:1309&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">2466929</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe4;ms&#xe4; R, Helisalmi S, Herukka SK, Tapiola T, Pirttil&#xe4; T, Veps&#xe4;l&#xe4;inen S, Hiltunen M, Soininen H. Genetic study evaluating LDLR polymorphisms and Alzheimer&#x2019;s disease. Neurobiol Aging. 2008;29:848&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239995</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1. Neuron. 2007;56:66&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869645</ArticleId></ArticleIdList></Reference><Reference><Citation>Menacherry S, Hubert W, Justice JB., Jr In vivo calibration of microdialysis probes for exogenous compounds. Anal Chem. 1992;64:577&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580357</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, Pfeifer M, Boncristiano S, Mathews PM, Mercken M, Abramowski D, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. Embo J. 2002;21:5691&#x2013;5700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131065</ArticleId><ArticleId IdType="pubmed">12411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan G, Xie C, Dietschy JM, Turley SD. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res. 2003;146:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643015</ArticleId></ArticleIdList></Reference><Reference><Citation>Retz W, Thome J, Durany N, Harsanyi A, Retz-Junginger P, Kornhuber J, Riederer P, Rosler M. Potential genetic markers of sporadic Alzheimer&#x2019;s dementia. Psychiatr Genet. 2001;11:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11702052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez E, Mateo I, Llorca J, Sanchez-Quintana C, Infante J, Berciano J, Combarros O. No association between low density lipoprotein receptor genetic variants and Alzheimer&#x2019;s disease risk. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:541&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer&#x2019;s disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">17380167</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol. 2000;1:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11252897</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha AY, Chen CT, Liu Z, Kim JH, Mount HT, Bazinet RP. Brainstem Concentrations of Cholesterol are not Influenced by Genetic Ablation of the Low-Density Lipoprotein Receptor. Neurochem Res. 2008;34:311&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">18607722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, et al. Loss of gamma-Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis. J Neurosci. 2008;28:12097&#x2013;12106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671640</ArticleId><ArticleId IdType="pubmed">19005074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer&#x2019;s disease. J Biol Chem. 2000;275:7410&#x2013;7415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Tanila H, Puolivali J, Kadish I, van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis. 2003;14:318&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med. 2005;43:470&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15899668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokode M, Hammer RE, Ishibashi S, Brown MS, Goldstein JL. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science. 1990;250:1273&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">2244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer&#x2019;s disease animal model. Proc Natl Acad Sci USA. 2005;102:19198&#x2013;19203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1323154</ArticleId><ArticleId IdType="pubmed">16365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem. 2006;281:36180&#x2013;36186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM, Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci USA. 2004;101:1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327153</ArticleId><ArticleId IdType="pubmed">14732699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, Simpson JF, Tucker HM, Kelly JF, Younkin SG, Dickson DW, et al. Sex-dependent Association of a Common Low Density Lipoprotein Receptor Polymorphism with RNA Splicing Efficiency in the Brain and Alzheimers Disease. Hum Mol Genet. 2008;17:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2361153</ArticleId><ArticleId IdType="pubmed">18065781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20007371</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>51</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>21777</StartPage><EndPage>21782</EndPage><MedlinePgn>21777-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0902174106</ELocationID><Abstract><AbstractText>Recently, chromogranins were reported to interact specifically with mutant forms of superoxide dismutase that are linked to amyotrophic lateral sclerosis (ALS). This interaction led us to analyze the frequencies of sequence variants of the CHGB gene in ALS patients and matched controls from three different countries. Of particular interest was the finding of the P413L CHGB variant present in 10% of ALS patients (n = 705) as compared to 4.5% in controls (n = 751), conferring a 2.2-fold greater relative risk to develop the disease (P &lt; 0.0001). This effect was mainly contributed by the samples of French origin that yielded a frequency of the P413L variation at 17% in ALS (n = 289) and 5% in controls (n = 448), conferring a 3.3-fold greater risk to develop ALS. Furthermore, the P413L CHGB variant is associated with an earlier age of onset by almost a decade in both sporadic ALS and familial ALS cases. Genetic variation influencing age of onset in ALS had not previously been reported. Expression of fusion CHGB-EGFP constructs in SHSY-5Y cells revealed that the P413L variation can cause defective sorting of CHGB into secretory granules. The finding that CHGB may act as a susceptibility gene and modifier of onset in ALS is consistent with the emerging view that dysfunction of the secretory pathway may contribute to increased vulnerability of motor neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gros-Louis</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre de Recherche du Centre Hospitalier Universitaire de Qu&#xe9;bec, D&#xe9;partement de psychiatrie et neurosciences, Universit&#xe9; Laval, Ste-Foy, QC, Canada G1V 4G2.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Dupre</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dion</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Souchon</LastName><ForeName>Frederique</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>D'Amour</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bouchard</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053378">Chromogranin B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 May 11;107(19):E77; author reply E78. doi: 10.1073/pnas.1002512107.</RefSource><PMID Version="1">20431044</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053378" MajorTopicYN="N">Chromogranin B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20007371</ArticleId><ArticleId IdType="pmc">PMC2799865</ArticleId><ArticleId IdType="doi">10.1073/pnas.0902174106</ArticleId><ArticleId IdType="pii">0902174106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18:271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">4051456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder DW, Kurland LT, Offord KP, Beard CM. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology. 1986;36:511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, et al. Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis. Am J Hum Genet. 1995;56:592&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1801158</ArticleId><ArticleId IdType="pubmed">7887412</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, et al. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler. 2008;9:108&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13:43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006;9:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrott-Fischer A, et al. Chromogranin peptides in amyotrophic lateral sclerosis. Regul Pept. 2009;152:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721831</ArticleId></ArticleIdList></Reference><Reference><Citation>Obayashi K, et al. Salivary chromogranin a: useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis. Intern Med. 2008;47:1875&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981630</ArticleId></ArticleIdList></Reference><Reference><Citation>Giess R, et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet. 2002;70:1277&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC447602</ArticleId><ArticleId IdType="pubmed">11951178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847526</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf JM, et al. Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet. 1998;20:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duijn CM, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet. 1994;7:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kromer A, Glombik MM, Huttner WB, Gerdes HH. Essential role of the disulfide-bonded loop of chromogranin B for sorting to secretory granules is revealed by expression of a deletion mutant in the absence of endogenous granin synthesis. J Cell Biol. 1998;140:1331&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132667</ArticleId><ArticleId IdType="pubmed">9508767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourelatos Z, et al. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle-specific antibodies. Proc Natl Acad Sci USA. 1990;87:4393&#x2013;4395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54116</ArticleId><ArticleId IdType="pubmed">2349244</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci. 2009;12:627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Matsuo A, Tooyama I, Julien JP. The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS. FASEB J. 2008;22:2476&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pubmed">18337461</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Labuda D, et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem. 1999;275:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunyaev S, et al. Prediction of deleterious human alleles. Hum Mol Genet. 2001;10:591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Costa C, Orozco M, de la Cruz X. Sequence-based prediction of pathological mutations. Proteins. 2004;57:811&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">15390262</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20007471</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>49</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression.</ArticleTitle><Pagination><StartPage>15472</StartPage><EndPage>15478</EndPage><MedlinePgn>15472-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3960-09.2009</ELocationID><Abstract><AbstractText>Sorting protein-related receptor with A-type repeats (SORLA) is a major risk factor in cellular processes leading to Alzheimer's disease (AD). It acts as sorting receptor for the amyloid precursor protein (APP) that regulates intracellular trafficking and processing into amyloidogenic-beta peptides (A beta). Overexpression of SORLA in neurons reduces while inactivation of gene expression (as in knock-out mouse models) accelerates amyloidogenic processing and senile plaque formation. The current study aimed at identifying molecular pathways that control SORLA gene transcription in vivo and that may contribute to low levels of receptor expression in the brain of patients with AD. Using screening approaches in primary neurons, we identified brain-derived neurotrophic factor (BDNF) as a major inducer of Sorla that activates receptor gene transcription through the ERK (extracellular regulated kinase) pathway. In line with a physiological role as regulator of Sorla, expression of the receptor is significantly impaired in mouse models with genetic (Bdnf(-/-)) or disease-related loss of BDNF activity in the brain (Huntington's disease). Intriguingly, exogenous application of BDNF reduced A beta production in primary neurons and in the brain of wild-type mice in vivo, but not in animals genetically deficient for Sorla. These findings demonstrate that the beneficial effects ascribed to BDNF in APP metabolism act through induction of Sorla that encodes a negative regulator of neuronal APP processing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rohe</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Delbrueck Center for Molecular Medicine, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, D-13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Synowitz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Nykjaer</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491168">Sorl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020813" MajorTopicYN="N">Receptor, trkB</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20007471</ArticleId><ArticleId IdType="pmc">PMC6666105</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3960-09.2009</ArticleId><ArticleId IdType="pii">29/49/15472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akatsu H, Yamagata HD, Kawamata J, Kamino K, Takeda M, Yamamoto T, Miki T, Tooyama I, Shimohama S, Kosaka K. Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord. 2006;22:216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899999</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso M, Vianna MR, Depino AM, Mello e Souza T, Pereira P, Szapiro G, Viola H, Pitossi F, Izquierdo I, Medina JH. BDNF-triggered events in the rat hippocampus are required for both short- and long-term memory formation. Hippocampus. 2002;12:551&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">12201640</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hm C, Seibel NM, Henkel B, Steiner H, Haass C, Hampe W. SorLA signaling by regulated intramembrane proteolysis. J Biol Chem. 2006;281:14547&#x2013;14553.</Citation><ArticleIdList><ArticleId IdType="pubmed">16531402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bothwell M. Evolution of the neurotrophin signaling system in invertebrates. Brain Behav Evol. 2006;68:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">16912466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671646</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res. 1997;49:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9387865</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, Ling LH, McMahon SB, Shelton DL, Levinson AD, Phillips HS. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell. 1994;76:1001&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137419</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai P, Nebes R, DeKosky ST, Kamboh MI. Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer's disease (AD) and quantitative measures of AD progression. Neurosci Lett. 2005;379:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">15843069</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci. 2008;28:12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernfors P, Lee KF, Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature. 1994;368:147&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Goutan E, Mar&#xed;n C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000;866:257&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825501</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge YW, Lahiri DK. Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann N Y Acad Sci. 2002;973:463&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat Neurosci. 2000;3:533&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">10816306</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000;166:127&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">11031089</ArticleId></ArticleIdList></Reference><Reference><Citation>Knusel B, Gao H, Okazaki T, Yoshida T, Mori N, Hefti F, Kaplan DR. Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. Neuroscience. 1997;78:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Chulikavit M, Pang D, Zigman WB, Silverman W, Schupf N. Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. Neurosci Lett. 2007;425:105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2131721</ArticleId><ArticleId IdType="pubmed">17826910</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnarsson S, Bj&#xf6;rklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci. 1997;9:2581&#x2013;2587.</Citation><ArticleIdList><ArticleId IdType="pubmed">9517463</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci U S A. 2008;105:13139&#x2013;13144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525562</ArticleId><ArticleId IdType="pubmed">18728191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport. 1996;7:2925&#x2013;2928.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyborg AC, Ladd TB, Zwizinski CW, Lah JJ, Golde TE. Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates. Mol Neurodegener. 2006;1:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513133</ArticleId><ArticleId IdType="pubmed">16930450</ArticleId></ArticleIdList></Reference><Reference><Citation>Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26:1596&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638122</ArticleId><ArticleId IdType="pubmed">16452683</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361:1545&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1664664</ArticleId><ArticleId IdType="pubmed">16939974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M, Carlo AS, Breyhan H, Sporbert A, Militz D, Schmidt V, Wozny C, Harmeier A, Erdmann B, Bales KR, Wolf S, Kempermann G, Paul SM, Schmitz D, Bayer TA, Willnow TE, Andersen OM. Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem. 2008;283:14826&#x2013;14834.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Le&#xf3;n Y, Pascual A. Regulation of beta-amyloid precursor protein expression by brain-derived neurotrophic factor involves activation of both the Ras and phosphatidylinositide 3-kinase signalling pathways. J Neurochem. 2004;88:1010&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">14756823</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 1999;8:397&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9949199</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Belarbi K, Bu&#xe9;e L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008;7(Suppl 1):43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2228393</ArticleId><ArticleId IdType="pubmed">18184369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow TE. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem. 2007;282:32956&#x2013;32964.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855360</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev. 2000;33:199&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11011066</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci. 2004;24:2270&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730435</ArticleId><ArticleId IdType="pubmed">14999077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18708092</ArticleId></ArticleIdList></Reference><Reference><Citation>Willnow TE, Petersen CM, Nykjaer A. VPS10P-domain receptors&#x2014;regulators of neuronal viability and function. Nat Rev Neurosci. 2008;9:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">19002190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293:493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20009055</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>302</Volume><Issue>23</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>2557</StartPage><EndPage>2564</EndPage><MedlinePgn>2557-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2009.1866</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the efficacy, safety, and tolerability of tarenflurbil.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Tarenflurbil, 800 mg, or placebo, administered twice a day.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00105547.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, 72 E Concord St, L-320, Boston, MA 02118, USA. rcgreen@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Amato</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Beelen</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Swabb</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Zavitz</LastName><ForeName>Kenton H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><CollectiveName>Tarenflurbil Phase 3 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00105547</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K24-AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000533</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00533</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>501W00OOWA</RegistryNumber><NameOfSubstance UI="C505522">tarenflurbil</NameOfSubstance></Chemical><Chemical><RegistryNumber>5GRO578KLP</RegistryNumber><NameOfSubstance UI="D005480">Flurbiprofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2009 Dec 16;302(23):2593-4. doi: 10.1001/jama.2009.1863.</RefSource><PMID Version="1">20009062</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2010 Jun;67(6):750-2. doi: 10.1001/archneurol.2010.94.</RefSource><PMID Version="1">20558395</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Neurol Neurosci Rep. 2010 Sep;10(5):336-7. doi: 10.1007/s11910-010-0130-6.</RefSource><PMID Version="1">20571933</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005480" MajorTopicYN="N">Flurbiprofen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Aaronson</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alva</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antuono</LastName><ForeName>Piero</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apter</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arguello</LastName><ForeName>Fares</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aronson</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Askins</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Au</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aumentado</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baskys</LastName><ForeName>Andrius</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzar</LastName><ForeName>Zinoviy</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berwald</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beyer</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biton</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bortnick</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campopiano</LastName><ForeName>Melinda</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Fen-Lei</ForeName><Initials>FL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cranmer</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuervo</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De la Gandara</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempsey</LastName><ForeName>G Michael</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellison</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ervin</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eslami</LastName><ForeName>Nasrollah</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferencz</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flitman</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galef</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazda</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geohas</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossberg</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hampsey</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heath</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Naveed</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isacescu</LastName><ForeName>Valentin</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwuagwu</LastName><ForeName>Cletus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Travis</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalafer</LastName><ForeName>Marvin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauffmann</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>Justine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>Louis</ForeName><Initials>L</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kishner</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klapper</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Licht</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losk</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luthra</LastName><ForeName>Veena</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcadis</LastName><ForeName>Abe</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margolin</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markind</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzeo</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michie</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nardandrea</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>Marshal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packman</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahl</LastName><ForeName>Jorg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pugach</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raese</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Randhawa</LastName><ForeName>Surinder</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rappaport</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richenstein</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rictor</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rovner</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royall</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaerf</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheinthal</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seltzer</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shrivastava</LastName><ForeName>Ram</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sloan</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spector</LastName><ForeName>Sidney</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stark</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stedman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steen</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoukides</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Herman</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swann</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thein</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toups</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tunkle</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Dyck</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>Navin</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendt</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>Kerri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willner</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winston</LastName><ForeName>Jaron</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20009055</ArticleId><ArticleId IdType="mid">NIHMS205268</ArticleId><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="doi">10.1001/jama.2009.1866</ArticleId><ArticleId IdType="pii">302/23/2557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47(2):191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166298</ArticleId><ArticleId IdType="pubmed">12897211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453(7197):925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar T, Prescott S, Eriksen JL, et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007;8:54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1948891</ArticleId><ArticleId IdType="pubmed">17650315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008;7(6):483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450517</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathologic verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5):486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7396427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR) Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. The neuropsychiatric inventory. Neurology. 1997;48(5)(suppl 6):S10&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Gibbons LE, McCurry SM, et al. Quality of life in Alzheimer's disease. J Ment Health Aging. 1999;5:21&#x2013;32.</Citation></Reference><Reference><Citation>Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist. 1989;29(6):798&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">2516000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant of the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Bioch Pharm. 2005;49(9):1269&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7763308</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord. 2007;21(4):292&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090435</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidgenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim G, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20(15):5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23(20):7504&#x2013;7509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740758</ArticleId><ArticleId IdType="pubmed">12930788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantzen PI, Connor K, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precurser protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22(6):2246&#x2013;2254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758281</ArticleId><ArticleId IdType="pubmed">11896164</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Chinnici C, Tang H. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation. 2004;1:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC527877</ArticleId><ArticleId IdType="pubmed">15500684</ArticleId></ArticleIdList></Reference><Reference><Citation>Brune K, Geisslinger G, Menzel-Soglowek S. Pure enantiomers of 2-arylproprionic acids. J Clin Pharmacol. 1992;32(10):944&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">1447403</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's Disease: A meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA. 2008;300(15):1774&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684821</ArticleId><ArticleId IdType="pubmed">18854539</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Douillet P, Doody R, Fox NC, Orgogozo JM. Effect of xaliproden, a compound with neurotrophic properties, on the progression of Alzheimer's disease. Clinical Trials in Alzheimer Disease; Montpellier, France. September 17&#x2013;19, 2008;.</Citation></Reference><Reference><Citation>Sano M. Multi-center, randomized, double-blind, placebo controlled trial of Simvastatin to slow the progression of Alzheimer's disease. Alzheimers Dement. 2008;4:T200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240843</ArticleId><ArticleId IdType="pubmed">30480082</ArticleId></ArticleIdList></Reference><Reference><Citation>PhRMA Web Synopsis: protocol A2581078 01 June 2008 Final.  [Accessed April 15, 2009].   http://www.clinicalstudyresults.org/documents/company-study_4374_0.pdf.</Citation></Reference><Reference><Citation>Schneider LS, Sano M. Current Alzheimer's disease clinical trials. Alzheimers Dement. 2009;5(5):388&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321732</ArticleId><ArticleId IdType="pubmed">19751918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20032300</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1939-4586</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular biology of the cell</Title><ISOAbbreviation>Mol Biol Cell</ISOAbbreviation></Journal><ArticleTitle>Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP.</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>520</EndPage><MedlinePgn>511-20</MedlinePgn></Pagination><Abstract><AbstractText>Both sporadic and familial Alzheimer's disease (AD) patients exhibit increased chromosome aneuploidy, particularly trisomy 21, in neurons and other cells. Significantly, trisomy 21/Down syndrome patients develop early onset AD pathology. We investigated the mechanism underlying mosaic chromosome aneuploidy in AD and report that FAD mutations in the Alzheimer Amyloid Precursor Protein gene, APP, induce chromosome mis-segregation and aneuploidy in transgenic mice and in transfected cells. Furthermore, adding synthetic Abeta peptide, the pathogenic product of APP, to cultured cells causes rapid and robust chromosome mis-segregation leading to aneuploid, including trisomy 21, daughters, which is prevented by LiCl addition or Ca(2+) chelation and is replicated in tau KO cells, implicating GSK-3beta, calpain, and Tau-dependent microtubule transport in the aneugenic activity of Abeta. Furthermore, APP KO cells are resistant to the aneugenic activity of Abeta, as they have been shown previously to be resistant to Abeta-induced tau phosphorylation and cell toxicity. These results indicate that Abeta-induced microtubule dysfunction leads to aneuploid neurons and may thereby contribute to the pathogenesis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Granic</LastName><ForeName>Antoneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eric Pfeiffer Suncoast Alzheimer's Center, University of South Florida, Tampa FL, 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Jaya</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Norden</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG25711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Biol Cell</MedlineTA><NlmUniqueID>9201390</NlmUniqueID><ISSNLinking>1059-1524</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000782" MajorTopicYN="Y">Aneuploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020090" MajorTopicYN="N">Chromosome Segregation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033481" MajorTopicYN="Y">Chromosomes, Mammalian</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20032300</ArticleId><ArticleId IdType="pmc">PMC2820417</ArticleId><ArticleId IdType="doi">10.1091/mbc.e09-10-0850</ArticleId><ArticleId IdType="pii">E09-10-0850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boeras D. I., Granic A., Crespo N. C., Rojiani A. M., Potter H. Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol. Aging. 2008;29:3119&#x2013;3128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692942</ArticleId><ArticleId IdType="pubmed">17169464</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J., Yankner B. A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 1997;378:776&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier N. L., Soriano S., Kang D. E., Masliah E., Hu G., Koo E. H. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am. J. Pathol. 2005;167:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603433</ArticleId><ArticleId IdType="pubmed">15972961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy B. A., et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003;42:12749&#x2013;12760.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui D. H., et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 1999;5:560&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229234</ArticleId></ArticleIdList></Reference><Reference><Citation>Duesberg P. Are centrosomes or aneuploidy the key to cancer? Science. 1999;284:2091&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409065</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein C. J. The consequences of chromosome imbalance. Am. J. Med. Genet. Suppl. 1990;7:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2149968</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R., et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller L. N., Potter H. Chromosome mis-segregation and trisomy 21 in Alzheimer's disease. Neurobiol. Dis. 1999;6:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408806</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G. G., Wong C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984;122:1131&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">6236805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi S., Muramatsu T., Matsushita S., Arai H., Sasaki H. Presenilin-1 polymorphism and Alzheimer's disease. Lancet. 1996;347:1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609783</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda T., Nihonmatsu N., Yasutake K., Ohtake A., Sato K., Tanaka S., Murayama O., Murayama M., Takashima A. Familial Alzheimer's disease-associated mutations block translocation of full-length presenilin 1 to the nuclear envelope. Neurosci. Res. 2000;37:101&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867173</ArticleId></ArticleIdList></Reference><Reference><Citation>Iourov I. Y., Vorsanova S. G., Liehr T., Yurov Y. B. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol. Disease. 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19344645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X. R., et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet. 1999;21:111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916802</ArticleId></ArticleIdList></Reference><Reference><Citation>Janicki S. M., Monteiro M. J. Presenilin overexpression arrests cells in the G1 phase of the cell cycle. Arrest potentiated by the Alzheimer's disease PS2(N141I)mutant. Am. J. Pathol. 1999;155:135&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866651</ArticleId><ArticleId IdType="pubmed">10393846</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsingh A. A., Johnston J. M., Merz G., Xu J., Kotula L., Jacobsen J. S., Tezapsidis N. Altered binding of mutated presenilin with cytoskeleton-interacting proteins. FEBS Lett. 2000;465:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">10620705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., Glabe C. G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura N., Nakamura S. I., Honda T., Takashima A., Nakayama H., Ono F., Sakakibara I., Doi K., Kawamura S., Yoshikawa Y. Age-related changes in the localization of presenilin-1 in cynomolgus monkey brain. Brain Res. 2001;922:30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11730699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane L. S., Lehman E. J., Hock B. J., Tsuchiya K. D., Lamb B. T. Rapid and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm. Genome. 2002;13:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O., Morfini G. A., Pigino G., Gadadhar A., Chen X., Robinson J., Ho H., Brady S. T., Sisodia S. S. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J. Neurosci. 2007;27:7011&#x2013;7020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801050</ArticleId><ArticleId IdType="pubmed">17596450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V. M. Regulation of tau phosphorylation in Alzheimer's disease. Ann. NY Acad. Sci. 1996;777:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M. S., Kwon Y. T., Li M., Peng J., Friedlander R. M., Tsai L. H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Xu M., Zhou H., Ma J., Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell. 1997;90:917&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A., Yuan M., Zhang Z., Paganetti P. A., Sturchler-Pierrat C., Staufenbiel M., Mautini J., Vigo F. S., Sommer B., Yankner B. A. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat. Neurosci. 2000;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucarelli P., Piciullo A., Palmarino M., Verdecchia M., Saccucci P., Arpino C., Curatolo P. Association between presenilin-1-48C/T polymorphism and Down's syndrome. Neurosci. Lett. 2004;367:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Yee A., Brewer H. B., Das S., Potter H. The Alzheimer amyloid-associated proteins &#x3b1;&#x3bb;&#x3c0;&#x3b7;&#x3b1;-1antichymotrypsin and apolipoprotein E promote the assembly of the Alzheimer &#xdf;-protein into filaments. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Brewer H. B., Jr, Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging. 1996;17:773&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892351</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L., Boni G., Bernardini R., Trippi F., Colognato R., Fontana I., Coppede F., Sbrana I. Susceptibility to chromosome malsegregation in lymphocytes of women who had a Down syndrome child in young age. Neurobiol. Aging. 2006;27:710&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005550</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliore L., Botto N., Scarpato R., Petrozzi L., Cipriani G., Bonuccelli U. Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer's disease patients. Cytogenet. Cell Genet. 1999;87:41&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10640809</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales C. P., Holt S. E., Ouellette M., Kaur K. J., Yan Y., Wilson K. S., White M. A., Wright W. E., Shay J. W. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Genet. 1999;21:115&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B., Morawski M., Mittag A., Lenz D., Tarnok A., Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J. Neurosci. 2007;27:6859&#x2013;6867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="pubmed">17596434</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzari M., et al. Amyloid precursor protein and presenilin1 interact with the adaptor GRB2 and modulate ERK 1,2 signaling. J. Biol. Chem. 2007;282:13833&#x2013;13844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17314098</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrenovich M. E., Raina A. K., Ogawa O., Atwood C. S., Morelli L., Smith M. A. Alzheimer disease&#x2014;a new beginning, or a final exit? In: Copani A., Nicoletti F., editors. Cell Cycle Mechanisms and Neuronal Cell Death. Austin, TX: Landes Bioscience; 2003. pp. 79&#x2013;93.</Citation></Reference><Reference><Citation>Olson M. I., Shaw C. M. Presenile dementia and Alzheimer's disease in mongolism. Brain. 1969;92:147&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">4237656</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.-Y., Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates &#x3b2;-amyloid-induced neurodegeneration. J. Neurosci. 2005;25:5365&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M. B., Karadima G., Samaritaki M., Avramopoulos D., Vassilopoulos D., Mikkelsen M. Association between presenilin-1 polymorphism and maternal meiosis II errors in Down syndrome. Am. J. Med. Genet. 2000;93:366&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">10951459</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G., Pelsman A., Mori H., Busciglio J. Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J. Neurosci. 2001;21:834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762317</ArticleId><ArticleId IdType="pubmed">11157069</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H. Review and hypothesis: Alzheimer disease and Down syndrome-chromosome 21 nondisjunction may underlie both disorders. Am. J. Hum. Genet. 1991;48:1192&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683102</ArticleId><ArticleId IdType="pubmed">1827946</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H. Cell cycle and chromosome segregation defects in Alzheimer's disease. In: Copani A., Nicoletti F., editors. Cell Cycle Mechanisms and Neuronal Cell Death. Austin, TX: Landes Bioscience; 2004. pp. 55&#x2013;78.</Citation></Reference><Reference><Citation>Potter H. Down syndrome and Alzheimer's disease: two sides of the same coin. Future Neurol. 2008;3:29&#x2013;37.</Citation></Reference><Reference><Citation>Potter H., Granic A., Boeras D., Padmanabhan J. Alzheimer's disease effectors, A&#x3b2; peptide and LDL cholesterol induce chromosome mis-segregation and anuploidy, including trisomy 21. Society for Neuroscience Meeting Abstract. 2008;611:4.</Citation></Reference><Reference><Citation>Potter H., Ma J., Das S., Geller L. N., Benjamin M., Kayyali U. S., Dressler D. Beyond &#x3b2;-protein: new steps in the pathogenic pathway to Alzheimer's disease. In: Iqbal K., Mortimer J. A., Winblad B., Wisniewski H. M., editors. Research Advances in Alzheimer's Disease and Related Disorders. New York: John Wiley &amp; Sons; 1995. pp. 643&#x2013;654.</Citation></Reference><Reference><Citation>Potter H., Wefes I. M., Nilsson L.N.G. The inflammation-induced pathological chaperones ACT and apoE are necessary catalysts of Alzheimer amyloid formation. Neurobiol. Aging. 2001;22:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope W. B., Lambert M. P., Leypold B., Seupaul R., Sletten L., Krafft G., Klein W. L. Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. Exper. Neurol. 1994;126:185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">7925819</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss U., D&#xf6;ring F., Illenberger S., Mandelkow E.-M. Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected in Chinese hamster ovary cells. Mol. Biol. Cell. 1995;6:1397&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC301295</ArticleId><ArticleId IdType="pubmed">8573794</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri B. K., Zhang Z., Singh I. SPECT in adult mosaic Down's syndrome with early dementia. Clin. Nucl. Med. 1994;19:989&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">7842596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M., Dawson H. N., Binder L. I., Vitek M. P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassoulzadegan M., Cuzin F., Yang Y. APLP2, a member of the Alzheimer precursor protein family, is required for correct genomic segregation in dividing mouse cells. EMBO J. 1998;17:4647&#x2013;4656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170794</ArticleId><ArticleId IdType="pubmed">9707424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen S. K., McConnell M. J., Kaushal D., Kingsbury M. A., Yang A. H., Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc. Natl. Acad. Sci. USA. 2001;98:13361&#x2013;13366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60876</ArticleId><ArticleId IdType="pubmed">11698687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman J. M., Rao P. N., Lu P. H., Cederbaum S. Mosaicism for trisomy 21 in a patient with young-onset dementia. Arch. Neurol. 2008;65:412&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">18332257</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E. D., Scearce-Levie K., Palop J. J., Yan F., Cheng I. H., Wu T., Gerstein H., Yu G. Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G., et al. A new function of microtubule-associated protein tau: involvement in chromosome stability. Cell Cycle. 2008;15:1788&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006;38:11&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe I. F., Ridler M. A., Gibberd F. B. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet. 1989;2:229.</Citation><ArticleIdList><ArticleId IdType="pubmed">2568565</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapiro M. B., Kumar A., White B., Grandy C. L., Friedland R. P., Rapoport S. I. Alzheimer's disease (AD) in mosaic/translocation Down's syndrome (Ds) without mental retardation. Neurology. 1989;39:169.</Citation></Reference><Reference><Citation>Schupf N., Kapell D., Lee J. H., Ottman R., Mayeux R. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome. Lancet. 1994;344:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914304</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked G. M., Kummer M. P., Lu D. C., Galvan V., Bredesen D. E., Koo E. H. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597&#x2013;624) FASEB J. 2006;20:1254&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847355</ArticleId><ArticleId IdType="pubmed">16636103</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., Del-Favero J., Cruts M., van Duijn C. M., Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S. A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola Vigo F., Kedikian G., Heredia L., A&#xf1;el A. D., Rosa A. L., Lorenzo A. Amyloid-beta precursor protein mediate neuronal toxicity of amyloid beta through Go protein activation. Neurobiol. Aging. 2009;30:1379&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187234</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin G. B., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Suizu F., Ryo A., Wulf G., Lim J., Lu K. P. Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol. Cell. Biol. 2006;26:1463&#x2013;1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1367188</ArticleId><ArticleId IdType="pubmed">16449657</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T., Oishi M., Marshak D. R., Czernik A. J., Nairn A. C., Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J. 1994;13:1114&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394920</ArticleId><ArticleId IdType="pubmed">8131745</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimer's Dis. 2006;9:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914869</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezapsidis N., Merz P. A., Merz G., Hong H. Microtubular interactions of presenilin direct kinesis of Abeta peptide and its precursors. FASEB J. 2003;17:1322&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738804</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P., Fenech M. Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. Mutagenesis. 2008;23:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048581</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M., Cleary J. P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D. M., Selkoe D. J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006;60:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192927</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel N. H., Bhaskar K., Patil A. R., Pimplikar S. W., Herrup K., Lamb B. T. Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J. Neurosci. 2008;28:10786&#x2013;10793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="pubmed">18945886</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L., Jankowsky J. L., Xu G. M., Borchelt D. R., Rampon C. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J. Neurosci. 2007;27:6771&#x2013;6780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439193</ArticleId><ArticleId IdType="pubmed">17581964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease? J. Cell Biol. 1996;132:423&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120731</ArticleId><ArticleId IdType="pubmed">8636218</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova M. V., Malanina G. G., Reddy A. S., Fletterick R. J. Structure of the complex of a mitotic kinesin with its calcium binding regulator. Proc. Natl. Acad. Sci. USA. 2009;106:8175&#x2013;8179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688874</ArticleId><ArticleId IdType="pubmed">19416847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakefield J. G., Stephens D. J., Tavare J. M. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. 2003;116:637&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Dineley K. T., Sweatt J. D., Zheng H. Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience. 2004;126:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Schwarz T. L. The mechanism of Ca2+-dependent regulation of kinesin-mediated mitochondrial motility. Cell. 2009;136:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768392</ArticleId><ArticleId IdType="pubmed">19135897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen P. H., et al. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp. Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T., Casta&#xf1;o E. M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M. S. The secretases of Alzheimer's disease. Curr. Top. Dev. Biol. 2003;54:233&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12696752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B., Iwasaki K., Vito P., Ganjei J. K., Lacana E., Sunderland T., Zhao B., Kusiak J. W., Wasco W., D'Adamio L. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science, 1996;274:1710&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg M., Hutton M., Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet. 1996;347:509&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Geldmacher D. S., Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Varvel N. H., Lamb B. T., Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J. Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B. A., Dawes L. R., Fisher S., Villa-Komaroff L., Oster-Granite M. L., Neve R. L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989;245:417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., McNeil E., Dressler L., Siman R. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp. Neurol. 2007;204:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853320</ArticleId><ArticleId IdType="pubmed">17070803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Deng W., Gage F. H. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Siedlak S. L., Wang Y., Perry G., Castellani R. J., Cohen M. L., Smith M. A. Neuronal binucleation in Alzheimer disease hippocampus. Neuropathol. Appl. Neurobiol. 2008;34:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17995921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann K., et al. Localization of the putative precursor of Alzheimer's disease-specific amyloid at nuclear envelopes of adult human muscle. EMBO J. 1988;7:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC454328</ArticleId><ArticleId IdType="pubmed">2896589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitnik G, Wang L., Martin G. M., Qubai Hu Q. Localizations of endogenous APP/APP-proteolytic products are consistent with microtubular transport. J. Mol. Neurosci. 2006;31:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17416970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20037581</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>70</EndPage><MedlinePgn>63-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nbt.1598</ELocationID><Abstract><AbstractText>Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions. Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation. This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-molecule allosteric modulators of PDE4D that do not completely inhibit enzymatic activity (I(max) approximately 80-90%). These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biological activity in cellular and in vivo models. Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burgin</LastName><ForeName>Alex B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>deCODE biostructures, Bainbridge Island, Washington, USA. aburgin@embios.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Olafur T</ForeName><Initials>OT</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jasbir</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Witte</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Staker</LastName><ForeName>Bart L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Jon M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Thorsteinsdottir</LastName><ForeName>Margret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hrafnsdottir</LastName><ForeName>Sigrun</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kiselyov</LastName><ForeName>Alex S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Lance J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Gurney</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM074961</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000596953">D159687</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058988">Phosphodiesterase 4 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.17</RegistryNumber><NameOfSubstance UI="D054703">Cyclic Nucleotide Phosphodiesterases, Type 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054703" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 4</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058988" MajorTopicYN="Y">Phosphodiesterase 4 Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010726" MajorTopicYN="N">Phosphodiesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014839" MajorTopicYN="N">Vomiting</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20037581</ArticleId><ArticleId IdType="doi">10.1038/nbt.1598</ArticleId><ArticleId IdType="pii">nbt.1598</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Pharmacol Exp Ther. 2007 Nov;323(2):708-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17684118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2001 Sep;298(3):1142-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11504812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2009 Jun 15;19(12):3174-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19447034</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2004 Mar 19;337(2):355-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15003452</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Apr 6;276(14):11189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">11134006</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1987 Jul 27;41(4):513-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3600192</ArticleId></ArticleIdList></Reference><Reference><Citation>Structure. 2004 Dec;12(12):2233-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15576036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 1998 Jun;10(6):427-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9720765</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001;40(2):262-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11114405</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaldi Arch Chest Dis. 2002 Feb;57(1):48-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12174704</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2005 Jun;5(3):238-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15907909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1997 May 19;234(2):320-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9177268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Mar;6(2):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11317219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Aug 29;278(35):33351-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12810716</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1995 May;115(1):39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">7647982</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1997 Nov 18;36(46):14250-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9369498</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1999 Feb;126(4):979-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10193778</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Jul 9;274(28):19677-85</Citation><ArticleIdList><ArticleId IdType="pubmed">10391907</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2009;15(14):1688-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19442182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 1997 May-Jun;9(3-4):227-36</Citation><ArticleIdList><ArticleId IdType="pubmed">9218122</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2002 Jun;136(3):421-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12023945</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2002 Aug;3(8):1165-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12211409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Dec 5;278(49):49230-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14500724</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1999 Feb;38(2):289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10218871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1993 Oct;13(10):6558-71</Citation><ArticleIdList><ArticleId IdType="pubmed">8413254</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1998 Jul 1;333 ( Pt 1):139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">9639573</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Oct 7;123(1):25-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16213210</ArticleId></ArticleIdList></Reference><Reference><Citation>Toxicol Pathol. 2008 Oct;36(6):827-39</Citation><ArticleIdList><ArticleId IdType="pubmed">18776163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2007 Oct;6(10):793-810</Citation><ArticleIdList><ArticleId IdType="pubmed">17906642</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2009 Apr 21;9:37</Citation><ArticleIdList><ArticleId IdType="pubmed">19383143</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2006;12(20):2511-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16842174</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2008 Jun;30(3):375-387</Citation><ArticleIdList><ArticleId IdType="pubmed">18424161</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2007 Nov 14;573(1-3):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17658510</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2002 Oct;110(7):1045-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12370283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2000 Feb 24;43(4):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10691693</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2009 Jan;8(1):41-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19116626</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Apr 7;275(14):10349-58</Citation><ArticleIdList><ArticleId IdType="pubmed">10744723</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Nov 18;310(5751):1187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8942955</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2008 Oct;155(3):308-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18660825</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2002 Jan;135(1):113-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11786486</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Biotechnol. 2009 Apr 21;9:36</Citation><ArticleIdList><ArticleId IdType="pubmed">19383142</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1996 Jul 12;271(28):16526-34</Citation><ArticleIdList><ArticleId IdType="pubmed">8663227</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2003 Feb 15;370(Pt 1):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">12444918</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2006 Aug 15;398(1):23-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16689683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Jun 2;275(22):16609-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10828059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2006 Feb;16(3):718-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16263279</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2005 Nov 15;10(22):1503-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16257373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Aug 29;27(35):9513-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17728464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1996 Oct;50(4):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8863835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2007 Aug 10;371(2):302-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17582435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 2005 Sep;17(9):1158-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15905070</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1993 Jun 15;292 ( Pt 3):677-86</Citation><ArticleIdList><ArticleId IdType="pubmed">7686364</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2007 Feb 16;100(3):309-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17307970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20041162</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes.</ArticleTitle><Pagination><StartPage>e8492</StartPage><MedlinePgn>e8492</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e8492</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0008492</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Protein aggregation plays a major role in the pathogenesis of neurodegenerative disorders, such as Alzheimer's disease. However, direct real-time imaging of protein aggregation, including oligomerization and fibrillization, has never been achieved. Here we demonstrate the preparation of fluorescent semiconductor nanocrystal (quantum dot; QD)-labeled amyloid-beta peptide (QDAbeta) and its advanced applications.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">The QDAbeta construct retained Abeta oligomer-forming ability, and the sizes of these oligomers could be estimated from the relative fluorescence intensities of the imaged spots. Both QDAbeta coaggregation with intact Abeta42 and insertion into fibrils were detected by fluorescence microscopy. The coaggregation process was observed by real-time 3D imaging using slit-scanning confocal microscopy, which showed a typical sigmoid curve with 1.5 h in the lag-time and 12 h until saturation. Inhibition of coaggregation using an anti-Abeta antibody can be observed as 3D images on a microscopic scale. Microglia ingested monomeric QDAbeta more significantly than oligomeric QDAbeta, and the ingested QDAbeta was mainly accumulated in the lysosome.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">These data demonstrate that QDAbeta is a novel nanoprobe for studying Abeta oligomerization and fibrillization in multiple modalities and may be applicable for high-throughput drug screening systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tokuraku</LastName><ForeName>Kiyotaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquardt</LastName><ForeName>Meg</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG032600</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032600</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057054" MajorTopicYN="N">Molecular Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045663" MajorTopicYN="Y">Quantum Dots</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20041162</ArticleId><ArticleId IdType="pmc">PMC2794548</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0008492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koo EH, Lansbury PT, Jr, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci U S A. 1999;96:9989&#x2013;9990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33726</ArticleId><ArticleId IdType="pubmed">10468546</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tew DJ, Bottomley SP, Smith DP, Ciccotosto GD, Babon J, et al. Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J. 2008;94:2752&#x2013;2766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267149</ArticleId><ArticleId IdType="pubmed">18065467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem. 1999;274:32301&#x2013;32308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542270</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, et al. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol. 2008;181:3877&#x2013;3886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603577</ArticleId><ArticleId IdType="pubmed">18768842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruchez M, Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998;281:2013&#x2013;2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748157</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998;281:2016&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748158</ArticleId></ArticleIdList></Reference><Reference><Citation>Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4:435&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928695</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, et al. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298:1759&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">15258594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan M, Levi S, Luccardini C, Rostaing P, Riveau B, et al. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science. 2003;302:442&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">14564008</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz A, Surrey T. Processive movement of single kinesins on crowded microtubules visualized using quantum dots. Embo J. 2006;25:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383520</ArticleId><ArticleId IdType="pubmed">16407972</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science. 2003;300:1434&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">12775841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X, Naistat D, Li C, Orbulesco J, Leblanc RM. An alternative approach to amyloid fibrils morphology: CdSe/ZnS quantum dots labelled beta-amyloid peptide fragments Abeta (31&#x2013;35), Abeta (1&#x2013;40) and Abeta (1&#x2013;42). Colloids Surf B Biointerfaces. 2006;50:104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard M, Hamada T, Saito M, Yajima Y, Kudou M, et al. Detection of Alzheimer's amyloid beta aggregation by capturing molecular trails of individual assemblies. Biochem Biophys Res Commun. 2008;377:725&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">18950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. PLoS ONE. 2009;4:e4627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645672</ArticleId><ArticleId IdType="pubmed">19247480</ArticleId></ArticleIdList></Reference><Reference><Citation>Howarth M, Ting AY. Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin. Nat Protoc. 2008;3:534&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671200</ArticleId><ArticleId IdType="pubmed">18323822</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay JM, Michalet X. New light on quantum dot cytotoxicity. Chem Biol. 2005;12:1159&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Stilwell JL, Gerion D, Ding L, Elboudwarej O, et al. Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett. 2006;6:800&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730586</ArticleId><ArticleId IdType="pubmed">16608287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty DP, Walsh SM, Kiyota T, Dong Y, Ikezu T, et al. Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands. J Med Chem. 2007;50:4986&#x2013;4992.</Citation><ArticleIdList><ArticleId IdType="pubmed">17845017</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT., Jr Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, et al. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, et al. A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, Yong KT, Roy I, Mahajan SD, Ding H, et al. Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem. 2008;19:1179&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">18473444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H. Tricine-SDS-PAGE. Nat Protoc. 2006;1:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406207</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170:680&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci. 2005;25:2566&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725188</ArticleId><ArticleId IdType="pubmed">15758166</ArticleId></ArticleIdList></Reference><Reference><Citation>Shlyakhtenko LS, Gall AA, Filonov A, Cerovac Z, Lushnikov A, et al. Silatrane-based surface chemistry for immobilization of DNA, protein-DNA complexes and other biological materials. Ultramicroscopy. 2003;97:279&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyubchenko YL, Shlyakhtenko LS. AFM for analysis of structure and dynamics of DNA and protein-DNA complexes. Methods. 2009;47:206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667448</ArticleId><ArticleId IdType="pubmed">18835446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interaction between A beta(1&#x2013;42) and A beta(1&#x2013;40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry. 1999;38:15514&#x2013;15521.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20041192</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month><Day>29</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Identification of beta-secretase (BACE1) substrates using quantitative proteomics.</ArticleTitle><Pagination><StartPage>e8477</StartPage><MedlinePgn>e8477</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e8477</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0008477</ELocationID><Abstract><AbstractText>Beta-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease with a lumenal active site that sheds the ectodomains of membrane proteins through juxtamembrane proteolysis. BACE1 has been studied principally for its role in Alzheimer's disease as the beta-secretase responsible for generating the amyloid-beta protein. Emerging evidence from mouse models has identified the importance of BACE1 in myelination and cognitive performance. However, the substrates that BACE1 processes to regulate these functions are unknown, and to date only a few beta-secretase substrates have been identified through candidate-based studies. Using an unbiased approach to substrate identification, we performed quantitative proteomic analysis of two human epithelial cell lines stably expressing BACE1 and identified 68 putative beta-secretase substrates, a number of which we validated in a cell culture system. The vast majority were of type I transmembrane topology, although one was type II and three were GPI-linked proteins. Intriguingly, a preponderance of these proteins are involved in contact-dependent intercellular communication or serve as receptors and have recognized roles in the nervous system and other organs. No consistent sequence motif predicting BACE1 cleavage was identified in substrates versus non-substrates. These findings expand our understanding of the proteins and cellular processes that BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hemming</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Joshua E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Gygi</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HG3456</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM067945</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM67945</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG003456</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017261">Glycosylphosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017261" MajorTopicYN="N">Glycosylphosphatidylinositols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>DJS is a founding scientist and consultant of Elan, plc. Otherwise, the authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20041192</ArticleId><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0008477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 2009;5:234&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008;5:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572079</ArticleId><ArticleId IdType="pubmed">18625450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, et al. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007;4:e262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952204</ArticleId><ArticleId IdType="pubmed">17760499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Koelsch G, Wu S, Downs D, Dashti A, et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000;97:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26455</ArticleId><ArticleId IdType="pubmed">10677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res. 2002;70:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211305</ArticleId><ArticleId IdType="pubmed">18005427</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem. 2007;100:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17156133</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron. 1995;14:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem. 2002;277:4687&#x2013;4693.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauder JM, Arthur JW, Dunbrack RL., Jr Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. J Mol Biol. 2000;300:241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873463</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Song L, Laird F, Wong PC, Lee HK. BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci. 2008;28:8677&#x2013;8681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728626</ArticleId><ArticleId IdType="pubmed">18753368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 2008;6:e257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570425</ArticleId><ArticleId IdType="pubmed">18942891</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem. 2000;275:33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung AY, Selkoe DJ. Selective ectodomain phosphorylation and regulated cleavage of beta-amyloid precursor protein. Embo J. 1994;13:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394842</ArticleId><ArticleId IdType="pubmed">8313898</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Capell A, Hung AY, Langen H, Schnolzer M, et al. Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. J Biol Chem. 1997;272:1896&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">8999878</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Sudhof TC. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem. 2004;279:10542&#x2013;10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, et al. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem. 2007;282:11982&#x2013;11995.</Citation><ArticleIdList><ArticleId IdType="pubmed">17307738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Kotani N, Ogawa K, et al. Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). J Biol Chem. 2003;278:14865&#x2013;14871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473667</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280:17777&#x2013;17785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007;17:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420126</ArticleId></ArticleIdList></Reference><Reference><Citation>Davy A, Gale NW, Murray EW, Klinghoffer RA, Soriano P, et al. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 1999;13:3125&#x2013;3135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317175</ArticleId><ArticleId IdType="pubmed">10601038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori M, Osterfield M, Flanagan JG. Regulated cleavage of a contact-mediated axon repellent. Science. 2000;289:1360&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958785</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T, Forsten-Williams K, Storrie B. Both post-Golgi and intra-Golgi cycling affect the distribution of the Golgi phosphoprotein GPP130. Traffic. 2007;8:1265&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">17605763</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan R, Linstedt AD. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. Mol Biol Cell. 2004;15:4798&#x2013;4806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524728</ArticleId><ArticleId IdType="pubmed">15331763</ArticleId></ArticleIdList></Reference><Reference><Citation>Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 2004;279:47050&#x2013;47056.</Citation><ArticleIdList><ArticleId IdType="pubmed">15345710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer. 2007;43:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239582</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene. 2007;26:368&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep. 2006;26:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16779663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, et al. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. J Mol Endocrinol. 2008;41:65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18495691</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shewy HM, Lee MH, Obeid LM, Jaffa AA, Luttrell LM. The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J Biol Chem. 2007;282:26150&#x2013;26157.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C, Kar S. The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system. Brain Res Brain Res Rev. 2004;44:117&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003389</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem. 1998;273:28610&#x2013;28616.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786853</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Fadeeva JV, LaVoie MJ, Paliga K, Eggert S, et al. gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry. 2003;42:6664&#x2013;6673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12779321</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit J, Verhaagen J. Role of semaphorins in the adult nervous system. Prog Neurobiol. 2003;71:249&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687984</ArticleId></ArticleIdList></Reference><Reference><Citation>Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature. 1996;383:525&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849723</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagaki S, Ohoka Y, Sugimoto H, Fujioka S, Amazaki M, et al. Sema4c, a transmembrane semaphorin, interacts with a post-synaptic density protein, PSD-95. J Biol Chem. 2001;276:9174&#x2013;9181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko JA, Gondo T, Inagaki S, Inui M. Requirement of the transmembrane semaphorin Sema4C for myogenic differentiation. FEBS Lett. 2005;579:2236&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15811348</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, et al. The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem. 2004;271:2539&#x2013;2547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280:37644&#x2013;37650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409196</ArticleId><ArticleId IdType="pubmed">16154999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Hawkins J, Shikotra A, Riddell DR, Faller A, et al. Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem. 2003;278:36264&#x2013;36268.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857759</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, et al. The International Protein Index: an integrated database for proteomics experiments. Proteomics. 2004;4:1985&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">15221759</ArticleId></ArticleIdList></Reference><Reference><Citation>Everley PA, Bakalarski CE, Elias JE, Waghorne CG, Beausoleil SA, et al. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res. 2006;5:1224&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16674112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakalarski CE, Elias JE, Villen J, Haas W, Gerber SA, et al. The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res. 2008;7:4756&#x2013;4765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746028</ArticleId><ArticleId IdType="pubmed">18798661</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20049331</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e8556</StartPage><MedlinePgn>e8556</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e8556</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0008556</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common form of dementia. The major molecular risk factor for late-onset AD is expression of the epsilon-4 allele of apolipoprotein E (apoE), the major cholesterol transporter in the brain. The low-density lipoprotein receptor (LDLR) has the highest affinity for apoE and plays an important role in brain cholesterol metabolism.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">Using RT-PCR and western blotting techniques we found that over-expression of APP caused increases in both LDLR mRNA and protein levels in APP transfected H4 neuroglioma cells compared to H4 controls. Furthermore, immunohistochemical experiments showed aberrant localization of LDLR in H4-APP neuroglioma cells, Abeta-treated primary neurons, and in the PSAPP transgenic mouse model of AD. Finally, immunofluorescent staining of LDLR and of gamma- and alpha-tubulin showed a change in LDLR localization preferentially away from the plasma membrane that was paralleled by and likely the result of a disruption of the microtubule-organizing center and associated microtubule network.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">These data suggest that increased APP expression and Abeta exposure alters microtubule function, leading to reduced transport of LDLR to the plasma membrane. Consequent deleterious effects on apoE uptake and function will have implications for AD pathogenesis and/or progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abisambra</LastName><ForeName>Jose F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute, Tampa, Florida, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorelli</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Jaya</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Neame</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wefes</LastName><ForeName>Inge</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20049331</ArticleId><ArticleId IdType="pmc">PMC2797391</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0008556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging. 2001;22:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel RJ, Kane JP. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A. 1973;70:2015&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC433655</ArticleId><ArticleId IdType="pubmed">4352966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet. 1981;33:11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1684875</ArticleId><ArticleId IdType="pubmed">7468588</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A. 1985;82:203&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397000</ArticleId><ArticleId IdType="pubmed">3918303</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26:4985&#x2013;4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC., Jr Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978;17:1440&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">206278</ArticleId></ArticleIdList></Reference><Reference><Citation>Innerarity TL, Pitas RE, Mahley RW. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem. 1979;254:4186&#x2013;4190.</Citation><ArticleIdList><ArticleId IdType="pubmed">220235</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, Brown MS. The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul. 1976;11:147&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">187385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 1985;228:815&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450672</ArticleId><ArticleId IdType="pubmed">2988123</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JR, Osborne TF, Goldstein JL, Brown MS. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem. 1990;265:2306&#x2013;2310.</Citation><ArticleIdList><ArticleId IdType="pubmed">2298751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez D, Abisambra Socarras JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta. 2007;1771:1216&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572141</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS. Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell. 1982;30:715&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">6291781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">6091915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhof TC, Russell DW, Goldstein JL, Brown MS, Sanchez-Pescador R, et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor. Science. 1985;228:893&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">3873704</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Goldstein JL, Sudhof TC, Anderson RG, Russell DW, et al. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature. 1987;326:760&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">3494949</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Elhammer A, Russell DW, Schneider WJ, Kornfeld S, et al. Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. J Biol Chem. 1986;261:2828&#x2013;2838.</Citation><ArticleIdList><ArticleId IdType="pubmed">3005267</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985;1:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrman MA, Schneider WJ, Sudhof TC, Brown MS, Goldstein JL, et al. Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science. 1985;227:140&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449727</ArticleId><ArticleId IdType="pubmed">3155573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrman MA, Russell DW, Goldstein JL, Brown MS. Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia. J Biol Chem. 1987;262:3354&#x2013;3361.</Citation><ArticleIdList><ArticleId IdType="pubmed">3818645</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, van Driel IR, Russell DW, Brown MS, Goldstein JL. The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem. 1987;262:4075&#x2013;4082.</Citation><ArticleIdList><ArticleId IdType="pubmed">3104336</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">3513311</ArticleId></ArticleIdList></Reference><Reference><Citation>Scacchi R, Gambina G, Martini MC, Ruggeri M, Ferrari G, et al. Polymorphisms of the apolipoprotein E gene regulatory region and of the LDL receptor gene in late-onset Alzheimer's disease in relation to the plasma lipidic pattern. Dement Geriatr Cogn Disord. 2001;12:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11173876</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry. 2005;66:940&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">16013913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamsa R, Helisalmi S, Herukka SK, Tapiola T, Pirttila T, et al. Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Neurobiol Aging. 2008;29:848&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Huang R, Lanham IS, Cathcart HM, Howard M, et al. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J Med Genet. 2005;42:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735987</ArticleId><ArticleId IdType="pubmed">15689450</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, et al. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet. 2003;12:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Daw EW, Yu CE, Payami H, Steinbart EJ, et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet. 2004;75:398&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182019</ArticleId><ArticleId IdType="pubmed">15248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Huang R, Cathcart HM, Lanham IS, Parker GR, et al. Membership in genetic groups predicts Alzheimer disease. Rejuvenation Res. 2006;9:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalraj RK, Zhu H, Kelly JF, Mendiondo M, Pulliam JF, et al. Genetic association of low density lipoprotein receptor and Alzheimer's disease. Neurobiol Aging. 2005;26:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585340</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, St Jean PL, Upmanyu R, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Retz W, Thome J, Durany N, Harsanyi A, Retz-Junginger P, et al. Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet. 2001;11:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11702052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez E, Mateo I, Llorca J, Sanchez-Quintana C, Infante J, et al. Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk. J Neurol. 2006;253:801&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">16311892</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzari M, Venezia V, Bianchini P, Caorsi V, Diaspro A, et al. Amyloid precursor protein and Presenilin 1 interaction studied by FRET in human H4 cells. Ann N Y Acad Sci. 2007;1096:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">17405936</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Xu M, Zhou H, Ma J, Potter H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell. 1997;90:917&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8157129</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998;273:16576&#x2013;16582.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632729</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport. 2002;13:455&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11930160</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, et al. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008;106:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897170</ArticleId><ArticleId IdType="pubmed">18410513</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856&#x2013;5861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33303</ArticleId><ArticleId IdType="pubmed">11296263</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A. 2001;98:5815&#x2013;5820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33296</ArticleId><ArticleId IdType="pubmed">11309494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271:4436&#x2013;4440.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, et al. Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. Hum Mol Genet. 2008;17:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2361153</ArticleId><ArticleId IdType="pubmed">18065781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, et al. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett. 1997;222:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9148246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280:25754&#x2013;25759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006;27:1632&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236385</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma-free model? Br Med J. 1977;2:226&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1631400</ArticleId><ArticleId IdType="pubmed">141966</ArticleId></ArticleIdList></Reference><Reference><Citation>Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down's syndrome and atherosclerosis. Atherosclerosis. 1989;76:269&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">2525042</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Ameida CG, Paul S, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Biniel MC, Furlow PW, Clement AS, Velasco PT, et al. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC294927</ArticleId><ArticleId IdType="pubmed">8349823</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, et al. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging. 2007;28:831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730391</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan J, Levy M, Dickson DW, Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain. 2006;129:3020&#x2013;3034.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ness GC, Sample CE, Smith M, Pendleton LC, Eichler DC. Characteristics of rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Biochem J. 1986;233:167&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1152999</ArticleId><ArticleId IdType="pubmed">3082322</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:1444&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762932</ArticleId><ArticleId IdType="pubmed">11222634</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasband WS. ImageJ. 1997&#x2013;2009</Citation></Reference><Reference><Citation>Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International. 2004;11:36&#x2013;42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20054010</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2010</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Hippocampal mean diffusivity and memory in healthy elderly individuals: a cross-sectional study.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>200</EndPage><MedlinePgn>194-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181cb3e39</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relationship between age-related memory decline and hippocampal anatomic changes is a matter of debate.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the relationship between age-related memory decline and MRI hippocampal anatomic changes in a cohort of healthy individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, 76 healthy individuals (44 male and 32 female), ranging in age from 20 to 80 years, were recruited from universities, community recreational centers, hospital personnel, and patients' relatives from 2005 to 2008. These individuals were submitted to a 3-T MRI protocol with a whole-brain T1-weighted and diffusion-weighted scanning and a neuropsychological assessment. For each subject, we calculated the volumes of the total brain (gray + white matter) and hippocampi. The segmented hippocampi defined the binary masks where mean values of mean diffusivity (MD) and fractional anisotropy (FA) were calculated. Neuropsychological evaluation included tests of verbal memory (15 minutes delayed recall of a 15-word list) and visuospatial memory (20 minutes delayed reproduction of Rey complex figure).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Hippocampal MD, but not hippocampal FA, hippocampal volume, or total brain volume, predicted performance of individuals beyond their 50s on tests of verbal and visuospatial memory.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High mean diffusivity values in the hippocampal formation of healthy elderly individuals predict memory decline, as reflected by performance on tests of declarative verbal and visual-spatial memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlesimo</LastName><ForeName>Giovanni A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Tor Vergata University, Rome. memolab@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherubini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="Y">Diffusion Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20054010</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181cb3e39</ArticleId><ArticleId IdType="pii">WNL.0b013e3181cb3e39</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20061638</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>191</StartPage><EndPage>210</EndPage><MedlinePgn>191-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-1228</ELocationID><Abstract><AbstractText>Despite numerous studies, there is no definitive evidence that high-frequency electromagnetic field (EMF) exposure is a risk to human health. To the contrary, this report presents the first evidence that long-term EMF exposure directly associated with cell phone use (918 MHz; 0.25 w/kg) provides cognitive benefits. Both cognitive-protective and cognitive-enhancing effects of EMF exposure were discovered for both normal mice and transgenic mice destined to develop Alzheimer's-like cognitive impairment. The cognitive interference task utilized in this study was designed from, and measure-for-measure analogous to, a human cognitive interference task. In Alzheimer's disease mice, long-term EMF exposure reduced brain amyloid-beta (Abeta) deposition through Abeta anti-aggregation actions and increased brain temperature during exposure periods. Several inter-related mechanisms of EMF action are proposed, including increased Abeta clearance from the brains of Alzheimer's disease mice, increased neuronal activity, and increased cerebral blood flow. Although caution should be taken in extrapolating these mouse studies to humans, we conclude that EMF exposure may represent a non-invasive, non-pharmacologic therapeutic against Alzheimer's disease and an effective memory-enhancing approach in general.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arendash</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>The Florida Alzheimer's Disease Research Center, Tampa, FL, USA. arendash@cas.usf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Ramos</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mamcarz</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Runfeldt</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guixin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sava</LastName><ForeName>Vasyl</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004574" MajorTopicYN="N">Electromagnetic Fields</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055909" MajorTopicYN="N">Magnetic Field Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20061638</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-1228</ArticleId><ArticleId IdType="pii">T3107113X861377U</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20062056</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>158</EndPage><MedlinePgn>151-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.1743</ELocationID><Abstract><AbstractText>Gamma-secretase is an aspartyl protease that cleaves multiple substrates within their transmembrane domains. Gamma-secretase processes the amyloid precursor protein (APP) to generate gamma-amyloid (Agamma) peptides associated with Alzheimer's disease. Here, we show that APP possesses a substrate inhibitory domain (ASID) that negatively modulates gamma-secretase activity for Agamma production by binding to an allosteric site within the gamma-secretase complex. Alteration of this ASID by deletion or mutation, as is seen with the Flemish mutation (A21G), reduces its inhibitory potency and promotes Agamma production. Notably, peptides derived from ASID show selective inhibition of gamma-secretase activity for Agamma production over Notch1 processing. Therefore, this mode of regulation represents an unprecedented mechanism for modulating gamma-secretase, providing insight into the molecular basis of Alzheimer's disease pathogenesis and a potential strategy for the development of therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassit</LastName><ForeName>Bhramdeo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Deming</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Struct Mol Biol. 2010 Feb;17(2):140-1. doi: 10.1038/nsmb0210-140.</RefSource><PMID Version="1">20130572</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20062056</ArticleId><ArticleId IdType="doi">10.1038/nsmb.1743</ArticleId><ArticleId IdType="pii">nsmb.1743</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochemistry. 1994 May 17;33(19):5661-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8180191</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6138-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Jun 20;278(25):22475-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12684521</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1999 Oct 22;286(5440):735-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2000 Feb 18;100(4):391-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 1999 Nov 1;13(21):2801-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10557208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2009 Feb 1;19(3):926-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19097890</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Jul 7;275(27):20806-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10764742</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Dec 3;279(49):50647-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15485850</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1997 Dec 9;36(49):15396-403</Citation><ArticleIdList><ArticleId IdType="pubmed">9398269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2001 Sep;4(9):887-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1991 Feb 21;349(6311):704-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2001 Aug 1;10(16):1665-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 May 27;264(5163):1336-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1994 Jul 1;269(26):17741-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8021287</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2001 Jul 6;293(5527):115-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1999 Jun 25;453(3):288-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10405162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1993 Sep 24;695:144-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8239273</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Rep. 2001 Sep;2(9):835-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11520861</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1997 Aug 1;277(5326):693-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9235893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Chem Soc. 2004 Dec 22;126(50):16288-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15600307</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Cell Dev Biol. 2002;18:421-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12142282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Org Chem. 2004 Oct 15;69(21):7344-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15471490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biotechnol. 2002 Sep;22(1):51-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12353914</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Biochem. 2006;75:655-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16756506</ArticleId></ArticleIdList></Reference><Reference><Citation>Biopolymers. 2005;80(2-3):67-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15729688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2004 Nov;17(2):205-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15474359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2005 Jan;3(1):54-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15634266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2007 Jan 11;50(1):165-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17201419</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1996 Oct 23;227(3):730-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8886002</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 May 28;393(6683):382-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Jun 8;405(6787):689-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Apr 15;23(8):3272-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12716934</ArticleId></ArticleIdList></Reference><Reference><Citation>Folia Neuropathol. 2003;41(1):35-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12862394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Oct;10(10):1128-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15448687</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiology (Bethesda). 2006 Dec;21:411-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17119154</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2000 Jul;2(7):428-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10878808</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1997 Aug 26;36(34):10498-505</Citation><ArticleIdList><ArticleId IdType="pubmed">9265630</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Aug 29;321(5893):1221-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2001 Apr;81(2):741-66</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2008 Dec 11;51(23):7348-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19012391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9765-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7937888</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3230-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Chem Soc. 2003 Oct 1;125(39):11794-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14505382</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 1999 Apr 22;9(8):393-404</Citation><ArticleIdList><ArticleId IdType="pubmed">10226025</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Aug 30;277(35):31499-505</Citation><ArticleIdList><ArticleId IdType="pubmed">12072428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 1998 Oct;5(4):281-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9848098</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1991 Oct;12(10):383-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1996 Sep 24;226(3):672-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8831674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Apr 8;398(6727):513-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2007 Aug 10;282(32):23639-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2000 Sep;6(3):625-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11030342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2009 Feb 1;19(3):922-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19097779</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Jun 12;453(7197):925-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Aug 12;122(3):435-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 15;13(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2003 Apr 10;38(1):9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1996 Jul;17(1):181-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20071510</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Differential effects of Tau on the integrity and function of neurons essential for learning in Drosophila.</ArticleTitle><Pagination><StartPage>464</StartPage><EndPage>477</EndPage><MedlinePgn>464-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1490-09.2010</ELocationID><Abstract><AbstractText>Tauopathies are a heterogeneous group of neurodegenerative dementias involving perturbations in the levels, phosphorylation, or mutations of the microtubule-binding protein Tau. The heterogeneous pathology in humans and model organisms suggests differential susceptibility of neuronal types to wild-type (WT) and mutant Tau. WT and mutant human Tau-encoding transgenes expressed pan-neuronally in the Drosophila CNS yielded specific and differential toxicity in the embryonic neuroblasts that generate the mushroom body (MB) neurons, suggesting cell type-specific effects of Tau in the CNS. Frontotemporal dementia with parkinsonism-17-linked mutant isoforms were significantly less toxic in MB development. Tau hyperphosphorylation was essential for these MB aberrations, and we identified two novel putative phosphorylation sites, Ser(238) and Thr(245), on WT hTau essential for its toxic effects on MB integrity. Significantly, blocking putative Ser(238) and Thr(245) phosphorylation yielded animals with apparently structurally normal but profoundly dysfunctional MBs, because animals accumulating this mutant protein exhibited strongly impaired associative learning. Interestingly, the mutant protein was hyperphosphorylated at epitopes typically associated with toxicity and neurodegeneration, such as AT8, AT100, and the Par-1 targets Ser(262) and Ser(356), suggesting that these sites in the context of adult intact MBs mediate dysfunction and occupation of these sites may precede the toxicity-associated Ser(238) and Thr(245) phosphorylation. The data support the notion that phosphorylation at particular sites rather than hyperphosphorylation per se mediates toxicity or dysfunction in a cell type-specific manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kosmidis</LastName><ForeName>Stylianos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology and Genetics, Biomedical Sciences Research Centre "Alexander Fleming," Vari 16672, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grammenoudi</LastName><ForeName>Sofia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Papanikolopoulou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Skoulakis</LastName><ForeName>Efthimios M C</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018122">B7-1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018122" MajorTopicYN="N">B7-1 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="N">Discrimination Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004625" MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007814" MajorTopicYN="N">Larva</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024521" MajorTopicYN="N">Mushroom Bodies</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009833" MajorTopicYN="N">Olfactory Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20071510</ArticleId><ArticleId IdType="pmc">PMC6632986</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1490-09.2010</ArticleId><ArticleId IdType="pii">30/2/464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acevedo SF, Froudarakis EI, Tsiorva AA, Skoulakis EM. Distinct neuronal circuits mediate experience-dependent, non-associative osmotactic responses in Drosophila. Mol Cell Neurosci. 2007;34:378&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">17197197</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem. 2004;279:34873&#x2013;34881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M, Kaneko T, Maeda A, Nakayama M, Ito M, Yamauchi T, Goto H, Fukata Y, Oshiro N, Shinohara A, Iwamatsu A, Kaibuchi K. Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J Neurochem. 2003;87:780&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">14535960</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044677</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger C, Renner S, L&#xfc;er K, Technau GM. The commonly used marker ELAV is transiently expressed in neuroblasts and glial cells in the Drosophila embryonic CNS. Dev Dyn. 2007;236:3562&#x2013;3568.</Citation><ArticleIdList><ArticleId IdType="pubmed">17994541</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussi&#xe8;re T, Bu&#xe9;e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet. 2009;18:164&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644648</ArticleId><ArticleId IdType="pubmed">18930955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee FC, Mudher A, Cuttle MF, Newman TA, MacKay D, Lovestone S, Shepherd D. Overexpression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis. 2005;20:918&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023860</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark ME, Anderson CL, Cande J, Karr TL. Widespread prevalence of Wolachia in laboratory stocks and the implications for Drosophila research. Genetics. 2005;170:1667&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449785</ArticleId><ArticleId IdType="pubmed">15937134</ArticleId></ArticleIdList></Reference><Reference><Citation>Crittenden JR, Skoulakis EM, Han KA, Kalderon D, Davis RL. Tripartite mushroom body architecture revealed by antigenic markers. Learn Mem. 1998;5:38&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311260</ArticleId><ArticleId IdType="pubmed">10454371</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RL. Olfactory memory formation in Drosophila: from molecular to systems neuroscience. Annu Rev Neurosci. 2005;28:275&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022597</ArticleId></ArticleIdList></Reference><Reference><Citation>de Belle JS, Heisenberg M. Associative odor learning in Drosophila abolished by chemical ablation of mushroom bodies. Science. 1994;263:692&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">8303280</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A. Tauopathies: recent insights into old diseases. Folia Neuropathologica. 2005;43:244&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">16416389</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M, Ko LW, Yen S, Nacharaju P, Easson C, Lewis J, van Slegtenhorst M, Hutton M, Yen SH. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. Brain Res. 2000;853:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10627302</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest. 2007;117:236&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1697799</ArticleId><ArticleId IdType="pubmed">17173140</ArticleId></ArticleIdList></Reference><Reference><Citation>Doe CQ. Neural stem cells: balancing self-renewal with differentiation. Development. 2008;135:1575&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pubmed">18356248</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron. 2003;40:457&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum Mol Genet. 2004;13:2011&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254017</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau gene mutations and their effects. Mov Disord. 2005;20(Suppl 12):S45&#x2013;S52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16092090</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammenoudi S, Kosmidis S, Skoulakis EM. Cell type-specific processing of human Tau proteins in Drosophila. FEBS Lett. 2006;580:4602&#x2013;4606.</Citation><ArticleIdList><ArticleId IdType="pubmed">16875690</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammenoudi S, Anezaki M, Kosmidis S, Skoulakis EMC. Modeling cell and isoform type specificity of tauopathies in Drosophila. In: Mudher A, Chapman T, editors. Symposia of the Society for Experimental Biology. London: Taylor and Francis; 2008. pp. 39&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartenstein V, Younossi-Hartenstein A, Lekven A. Delamination and division in the Drosophila neuroectoderm: spatio-temporal pattern, cytoskeletal dynamics, and common control by neurogenic and segment polarity genes. Dev Biol. 1994;165:480&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">7958415</ArticleId></ArticleIdList></Reference><Reference><Citation>Heisenberg M. Mushroom body memoir: from maps to models. Nat Rev Neurosci. 2003;4:266&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Zhang B, Higuchi M, Yoshiyama Y, Trojanowski JQ, Lee VM. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol. 2001;158:555&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850303</ArticleId><ArticleId IdType="pubmed">11159192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Hotta Y. Proliferation pattern of postembryonic neuroblasts in the brain of Drosophila melanogaster. Dev Biol. 1992;149:134&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">1728583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Awano W, Suzuki K, Hiromi Y, Yamamoto D. The Drosophila mushroom body is a quadruple structure of clonal units each of which contains a virtually identical set of neurones and glial cells. Development. 1997a;124:761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Sass H, Urban J, Hofbauer A, Schneuwly S. GAL4-responsive UAS-tau as a tool for studying the anatomy and development of the Drosophila central nervous system. Cell Tissue Res. 1997b;290:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9377629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, Geschwind DH. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062036</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V. Modeling tauopathy in the fruit fly Drosophila melanogaster. J Alzheimers Dis. 2008;15:541&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096155</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol. 2006;16:230&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A. Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J. 2007;26:5143&#x2013;5152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140104</ArticleId><ArticleId IdType="pubmed">18007595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Kenyon TK, Trojanowski JQ. Transgenic animal models of tauopathies. Biochim Biophys Acta. 2005;1739:251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen M, Ayaz D, H&#xe9;bert SS, Reeve S, De Strooper B, Hassan BA. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J. 2005;24:2944&#x2013;2955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187942</ArticleId><ArticleId IdType="pubmed">16052209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DM, Goodman CS. Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. Neuron. 1994;13:507&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7917288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailliot C, Bussi&#xe8;re T, Caillet-Boudin ML, Delacourte A, Bu&#xe9;e L. Alzheimer-specific epitope of AT100 in transfected cell lines with tau: toward an efficient cell model of tau abnormal phosphorylation. Neurosci Lett. 1998;255:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9839715</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini SR, Davis RL. The dachshund gene is required for the proper guidance and branching of mushroom body axons in Drosophila melanogaster. J Neurobiol. 2005;64:133&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">15818552</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini SR, Roman G, Meuser S, Mardon G, Davis RL. The retinal determination gene, dachshund, is required for mushroom body cell differentiation. Development. 2000;127:2663&#x2013;2672.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821764</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, Lee VM. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13:989&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">7946342</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of memory dysfunction in Drosophila. Science. 2003;302:1765&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">14657498</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in Drosophila. Sci STKE. 2004;2004:pl6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14970377</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel R. Searching for the memory trace in a mini-brain, the honeybee. Learn Mem. 2001;8:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, Skoulakis EM. Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. Learn Mem. 2004;11:277&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419730</ArticleId><ArticleId IdType="pubmed">15169857</ArticleId></ArticleIdList></Reference><Reference><Citation>Moressis A, Friedrich AR, Pavlopoulos E, Davis RL, Skoulakis EMC. A dual role for the adaptor protein DRK in Drosophila olfactory learning and memory. J Neurosci. 2009;29:2611&#x2013;2625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693346</ArticleId><ArticleId IdType="pubmed">19244537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9:522&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006350</ArticleId></ArticleIdList></Reference><Reference><Citation>Noveen A, Daniel A, Hartenstein V. Early development of the Drosophila mushroom body: the roles of eyless and dachshund. Development. 2000;127:3475&#x2013;3488.</Citation><ArticleIdList><ArticleId IdType="pubmed">10903173</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NH. Imaging neuronal subsets and other cell types in whole-mount Drosophila embryos and larvae using antibody probes. Methods Cell Biol. 1994;44:445&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">7707967</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip N, Acevedo SF, Skoulakis EM. Conditional rescue of olfactory learning and memory defects in mutants of the 14-3-3&#x3b6; gene leonardo. J Neurosci. 2001;21:8417&#x2013;8425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762794</ArticleId><ArticleId IdType="pubmed">11606630</ArticleId></ArticleIdList></Reference><Reference><Citation>Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006;281:25457&#x2013;25465.</Citation><ArticleIdList><ArticleId IdType="pubmed">16803897</ArticleId></ArticleIdList></Reference><Reference><Citation>Raabe T, Clemens-Richter S, Twardzik T, Ebert A, Gramlich G, Heisenberg M. Identification of mushroom body miniature, a zinc-finger protein implicated in brain development of Drosophila. Proc Natl Acad Sci U S A. 2004;101:14276&#x2013;14281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521146</ArticleId><ArticleId IdType="pubmed">15375215</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging. 2001;22:89&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164280</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinow S, White K. The locus elav of Drosophila melanogaster is expressed in neurons at all developmental stages. Dev Biol. 1988;126:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">3127258</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinow S, White K. Characterization and spatial distribution of the ELAV protein during Drosophila melanogaster development. J Neurobiol. 1991;22:443&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">1716300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang TK, Jackson GR. Drosophila models of neurodegenerative disease. NeuroRx. 2005;2:438&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1144487</ArticleId><ArticleId IdType="pubmed">16389307</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, B&#xe9;gard S, Brion JP, Hamdane M, Bu&#xe9;e L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Delacourte A, Bu&#xe9;e L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta. 2005;1739:179&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Bu&#xe9;e L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics. 2008;5:207&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466052</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiarli AM, Jennings R, Shi J, Bailey K, Davidson Y, Tian J, Bigio EH, Ghetti B, Murrell JR, Delisle MB, Mirra S, Crain B, Zolo P, Arima K, Iseki E, Murayama S, Kretzschmar H, Neumann M, Lippa C, Halliday G, et al. Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathol Appl Neurobiol. 2006;32:374&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866983</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulakis EM, Davis RL. Olfactory learning deficits in mutants for leonardo, a Drosophila gene encoding a 14-3-3 protein. Neuron. 1996;17:931&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938125</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulakis EM, Grammenoudi S. Dunces and da Vincis: the genetics of learning and memory in Drosophila. Cell Mol Life Sci. 2006;63:975&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136322</ArticleId><ArticleId IdType="pubmed">16596334</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell. 2007a;18:5060&#x2013;5068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2096612</ArticleId><ArticleId IdType="pubmed">17928404</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow EM, Feany MB. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res. 2007b;85:1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">17335084</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta. 2005;1739:280&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615646</ArticleId></ArticleIdList></Reference><Reference><Citation>Strausfeld NJ. New York: Springer; 1976. Atlas of an insect brain.</Citation></Reference><Reference><Citation>Strausfeld NJ, Sinakevitch I, Vilinsky I. The mushroom bodies of Drosophila melanogaster: an immunocytological and golgi study of Kenyon cell organization in the calyces and lobes. Microsc Res Tech. 2003;62:151&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966500</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Fitzgerald K, Greenwald I. Intrinsic activity of the Lin-12 and Notch intracellualr domains in vivo. Cell. 1993;74:331&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">8343960</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka NK, Awasaki T, Shimada T, Ito K. Integration of chemosensory pathways in the Drosophila second-order olfactory centers. Curr Biol. 2004;14:449&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">15043809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tettamanti M, Armstrong JD, Endo K, Yang MY, Furukubo-Tokunaga K, Kaiser K, Reichert H. Early development of the Drosophila mushroom bodies, brain centres for associative learning and memory. Dev Genes Evol. 1997;207:242&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">27747422</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BJ, Wassarman DA. A fly's eye view of biology. Trends Genet. 1999;15:184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322485</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A, Boekhoorn K, Van Dam AM, Lucassen PJ. Changes in adult neurogenesis in neurodegenerative diseases: cause or consequence? Genes Brain Behav. 2008;7(Suppl 1):28&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184368</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Pathological tau: a loss of normal function or a gain in toxicity? Nat Neurosci. 2005;8:1136&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully T, Quinn WG. Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol A. 1985;157:263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">3939242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzortzopoulos A, Skoulakis EMC. Paternally and maternally transmitted GAL4 transcripts contribute to UAS transgene expression in early Drosophila embryos. Genesis. 2007;45:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh E, Gustafson K, Boulianne GL. Green fluorescent protein as a vital marker and reporter of gene expression in Drosophila. Proc Natl Acad Sci U S A. 1995;92:7036&#x2013;7040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41466</ArticleId><ArticleId IdType="pubmed">7624365</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi-Hartenstein A, Nassif C, Green P, Hartenstein V. Early neurogenesis of the Drosophila brain. J Comp Neurol. 1996;370:313&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8799858</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Schnitzler A, Agapite J, Schwartz LM, Steller H, Nambu JR. Cooperative functions of the reaper and head involution defective genes in the programmed cell death of Drosophila central nervous system midline cells. Proc Natl Acad Sci U S A. 1997;94:5131&#x2013;5136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24643</ArticleId><ArticleId IdType="pubmed">9144202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Lin S, Kao CF, Awasaki T, Chiang AS, Lee T. Gradients of the Drosophila Chinmo BTB-zinc finger protein govern neuronal temporal identity. Cell. 2006;127:409&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055440</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20107079</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in Drosophila.</ArticleTitle><Pagination><StartPage>1512</StartPage><EndPage>1522</EndPage><MedlinePgn>1512-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3699-09.2010</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is attributable to synapse dysfunction and loss, but the nature and progression of the presynaptic structural and functional changes in AD are essentially unknown. We expressed wild-type or arctic form of beta amyloid(1-42) (Abeta) in a small group of neurons in the adult fly and performed extensive time course analysis of the function and structure of both axon and presynaptic terminals at the identified single-neuron level. Abeta accumulated intracellularly and induced a range of age-dependent changes, including depletion of presynaptic mitochondria, slowdown of bi-directional transports of axonal mitochondria, decreased synaptic vesicles, increased large vacuoles, and elevated synaptic fatigue. These structural and functional synaptic changes correlated with age-dependent deficit in motor behavior. All these alterations were accelerated in flies expressing the arctic form of Abeta. The depletion of presynaptic mitochondria was the earliest detected phenotype and was not caused by the change in axonal transport of mitochondria. Moreover, axonal mitochondria exhibited a dramatic reduction in number but a significant increase in size in aged Abeta-expressing flies, indicating a global depletion of mitochondria in the neuron and an impairment of mitochondria fission. These results suggest that Abeta accumulation depletes presynaptic and axonal mitochondria, leading to other presynaptic deficits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiao-Liang</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wen-An</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jiang-Xiu</ForeName><Initials>JX</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jian-Kang</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bao-Zhu</ForeName><Initials>BZ</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu-Hang</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>YangCheng</LastName><ForeName>Han-Yu</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hong-Lian</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiao-Jiang</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Fu-De</ForeName><Initials>FD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014617" MajorTopicYN="N">Vacuoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014855" MajorTopicYN="N">Wallerian Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20107079</ArticleId><ArticleId IdType="pmc">PMC6633795</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3699-09.2010</ArticleId><ArticleId IdType="pii">30/4/1512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen MJ, Shan X, Caruccio P, Froggett SJ, Moffat KG, Murphey RK. Targeted expression of truncated glued disrupts giant fiber synapse formation in Drosophila . J Neurosci. 1999;19:9374&#x2013;9384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782895</ArticleId><ArticleId IdType="pubmed">10531442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet. 2005;39:153&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16285856</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol. 2003;184:247&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauchi RJ, van den Heuvel M. The fly as a model for neurodegenerative diseases: is it worth the jump? Neurodegener Dis. 2006;3:338&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192723</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, Lomas DA. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132:123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15780472</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med. 2008;14:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789841</ArticleId><ArticleId IdType="pubmed">18806802</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert A, Hauptmann S, Scherping I, Rhein V, M&#xfc;ller-Spahn F, G&#xf6;tz J, M&#xfc;ller WE. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis. 2008;5:157&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322377</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayyazuddin A, Zaheer MA, Hiesinger PR, Bellen HJ. The nicotinic acetylcholine receptor Dalpha7 is required for an escape behavior in Drosophila . PLoS Biol. 2006;4:e63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382016</ArticleId><ArticleId IdType="pubmed">16494528</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster . Mol Cell Neurosci. 2004;26:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234342</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, Smith D, Reynolds DS, Davies CH, Collingridge GL, Seabrook GR. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci. 2001;21:4691&#x2013;4698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762352</ArticleId><ArticleId IdType="pubmed">11425896</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005;26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, Kretzschmar D, Tsch&#xe4;pe JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila . J Neurosci. 2004;24:3899&#x2013;3906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729409</ArticleId><ArticleId IdType="pubmed">15102905</ArticleId></ArticleIdList></Reference><Reference><Citation>Gureviciene I, Ikonen S, Gurevicius K, Sarkaki A, van Groen T, Pussinen R, Ylinen A, Tanila H. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol Dis. 2004;15:188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauptmann S, Scherping I, Dr&#xf6;se S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, M&#xfc;ller WE. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30:1574&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang FD, Woodruff E, Mohrmann R, Broadie K. Rolling blackout is required for synaptic vesicle exocytosis. J Neurosci. 2006;26:2369&#x2013;2379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793665</ArticleId><ArticleId IdType="pubmed">16510714</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y, Iijima K. Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila . J Biol Chem. 2008;283:19066&#x2013;19076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441542</ArticleId><ArticleId IdType="pubmed">18463098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Koenig JH, Tsuruhara T. Organization of identified axons innervating the dorsal longitudinal flight muscle of Drosophila melanogaster . J Neurocytol. 1980;9:799&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pubmed">6162923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolas T, Zhang XS, Zhang Q, Wong G, Del Vecchio R, Gold L, Priestley T. Long-term potentiation is increased in the CA1 area of the hippocampus of APP(swe/ind) CRND8 mice. Neurobiol Dis. 2002;11:394&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, M&#xfc;ller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>King DG, Wyman RJ. Anatomy of the giant fibre pathway in Drosophila. I. Three thoracic components of the pathway. J Neurocytol. 1980;9:753&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">6782199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuromi H, Kidokoro Y. Selective replenishment of two vesicle pools depends on the source of Ca2+ at the Drosophila synapse. Neuron. 2002;35:333&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160750</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999;840:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10517949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Llin&#xe1;s R, Sugimori M, Lin JW, Leopold PL, Brady ST. ATP-dependent directional movement of rat synaptic vesicles injected into the presynaptic terminal of squid giant synapse. Proc Natl Acad Sci U S A. 1989;86:5656&#x2013;5660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297683</ArticleId><ArticleId IdType="pubmed">2748609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15:1437&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron. 2006;52:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015234</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T. Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1&#x2013;42 mutants of familial Alzheimer's disease at positions 21&#x2013;23. Biochem Biophys Res Commun. 2002;294:5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, N&#xe4;slund J, Lannfelt L. The &#x201c;Arctic&#x201d; APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008;4:590&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">18497567</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576726</ArticleId><ArticleId IdType="pubmed">8463843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilling AD, Horiuchi D, Lively CM, Saxton WM. Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in Drosophila motor axons. Mol Biol Cell. 2006;17:2057&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415296</ArticleId><ArticleId IdType="pubmed">16467387</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107703</ArticleId><ArticleId IdType="pubmed">18218341</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis. 2006;9(Suppl 3):101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914849</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroer TA, Brady ST, Kelly RB. Fast axonal transport of foreign synaptic vesicles in squid axoplasm. J Cell Biol. 1985;101:568&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113654</ArticleId><ArticleId IdType="pubmed">3848436</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., 3rd The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Simakova O, Arispe NJ. The cell-selective neurotoxicity of the Alzheimer's A&#x3b2; peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for A&#x3b2; toxicity. J Neurosci. 2007;27:13719&#x2013;13729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673638</ArticleId><ArticleId IdType="pubmed">18077683</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001;2:595&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484003</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:6037&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;llner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, Rothman JE. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993;362:318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">8455717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:933&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258263</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer's &#x3b2;-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987;235:880&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron. 2005;47:365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055061</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6:404&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 2002;12:275&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095864</ArticleId><ArticleId IdType="pubmed">12146796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide&#x2014;the first step of a fatal cascade. J Neurochem. 2004;91:513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Weis J, Kayed R, Saido TC, Bayer TA. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging. 2007;28:1689&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963164</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD) Int J Exp Pathol. 2005;86:161&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2517415</ArticleId><ArticleId IdType="pubmed">15910550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Gong B, Liu S, F&#xe1; M, Ninan I, Staniszewski A, Arancio O. Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 2005;2:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20130175</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin.</ArticleTitle><Pagination><StartPage>1648</StartPage><EndPage>1656</EndPage><MedlinePgn>1648-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3826-09.2010</ELocationID><Abstract><AbstractText>Gamma-secretase is a multiprotein, intramembrane-cleaving protease with a growing list of protein substrates, including the Notch receptors and the amyloid precursor protein. The four components of gamma-secretase complex--presenilin (PS), nicastrin (NCT), Pen2, and Aph1--are all thought to be essential for activity. The catalytic domain resides within PS proteins, NCT has been suggested to be critical for substrate recognition, and the contributions of Pen2 and Aph1 remain unclear. The role of NCT has been challenged recently by the observation that a critical residue (E332) in NCT, which had been thought to be essential for gamma-secretase activity, is instead involved in complex maturation. Here, we report that NCT is dispensable for gamma-secretase activity. NCT-independent gamma-secretase activity can be detected in two independent NCT-deficient mouse embryonic fibroblast lines and blocked by the gamma-secretase inhibitors N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester and L-685,458. This catalytic activity requires prior ectodomain shedding of the substrate and can cleave ligand-activated endogenous Notch receptors, indicating presence of this activity at the plasma membrane. Small interfering RNA knockdown experiments demonstrated that NCT-independent gamma-secretase activity requires the presence of PS1, Pen2, and Aph1a but can tolerate knockdown of PS2 or Aph1b. We conclude that a PS1/Pen2/Aph1a trimeric complex is an active enzyme, displaying biochemical properties similar to those of gamma-secretase and roughly 50% of its activity when normalized to PS1 N-terminal fragment levels. This PS1/Pen2/Aph1a complex, however, is highly unstable. Thus, NCT acts to stabilize gamma-secretase but is not required for substrate recognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. guojunzhao@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhenyi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ilagan</LastName><ForeName>Ma Xenia G</ForeName><Initials>MX</Initials></Author><Author ValidYN="Y"><LastName>Kopan</LastName><ForeName>Raphael</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.99.-</RegistryNumber><NameOfSubstance UI="C498194">Aph1a protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20130175</ArticleId><ArticleId IdType="mid">NIHMS176374</ArticleId><ArticleId IdType="pmc">PMC2853942</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3826-09.2010</ArticleId><ArticleId IdType="pii">30/5/1648</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol. 2008;3:587&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934586</ArticleId><ArticleId IdType="pubmed">18039126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao J, Wolpowitz D, Role LW, Talmage DA. Back signaling by the Nrg-1 intracellular domain. J Cell Biol. 2003;161:1133&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172983</ArticleId><ArticleId IdType="pubmed">12821646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Tolia A, Maes E, Li T, Wong PC, de Strooper B. Glu(332) in the Nicastrin ectodomain is essential for &#x3b3;-secretase complex maturation but not for its activity. J Biol Chem. 2008;283:20096&#x2013;20105.</Citation><ArticleIdList><ArticleId IdType="pubmed">18502756</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Yu G, Arawaka S, Nishimura M, Kawarai T, Yu H, Tandon A, Supala A, Song YQ, Rogaeva E, Milman P, Sato C, Yu C, Janus C, Lee J, Song L, Zhang L, Fraser PE, St George-Hyslop PH. Nicastrin binds to membrane-tethered Notch. Nat Cell Biol. 2001;3:751&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483961</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejaegere T, Serneels L, Schafer MK, Van Biervliet J, Horre K, Depboylu C, Alvarez-Fischer D, Herreman A, Willem M, Haass C, Hoglinger GU, D'Hooge R, De Strooper B. Deficiency of Aph1B/C-&#x3b3; -secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci U S A. 2008;105:9775&#x2013;9780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474502</ArticleId><ArticleId IdType="pubmed">18626010</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active &#x3b3;-secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Nicastrin: gatekeeper of the &#x3b3;-secretase complex. Cell. 2005;122:318&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096051</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent &#x3b3;-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, Shah S, Han YH, Yu C, Yu S, Shearman MS, Yu G. Glu-333 of nicastrin directly participates in &#x3b3;-secretase activity. J Biol Chem. 2009;284:29714&#x2013;29724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of &#x3b3;-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Futai E, Yagishita S, Ishiura S. Nicastrin is dispensable for &#x3b3;-secretase protease activity in the presence of specific presenilin mutations. J Biol Chem. 2009;284:13013&#x2013;13022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676034</ArticleId><ArticleId IdType="pubmed">19254953</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Wolfe MS, Greenbaum DC. Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. Semin Cell Dev Biol. 2009;20:225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701170</ArticleId><ArticleId IdType="pubmed">19429495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of Notch. Nat Struct Mol Biol. 2007;14:295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17401372</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Hepler W, Mickey KM, Priess JR. aph-2 encodes a novel extracellular protein required for GLP-1-mediated signaling. Development. 2000;127:2481&#x2013;2492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10804188</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Take five&#x2013;BACE and the &#x3b3;-secretase quartet conduct Alzheimer's amyloid &#x3b2;-peptide generation. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. 2002;12:556&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">12495843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi I, Urano Y, Fukuda R, Isoo N, Kodama T, Hamakubo T, Tomita T, Iwatsubo T. Selective reconstitution and recovery of functional &#x3b3;-secretase complex on budded baculovirus particles. J Biol Chem. 2004;279:38040&#x2013;38046.</Citation><ArticleIdList><ArticleId IdType="pubmed">15215237</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A. 1999;96:11872&#x2013;11877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Ye Y, Fortini ME. Nicastrin is required for &#x3b3;-secretase cleavage of the Drosophila Notch receptor. Dev Cell. 2002;2:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782315</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert S, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, Kopan R. Embryonic lethality in mice homozygous for a processing deficient allele of Notch1. Nature. 2000;405:966&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879540</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert S, Ilagan MXG, De Strooper B, Kopan R. Analysis of Notch function in presomitic mesoderm suggests a &#x3b3;-secretase-independent role for presenilins in somite differentiation. Dev Cell. 2005;8:677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15866159</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T. Assembly and activation of the &#x3b3;-secretase complex: roles of presenilin cofactors. Mol Psychiatry. 2004;9:8&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14581930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827930</ArticleId><ArticleId IdType="pubmed">19379690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Schroeter EH, Weintraub H, Nye JS. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A. 1996;93:1683&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of &#x3b3;-secretase is located on presenilin near the active site. Proc Natl Acad Sci U S A. 2005;102:3230&#x2013;3235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552920</ArticleId><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, et al. Substrate-targeting &#x3b3;-secretase modulators. Nature. 2008;453:925&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678541</ArticleId><ArticleId IdType="pubmed">18548070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Basak JM, Demehri S, Kopan R. Bi-compartmental communication contributes to the opposite proliferative behavior of Notch1-deficient hair follicle and epidermal keratinocytes. Development. 2007;134:2795&#x2013;2806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583345</ArticleId><ArticleId IdType="pubmed">17611229</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Ma G, Cai H, Price DL, Wong PC. Nicastrin is required for assembly of presenilin/&#x3b3; -secretase complexes to mediate Notch signaling and for processing and trafficking of &#x3b2;-amyloid precursor protein in mammals. J Neurosci. 2003;23:3272&#x2013;3277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742329</ArticleId><ArticleId IdType="pubmed">12716934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ. Photoactivated &#x3b3;-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J Neurosci. 2005;25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Fluhrer R, Haass C. Substrate requirements for SPPL2b-dependent regulated intramembrane proteolysis. J Biol Chem. 2009;284:5662&#x2013;5670.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114711</ArticleId></ArticleIdList></Reference><Reference><Citation>Miele L, Miao H, Nickoloff BJ. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">16848722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. A ligand-induced extracellular cleavage regulates &#x3b3;-secretase-like proteolytic activation of Notch1. Mol Cell. 2000;5:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882062</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen V, Hawkins C, Bergeron C, Supala A, Huang J, Westaway D, St George-Hyslop P, Rozmahel R. Loss of nicastrin elicits an apoptotic phenotype in mouse embryos. Brain Res. 2006;1086:76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294:2179&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong CT, Sedy JR, Murphy KM, Kopan R. Notch and presenilin regulate cellular expansion and cytokine secretion but cannot instruct Th1/Th2 fate acquisition. PLoS One. 2008;3:e2823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474705</ArticleId><ArticleId IdType="pubmed">18665263</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand DM, Grimm MLM, Artavanis-Tsakonas S, Patriub V, Blacklow CS, Sklar CJ, Aster CJ. Calcium depletion dissociates and activates heterodimeric Notch receptors. Mol Cell Biol. 2000;20:1825&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85363</ArticleId><ArticleId IdType="pubmed">10669757</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 2007;17:52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17178457</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R. A presenilin dimer at the core of the &#x3b3;-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A. 2003;100:13075&#x2013;13080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240747</ArticleId><ArticleId IdType="pubmed">14566063</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003;26:565&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, Annaert W, Hartmann D, De Strooper B. Differential contribution of the three Aph1 genes to &#x3b3;-secretase activity in vivo. Proc Natl Acad Sci U S A. 2005;102:1719&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547495</ArticleId><ArticleId IdType="pubmed">15665098</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D'Hooge R, et al. &#x3b3; -Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science. 2009;324:639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q, Ball H, Dann CE, 3rd, Sudhof T, Yu G. Nicastrin functions as a &#x3b3;-secretase-substrate receptor. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Edbauer D, Kostka M, Steiner H, Haass C. Immature nicastrin stabilizes APH-1 independent of PEN-2 and presenilin: identification of nicastrin mutants that selectively interact with APH-1. J Neurochem. 2004;89:1520&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189355</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasic D, Annaert W. Building &#x3b3;-secretase: the bits and pieces. J Cell Sci. 2008;121:413&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">18256384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagami S, Okochi M, Yanagida K, Ikuta A, Fukumori A, Matsumoto N, Ishizuka-Katsura Y, Nakayama T, Itoh N, Jiang J, Nishitomi K, Kamino K, Morihara T, Hashimoto R, Tanaka T, Kudo T, Chiba S, Takeda M. Regulation of Notch signaling by dynamic changes in the precision of S3 cleavage of Notch-1. Mol Cell Biol. 2008;28:165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223315</ArticleId><ArticleId IdType="pubmed">17967888</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the &#x3b3;-secretase complex. Nature. 2003;422:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9:661&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Tokuhiro S, Hashimoto T, Aiba K, Saido TC, Maruyama K, Iwatsubo T. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid &#x3b2; peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of A&#x3b2;42. J Biol Chem. 1998;273:21153&#x2013;21160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9694871</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M. The metalloprotease ADAM10 is required for notch1 S2 cleavage. J Biol Chem. 2009;284:31018&#x2013;31027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781502</ArticleId><ArticleId IdType="pubmed">19726682</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, Rovelli G, Martoglio B. Targeting presenilin-type aspartic protease signal peptide peptidase with &#x3b3;-secretase inhibitors. J Biol Chem. 2003;278:16528&#x2013;16533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. &#x3b3;-Secretase inhibition and modulation for Alzheimer's disease. Curr Alzheimer Res. 2008;5:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675939</ArticleId><ArticleId IdType="pubmed">18393800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. Intramembrane-cleaving proteases. J Biol Chem. 2009;284:13969&#x2013;13973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682844</ArticleId><ArticleId IdType="pubmed">19189971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and &#x3b3;-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, Baumeister R, Haass C, Steiner H. The GxGD motif of presenilin contributes to catalytic function and substrate identification of &#x3b3;-secretase. J Neurosci. 2006;26:3821&#x2013;3828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674133</ArticleId><ArticleId IdType="pubmed">16597736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Luo WJ, Wang H, Lin P, Vetrivel KS, Liao F, Li F, Wong PC, Farquhar MG, Thinakaran G, Xu H. Nicastrin is critical for stability and trafficking but not association of other presenilin/&#x3b3;-secretase components. J Biol Chem. 2005;280:17020&#x2013;17026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Mao G, Tan J, Dong Y, Cui MZ, Kim SH, Xu X. Identification of a new presenilin-dependent &#x3b6;-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem. 2004;279:50647&#x2013;50650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20130173</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?</ArticleTitle><Pagination><StartPage>1631</StartPage><EndPage>1636</EndPage><MedlinePgn>1631-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5255-09.2010</ELocationID><Abstract><AbstractText>Zinc transporter-3 (ZnT3) protein controls synaptic vesicular Zn(2+) levels, which is predicted to regulate normal cognitive function. Surprisingly, previous studies found that 6- to 10-week-old ZnT3 knock-out (KO) mice did not show impairment in the Morris water maze. We hypothesized that older ZnT3 KO animals would display a cognitive phenotype. Here, we report that ZnT3 KO mice exhibit age-dependent deficits in learning and memory that are manifest at 6 months but not at 3 months of age. These deficits are associated with significant alterations in key hippocampal proteins involved in learning and memory, as assessed by Western blot. These include decreased levels of the presynaptic protein SNAP25 (-46%; p &lt; 0.01); the postsynaptic protein PSD95 (-37%; p &lt; 0.01); the glutamate receptors AMPAR (-34%; p &lt; 0.01), NMDAR2a (-64%; p &lt; 0.001), and NMDAR2b (-49%; p &lt; 0.05); the surrogate marker of neurogenesis doublecortin (-31%; p &lt; 0.001); and elements of the BDNF pathway, pro-BDNF (-30%; p &lt; 0.05) and TrkB (-22%; p &lt; 0.01). In addition, there is a concomitant decrease in neuronal spine density (-6%; p &lt; 0.05). We also found that cortical ZnT3 levels fall with age in wild-type mice (-50%; p &lt; 0.01) in healthy older humans (ages, 48-91 years; r(2) = 0.47; p = 0.00019) and particularly in Alzheimer's disease (AD) (-36%; p &lt; 0.0001). Thus, age-dependent loss of transsynaptic Zn(2+) movement leads to cognitive loss, and since extracellular beta-amyloid is aggregated by and traps this pool of Zn(2+), the genetic ablation of ZnT3 may represent a phenocopy for the synaptic and memory deficits of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Oxidation Biology Laboratory, The Mental Health Research Institute, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parncutt</LastName><ForeName>Jacqui M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Finkelstein</LastName><ForeName>David I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491177">Slc30a3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20130173</ArticleId><ArticleId IdType="pmc">PMC6633978</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5255-09.2010</ArticleId><ArticleId IdType="pii">30/5/1631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614028</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, Hershfinkel M. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. J Neurosci. 2009;29:2890&#x2013;2901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175799</ArticleId><ArticleId IdType="pubmed">19261885</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer N, Coulson DT, Heggarty S, Ravid R, Irvine GB, Hellemans J, Johnston JA. ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain. Mol Neurodegener. 2009;4:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806356</ArticleId><ArticleId IdType="pubmed">20030848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowanadisai W, Kelleher SL, L&#xf6;nnerdal B. Maternal zinc deficiency reduces NMDA receptor expression in neonatal rat brain, which persists into early adulthood. J Neurochem. 2005;94:510&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">15998301</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci U S A. 1999;96:1716&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15571</ArticleId><ArticleId IdType="pubmed">9990090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole TB, Martyanova A, Palmiter RD. Removing zinc from synaptic vesicles does not impair spatial learning, memory, or sensorimotor functions in the mouse. Brain Res. 2001;891:253&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164830</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent A&#x3b2; oligomer formation and accumulation at excitatory synapses. J Neurosci. 2009;29:4004&#x2013;4015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665357</ArticleId><ArticleId IdType="pubmed">19339596</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson CJ, Giblin LJ, 3rd, Balaji RV, Rengarajan B, Masalha R, Frederickson CJ, Zeng Y, Lopez EV, Koh JY, Chorin U, Besser L, Hershfinkel M, Li Y, Thompson RB, Krezel A. Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods. 2006;154:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460810</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlich AL, Lee JY, van Groen T, Cherny RA, Volitakis I, Cole TB, Palmiter RD, Koh JY, Bush AI. Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci. 2004;24:3453&#x2013;3459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730042</ArticleId><ArticleId IdType="pubmed">15056725</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron. 2008;57:546&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18304484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang JJ, Park MH, Choi SY, Koh JY. Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. J Biol Chem. 2005;280:11995&#x2013;12001.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659400</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller KA, Grider A, Coffield JA. Age-dependent influence of dietary zinc restriction on short-term memory in male rats. Physiol Behav. 2001;72:339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TY, Hwang JJ, Yun SH, Jung MW, Koh JY. Augmentation by zinc of NMDA receptor-mediated synaptic responses in CA1 of rat hippocampal slices: mediation by Src family tyrosine kinases. Synapse. 2002;46:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12211081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">18672400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the Swedish mutant &#x3b2;-amyloid precursor protein transgenic mice. J Neurosci. 1999;19(RC10):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782620</ArticleId><ArticleId IdType="pubmed">10341271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A. 2002;99:7705&#x2013;7710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124328</ArticleId><ArticleId IdType="pubmed">12032347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Kim YJ, Kim TY, Koh JY, Kim YH. Essential role for zinc-triggered p75NTR activation in preconditioning neuroprotection. J Neurosci. 2008;28:10919&#x2013;10927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671367</ArticleId><ArticleId IdType="pubmed">18945899</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkous DH, Flinn JM, Koh JY, Lanzirotti A, Bertsch PM, Jones BF, Giblin LJ, Frederickson CJ. Evidence that the ZNT3 protein controls the total amount of elemental zinc in synaptic vesicles. J Histochem Cytochem. 2008;56:3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323120</ArticleId><ArticleId IdType="pubmed">17712179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667777</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX, Bush AI. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem. 2006;100:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574231</ArticleId></ArticleIdList></Reference><Reference><Citation>Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C, Masters CL, Volitakis I, Li QX, Laughton K, Hubbard A, Cherny RA, Gibson B, Bush AI. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One. 2007;2:e536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888726</ArticleId><ArticleId IdType="pubmed">17579710</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmiter RD, Cole TB, Quaife CJ, Findley SD. ZnT-3, a putative transporter of zinc into synaptic vesicles. Proc Natl Acad Sci U S A. 1996;93:14934&#x2013;14939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26240</ArticleId><ArticleId IdType="pubmed">8962159</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Vergnano AM, Barbour B, Casado M. Zinc at glutamatergic synapses. Neuroscience. 2009;158:126&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">18353558</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.</Citation></Reference><Reference><Citation>Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676042</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart TG, Hosie AM, Miller PS. Zn2+ ions: modulators of excitatory and inhibitory synaptic activity. Neuroscientist. 2004;10:432&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">15359010</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoecker BJ, Abebe Y, Hubbs-Tait L, Kennedy TS, Gibson RS, Arbide I, Teshome A, Westcott J, Krebs NF, Hambidge KM. Zinc status and cognitive function of pregnant women in southern Ethiopia. Eur J Clin Nutr. 2009;63:916&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4583768</ArticleId><ArticleId IdType="pubmed">19190668</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltenberg M, Bush AI, Bach G, Smidt K, Larsen A, Rungby J, Lund S, Doering P, Danscher G. Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience. 2007;150:357&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">17949919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahmasebi Boroujeni S, Naghdi N, Shahbazi M, Farrokhi A, Bagherzadeh F, Kazemnejad A, Javadian M. The effect of severe zinc deficiency and zinc supplement on spatial learning and memory. Biol Trace Elem Res. 2009;130:48&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19183867</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente T, Auladell C. Developmental expression of ZnT3 in mouse brain: correlation between the vesicular zinc transporter protein and chelatable vesicular zinc (CVZ) cells. Glial and neuronal CVZ cells interact. Mol Cell Neurosci. 2002;21:189&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401442</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20147621</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Communication via gap junctions underlies early functional and beneficial interactions between grafted neural stem cells and the host.</ArticleTitle><Pagination><StartPage>5184</StartPage><EndPage>5189</EndPage><MedlinePgn>5184-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0915134107</ELocationID><Abstract><AbstractText>How grafted neural stem cells (NSCs) and their progeny integrate into recipient brain tissue and functionally interact with host cells is as yet unanswered. We report that, in organotypic slice cultures analyzed by ratiometric time-lapse calcium imaging, current-clamp recordings, and dye-coupling methods, an early and essential way in which grafted murine or human NSCs integrate functionally into host neural circuitry and affect host cells is via gap-junctional coupling, even before electrophysiologically mature neuronal differentiation. The gap junctions, which are established rapidly, permit exogenous NSCs to influence directly host network activity, including synchronized calcium transients with host cells in fluctuating networks. The exogenous NSCs also protect host neurons from death and reduce such signs of secondary injury as reactive astrogliosis. To determine whether gap junctions between NSCs and host cells may also mediate neuroprotection in vivo, we examined NSC transplantation in two murine models characterized by degeneration of the same cell type (Purkinje neurons) from different etiologies, namely, the nervous and SCA1 mutants. In both, gap junctions (containing connexin 43) formed between NSCs and host cells at risk, and were associated with rescue of neurons and behavior (when implantation was performed before overt neuron loss). Both in vitro and in vivo beneficial NSC effects were abrogated when gap junction formation or function was suppressed by pharmacologic and/or RNA-inhibition strategies, supporting the pivotal mediation by gap-junctional coupling of some modulatory, homeostatic, and protective actions on host systems as well as establishing a template for the subsequent development of electrochemical synaptic intercellular communication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>J&#xe4;derstad</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, Karolinska Institutet, 17176 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xe4;derstad</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jianxue</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chintawar</LastName><ForeName>Satyan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Salto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pandolfo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ourednik</LastName><ForeName>Vaclav</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Yang D</ForeName><Initials>YD</Initials></Author><Author ValidYN="Y"><LastName>Sidman</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Arenas</LastName><ForeName>Ernest</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Evan Y</ForeName><Initials>EY</Initials></Author><Author ValidYN="Y"><LastName>Herlenius</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593749">ATXN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067696">Ataxin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067528">Ataxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593750">Atxn1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067696" MajorTopicYN="N">Ataxin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067528" MajorTopicYN="N">Ataxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="Y">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017629" MajorTopicYN="N">Gap Junctions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006262" MajorTopicYN="N">Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="Y">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20147621</ArticleId><ArticleId IdType="pmc">PMC2841882</ArticleId><ArticleId IdType="doi">10.1073/pnas.0915134107</ArticleId><ArticleId IdType="pii">0915134107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li J, Imitola J, Snyder EY, Sidman RL. Neural stem cells rescue nervous Purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets. J Neurosci. 2006;26:7839&#x2013;7848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674224</ArticleId><ArticleId IdType="pubmed">16870729</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond DE, Jr., et al. Behavioral improvement in a primate Parkinson&#x2019;s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA. 2007;104:12175&#x2013;12180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1896134</ArticleId><ArticleId IdType="pubmed">17586681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JP, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med. 2007;13:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351625</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe4;hwiler BH, Capogna M, Debanne D, McKinney RA, Thompson SM. Organotypic slice cultures: A technique has come of age. Trends Neurosci. 1997;20:471&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">9347615</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MA, et al. Expression profile of an operationally-defined neural stem cell clone. Exp Neurol. 2005;194:320&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992799</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, et al. Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem. 2004;88:212&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675165</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo RE, Reali C, Radmilovich M, Fern&#xe1;ndez A, Trujillo-Cen&#xf3;z O. Connexin 43 delimits functional domains of neurogenic precursors in the spinal cord. J Neurosci. 2008;28:3298&#x2013;3309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670595</ArticleId><ArticleId IdType="pubmed">18367597</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias LA, Kriegstein AR. Gap junctions: Multifaceted regulators of embryonic cortical development. Trends Neurosci. 2008;31:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2610634</ArticleId><ArticleId IdType="pubmed">18403031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cina C, Bechberger JF, Ozog MA, Naus CC. Expression of connexins in embryonic mouse neocortical development. J Comp Neurol. 2007;504:298&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">17640036</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodenough D, Paul DL. Gap junctions. Cold Spring Harbor Perspect Biol. 2009;1(1):a002576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742079</ArticleId><ArticleId IdType="pubmed">20066080</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science. 2008;322:1551&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chintawar S, et al. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J Neurosci. 2009;29:13126&#x2013;13135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665209</ArticleId><ArticleId IdType="pubmed">19846700</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator. Proc Natl Acad Sci USA. 2006;103:7847&#x2013;7852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472533</ArticleId><ArticleId IdType="pubmed">16682647</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, et al. Synapse formation on neurons born in the adult hippocampus. Nat Neurosci. 2007;10:727&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486101</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman EA, Zahs KR. Calcium waves in retinal glial cells. Science. 1997;275:844&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2410141</ArticleId><ArticleId IdType="pubmed">9012354</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman TA, Riquelme PA, Ivic L, Flint AC, Kriegstein AR. Calcium waves propagate through radial glial cells and modulate proliferation in the developing neocortex. Neuron. 2004;43:647&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339647</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninger F, et al. Functional integration of embryonic stem cell-derived neurons in hippocampal slice cultures. J Neurosci. 2003;23:7075&#x2013;7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740655</ArticleId><ArticleId IdType="pubmed">12904468</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiunas V, et al. Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions. J Physiol. 2005;568:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474730</ArticleId><ArticleId IdType="pubmed">16037090</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20173339</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1660-2862</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Neuro-degenerative diseases</Title><ISOAbbreviation>Neurodegener Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases.</ArticleTitle><Pagination><StartPage>112</StartPage><EndPage>115</EndPage><MedlinePgn>112-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000285518</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Data on the prevalence of cerebrovascular lesions (CVLs) and their impact on cognitive decline in Alzheimer disease (AD) and Lewy body disease are conflicting.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Retrospective examination of the prevalence of CVL in a consecutive autopsy series.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">1,339 cases of autopsy-proven AD, Parkinson disease (PD), dementia with Lewy bodies (+ or - AD), and 486 age-matched controls were examined according to standardized neuropathologic methods including immunohistochemistry. Diagnoses followed current consensus criteria, classification of CVLs and of cerebral amyloid angiopathy (CAA) in 5 grades [Acta Neurol Scand 2006;114:38-46; Acta Neuropathol 2005;110:345-359].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lewy body variant of AD and AD showed significantly more frequent CVLs (91.9 and 67.8%) than the other groups (29.4 to 45.7%), with the highest frequency of severe CVLs (old, recent infarcts and hemorrhages) in AD (23.6%), but 2.0-8.3% in the other groups. Severe CAA was most frequent in AD and the Lewy body variant of AD (97.9 and 85%), less in PD (36%) and controls (30%). CAA was more frequent/severe in demented than in nondemented cases. CVLs in cortico-subcortical and hippocampal areas were most frequent in AD; subcortical CVLs (lacunes) in both AD and PD were more frequent than in controls. The incidence and severity of CVLs significantly correlated with neuritic Braak stages. Cognitive impairment was largely independent of coexisting CVLs, but related to the severity/location of AD and/or Lewy pathology.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present data confirm the importance of CVLs in AD and in dementia with Lewy bodies with severe AD, and the little impact of CVLs alone, but show a close association of CAA with clinical dementia associated with AD pathology.</AbstractText><CopyrightInformation>Copyright 2010 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jellinger</LastName><ForeName>Kurt A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, Kenyongasse 18, AT-1070 Vienna, Austria. kurt.jellinger@univie.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurodegener Dis</MedlineTA><NlmUniqueID>101189034</NlmUniqueID><ISSNLinking>1660-2854</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20173339</ArticleId><ArticleId IdType="doi">10.1159/000285518</ArticleId><ArticleId IdType="pii">000285518</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20186853</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>131</EndPage><MedlinePgn>122-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.21843</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine interactions of apolipoprotein E (APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred forty-one cognitively normal individuals, aged 45-88 years, had cerebral amyloid imaging studies with Pittsburgh Compound-B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid-beta(42) (Abeta(42)), tau, and phosphorylated tau (ptau(181)). All individuals were genotyped for APOE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age-dependent manner from 0% at ages 45-49 years to 30.3% at 80-88 years. Reduced levels of CSF Abeta(42) appeared to begin earlier (18.2% of those aged 45-49 years) and increase with age in higher frequencies (50% at age 80-88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Abeta(42) with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Abeta(42) levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau(181).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Increasing cerebral Abeta deposition with age is the pathobiological phenotype of APOE4. The biomarker sequence that detects Abeta deposition may first be lowered CSF Abeta(42), followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA. morrisj@abraxas.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1UL1RR024992-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20186853</ArticleId><ArticleId IdType="mid">NIHMS141723</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="doi">10.1002/ana.21843</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Cataldo M, Nixon RA, et al. Neuropathology of preclinical and clinical late-onset Alzheimer&#x2019;s disease. Ann Neurol. 1998;43:673&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">9585365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, et al. Preclinical AD revisited Neuropathology of cognitively normal older adults. Neurology. 2000;55:370&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairrment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer&#x2019;s disease in Down&#x2019;s syndrome. Ann Neurol. 1985;17:278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">3158266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genetics. 1990;37:282&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">2149963</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alz Dis Assoc Disord. 2006;20:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, Borenstein AR, Gosche KM, et al. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2008;18:218&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405917</ArticleId><ArticleId IdType="pubmed">16306243</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Xiong C, Grant E, et al. Education and reported onset of symptoms among individuals with Alzheimer&#x2019;s disease. Arch Neurol. 2008;65:108&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830808</ArticleId><ArticleId IdType="pubmed">18195147</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging &#x3b2;-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE I activity is associated with ApoE-E4 genotype in subjects with mild cognitive impairment and Alzheimer&#x2019;s disease. Brain. 2008;131:1252&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Lowe VJ, Senjem ML, et al. 11C PIB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD; regional thinning predicts mild AD dementia. Neurology. 2009;72:1048&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid A&#x3b2;42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, et al. Decreased &#xdf;-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, et al. CSF tau and &#x3b2;-amyloid: How well do these biomarkers reflect autopsy confirmed dementia diagnoses? Arch Neurol. 2003;60:1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (A&#x3b2;) peptide-related cerebral amyloidosis. Brain. 2007;130:2607&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65:1304&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol. 2007;64:366&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353378</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, et al. Cerebrospinal fluid &#x3b2;-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, deLeon MJ, Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer L, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeaux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-affinity binding to &#x3b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer&#x2019;s disease with apoE &#x3b5;2 [letter] Lancet. 1994;343:1432&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee DYD, Mandrekar S, et al. ApoE promotes the proteolytic degradation of A&#x3b2;. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, et al. Amyloid-associated proteins &#x3b1;1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer &#x3b2;-protein into filaments. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress A&#x3b2; levels and deposition: Evidence that apoE regulates extracellular A&#x3b2; metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, et al. Human and murine apoE markedly influence Abeta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2002;9:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, Sulkava R, Haltia M. Apolipoprotein E, dementia, and cortical deposition of &#x3b2;-amyloid protein. N Engl J Med. 1995;333:1242&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566000</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid &#x3b2;-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. PNAS. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 1993;11:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E E4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology. 2003;60:246&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">19339712</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. Fibrililar amyloid-&#x3b2; burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. PNAS. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009;66:81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693405</ArticleId><ArticleId IdType="pubmed">19124691</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Coats MA, Morris JC. Antecedent biomarkers of Alzheimer&#x2019;s disease: The Adult Children Study. J Geriatr Psychiatry Neurol. 2005;18:242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306247</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, et al. Longitudinal course and neuropathological outcomes in original versus revised MCI and in PreMCI. Neurology. 2006;67:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental State: A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alz Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, et al. Rates of progression in mild cognitive impairment and early Alzheimer&#x2019;s disease. Neurology. 2002;59:1034&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, LaRossa GN, Sheline YI, et al. [11C] PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-D Proportional System: An approach to cerebral imaging. Stuttgart: Thieme Medical Publishers; Jan 15, 1988.</Citation></Reference><Reference><Citation>Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage. 2004;23:724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary NC: SAS Institute Inc.; 1996.</Citation></Reference><Reference><Citation>Kauwe JSK, Wang J, Mayo K, et al. Alzheimer&#x2019;s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10:13&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726757</ArticleId><ArticleId IdType="pubmed">18813964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Cauley J, Sands L, et al. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9311354</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretsky P, Guralnik JM, Launer L, et al. The role of APOE-&#x3b5;4 in longitudinal cognitive decline; MacArthur studies of successful aging. Neurol. 2003;60:1077&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682309</ArticleId></ArticleIdList></Reference><Reference><Citation>Haan MN, Shemanki L, Jagust WJ, et al. The role of APOE &#x3b5;4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282:40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10404910</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart HA, Saykin AJ, McAllister TW, et al. Regional brain atrophy in cognitively intact adults with a single APOEE4 allele. Neurology. 2006;67:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030756</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E E4 gene dose and whole brain atrophy rates. Am J Psychiatry. 2007;164:916&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">17541051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20189881</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.</ArticleTitle><Pagination><StartPage>363</StartPage><EndPage>372</EndPage><MedlinePgn>363-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70043-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with mild-to-moderate Alzheimer's disease were randomly assigned to receive intravenous bapineuzumab or placebo in a ratio of seven to three in three ascending dose groups (0.5, 1.0, or 2.0 mg/kg). Each dose group was enrolled after safety review of the previous group. Randomisation was by interactive voice response system; masking was achieved with numbered kit allocation. Patients, investigators, study site personnel, sponsor staff, and carers were masked to treatment. Patients received up to six infusions, 13 weeks apart, and had (11)C-PiB PET scans at baseline and at weeks 20, 45, and 78. The primary outcome was the difference between the pooled bapineuzumab group and the pooled placebo group in mean change from screening to week 78 in (11)C-PiB cortical to cerebellar retention ratio averaged across six cortical regions of interest. Analysis was by modified intention to treat. This study is registered with EudraCT, number 2004-004120-12; ISRCTN17517446.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">28 patients were assigned to bapineuzumab (n=20) or placebo (n=8). 19 patients in the bapineuzumab group and seven in the placebo group were included in the modified intention-to-treat analysis. Estimated mean (11)C-PiB retention ratio change from baseline to week 78 was -0.09 (95% CI -0.16 to -0.02; p=0.014) in the bapineuzumab group and 0.15 (95% CI 0.02 to 0.28; p=0.022) in the placebo group. Estimated mean difference in (11)C-PiB retention ratio change from baseline to week 78 between the bapineuzumab group and the placebo group was -0.24 (95% CI -0.39 to -0.09; p=0.003). Differences between the bapineuzumab group and the placebo group in the individual regions of interest were similar to the overall mean difference. Adverse events were typically mild to moderate in severity and transient. Two patients in the 2.0 mg/kg bapineuzumab group had transient cerebral vasogenic oedema.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Treatment with bapineuzumab for 78 weeks reduced cortical (11)C-PiB retention compared with both baseline and placebo. (11)C-PiB PET seems to be useful in assessing the effects of potential Alzheimer's disease treatments on cortical fibrillar amyloid-beta load in vivo.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Elan Pharmaceuticals and Wyeth Research.</AbstractText><CopyrightInformation>2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre and Clinical Research Services Turku, University of Turku and Turku University Hospital, Turku, Finland. juha.rinne@tyks.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Barakos</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Okello</LastName><ForeName>Aren A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez Martinez de Liano</LastName><ForeName>Sofia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gregg</LastName><ForeName>Keith M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN17517446</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>NC11WKO35D</RegistryNumber><NameOfSubstance UI="C545458">bapineuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7.</RefSource><PMID Version="1">20189880</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70043-0</ArticleId><ArticleId IdType="pii">S1474-4422(10)70043-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20197096</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>542</StartPage><EndPage>554</EndPage><MedlinePgn>542-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2010.02.068</ELocationID><Abstract><AbstractText>In a genome-wide association study of structural brain degeneration, we mapped the 3D profile of temporal lobe volume differences in 742 brain MRI scans of Alzheimer's disease patients, mildly impaired, and healthy elderly subjects. After searching 546,314 genomic markers, 2 single nucleotide polymorphisms (SNPs) were associated with bilateral temporal lobe volume (P&lt;5 x 10(-7)). One SNP, rs10845840, is located in the GRIN2B gene which encodes the N-methyl-d-aspartate (NMDA) glutamate receptor NR2B subunit. This protein - involved in learning and memory, and excitotoxic cell death - has age-dependent prevalence in the synapse and is already a therapeutic target in Alzheimer's disease. Risk alleles for lower temporal lobe volume at this SNP were significantly over-represented in AD and MCI subjects vs. controls (odds ratio=1.273; P=0.039) and were associated with mini-mental state exam scores (MMSE; t=-2.114; P=0.035) demonstrating a negative effect on global cognitive function. Voxelwise maps of genetic association of this SNP with regional brain volumes, revealed intense temporal lobe effects (FDR correction at q=0.05; critical P=0.0257). This study uses large-scale brain mapping for gene discovery with implications for Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Morra</LastName><ForeName>Jonathan H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hibar</LastName><ForeName>Derrek P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>April J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Leow</LastName><ForeName>Alex D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Sul</LastName><ForeName>Jae Hoon</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyun Min</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Eskin</LastName><ForeName>Eleazar</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Jill D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>April N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Corneveaux</LastName><ForeName>Jason J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Dietrich A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>DeChairo</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB007813</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-T90-DA022768:02</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 HL080079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR013642</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 RR021813</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008281</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T90 DA022768</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20197096</ArticleId><ArticleId IdType="mid">NIHMS184847</ArticleId><ArticleId IdType="pmc">PMC2856746</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2010.02.068</ArticleId><ArticleId IdType="pii">S1053-8119(10)00255-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen Institute for Brain Science. Allen Institute Human Cortex Study. Seatle, WA: 2009.  Available from:  http://humancortex.alleninstitute.org.</Citation></Reference><Reference><Citation>Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol. 2007;64(10):1489&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197839</ArticleId><ArticleId IdType="pubmed">17923632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Roeder K. The power of genomic control. Am J Hum Genet. 2000;66(6):1933&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1378064</ArticleId><ArticleId IdType="pubmed">10801388</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological. 1995;57(1):289&#x2013;300.</Citation></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM. Plaque and tangle imaging and cognition in normal aging and Alzheimer&#x2019;s disease. Neurobiol Aging 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891885</ArticleId><ArticleId IdType="pubmed">19004525</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Englund E. Regional pattern of degeneration in Alzheimer&#x2019;s disease: neuronal loss and histopathological grading. Histopathology. 1981;5(5):549&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">7286917</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun C, Lepore N, Pennec X, Chou YY, Lee AD, Barysheva M, de Zubicaray G, Meredith M, McMahon K, Wright MJ, Toga AW, Thompson PM. A tensor-based morphometry study of genetic influences on brain structure using a new fluid registration method. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv. 2008;11(Pt 2):914&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086551</ArticleId><ArticleId IdType="pubmed">18982692</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun CC, Lepore N, Luders E, Chou YY, Madsen SK, Toga AW, Thompson PM. Sex differences in brain structure in auditory and cingulate regions. Neuroreport. 2009;20(10):930&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773139</ArticleId><ArticleId IdType="pubmed">19562831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon TD, Keller MC. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol. 2006;2:267&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE) Psychopharmacol Bull. 1988;24(4):689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249771</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Yaffe K, Kramer JH, Reed B, Norman D, Chui HC, Weiner MW. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2001;71(4):441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763497</ArticleId><ArticleId IdType="pubmed">11561025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol. 2008;32(3):227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573032</ArticleId><ArticleId IdType="pubmed">18300295</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Sun W, Wang H, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe&#x2019;er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Yakub I, Birren BW, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L&#x2019;Archeveque P, Bellemare G, Saeki K, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689609</ArticleId><ArticleId IdType="pubmed">17943122</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund Y, Schapire RE. A Decision-Theoretic Generalization of On-Line Learning and an Application to Boosting. J Comput Sys Sci. 1997;55(1):119&#x2013;139.</Citation></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The Clinical Use of Structural MRI in Alzheimer&#x2019;s Disease. Nat Rev Neurol in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15(4):870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O&#x2019;Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer&#x2019;s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43(3):458&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197851</ArticleId><ArticleId IdType="pubmed">18691658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, JLW, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jancke L, Staiger JF, Schlaug G, Huang Y, Steinmetz H. The relationship between corpus callosum size and forebrain volume. Cereb Cortex. 1997;7(1):48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9023431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HM, Zaitlen NA, Wade CM, Kirby A, Heckerman D, Daly MJ, Eskin E. Efficient control of population structure in model organism association mapping. Genetics. 2008;178(3):1709&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278096</ArticleId><ArticleId IdType="pubmed">18385116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci. 2002;5(Suppl):1039&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002;12(6):996&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186604</ArticleId><ArticleId IdType="pubmed">12045153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T, Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T, Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006;16(1):55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356129</ArticleId><ArticleId IdType="pubmed">16344560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Bye S, Nurnberger JI, Jr, Hodes ME, Crisp M. A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested. J Biochem Biophys Methods. 1992;25(4):193&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">1494032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprecht R, LeDoux J. Structural plasticity and memory. Nat Rev Neurosci. 2004;5(1):45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265(5181):2037&#x2013;2048.</Citation><ArticleIdList><ArticleId IdType="pubmed">8091226</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow A, Huang SC, Geng A, Becker J, Davis S, Toga A, Thompson P. Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging. 2005;19:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher B. Personal genomes: The case of the missing heritability. Nature. 2008;456(7218):18&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18987709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, Holmes C, Collins L, Thompson P, MacDonald D, Iacoboni M, Schormann T, Amunts K, Palomero-Gallagher N, Geyer S, Parsons L, Narr K, Kabani N, Le Goualher G, Boomsma D, Cannon T, Kawashima R, Mazoyer B. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356(1412):1293&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9(5):356&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398418</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Jr, Schuff N, Weiner MW, Thompson PM. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp. 2009;30(9):2766&#x2013;2788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733926</ArticleId><ArticleId IdType="pubmed">19172649</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer&#x2019;s disease mild cognitive impairment, and elderly controls. Neuroimage. 2008;43(1):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624575</ArticleId><ArticleId IdType="pubmed">18675918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986;73(4):320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">3017841</ArticleId></ArticleIdList></Reference><Reference><Citation>Paling SM, Williams ED, Barber R, Burton EJ, Crum WR, Fox NC, O&#x2019;Brien JT. The application of serial MRI analysis techniques to the study of cerebral atrophy in late-onset dementia. Med Image Anal. 2004;8(1):69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14644147</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoerndli FJ, Craig DW, Pearson JV, Huynh KD, Brunner F, Corneveaux J, Osborne D, Wollmer MA, Aerni A, Coluccia D, Hanggi J, Mondadori CR, Buchmann A, Reiman EM, Caselli RJ, Henke K, de Quervain DJ. Common Kibra alleles are associated with human memory performance. Science. 2006;314(5798):475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053149</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904591</ArticleId></ArticleIdList></Reference><Reference><Citation>Peper JS, Brouwer RM, Boomsma DI, Kahn RS, Hulshoff Pol HE. Genetic influences on human brain structure: a review of brain imaging studies in twins. Hum Brain Mapp. 2007;28(6):464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871295</ArticleId><ArticleId IdType="pubmed">17415783</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Aging, mild cognitive impairment, and Alzheimer&#x2019;s disease. Neurol Clin. 2000;18(4):789&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072261</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Turner JA, Fallon JA, Lakatos A, Keator DB, Guffanti G, Macciardi F. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol Psychiatry. 2009a;14(4):416&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254586</ArticleId><ArticleId IdType="pubmed">19065146</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Cogn Neuropsychiatry. 2009b;14(4&#x2013;5):391&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037334</ArticleId><ArticleId IdType="pubmed">19634037</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, Brodsky J, Jones CG, Zaitlen NA, Varilo T, Kaakinen M, Sovio U, Ruokonen A, Laitinen J, Jakkula E, Coin L, Hoggart C, Collins A, Turunen H, Gabriel S, Elliot P, McCarthy MI, Daly MJ, Jarvelin MR, Freimer NB, Peltonen L. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2009;41(1):35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687077</ArticleId><ArticleId IdType="pubmed">19060910</ArticleId></ArticleIdList></Reference><Reference><Citation>Schito AM, Pizzuti A, Di Maria E, Schenone A, Ratti A, Defferrari R, Bellone E, Mancardi GL, Ajmar F, Mandich P. mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit. Neurosci Lett. 1997;239(1):49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9547169</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwirzke M, Gnirke A, Bork P, Tarin D, Weidle UH. Differential gene expression in mammary carcinoma cell lines: identification of DRIM, a new gene down-regulated in metastasis. Anticancer Res. 1998;18(3A):1409&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9673349</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M, Kase CS, D&#x2019;Agostino RB, Sr, Decarli C, Atwood LD, Wolf PA. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet. 2007;8(Suppl 1):S15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995608</ArticleId><ArticleId IdType="pubmed">17903297</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009;66(1):81&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693405</ArticleId><ArticleId IdType="pubmed">19124691</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401(6748):63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer&#x2019;s disease and common age-related disorders. J Clin Invest. 1999;104(9):1175&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409831</ArticleId><ArticleId IdType="pubmed">10545516</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer&#x2019;s disease. J Neurosci. 2003;23(3):994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, Dutton RA, Chiang MC, Leow AD, Sowell ER, De Zubicaray G, Becker JT, Lopez OL, Aizenstein HJ, Toga AW. Tracking Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2007;1097:183&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197831</ArticleId><ArticleId IdType="pubmed">17413023</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Martin NG. The ENIGMA Network. 2010.  URL:  http://enigma.loni.ucla.edu.</Citation></Reference><Reference><Citation>Thompson PM, Narr KL, Blanton RE, Toga AW. Mapping Structural Alterations of the Corpus Callosum during Brain Development and Degeneration. In: Zaidel E, Iacoboni M, editors. The Parallel Brain: The Cognitive Neuroscience of the Corpus Callosum. MIT Press; 2002.</Citation></Reference><Reference><Citation>Toro R, Perron M, Pike B, Richer L, Veillette S, Pausova Z, Paus T. Brain size and folding of the human cerebral cortex. Cereb Cortex. 2008;18(10):2352&#x2013;2357.</Citation><ArticleIdList><ArticleId IdType="pubmed">18267953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushkaryov YA, Petrenko AG, Geppert M, Sudhof TC. Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. Science. 1992;257(5066):50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">1621094</ArticleId></ArticleIdList></Reference><Reference><Citation>Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol. 2008;65(3):329&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">18332245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Yashiro K, Philpot BD. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology. 2008;55(7):1081&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590778</ArticleId><ArticleId IdType="pubmed">18755202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20198479</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology.</ArticleTitle><Pagination><StartPage>543</StartPage><EndPage>554</EndPage><MedlinePgn>543-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-010-0661-6</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), Purkinje neurons in the cerebellum are spared, while, for instance, pyramidal neurons in the hippocampus are neuropathologically affected. Several lines of evidence suggest that the pathogenesis could be induced by the concentration-dependent polymerization of the amyloid beta-peptide (Abeta) into extracellular oligomers. The role of intracellular Abeta is not fully investigated, but recent data indicate that also this pool could be of importance. Here, we use laser capture microdissection microscopy for isolation of Purkinje neurons from AD cases and controls, and quantify the low levels of intracellular Abeta using a novel and highly sensitive ELISA. Similar to Cornu Ammonis 1 pyramidal neurons, the intracellular levels of the most toxic variant, Abeta42, as well as the Abeta42/Abeta40 ratio, were increased in Purkinje neurons from sporadic AD cases as compared to controls. However, the levels of Abeta42 as well as Abeta40 were clearly lower in Purkinje neurons than in pyramidal neurons. Based on the volume of the captured Purkinje neurons, the intraneuronal concentrations of Abeta42 were calculated to be 200 nM in sporadic AD cases and 90 nM in controls. The corresponding concentrations in pyramidal neurons from hippocampus were 3 muM and 660 nM, respectively. The Abeta40 concentration was not significantly altered in AD cases compared to controls. However, we found ten times higher concentration of Abeta40 in pyramidal neurons (10 muM) compared to Purkinje neurons (1 muM). Finally, we suggest that high concentration of intracellular Abeta42 correlates with vulnerability to AD neuropathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Masakazu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet and Dainippon Sumitomo Pharma Alzheimer Center (KASPAC), KI-Alzheimer's Disease Research Center, Karolinska Institutet, Novum plan 5, Huddinge, Sweden. masakazu.hashimoto@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Volkmann</LastName><ForeName>Inga</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Mikio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tjernberg</LastName><ForeName>Lars O</ForeName><Initials>LO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042282" MajorTopicYN="N">Microdissection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20198479</ArticleId><ArticleId IdType="doi">10.1007/s00401-010-0661-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20198482</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Focal demyelination in Alzheimer's disease and transgenic mouse models.</ArticleTitle><Pagination><StartPage>567</StartPage><EndPage>577</EndPage><MedlinePgn>567-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-010-0657-2</ELocationID><Abstract><AbstractText>We have investigated alterations in myelin associated with Abeta plaques, a major pathological hallmark of Alzheimer's disease (AD), in human tissue and relevant transgenic mice models. Using quantitative morphological techniques, we determined that fibrillar Abeta pathology in the grey matter of the neocortex was associated with focal demyelination in human presenilin-1 familial, sporadic and preclinical AD cases, as well as in two mouse transgenic models of AD, compared with age-matched control tissue. This demyelination was most pronounced at the core of Abeta plaques. Furthermore, we found a focal loss of oligodendrocytes in sporadic and preclinical AD cases associated with Abeta plaque cores. In human and transgenic mice alike, plaque-free neocortical regions showed no significant demyelination or oligodendrocyte loss compared with controls. Dystrophic neurites associated with the plaques were also demyelinated. We suggest that such plaque-associated focal demyelination of the cortical grey matter might impair cortical processing, and may also be associated with aberrant axonal sprouting that underlies dystrophic neurite formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitew</LastName><ForeName>Stanislaw</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NeuroRepair Group, Wicking Dementia Research and Education Centre, Menzies Research Institute, University of Tasmania, Hobart, TAS 7000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkcaldie</LastName><ForeName>Matthew T K</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Vickers</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Tracey C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20198482</ArticleId><ArticleId IdType="doi">10.1007/s00401-010-0657-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20203178</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.</ArticleTitle><Pagination><StartPage>3184</StartPage><EndPage>3198</EndPage><MedlinePgn>3184-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5922-09.2010</ELocationID><Abstract><AbstractText>Increasing evidence suggests that phosphorylation may play an important role in the oligomerization, fibrillogenesis, Lewy body (LB) formation, and neurotoxicity of alpha-synuclein (alpha-syn) in Parkinson disease. Herein we demonstrate that alpha-syn is phosphorylated at S87 in vivo and within LBs. The levels of S87-P are increased in brains of transgenic (TG) models of synucleinopathies and human brains from Alzheimer disease (AD), LB disease (LBD), and multiple system atrophy (MSA) patients. Using antibodies against phosphorylated alpha-syn (S129-P and S87-P), a significant amount of immunoreactivity was detected in the membrane in the LBD, MSA, and AD cases but not in normal controls. In brain homogenates from diseased human brains and TG animals, the majority of S87-P alpha-syn was detected in the membrane fractions. A battery of biophysical methods were used to dissect the effect of S87 phosphorylation on the structure, aggregation, and membrane-binding properties of monomeric alpha-syn. These studies demonstrated that phosphorylation at S87 expands the structure of alpha-syn, increases its conformational flexibility, and blocks its fibrillization in vitro. Furthermore, phosphorylation at S87, but not S129, results in significant reduction of alpha-syn binding to membranes. Together, our findings provide novel mechanistic insight into the role of phosphorylation at S87 and S129 in the pathogenesis of synucleinopathies and potential roles of phosphorylation in alpha-syn normal biology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paleologou</LastName><ForeName>Katerina E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology and Neuroproteomics, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oueslati</LastName><ForeName>Abid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shakked</LastName><ForeName>Gideon</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rospigliosi</LastName><ForeName>Carla C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hai-Young</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Lamberto</LastName><ForeName>Gonzalo R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Claudio O</ForeName><Initials>CO</Initials></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chegini</LastName><ForeName>Fariba</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Wei Ping</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Chiappe</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Moniatte</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Bernard L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Aebischer</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Eliezer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zweckstetter</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lashuel</LastName><ForeName>Hilal A</ForeName><Initials>HA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM66354</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG019391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM66354</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM066354</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20203178</ArticleId><ArticleId IdType="mid">NIHMS183868</ArticleId><ArticleId IdType="pmc">PMC2947449</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5922-09.2010</ArticleId><ArticleId IdType="pii">30/9/3184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeliovich A, Schmitz Y, Fari&#xf1;as I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS. alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem. 2002;277:12334&#x2013;12342.</Citation><ArticleIdList><ArticleId IdType="pubmed">11821392</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281:29739&#x2013;29752.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, Ren CH, Koyama S, Nagasawa H, Kimura H, Kawanami T, Kurita K, Tajima K, Daimon M, Baba M, Kido T, Saino S, Goto K, Asao H, Kitanaka C, Takashita E, et al. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J Neurosci. 2006;26:9227&#x2013;9238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674490</ArticleId><ArticleId IdType="pubmed">16957079</ArticleId></ArticleIdList></Reference><Reference><Citation>Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet. 2009;1:872&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bax A, Grzesiek S. Methodological advances in NMR. Acc Chem Res. 1993;26:131&#x2013;138.</Citation></Reference><Reference><Citation>Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A. 2005;102:1430&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547830</ArticleId><ArticleId IdType="pubmed">15671169</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DR. Interactions between metals and alpha-synuclein&#x2013;function or artefact? FEBS J. 2007;274:3766&#x2013;3774.</Citation><ArticleIdList><ArticleId IdType="pubmed">17617226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussell R, Jr, Eliezer D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol. 2003;329:763&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Chen X, Rizo J, Jahn R, S&#xfc;dhof TC. A broken alpha -helix in folded alpha -Synuclein. J Biol Chem. 2003;278:15313&#x2013;15318.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834418</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6:277&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Bodles AM, Guthrie DJ, Harriott P, Irvine GB. The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur J Biochem. 1998;258:157&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9851705</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliezer D, Kutluay E, Bussell R, Jr, Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol. 2001;307:1061&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">11286556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL. alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem. 2001;276:3879&#x2013;3884.</Citation><ArticleIdList><ArticleId IdType="pubmed">11078745</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T, Forman-Kay JD, Kay LE. Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry. 1994;33:5984&#x2013;6003.</Citation><ArticleIdList><ArticleId IdType="pubmed">7514039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 2004;23:2039&#x2013;2046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424375</ArticleId><ArticleId IdType="pubmed">15103328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier M, Vitte J, Garrigue J, Langui D, Dullin JP, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, Ardila-Osorio H, Traver S, Duchateau R, Goujet-Zalc C, Paleologou K, Lashuel HA, Haass C, Duyckaerts C, Cohen-Salmon C, Kahle PJ, Hamon M, Brice A, Corti O. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One. 2009;4:e6629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722082</ArticleId><ArticleId IdType="pubmed">19680561</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai WP, Power JH, Blumbergs PC, Culvenor JG, Jensen PH. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem. 1999;73:2093&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol. 2000;166:324&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085897</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksman MA, Cuny GD, Liu M, Dobson B, Auerbach K, Stein RL, Kosik KS. New approaches to the discovery of cdk5 inhibitors. Current Alzheimer Research. 2007;4:547&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008;105:763&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206610</ArticleId><ArticleId IdType="pubmed">18178617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002;277:49071&#x2013;49076.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377775</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise H, Celej MS, Becker S, Riedel D, Pelah A, Kumar A, Jovin TM, Baldus M. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. J Mol Biol. 2008;380:444&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">18539297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol. 2002;322:383&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12217698</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglis KJ, Chereau D, Brigham EF, Chiou SS, Sch&#xf6;bel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, Wright S, Chian D, Santiago P, Soriano F, Ramos C, Powell K, Goldstein JM, Babcock M, Yednock T, Bard F, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009;284:2598&#x2013;2602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631975</ArticleId><ArticleId IdType="pubmed">19004816</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R. alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274:25481&#x2013;25489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464279</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BA, Blevins RA. NMRView: a computer program for the visualization and analysis of NMR data. J Biomol NMR. 1994;4:603&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">22911360</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones JA, Wilkins DK, Smith LJ, Dobson CM. Characterisation of protein unfolding by NMR diffusion measurements. J Biomol NMR. 1997;10:199&#x2013;203.</Citation></Reference><Reference><Citation>Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365&#x2013;6373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler JC, Rochet JC, Lansbury PT., Jr The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry. 2003;42:672&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">12534279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Sung JY, Lee HJ, Rhim H, Hasegawa M, Iwatsubo T, Min do S, Kim J, Paik SR, Chung KC. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem. 2006;281:33250&#x2013;33257.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloepper KD, Zhou DH, Li Y, Winter KA, George JM, Rienstra CM. Temperature-dependent sensitivity enhancement of solid-state NMR spectra of alpha-synuclein fibrils. J Biomol NMR. 2007;39:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">17899395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn JE, Millett IS, Jacob J, Zagrovic B, Dillon TM, Cingel N, Dothager RS, Seifert S, Thiyagarajan P, Sosnick TR, Hasan MZ, Pande VS, Ruczinski I, Doniach S, Plaxco KW. Random-coil behavior and the dimensions of chemically unfolded proteins. Proc Natl Acad Sci U S A. 2004;101:12491&#x2013;12496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515087</ArticleId><ArticleId IdType="pubmed">15314214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A. 2002;99:10813&#x2013;10818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125054</ArticleId><ArticleId IdType="pubmed">12122208</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E. Genetically altered transgenic models of Alzheimer's disease. J Neural Transm Suppl. 2000;59:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA. Phosphorylation of synucleins by members of the polo-like kinase family. J Biol Chem. 2010;285:2807&#x2013;2822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807335</ArticleId><ArticleId IdType="pubmed">19889641</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics. 2008;7:2123&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577212</ArticleId><ArticleId IdType="pubmed">18614564</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009;68:515&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753269</ArticleId><ArticleId IdType="pubmed">19525899</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Yamashita H, Takahashi T, Nakamura S. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun. 2001;280:1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162638</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 2002;16:210&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744621</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem. 2000;275:390&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617630</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik SR, Shin HJ, Lee JH, Chang CS, Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J. 1999;340:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220316</ArticleId><ArticleId IdType="pubmed">10359669</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Jr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. Phosphorylation at S129, but not the phosphomimics S129E/D inhibits the fibrilization of alpha-synuclein. J Biol Chem. 2008;238:16895&#x2013;16905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2423264</ArticleId><ArticleId IdType="pubmed">18343814</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic; 1986.</Citation><ArticleIdList><ArticleId IdType="pubmed">6110810</ArticleId></ArticleIdList></Reference><Reference><Citation>Payton JE, Perrin RJ, Woods WS, George JM. Structural determinants of PLD2 inhibition by alpha-synuclein. J Mol Biol. 2004;337:1001&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033366</ArticleId></ArticleIdList></Reference><Reference><Citation>Permi P, Kilpel&#xe4;inen I, Annila A, Heikkinen S. Intensity modulated HSQC and HMQC: Two simple methods to measure (3)J(HNH alpha) in proteins. J Biomol NMR. 2000;16:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">10718610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem. 2000;275:26515&#x2013;26522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852916</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha-synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun. 2009;387:149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K, Douglas Shytle R, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J of Cellular and Mol Med. 2009;13:574&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671567</ArticleId><ArticleId IdType="pubmed">18410522</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68:568&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu MY, Kim DW, Arima K, Mouradian MM, Kim SU, Lee G. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J Neurol Sci. 2008;266:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17884098</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci. 2005;25:10689&#x2013;10699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725840</ArticleId><ArticleId IdType="pubmed">16291942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung YH, Eliezer D. Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. Protein Sci. 2006;15:1162&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242515</ArticleId><ArticleId IdType="pubmed">16597821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung YH, Eliezer D. Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol. 2007;372:689&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2094134</ArticleId><ArticleId IdType="pubmed">17681534</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Kanuka H, Fujiwara H, Koyama A, Hasegawa M, Miura M, Iwatsubo T. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett. 2003a;336:155&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">12505616</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Yamashita H, Nagano Y, Nakamura T, Ohmori H, Avraham H, Avraham S, Yasuda M, Matsumoto M. Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation. J Biol Chem. 2003b;278:42225&#x2013;42233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12893833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer TS, Bax A. Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. J Biol Chem. 2005;280:43179&#x2013;43187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16166095</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000;20:6021&#x2013;6029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772584</ArticleId><ArticleId IdType="pubmed">10934251</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar M, Chou HT, L&#xfc;hrs T, Maji SK, Riek-Loher D, Verel R, Manning G, Stahlberg H, Riek R. The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A. 2008;105:8637&#x2013;8642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438424</ArticleId><ArticleId IdType="pubmed">18550842</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 2008;67:402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930078</ArticleId><ArticleId IdType="pubmed">18451726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci. 2008;28:2624&#x2013;2632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671193</ArticleId><ArticleId IdType="pubmed">18322105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins DK, Grimshaw SB, Receveur V, Dobson CM, Jones JA, Smith LJ. Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry. 1999;38:16424&#x2013;16431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, Markley JL, Sykes BD. H-1, C-3 and N-15 chemical-shift referencing in biomolecular NMR. J Biomol NMR. 1995;6:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589602</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004;91:451&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15447678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20203200</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.</ArticleTitle><Pagination><StartPage>3409</StartPage><EndPage>3418</EndPage><MedlinePgn>3409-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4977-09.2010</ELocationID><Abstract><AbstractText>Aggregation of alpha-synuclein (alpha-syn), a process that generates oligomeric intermediates, is a common pathological feature of several neurodegenerative disorders. Despite the potential importance of the oligomeric alpha-syn intermediates in neuron function, their biochemical properties and pathobiological functions in vivo remain vastly unknown. Here we used two-dimensional analytical separation and an array of biochemical and cell-based assays to characterize alpha-syn oligomers that are present in the nervous system of A53T alpha-syn transgenic mice. The most prominent species identified were 53 A detergent-soluble oligomers, which preceded neurological symptom onset, and were found at equivalent amounts in regions containing alpha-syn inclusions as well as histologically unaffected regions. These oligomers were resistant to SDS, heat, and urea but were sensitive to proteinase-K digestion. Although the oligomers shared similar basic biochemical properties, those obtained from inclusion-bearing regions were prominently reactive to antibodies that recognize oxidized alpha-syn oligomers, significantly accelerated aggregation of alpha-syn in vitro, and caused primary cortical neuron degeneration. In contrast, oligomers obtained from non-inclusion-bearing regions were not toxic and delayed the in vitro formation of alpha-syn fibrils. These data indicate that specific conformations of alpha-syn oligomers are present in distinct brain regions of A53T alpha-syn transgenic mice. The contribution of these oligomers to the development of neuron dysfunction appears to be independent of their absolute quantities and basic biochemical properties but is dictated by the composition and conformation of the intermediates as well as unrecognized brain-region-specific intrinsic factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsika</LastName><ForeName>Elpida</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia Research Institute, Philadelphia Pennsylvania 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moysidou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cushman</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gannon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sandaltzopoulos</LastName><ForeName>Raphael</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ischiropoulos</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mazzulli</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG13966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES013508</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES013508</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS051303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32NS066730</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS066730</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018621">PrPC Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018621" MajorTopicYN="N">PrPC Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20203200</ArticleId><ArticleId IdType="mid">NIHMS183862</ArticleId><ArticleId IdType="pmc">PMC2844128</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4977-09.2010</ArticleId><ArticleId IdType="pii">30/9/3409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apetri MM, Maiti NC, Zagorski MG, Carey PR, Anderson VE. Secondary structure of &#x3b1;-Synuclein oligomers: characterization by Raman and atomic force microscopy. J Mol Biol. 2006;355:63&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303137</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, R&#xfc;b U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002;22:8797&#x2013;8807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fern&#xe1;ndez-Chac&#xf3;n R, Schl&#xfc;ter OM, S&#xfc;dhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123:383&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT., Jr Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000a;39:2552&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704204</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT., Jr Acceleration of oligomerization, not fibrillization, is a shared property of both &#x3b1;-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000b;97:571&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Rochet JC, Bieganski RM, Lansbury PT., Jr Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294:1346&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701929</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of &#x3b1;-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220&#x2013;9232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672196</ArticleId><ArticleId IdType="pubmed">17715357</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106:13010&#x2013;13015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, Yen SH. Widespread alterations of &#x3b1;-synuclein in multiple system atrophy. Am J Pathol. 1999;155:1241&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867032</ArticleId><ArticleId IdType="pubmed">10514406</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick PF. The metal requirement of rat tyrosine hydroxylase. Biochem Biophys Res Commun. 1989;161:211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">2567163</ArticleId></ArticleIdList></Reference><Reference><Citation>Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786384</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem. 1999;274:7619&#x2013;7622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075647</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VM. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res. 2000;59:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433374</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg MS, Lansbury PT., Jr Is there a cause-and-effect relationship between &#x3b1;-synuclein fibrillization and Parkinson/'s disease? Nat Cell Biol. 2000;2:E115&#x2013;E119.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878819</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. The E46K mutation in &#x3b1;-synuclein increases amyloid fibril formation. J Biol Chem. 2005;280:7800&#x2013;7807.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632170</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett. 1999;269:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004;279:46363&#x2013;46366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry. 2003;42:829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">12534296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem. 1996;67:443&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">8764568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 &#x2192; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:8968&#x2013;8973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124407</ArticleId><ArticleId IdType="pubmed">12084935</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, Song GQ, Hu J, Zhou JW, Hu HY. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 2005;272:3661&#x2013;3672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008565</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and l-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 2004;18:962&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">15059976</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804&#x2013;2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569395</ArticleId><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H. Cytosolic catechols inhibit &#x3b1;-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci. 2006;26:10068&#x2013;10078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674486</ArticleId><ArticleId IdType="pubmed">17005870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H. Cellular oligomerization of &#x3b1;-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem. 2007;282:31621&#x2013;31630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tanji K, Zhang H, Kakita A, Takahashi H, Wakabayashi K. &#x3b1;-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol. 2008;115:453&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">18000672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D. Interplay between cytosolic dopamine, calcium, and &#x3b1;-synuclein causes selective death of substantia nigra neurons. Neuron. 2009;62:218&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677560</ArticleId><ArticleId IdType="pubmed">19409267</ArticleId></ArticleIdList></Reference><Reference><Citation>Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999;274:9843&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092675</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004;60:17&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094295</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem. 2005;280:21212&#x2013;21219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817478</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Klucken J, Bercury K, Tetzlaff J, Putcha P, Oliveira LM, Quintas A, McLean PJ, Hyman BT. Dopamine-induced conformational changes in alpha-synuclein. PLoS ONE. 2009;4:e6906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2731858</ArticleId><ArticleId IdType="pubmed">19730729</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 2000;97:4897&#x2013;4902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="pubmed">10781096</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 2000a;275:18344&#x2013;18349.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747881</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza JM, Giasson BI, Lee VM, Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett. 2000b;474:116&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">10828462</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. &#x3b1;-Synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron. 2001;30:819&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430814</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, McLean PJ. CHIP targets toxic &#x3b1;-synuclein oligomers for degradation. J Biol Chem. 2008;283:17962&#x2013;17968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936239</ArticleId><ArticleId IdType="pubmed">18436529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanoswki JQ, Lee VM. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998;44:415&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulmer TS, Bax A, Cole NB, Nussbaum RL. Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem. 2005;280:9595&#x2013;9603.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615727</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 2001;276:10737&#x2013;10744.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152691</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT., Jr Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001;40:7812&#x2013;7819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425308</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35:13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem. 1999;274:19509&#x2013;19512.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, D&#xe9;glon N. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis. 2005;20:785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond MJ, Stricker EM. Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science. 1972;177:1211&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">5057630</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20209079</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.</ArticleTitle><Pagination><StartPage>e9505</StartPage><MedlinePgn>e9505</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e9505</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0009505</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The amyloid beta-protein (Abeta) is believed to be the key mediator of Alzheimer's disease (AD) pathology. Abeta is most often characterized as an incidental catabolic byproduct that lacks a normal physiological role. However, Abeta has been shown to be a specific ligand for a number of different receptors and other molecules, transported by complex trafficking pathways, modulated in response to a variety of environmental stressors, and able to induce pro-inflammatory activities.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">Here, we provide data supporting an in vivo function for Abeta as an antimicrobial peptide (AMP). Experiments used established in vitro assays to compare antimicrobial activities of Abeta and LL-37, an archetypical human AMP. Findings reveal that Abeta exerts antimicrobial activity against eight common and clinically relevant microorganisms with a potency equivalent to, and in some cases greater than, LL-37. Furthermore, we show that AD whole brain homogenates have significantly higher antimicrobial activity than aged matched non-AD samples and that AMP action correlates with tissue Abeta levels. Consistent with Abeta-mediated activity, the increased antimicrobial action was ablated by immunodepletion of AD brain homogenates with anti-Abeta antibodies.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Our findings suggest Abeta is a hitherto unrecognized AMP that may normally function in the innate immune system. This finding stands in stark contrast to current models of Abeta-mediated pathology and has important implications for ongoing and future AD treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soscia</LastName><ForeName>Stephanie J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Washicosky</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Burton</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lee E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI081990</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023181">Antimicrobial Cationic Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010078">Oxazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014966">Xanthenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>1FN9YD6968</RegistryNumber><NameOfSubstance UI="C005843">resazurin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054804">Cathelicidins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023181" MajorTopicYN="N">Antimicrobial Cationic Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002176" MajorTopicYN="N">Candida albicans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010078" MajorTopicYN="N">Oxazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014966" MajorTopicYN="N">Xanthenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054804" MajorTopicYN="N">Cathelicidins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Dr Tanzi is a consultant to and holds stock options in Prana Biotechnology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20209079</ArticleId><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0009505</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's A&#x3b2; peptide: the many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, et al. Amyloid (&#x3b2;)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci. 2001;21:RC123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763825</ArticleId><ArticleId IdType="pubmed">11160457</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A&#x3b2; aggregation and toxicity. Biochemistry. 2001;40:3553&#x2013;3560.</Citation><ArticleIdList><ArticleId IdType="pubmed">11297421</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, et al. Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem. 2004;91:1312&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid &#x3b2;-peptide from brain: transport or metabolism? Nat Med. 2000;6:718&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, You HJ, Cho SH, Woo CH, Yoo MH, et al. Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to &#x3b2;-amyloid in C6 astroglioma cells. Biochem J. 2002;366:937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222817</ArticleId><ArticleId IdType="pubmed">12038964</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Town T, Parker TA, Tan J, Humphrey J, et al. Inhibition of Alzheimer's &#x3b2;-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol. 1999;157:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10222124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaiou M. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med. 2007;85:317&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17216206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238:325&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">8681941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P, Johansson L, Wan H, Jones A, Gallo RL, et al. Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun. 2006;74:6982&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698100</ArticleId><ArticleId IdType="pubmed">17030578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374875</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2008;59:12&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17764778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc Disord. 2006;6:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764755</ArticleId><ArticleId IdType="pubmed">17181861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res. 2002;69:567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, et al. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci. 2005;25:1071&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725948</ArticleId><ArticleId IdType="pubmed">15689542</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, et al. The role of cell-derived oligomers of A&#x3b2; in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005;33:1087&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246051</ArticleId></ArticleIdList></Reference><Reference><Citation>Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J. 1999;341(Pt 3):501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220385</ArticleId><ArticleId IdType="pubmed">10417311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood R, Domanov Y, Pieti&#xe4;inen M, Kontinen VP, Kinnunen PK. Binding of LL-37 to model biomembranes: insight into target vs host cell recognition. Biochim Biophys Acta. 2008;1778:983&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166145</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42:2206&#x2013;2214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105778</ArticleId><ArticleId IdType="pubmed">9736536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieprawska-Lupa M, Mydel P, Krawczyk K, W&#xf3;jcik K, Puklo M, et al. Degradation of human antimicrobial peptide LL-37 by staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother. 2004;48:4673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529204</ArticleId><ArticleId IdType="pubmed">15561843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta. 2006;1758:1529&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16928357</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomski SJ, Murphy RM. Kinetics of aggregation of synthetic &#x3b2;-amyloid peptide. Arch Biochem Biophys. 1992;294:630&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">1567217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A, Ray I, Chauhan VP. Interaction of amyloid &#x3b2;-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. Neurochem Res. 2000;25:423&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">10761989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi E, Ege C, Winans A, Majewski J, Wu G, et al. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-&#x3b2; peptide. Proteins. 2008;72:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18186465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Sol&#xe1; S, Silva R, Brites D. Bilirubin and amyloid-&#x3b2; peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol Med. 2000;6:936&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949925</ArticleId><ArticleId IdType="pubmed">11147571</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert GP, Wood WG, M&#xfc;ller WE. Effects of aging and &#x3b2;-amyloid on the properties of brain synaptic and mitochondrial membranes. Journal of Neural Transmission. 2001;108:1051&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer's disease. Curr Alzheimer Res. 2006;3:515&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168650</ArticleId></ArticleIdList></Reference><Reference><Citation>Repp KK, Menor SA, Pettit RK. Microplate Alamar blue assay for susceptibility testing of Candida albicans biofilms. Med Mycol. 2007;45:603&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">17885957</ArticleId></ArticleIdList></Reference><Reference><Citation>Leib SL, T&#xe4;uber MG. Pathogenesis of bacterial meningitis. Infect Dis Clin North Am. 1999;13:527&#x2013;548, v&#x2013;vi.</Citation><ArticleIdList><ArticleId IdType="pubmed">10470554</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti A. Epidemiology of central nervous system mycoses. Neurology India. 2007;55:191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17921647</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xfc;tsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002;360:1144&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">12387964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Bupp K, Magendantz M, Gusella JF, Tanzi RE, et al. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid &#x3b2; protein precursor. Proc Natl Acad Sci USA. 1992;89:10758&#x2013;10762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50421</ArticleId><ArticleId IdType="pubmed">1279693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco W, Brook JD, Tanzi RE. The amyloid precursor-like protein (APLP) gene maps to the long arm of human chromosome 19. Genomics. 1993;15:237&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8432545</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, S&#xfc;dhof TC. Cleavage of amyloid-&#x3b2; precursor protein and amyloid-&#x3b2; precursor-like protein by BACE 1. J Biol Chem. 2004;279:10542&#x2013;10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, et al. BACE (&#x3b2;-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci. 2004;25:642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">15080893</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen KT, Iverfeldt K. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell Mol Life Sci. 2009;66:2299&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115575</ArticleId><ArticleId IdType="pubmed">19333550</ArticleId></ArticleIdList></Reference><Reference><Citation>Minogue AM, Stubbs AK, Frigerio CS, Boland B, Fadeeva JV, et al. gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons. Brain Res. 2009;1262:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19401174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, et al. &#x3b2;-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Tang BL. The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem Biophys Res Commun. 2006;341:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406235</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Magara F, M&#xfc;ller U, Li ZW, Lipp HP, Weissmann C, et al. Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the &#x3b2;-amyloid-precursor protein. Proc Natl Acad Sci USA. 1999;96:4656&#x2013;4661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16388</ArticleId><ArticleId IdType="pubmed">10200318</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shooshtarizadeh P, Zhang D, Chich J-F, Gasnier C, Schneider F, et al. The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. 2009. Regulatory peptides: In Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">19932135</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogden KA, Guthmiller JM, Salzet M, Zasloff M. The nervous system and innate immunity: the neuropeptide connection. Nat Immunol. 2005;6:558&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">15908937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, et al. Aqueous dissolution of Alzheimer's disease A&#x3b2; amyloid deposits by biometal depletion. J Biol Chem. 1999;274:23223&#x2013;23228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438495</ArticleId></ArticleIdList></Reference><Reference><Citation>McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol. 1999;3:672&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P, Term&#xe9;n S, Johansson L, Nystr&#xf6;m L, Arenas E, et al. The antimicrobial peptide rCRAMP is present in the central nervous system of the rat. J Neurochem. 2005;93:1132&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15934934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, et al. Water-soluble A&#x3b2; (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, et al. Morphology and toxicity of A&#x3b2;-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996;271:20631&#x2013;20635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sal-Man N, Oren Z, Shai Y. Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry. 2002;41:11921&#x2013;11930.</Citation><ArticleIdList><ArticleId IdType="pubmed">12269837</ArticleId></ArticleIdList></Reference><Reference><Citation>Glukhov E, Stark M, Burrows LL, Deber CM. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem. 2005;280:33960&#x2013;33967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37:289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474976</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend KP, Obregon D, Quadros A, Patel N, Volmar Ch, et al. Proinflammatory and vasoactive effects of A&#x3b2; in the cerebrovasculature. Ann N Y Acad Sci. 2002;977:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando Y, Nakamura M, Kai H, Katsuragi S, Terazaki H, et al. A novel localized amyloidosis associated with lactoferrin in the cornea. Lab Invest. 2002;82:757&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065686</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki-Sasaki K, Ando Y, Nakamura M, Kitagawa K, Ikemizu S, et al. Lactoferrin Glu561Asp facilitates secondary amyloidosis in the cornea. Br J Ophthalmol. 2005;89:684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772658</ArticleId><ArticleId IdType="pubmed">15923502</ArticleId></ArticleIdList></Reference><Reference><Citation>Edstr&#xf6;m AML, Malm J, Frohm B, Martellini JA, Giwercman A, et al. The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins. J Immunol. 2008;181:3413&#x2013;3421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585754</ArticleId><ArticleId IdType="pubmed">18714013</ArticleId></ArticleIdList></Reference><Reference><Citation>Linke RP, Joswig R, Murphy CL, Wang S, Zhou H, et al. Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med. 2005;145:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15962837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee KH, Lee MJ, Shen SS, Suh JH, Lee O-J, et al. Amyloidosis of seminal vesicles and ejaculatory ducts: a histologic analysis of 21 cases among 447 prostatectomy specimens. Ann Diagn Pathol. 2008;12:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">18620988</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 2004;25:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172740</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J, Kis A, Radenovic A, Miller L, Forro L, et al. &#x3b2;-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 2006;27:228&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kountouras J, Tsolaki M, Gavalas E, Boziki M, Zavos C, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66:938&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567719</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 1997;349:241&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014911</ArticleId></ArticleIdList></Reference><Reference><Citation>Youngsteadt E. Virology. Alzheimer's risk factor also aids HIV. Science. 2008;320:1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">18566258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis. 1996;3:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980016</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, et al. Apolipoprotein E: high-avidity binding to &#x3b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Urosevic N, Martins RN. Infection and Alzheimer's disease: the APOE epsilon4 connection and lipid metabolism. J Alzheimers Dis. 2008;13:421&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">18487850</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Graham DI. &#x3b2; A4 amyloid protein deposition in brain after head trauma. Lancet. 1991;338:1422&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, et al. Depletion of GGA3 stabilizes BACE and enhances &#x3b2;-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Dong Y, Maeda U, Moir R, Inouye SK, et al. Isoflurane-induced apoptosis: a potential pathogenic link between delirium and dementia. J Gerontol A Biol Sci Med Sci. 2006;61:1300&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17234824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi N, Masuda J, Kudoh J, Shimizu N, Yoshida T. Binding sites on tau proteins as components for antimicrobial peptides. Biocontrol Sci. 2008;13:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18661680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolintineanu D, Hazrati E, Davis HT, Lehrer RI, Kaznessis YN. Antimicrobial mechanism of pore-forming protegrin peptides: 100 pores to kill E. coli. Peptides. 2009;31:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825693</ArticleId><ArticleId IdType="pubmed">19931583</ArticleId></ArticleIdList></Reference><Reference><Citation>Goumon Y, Lugardon K, Kieffer B, Lefevre J, Van Dorsselaer A, et al. Characterization of Antibacterial COOH-terminal Proenkephalin-A-derived Peptides (PEAP) in Infectious Fluids. Importance of enkelytin, the antibacterial PEAP209-237 secreted by stimulated chromaffin cells. J Biol Chem. 1998;273:29847.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792701</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen H, Rieg S, Wiedemann I, Kalbacher H, Deeg M, et al. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother. 2006;50:2608&#x2013;2620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538671</ArticleId><ArticleId IdType="pubmed">16870749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennison SR, Morton LH, Brandenburg K, Harris F, Phoenix DA. Investigations into the ability of an oblique alpha-helical template to provide the basis for design of an antimicrobial anionic amphiphilic peptide. FEBS J. 2006;273:3792&#x2013;3803.</Citation><ArticleIdList><ArticleId IdType="pubmed">16911526</ArticleId></ArticleIdList></Reference><Reference><Citation>Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, et al. Cholesterol is necessary both for the toxic effect of A&#x3b2; peptides on vascular smooth muscle cells and for A&#x3b2; binding to vascular smooth muscle cell membranes. J Neurochem. 2003;84:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558967</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso A, Braidot E, Sordano MC, Vianello A, Macr&#xec; F, et al. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol. 2002;22:1926&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC135593</ArticleId><ArticleId IdType="pubmed">11865069</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarbiou J, Tjabringa GS, Verhoosel RM, Ninaber DK, White SR, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Inflamm Res. 2006;55:119&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16673155</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, et al. Zinc-induced Alzheimer's A&#x3b2;1-40 aggregation is mediated by conformational factors. J Biol Chem. 1997;272:26464&#x2013;26470.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334223</ArticleId></ArticleIdList></Reference><Reference><Citation>National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Wayne, PA: NCCLS Document M26-A; 2009.</Citation></Reference><Reference><Citation>Shiloh MU, Ruan J, Nathan C. Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay. Infect Immun. 1997;65:3193&#x2013;3198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC175451</ArticleId><ArticleId IdType="pubmed">9234774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro. 2004;18:703&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">15251189</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20209626</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4547</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice.</ArticleTitle><Pagination><StartPage>2103</StartPage><EndPage>2117</EndPage><MedlinePgn>2103-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jnr.22387</ELocationID><Abstract><AbstractText>Formation of new neurons in the adult brain takes place in the subventricular zone and in the subgranule layer of the dentate gyrus throughout life. Neurogenesis is thought to play a role in hippocampus- and olfaction-dependent learning and memory. However, whether impairments in neurogenesis take place in learning and memory disorders, such as Alzheimer's disease, is yet to be established. Importantly, it remains to be elucidated whether neurogenic impairments play a role in the course of the disease or are the result of extensive neuropathology. We now report that transgenic mice harboring familial Alzheimer's disease-linked mutant APPswe/PS1DeltaE9 exhibit severe impairments in neurogenesis that are evident as early as 2 months of age. These mice exhibit a significant reduction in the proliferation of neural progenitor cells and their neuronal differentiation. Interestingly, levels of hyperphosphorylated tau, the cytotoxic precursor of the Alzheimer's disease hallmark neurofibrillary tangles, are particularly high in the neurogenic niches. Isolation of neural progenitor cells in culture reveals that APPswe/PS1DeltaE9-expressing neurospheres exhibit impaired proliferation and tau hyperphosphorylation compared with wildtype neurospheres isolated from nontransgenic littermates. This study suggests that impaired neurogenesis is an early critical event in the course of Alzheimer's disease that may underlie memory impairments, at least in part, and exacerbate neuronal vulnerability in the hippocampal formation and olfaction circuits. Furthermore, impaired neurogenesis is the result of both intrinsic pathology in neural progenitor cells and extrinsic neuropathology in the neurogenic niches. Finally, hyperphosphorylation of the microtubule-associated protein tau, a critical player in cell proliferation, neuronal maturation, and axonal transport, is a major contributor to impaired neurogenesis in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demars</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, College of Medicine, The University of Illinois at Chicago, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yuan-Shih</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Gadadhar</LastName><ForeName>Archana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Orly</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C533390">Phf1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063146">Polycomb-Group Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063146" MajorTopicYN="N">Polycomb-Group Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055153" MajorTopicYN="N">Stem Cell Niche</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20209626</ArticleId><ArticleId IdType="mid">NIHMS482713</ArticleId><ArticleId IdType="pmc">PMC3696038</ArticleId><ArticleId IdType="doi">10.1002/jnr.22387</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in the encoding of time in new memories. Nature neuroscience. 2006;9(6):723&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732202</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep. 2006;6(5):379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">16928347</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42(3 Pt 1):631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashe KH. Learning and memory in transgenic mice modeling Alzheimer&#x2019;s disease. Learning &amp; memory (Cold Spring Harbor, NY. 2001;8(6):301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11773429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacon AW, Bondi MW, Salmon DP, Murphy C. Very early changes in olfactory functioning due to Alzheimer&#x2019;s disease and the role of apolipoprotein E in olfaction. Ann N Y Acad Sci. 1998;855:723&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">9929677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bez A, Corsini E, Curti D, Biggiogera M, Colombo A, Nicosia RF, Pagano SF, Parati EA. Neurosphere and neurosphere-forming cells: morphological and ultrastructural characterization. Brain research. 2003;993(1&#x2013;2):18&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642827</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. The EMBO journal. 1992;11(4):1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer&#x2019;s disease. Biochimica et biophysica acta. 2005;1739(2&#x2013;3):216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615640</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekhoorn K, Joels M, Lucassen PJ. Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis. 2006;24(1):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814555</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17(5):1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer&#x2019;s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10(6):1089&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer&#x2019;s disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2006;3(3):185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842093</ArticleId></ArticleIdList></Reference><Reference><Citation>Caille I, Allinquant B, Dupont E, Bouillot C, Langer A, Muller U, Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development (Cambridge, England) 2004;131(9):2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Nakajima A, Choi SH, Xiong X, Sisodia SS, Tang YP. Adult neurogenesis is functionally associated with AD-like neurodegeneration. Neurobiology of disease. 2008;29(2):316&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254142</ArticleId><ArticleId IdType="pubmed">17980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier NL, Soriano S, Kang DE, Masliah E, Hu G, Koo EH. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol. 2005;167(1):151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603433</ArticleId><ArticleId IdType="pubmed">15972961</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398(6727):518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan MH, Yazdani U, Norris RD, Games D, German DC, Eisch AJ. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer&#x2019;s disease. The Journal of comparative neurology. 2006;495(1):70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermini FV, Grathwohl S, Radde R, Yamaguchi M, Staufenbiel M, Palmer TD, Jucker M. Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. The American journal of pathology. 2008;172(6):1520&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408413</ArticleId><ArticleId IdType="pubmed">18467698</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure A, Verret L, Bozon B, El Tannir, El Tayara N, Ly M, Kober F, Dhenain M, Rampon C, Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer&#x2019;s disease. Neurobiology of aging 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19398247</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32(5):911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. The Biochemical journal. 2001;359(Pt 1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222116</ArticleId><ArticleId IdType="pubmed">11563964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Qiao S, Lan X, Chi L, Luo C, Lien L, Yan Liu Q, Liu R. Neurogenic responses to amyloid-beta plaques in the brain of Alzheimer&#x2019;s disease-like transgenic (pPDGF-APPSw, Ind) mice. Neurobiology of disease. 2008;29(1):71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2180424</ArticleId><ArticleId IdType="pubmed">17916429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder LI. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer&#x2019;s disease. Experimental neurology. 2002;177(2):475&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429193</ArticleId></ArticleIdList></Reference><Reference><Citation>Godemann R, Biernat J, Mandelkow E, Mandelkow EM. Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS letters. 1999;454(1&#x2013;2):157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413115</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther RA, Six J, Lubke U, Vandermeeren M, Cras P, Trojanowski JQ, Lee VM. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(11):5066&#x2013;5070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46655</ArticleId><ArticleId IdType="pubmed">8506352</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neuroscience letters. 1995;189(3):167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer&#x2019;s disease. Neuromolecular Med. 2002a;1(2):125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12025858</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer&#x2019;s disease. J Neurochem. 2002b;83(6):1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F, Lucas JJ, Cuadros R, Avila J. GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiology of aging. 2003;24(8):1087&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643380</ArticleId></ArticleIdList></Reference><Reference><Citation>Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, Mori K, Ikeda T, Itohara S, Kageyama R. Roles of continuous neurogenesis in the structural and functional integrity of the adult forebrain. Nature neuroscience. 2008;11(10):1153&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758458</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagasia R, Song H, Gage FH, Lie DC. New regulators in adult neurogenesis and their potential role for repair. Trends in molecular medicine. 2006;12(9):400&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">16890023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25(21):5217&#x2013;5224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440804</ArticleId><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular engineering. 2001;17(6):157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA. Enhanced neurogenesis in Alzheimer&#x2019;s disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A. 2004a;101(36):13363&#x2013;13367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516572</ArticleId><ArticleId IdType="pubmed">15340159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2004b;101(1):343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci. 2004;117(Pt 24):5721&#x2013;5729.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Brandon EP, Gage FH. Environmental stimulation of 129/SvJ mice causes increased cell proliferation and neurogenesis in the adult dentate gyrus. Curr Biol. 1998;8(16):939&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">9707406</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002;52(2):135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesslak JP, Cotman CW, Chui HC, Van den Noort S, Fang H, Pfeffer R, Lynch G. Olfactory tests as possible probes for detecting and monitoring Alzheimer&#x2019;s disease. Neurobiol Aging. 1988;9(4):399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolecki R, Lafauci G, Rubenstein R, Mazur-Kolecka B, Kaczmarski W, Frackowiak J. The effect of amyloidosis-beta and ageing on proliferation of neuronal progenitor cells in APP-transgenic mouse hippocampus and in culture. Acta neuropathologica. 2008;116(4):419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18483741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. The Journal of neuroscience. 1996;16(6):2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiology of disease. 2003;14(1):89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neuroscience letters. 2005;390(2):87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16169151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Marr R. Neurogenesis and Alzheimer&#x2019;s disease: At the Crossroads. Experimental Neurology. 2009a In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864344</ArticleId><ArticleId IdType="pubmed">19699201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. The Journal of neuroscience. 2005;25(9):2386&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Marr R. Neurogenesis and Alzheimer&#x2019;s disease: At the crossroads. Experimental Neurology. 2009 (In Press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864344</ArticleId><ArticleId IdType="pubmed">19699201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Lau KF, Miller CC, Shaw PC. Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. Neuroreport. 2003;14(2):257&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med. 1997;3(7):756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Tang J, Xu H, Fan X, Bai Y, Yang L. Decreased hippocampal cell proliferation correlates with increased expression of BMP4 in the APPswe/PS1DeltaE9 mouse model of Alzheimer&#x2019;s disease. Hippocampus. 2008;18(7):692&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437(7063):1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. The Journal of biological chemistry. 1984;259(8):5301&#x2013;5305.</Citation><ArticleIdList><ArticleId IdType="pubmed">6425287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci U S A. 1993;90(5):2074&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46023</ArticleId><ArticleId IdType="pubmed">8446631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Toledano MA, Shelanski ML. Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind) J Alzheimers Dis. 2007;12(3):229&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, Martin JJ, Gheuens J. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta neuropathologica. 1992;84(3):265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirochnic S, Wolf S, Staufenbiel M, Kempermann G. Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. Hippocampus 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19219917</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY, Bienias JL, Lee VM, Trojanowski JQ, Bennett DA, Arnold SE. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer&#x2019;s disease. Annals of neurology. 2002;51(2):182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer&#x2019;s disease. Neuromolecular medicine. 2002a;2(2):89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428805</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. The EMBO journal. 2002b;21(3):281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Niidome T, Taniuchi N, Akaike A, Kihara T, Sugimoto H. Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice. Neuroreport. 2008;19(14):1361&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">18766011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S. Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. The European journal of neuroscience. 1999;11(6):1907&#x2013;1913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336659</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. Journal of neuroscience research. 1994;39(6):669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Paton JA, Nottebohm FN. Neurons generated in the adult brain are recruited into functional circuits. Science (New York, NY. 1984;225(4666):1046&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474166</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson DA. Quantitative histology using confocal microscopy: implementation of unbiased stereology procedures. Methods. 1999;18(4):493&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">10491280</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson DA. Stem cells in brain plasticity and repair. Current opinion in pharmacology. 2002;2(1):34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786306</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 1998;282(5391):1079&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804539</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science (New York, NY. 1992;255(5052):1707&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">1553558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G, Dalpra L, Crosti F, Lissoni S, Sciacca FL, Catania M, Di Fede G, Mangieri M, Giaccone G, Croci D, Tagliavini F. A new function of microtubule-associated protein tau: involvement in chromosome stability. Cell cycle (Georgetown, Tex. 2008;7(12):1788&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">18583940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell. 2006;127(1):185&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018285</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T, Arai Y. Age-related production of new granule cells in the adult dentate gyrus. Neuroreport. 1995;6(18):2479&#x2013;2482.</Citation><ArticleIdList><ArticleId IdType="pubmed">8741746</ArticleId></ArticleIdList></Reference><Reference><Citation>Serby M. Olfactory deficits in Alzheimer&#x2019;s disease. J Neural Transm Suppl. 1987;24:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">3316502</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ, et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. The Journal of biological chemistry. 1995;270(32):18917&#x2013;18922.</Citation><ArticleIdList><ArticleId IdType="pubmed">7642549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89(4):629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(16):9637&#x2013;9641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21391</ArticleId><ArticleId IdType="pubmed">9689133</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniuchi N, Niidome T, Goto Y, Akaike A, Kihara T, Sugimoto H. Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Neuroreport. 2007;18(17):1801&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Kim TW, Diehlmann A, Beyreuther K, Tanzi RE. Abrogation of the presenilin 1/beta-catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation. The Journal of biological chemistry. 1998;273(51):33909&#x2013;33914.</Citation><ArticleIdList><ArticleId IdType="pubmed">9852041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Tanzi RE. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Annals of the New York Academy of Sciences. 2000;920:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193155</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the &#x201c;Swedish&#x201d; amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the &#x201c;beta-secretase&#x201d; site occurs in the golgi apparatus. The Journal of biological chemistry. 1996;271(16):9390&#x2013;9397.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuret S, Toni N, Aigner S, Yeo GW, Gage FH. Hippocampus-dependent learning is associated with adult neurogenesis in MRL/MpJ mice. Hippocampus 2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19140178</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Paired helical filament tau in Alzheimer&#x2019;s disease. The kinase connection. The American journal of pathology. 1994;144(3):449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887092</ArticleId><ArticleId IdType="pubmed">8129030</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Phosphorylation of paired helical filament tau in Alzheimer&#x2019;s disease neurofibrillary lesions: focusing on phosphatases. The FASEB journal. 1995;9(15):1570&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">8529836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropepe V, Craig CG, Morshead CM, van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. J Neurosci. 1997;17(20):7850&#x2013;7859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793925</ArticleId><ArticleId IdType="pubmed">9315905</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis in the adult hippocampus. Nature. 2002;415(6875):1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C. Alzheimer&#x2019;s-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. The Journal of neuroscience. 2007;27(25):6771&#x2013;6780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439193</ArticleId><ArticleId IdType="pubmed">17581964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vescovi AL, Reynolds BA, Fraser DD, Weiss S. bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron. 1993;11(5):951&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">8240816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS letters. 1998;436(1):28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Dineley KT, Sweatt JD, Zheng H. Presenilin 1 familial Alzheimer&#x2019;s disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience. 2004;126(2):305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR. Olfactory deficits and Alzheimer&#x2019;s disease. Biol Psychiatry. 1986;21(1):116&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">3942798</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Ghadge GD, Kennedy SG, Hay N, Miller RJ, Roos RP. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. The Journal of neuroscience. 1999a;19(13):5360&#x2013;5369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782321</ArticleId><ArticleId IdType="pubmed">10377346</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Ghadge GD, Miller RJ, Roos RP. Processing of wild-type and mutant familial Alzheimer&#x2019;s disease-associated presenilin-1 in cultured neurons. Journal of neurochemistry. 1999b;73(1):31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10386952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, Younkin LH, DeGasperi R, Gama Sosa MA, Robakis NK, Haroutunian V, Elder GA. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Experimental neurology. 2004;188(2):224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, McNeil E, Dressler L, Siman R. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer&#x2019;s disease. Experimental neurology. 2007;204(1):77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853320</ArticleId><ArticleId IdType="pubmed">17070803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132(4):645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20219993</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Histone methylation regulates memory formation.</ArticleTitle><Pagination><StartPage>3589</StartPage><EndPage>3599</EndPage><MedlinePgn>3589-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3732-09.2010</ELocationID><Abstract><AbstractText>It has been established that regulation of chromatin structure through post-translational modification of histone proteins, primarily histone H3 phosphorylation and acetylation, is an important early step in the induction of synaptic plasticity and formation of long-term memory. In this study, we investigated the contribution of another histone modification, histone methylation, to memory formation in the adult hippocampus. We found that trimethylation of histone H3 at lysine 4 (H3K4), an active mark for transcription, is upregulated in hippocampus 1 h following contextual fear conditioning. In addition, we found that dimethylation of histone H3 at lysine 9 (H3K9), a molecular mark associated with transcriptional silencing, is increased 1 h after fear conditioning and decreased 24 h after context exposure alone and contextual fear conditioning. Trimethylated H3K4 levels returned to baseline levels at 24 h. We also found that mice deficient in the H3K4-specific histone methyltransferase, Mll, displayed deficits in contextual fear conditioning relative to wild-type animals. This suggests that histone methylation is required for proper long-term consolidation of contextual fear memories. Interestingly, inhibition of histone deacetylases (HDACs) with sodium butyrate (NaB) resulted in increased H3K4 trimethylation and decreased H3K9 dimethylation in hippocampus following contextual fear conditioning. Correspondingly, we found that fear learning triggered increases in H3K4 trimethylation at specific gene promoter regions (Zif268 and bdnf) with altered DNA methylation and MeCP2 DNA binding. Zif268 DNA methylation levels returned to baseline at 24 h. Together, these data demonstrate that histone methylation is actively regulated in the hippocampus and facilitates long-term memory formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Swati</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evelyn F. McKnight Brain Institute, Department of Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Se Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Artis</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Molfese</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sweatt</LastName><ForeName>J David</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Paylor</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Lubin</LastName><ForeName>Farah D</ForeName><Initials>FD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG031722</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS37444</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS013546</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS013546</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031722</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH057014</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS037444</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH082106</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS048811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH57014</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 MH082106</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097909</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS048811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 MH082106</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20219993</ArticleId><ArticleId IdType="mid">NIHMS186279</ArticleId><ArticleId IdType="pmc">PMC2859898</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3732-09.2010</ArticleId><ArticleId IdType="pii">30/10/3589</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbarian S, Huang HS. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry. 2009;65:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637452</ArticleId><ArticleId IdType="pubmed">18814864</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A. Chromatin acetylation, memory, and LTP are impaired in CBP+/&#x2212; mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron. 2004;42:947&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207239</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev. 2009;89:121&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883056</ArticleId><ArticleId IdType="pubmed">19126756</ArticleId></ArticleIdList></Reference><Reference><Citation>Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J, Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell. 2007;131:633&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">18022353</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nat Neurosci. 1998;1:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196568</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramham CR. Control of synaptic consolidation in the dentate gyrus: mechanisms, functions, and therapeutic implications. Prog Brain Res. 2007;163:453&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem. 2007;14:268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2216532</ArticleId><ArticleId IdType="pubmed">17522015</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443785</ArticleId><ArticleId IdType="pubmed">18511691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chwang WB, O'Riordan KJ, Levenson JM, Sweatt JD. ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn Mem. 2006;13:322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1475813</ArticleId><ArticleId IdType="pubmed">16741283</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvis CM, Pollock JD, Goodman RH, Impey S, Dunn J, Mandel G, Champagne FA, Mayford M, Korzus E, Kumar A, Renthal W, Theobald DE, Nestler EJ. Epigenetic mechanisms and gene networks in the nervous system. J Neurosci. 2005;25:10379&#x2013;10389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725821</ArticleId><ArticleId IdType="pubmed">16280577</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch SI, Rosse RB, Mastropaolo J, Long KD, Gaskins BL. Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time? Clin Neuropharmacol. 2008;31:104&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">18382183</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447:178&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 2005;15:490&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098738</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007;128:635&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">17320500</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498958</ArticleId><ArticleId IdType="pubmed">19424149</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Z, Giustetto M, Lomvardas S, Kim JH, Miniaci MC, Schwartz JH, Thanos D, Kandel ER. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell. 2002;111:483&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437922</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One. 2007;2:e809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950080</ArticleId><ArticleId IdType="pubmed">17726539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27:11254&#x2013;11262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673022</ArticleId><ArticleId IdType="pubmed">17942719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A. Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. J Biol Chem. 2007;282:9962&#x2013;9972.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT, Russo SJ, Laplant Q, Sasaki TS, Whistler KN, Neve RL, Self DW, Nestler EJ. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron. 2005;48:303&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell. 2004;14:183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15099518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002;14:286&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067650</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nat Rev Neurosci. 2005;6:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654323</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, O'Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 2004a;279:40545&#x2013;40559.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273246</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, Pizzi M, Liou HC, Sweatt JD. A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel. J Neurosci. 2004b;24:3933&#x2013;3943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729420</ArticleId><ArticleId IdType="pubmed">15102909</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424112</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Zhang FX. [On the research of histone methylation] Yi Chuan. 2004;26:244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639996</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin FD, Sweatt JD. The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron. 2007;55:942&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587178</ArticleId><ArticleId IdType="pubmed">17880897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin FD, Ren Y, Xu X, Anderson AE. Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. J Neurochem. 2007;103:1381&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">17727632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin FD, Roth TL, Sweatt JD. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci. 2008;28:10576&#x2013;10586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312036</ArticleId><ArticleId IdType="pubmed">18923034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubow RE, Josman ZE. Latent inhibition deficits in hyperactive children. J Child Psychol Psychiatry. 1993;34:959&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">8408378</ArticleId></ArticleIdList></Reference><Reference><Citation>Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code? Curr Opin Genet Dev. 2005;15:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797199</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6:838&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261189</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R. The use of behavioral test batteries: effects of training history. Physiol Behav. 2001;73:705&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566205</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10:1107&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453418</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science. 2001;292:110&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng HH, Robert F, Young RA, Struhl K. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol Cell. 2003;11:709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">12667453</ArticleId></ArticleIdList></Reference><Reference><Citation>Paylor R, Tracy R, Wehner J, Rudy JW. DBA/2 and C57BL/6 mice differ in contextual fear but not auditory fear conditioning. Behav Neurosci. 1994;108:810&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">7986374</ArticleId></ArticleIdList></Reference><Reference><Citation>Paylor R, Spencer CM, Yuva-Paylor LA, Pieke-Dahl S. The use of behavioral test batteries, II: effect of test interval. Physiol Behav. 2006;87:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol. 2004;14:R546&#x2013;R551.</Citation><ArticleIdList><ArticleId IdType="pubmed">15268870</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier R, Cheval H, Mailhes C, Charnay P, Davis S, Laroche S. Paradoxical role of an egr transcription factor family member, egr2/krox20, in learning and memory. Front Behav Neurosci. 2007;1:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525857</ArticleId><ArticleId IdType="pubmed">18958188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler KJ, Paschall G, Zhou XL, Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci. 2002;22:7892&#x2013;7902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758105</ArticleId><ArticleId IdType="pubmed">12223542</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol. 2001;13:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343896</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice JC, Futscher BW. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 2000;28:3233&#x2013;3239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110706</ArticleId><ArticleId IdType="pubmed">10954590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007;25:15&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17218268</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T. Active genes are trimethylated at K4 of histone H3. Nature. 2002;419:407&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">12353038</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider R, Bannister AJ, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol. 2004;6:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">14661024</ArticleId></ArticleIdList></Reference><Reference><Citation>Schotta G, Ebert A, Krauss V, Fischer A, Hoffmann J, Rea S, Jenuwein T, Dorn R, Reuter G. Central role of Drosophila SU(VAR)3&#x2013;9 in histone H3&#x2013;K9 methylation and heterochromatic gene silencing. EMBO J. 2002;21:1121&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125909</ArticleId><ArticleId IdType="pubmed">11867540</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher A, Faust C, Magnuson T. Positional cloning of a global regulator of anterior-posterior patterning in mice. Nature. 1996;384:648.</Citation><ArticleIdList><ArticleId IdType="pubmed">8984348</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">15620353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims RJ, 3rd, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet. 2003;19:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">14585615</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A. 1999;96:14967&#x2013;14972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24756</ArticleId><ArticleId IdType="pubmed">10611321</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank MW, Sweatt JD. Increased histone acetyltransferase and lysine acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular cortex during novel taste learning. J Neurosci. 2001;21:3383&#x2013;3391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762472</ArticleId><ArticleId IdType="pubmed">11331368</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F, Li J, Rao A, Shi Y. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature. 2007;447:601&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">16501568</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439:811&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362057</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet (1999) 1999;23:474&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">10581039</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen M, Mulder KW, Denissov S, Pijnappel WW, van Schaik FM, Varier RA, Baltissen MP, Stunnenberg HG, Mann M, Timmers HT. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007;131:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17884155</ArticleId></ArticleIdList></Reference><Reference><Citation>Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, Shi Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125:467&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">16603238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood MA, Attner MA, Oliveira AM, Brindle PK, Abel T. A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn Mem. 2006;13:609&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783615</ArticleId><ArticleId IdType="pubmed">16980541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature. 1995;378:505&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Siino JS, Jones PR, Yau PM, Bradbury EM. A mass spectrometric Western blot to evaluate the correlations between histone methylation and histone acetylation. Proteomics. 2004;4:3765&#x2013;3775.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378694</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci U S A. 2003;100:8342&#x2013;8347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166231</ArticleId><ArticleId IdType="pubmed">12829790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20231448</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>13</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.</ArticleTitle><Pagination><StartPage>5949</StartPage><EndPage>5954</EndPage><MedlinePgn>5949-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0914141107</ELocationID><Abstract><AbstractText>Having a parent affected with late-onset Alzheimer's disease (LOAD) is a major risk factor among cognitively normal (NL) individuals. This (11)C-Pittsburgh Compound B (PiB)-PET study examines whether NL individuals with LOAD parents show increased fibrillar amyloid-beta (Abeta) deposition, a hallmark of Alzheimer's disease (AD) pathology and whether there are parent-of-origin effects. Forty-two 50- to 80-year-old NL persons were examined with PiB-PET. These individuals included 14 NL subjects with a maternal family history (FH) of LOAD (FHm), 14 NL subjects with a paternal FH (FHp), and 14 NL subjects with a negative family history of any dementia (FH-). Statistical parametric mapping and automated regions-of-interest were used to compare cerebral-to-cerebellar PiB standardized uptake value ratios, reflecting fibrillar Abeta burden, across groups. FH groups did not differ in age, gender, education, and apolipoprotein E (ApoE) status. NL FHm subjects showed higher PiB retention in AD-affected anterior and posterior cingulate cortex (PCC), precuneus, parietal, temporal, occipital, and frontal cortices, right basal ganglia, and thalamus, compared with FH- and FHp subjects. FHp subjects showed increased PiB retention in the PCC and frontal cortex, intermediate between FHm and FH- subjects. Results remained significant after controlling for age, gender, education, and ApoE status. Children of parents with LOAD, particularly those with affected mothers, have increased fibrillar Abeta load in AD-vulnerable regions compared with controls, perhaps accounting for the known increased risk for AD. Present findings may motivate further research on familial transmission and parent-of-origin effects in LOAD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosconi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>New York University School of Medicine, New York, NY 10016, USA. lisa.mosconi@med.nyu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Wai H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Berti</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiyu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Scheinin</LastName><ForeName>Noora</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>N&#xe5;gren</LastName><ForeName>Kjell</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Schantel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vallabhajosula</LastName><ForeName>Shankar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG032554</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032554</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01RR0096</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231448</ArticleId><ArticleId IdType="pmc">PMC2851906</ArticleId><ArticleId IdType="doi">10.1073/pnas.0914141107</ArticleId><ArticleId IdType="pii">0914141107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, et al. MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, et al. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun M, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA. 2007;48:19067&#x2013;19072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141909</ArticleId><ArticleId IdType="pubmed">18003925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer's. Neurology. 2009;72:513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677512</ArticleId><ArticleId IdType="pubmed">19005175</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Swerdlow RH, Vidoni E, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology. 2010;74:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809030</ArticleId><ArticleId IdType="pubmed">20065246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Imaging {beta}-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen N, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008;35:2169&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693402</ArticleId><ArticleId IdType="pubmed">18566819</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, et al. Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830881</ArticleId><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Remes AM, et al. Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol. 2008;65:540&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413480</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci. 2006;26:6069&#x2013;6076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET) Proc Natl Acad Sci USA. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008;29:676&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer's disease. Neuron. 2008;59:190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667147</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, et al. Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. Neurology. 1996;47:254&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenkrantz D, et al. Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am J Med Genet. 1999;88:378&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402505</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, et al. Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol. 2007;64:1743&#x2013;1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071037</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry. 2005;62:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15867110</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology. 2009;73:2071&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790222</ArticleId><ArticleId IdType="pubmed">20007524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol. 1994;51:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, et al. Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp. 1995;2:189&#x2013;210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20231468</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>15</Issue><PubDate><Year>2010</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes.</ArticleTitle><Pagination><StartPage>7036</StartPage><EndPage>7041</EndPage><MedlinePgn>7036-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1000645107</ELocationID><Abstract><AbstractText>Recent epidemiological studies suggest that diabetes mellitus is a strong risk factor for Alzheimer disease. However, the underlying mechanisms remain largely unknown. In this study, to investigate the pathophysiological interaction between these diseases, we generated animal models that reflect the pathologic conditions of both diseases. We crossed Alzheimer transgenic mice (APP23) with two types of diabetic mice (ob/ob and NSY mice), and analyzed their metabolic and brain pathology. The onset of diabetes exacerbated Alzheimer-like cognitive dysfunction without an increase in brain amyloid-beta burden in double-mutant (APP(+)-ob/ob) mice. Notably, APP(+)-ob/ob mice showed cerebrovascular inflammation and severe amyloid angiopathy. Conversely, the cross-bred mice showed an accelerated diabetic phenotype compared with ob/ob mice, suggesting that Alzheimer amyloid pathology could aggravate diabetes. Similarly, APP(+)-NSY fusion mice showed more severe glucose intolerance compared with diabetic NSY mice. Furthermore, high-fat diet feeding induced severe memory deficits in APP(+)-NSY mice without an increase in brain amyloid-beta load. Here, we created Alzheimer mouse models with early onset of cognitive dysfunction. Cerebrovascular changes and alteration in brain insulin signaling might play a pivotal role in this relationship. These findings could provide insights into this intensely debated association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Shuko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Uchio-Yamada</LastName><ForeName>Kozue</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sawada</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kunieda</LastName><ForeName>Takanori</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kurinami</LastName><ForeName>Hitomi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rakugi</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.</RefSource><PMID Version="1">20385830</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000821" MajorTopicYN="N">Animal Feed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231468</ArticleId><ArticleId IdType="pmc">PMC2872449</ArticleId><ArticleId IdType="doi">10.1073/pnas.1000645107</ArticleId><ArticleId IdType="pii">1000645107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744442</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother. 2009;9:617&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Netzer WJ, Greengard P, Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci. 2002;23:288&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084635</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27:190&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004;18:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol. 2009;35:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18346114</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006;67:1960&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159101</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira-Machado JA, Chaves MM. From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients. Expert Opin Ther Targets. 2008;12:871&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">18554155</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23:4096&#x2013;4105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524347</ArticleId><ArticleId IdType="pubmed">15457210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda H, et al. Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of type II diabetes mellitus; NSY mouse. Diabetologia. 2000;43:932&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952468</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke. 2009;40:2601&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704252</ArticleId><ArticleId IdType="pubmed">19443808</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570&#x2013;2581.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab. 2005;25:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">15729290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58:708&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057650</ArticleId><ArticleId IdType="pubmed">18549783</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA. 2004;101:3100&#x2013;3105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365750</ArticleId><ArticleId IdType="pubmed">14981233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, et al. Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler Thromb Vasc Biol. 2009;29:1909&#x2013;1915.</Citation><ArticleIdList><ArticleId IdType="pubmed">19815818</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LP, et al. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse. 2009;63:636&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">19347957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric abeta. J Biol Chem. 2009;284:18742&#x2013;18753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707198</ArticleId><ArticleId IdType="pubmed">19406747</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(Suppl 1):65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">16266773</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Zallen G, Baker LD. Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol. 1992;14:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">1572948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry. 1991;30:1219&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pubmed">1790263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz MW, Porte D., Jr. Diabetes, obesity, and the brain. Science. 2005;307:375&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15662002</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno K, et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science. 2006;312:1656&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17720802</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, et al. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun. 2009;385:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19450564</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison CD. Leptin signaling in brain: A link between nutrition and cognition? Biochim Biophys Acta. 2009;1792:401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670357</ArticleId><ArticleId IdType="pubmed">19130879</ArticleId></ArticleIdList></Reference><Reference><Citation>Niswender KD, et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes. 2003;52:227&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20231476</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>13</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.</ArticleTitle><Pagination><StartPage>6058</StartPage><EndPage>6063</EndPage><MedlinePgn>6058-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0909586107</ELocationID><Abstract><AbstractText>Locus ceruleus (LC)-supplied norepinephrine (NE) suppresses neuroinflammation in the brain. To elucidate the effect of LC degeneration and subsequent NE deficiency on Alzheimer's disease pathology, we evaluated NE effects on microglial key functions. NE stimulation of mouse microglia suppressed Abeta-induced cytokine and chemokine production and increased microglial migration and phagocytosis of Abeta. Induced degeneration of the locus ceruleus increased expression of inflammatory mediators in APP-transgenic mice and resulted in elevated Abeta deposition. In vivo laser microscopy confirmed a reduced recruitment of microglia to Abeta plaque sites and impaired microglial Abeta phagocytosis in NE-depleted APP-transgenic mice. Supplying the mice the norepinephrine precursor L-threo-DOPS restored microglial functions in NE-depleted mice. This indicates that decrease of NE in locus ceruleus projection areas facilitates the inflammatory reaction of microglial cells in AD and impairs microglial migration and phagocytosis, thereby contributing to reduced Abeta clearance. Consequently, therapies targeting microglial phagocytosis should be tested under NE depletion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, University of Bonn, 53105 Bonn, Germany. michael.heneka@ukb.uni-bonn.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadrigny</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Regen</LastName><ForeName>Tommy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Martinez-Hernandez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dumitrescu-Ozimek</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Terwel</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jardanhazi-Kurutz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hanisch</LastName><ForeName>Uwe-Karsten</ForeName><Initials>UK</Initials></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2010 May;11(5):297. doi: 10.1038/nrn2843.</RefSource><PMID Version="1">20419860</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231476</ArticleId><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="doi">10.1073/pnas.0909586107</ArticleId><ArticleId IdType="pii">0909586107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Forno L. Pathology of Parkinsonism: A preliminary report of 24 cases. J Neurosurg. 1966;(Supplement, Part II):266&#x2013;271.</Citation></Reference><Reference><Citation>Iversen LL, et al. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett. 1983;39:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">6633940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord. 1987;1:256&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">3453748</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews KL, et al. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002;51:407&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">11904135</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien A, et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007;28:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev. 2004;45:38&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15063099</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein DL, et al. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002;41:357&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology. 2002;43:1026&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">12423672</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26:1343&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675491</ArticleId><ArticleId IdType="pubmed">16452658</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschy JM, Grzanna R. Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog Brain Res. 1991;88:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">1726027</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SA, Marck BT, Palmiter RD, Matsumoto AM. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem. 1998;70:2468&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603211</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry. 1979;135:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">486847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry. 1980;136:533&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">6155966</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstl H, Levy R, Burns A, Luthert P, Cairns N. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease&#x2014;a hypothesis. Pharmacopsychiatry. 1994;27:11&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8159776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry. 1999;46:756&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">10494443</ArticleId></ArticleIdList></Reference><Reference><Citation>Szot P, et al. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci. 2006;26:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674412</ArticleId><ArticleId IdType="pubmed">16407544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendijk WJ, et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol. 1999;45:82&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894881</ArticleId></ArticleIdList></Reference><Reference><Citation>Murchison CF, et al. A distinct role for norepinephrine in memory retrieval. Cell. 2004;117:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066288</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi V, et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett. 1992;146:176&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">1337194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi V, et al. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem. 2000;75:634&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899938</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999;13:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrigal JLM, Leza JC, Polak P, Kalinin S, Feinstein DL. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci. 2009;29:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664914</ArticleId><ArticleId IdType="pubmed">19129402</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrigal JLM, Kalinin S, Richardson JC, Feinstein DL. Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem. 2007;103:2092&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfman C, et al. Recovery of central noradrenergic neurons one year after the administration of the neurotoxin DSP4. Neurochem Int. 1994;25:395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">7820072</ArticleId></ArticleIdList></Reference><Reference><Citation>Puoliv&#xe4;li J, Pradier L, Riekkinen P., Jr Impaired recovery of noradrenaline levels in apolipoprotein E-deficient mice after N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine lesion. Neuroscience. 2000;95:353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10658614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschy JM, Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol. 1992;321:421&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">1506478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, et al. The microglia-activating potential of thrombin: the protease is not involved in the induction of proinflammatory cytokines and chemokines. J Biol Chem. 2004;279:51880&#x2013;51887.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle T, et al. GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci. 2006;26:12838&#x2013;12846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674839</ArticleId><ArticleId IdType="pubmed">17151287</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci. 2002;22:2434&#x2013;2442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758307</ArticleId><ArticleId IdType="pubmed">11923407</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Pologruto TA, Sabatini BL, Svoboda K. ScanImage: flexible software for operating laser scanning microscopes. Biomed Eng Online. 2003;2:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161784</ArticleId><ArticleId IdType="pubmed">12801419</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20237255</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Protein disulfide isomerase and the endoplasmic reticulum in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>3865</StartPage><EndPage>3867</EndPage><MedlinePgn>3865-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0408-10.2010</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Adam K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Howard Florey Institute, Florey Neuroscience Institutes, and Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010, Australia. adam.walker@florey.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 5.3.4.1</RegistryNumber><NameOfSubstance UI="D019704">Protein Disulfide-Isomerases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Neurosci. 29:13850.</RefSource><PMID Version="1">19889996</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019704" MajorTopicYN="N">Protein Disulfide-Isomerases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20237255</ArticleId><ArticleId IdType="pmc">PMC6632276</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0408-10.2010</ArticleId><ArticleId IdType="pii">30/11/3865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, Nunan J, Rembach A, Nagley P, Beart PM, Cheema SS, Horne MK. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J Biol Chem. 2006;281:30152&#x2013;30165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847061</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, Horne MK. Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis. 2008;30:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">18440237</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Sano F, Fazi B, Tufi R, Nardacci R, Piacentini M. Reticulon-1C acts as a molecular switch between endoplasmic reticulum stress and genotoxic cell death pathway in human neuroblastoma cells. J Neurochem. 2007;102:345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596210</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans K, Keller C, Pavur K, Glasgow K, Conn B, Lauring B. Interaction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenance. Proc Natl Acad Sci U S A. 2006;103:10666&#x2013;10671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502289</ArticleId><ArticleId IdType="pubmed">16815977</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasana E, Fossati M, Ruggiano A, Brambillasca S, Hoogenraad CC, Navone F, Francolini M, Borgese N. A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum. FASEB J. 2010 doi: 10.1096/fj.09-147850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-147850</ArticleId><ArticleId IdType="pubmed">20008544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo AM, Brown RH, Glimcher LH. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 2009;23:2294&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758741</ArticleId><ArticleId IdType="pubmed">19762508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Shibata Y, Zhu PP, Voss C, Rismanchi N, Prinz WA, Rapoport TA, Blackstone C. A class of dynamin-like GTPases involved in the generation of the tubular ER network. Cell. 2009;138:549&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746359</ArticleId><ArticleId IdType="pubmed">19665976</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776&#x2013;12786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801051</ArticleId><ArticleId IdType="pubmed">19828789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrywka NJ, Payne-Tobin A, Raley-Susman KM, Swartzman S. Microtubules, the ER and Exu: new associations revealed by analysis of mini spindles mutations. Mech Dev. 2009;126:289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2731561</ArticleId><ArticleId IdType="pubmed">19303437</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci. 2009;12:627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Hu X, Prior M, Yan R. The occurrence of aging-dependent reticulon 3 immunoreactive dystrophic neurites decreases cognitive function. J Neurosci. 2009;29:5108&#x2013;5115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707820</ArticleId><ArticleId IdType="pubmed">19386906</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata Y, Voss C, Rist JM, Hu J, Rapoport TA, Prinz WA, Voeltz GK. The reticulon and DP1/Yop1p proteins form immobile oligomers in the tubular endoplasmic reticulum. J Biol Chem. 2008;283:18892&#x2013;18904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441541</ArticleId><ArticleId IdType="pubmed">18442980</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng FY, Tang BL. Cell autonomous function of Nogo and reticulons: the emerging story at the endoplasmic reticulum. J Cell Physiol. 2008;216:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">18330888</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Farg MA, Bye CR, McLean CA, Horne MK, Atkin JD. Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis. Brain. 2010;133:105&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19903735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Q, Kuang E, Dong W, Zhou S, Xu H, Qi Y, Liu Y. Reticulon 3 mediates Bcl-2 accumulation in mitochondria in response to endoplasmic reticulum stress. Apoptosis. 2007;12:319&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">17191123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YS, Harel NY, Strittmatter SM. Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis. J Neurosci. 2009;29:13850&#x2013;13859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797811</ArticleId><ArticleId IdType="pubmed">19889996</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2029618</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>541</Volume><Issue>1</Issue><PubDate><Year>1991</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>166</EndPage><MedlinePgn>163-6</MedlinePgn></Pagination><Abstract><AbstractText>During the course of our immunohistochemical studies on the change of lipids in Alzheimer's disease brains by using antibody to apolipoprotein E, a protein having a special relevance to nervous tissue, we unexpectedly found that apo E immunoreactivity was associated with amyloid in both senile plaques and cerebral vessels and neurofibrillary tangles. The immunoreactivity was also found in amyloid of kuru plaques in Creutzfeldt-Jakob disease. Pretreatment of the sections with formic acid greatly enhanced immunoreactivity of senile and kuru plaques to antibody to apo E.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Namba</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Faculty of Medicine, University of Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomonaga</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kawasaki</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Otomo</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007729" MajorTopicYN="N">Kuru</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>2</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>2</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId><ArticleId IdType="doi">10.1016/0006-8993(91)91092-f</ArticleId><ArticleId IdType="pii">0006-8993(91)91092-F</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20305648</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>413</EndPage><MedlinePgn>411-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2511</ELocationID><Abstract><AbstractText>Microglia, the immune cells of the brain, can have a beneficial effect in Alzheimer's disease by phagocytosing amyloid-beta. Two-photon in vivo imaging of neuron loss in the intact brain of living Alzheimer's disease mice revealed an involvement of microglia in neuron elimination, indicated by locally increased number and migration velocity of microglia around lost neurons. Knockout of the microglial chemokine receptor Cx3cr1, which is critical in neuron-microglia communication, prevented neuron loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuhrmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Christian K E</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Burgold</LastName><ForeName>Steffen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Page</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Mitteregger</LastName><ForeName>Gerda</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Kretzschmar</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20305648</ArticleId><ArticleId IdType="mid">NIHMS584345</ArticleId><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="doi">10.1038/nn.2511</ArticleId><ArticleId IdType="pii">nn.2511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Nat. Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, et al. Nat. Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Nat. Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>London JA, Biegel D, Pachter JS. Proc. Natl. Acad. Sci. USA. 1996;93:4147&#x2013;4152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39502</ArticleId><ArticleId IdType="pubmed">8633031</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, et al. J. Neurosci. 1996;16:6021&#x2013;6037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579176</ArticleId><ArticleId IdType="pubmed">8815885</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, et al. J. Neurosci. 2007;27:6224&#x2013;6233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672160</ArticleId><ArticleId IdType="pubmed">17553995</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JK, et al. Proc. Natl. Acad. Sci. USA. 1998;95:10896&#x2013;10901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27992</ArticleId><ArticleId IdType="pubmed">9724801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman GA, et al. J. Neurosci. 2000;20:RC87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772533</ArticleId><ArticleId IdType="pubmed">10899174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, et al. J. Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, et al. Nat. Neurosci. 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;nes A, et al. J. Cereb. Blood Flow Metab. 2008;28:1707&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">18575457</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, et al. Nat. Neurosci. 2005;8:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, et al. Mol. Cell. Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20308552</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>14</Issue><PubDate><Year>2010</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome.</ArticleTitle><Pagination><StartPage>6538</StartPage><EndPage>6543</EndPage><MedlinePgn>6538-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0914251107</ELocationID><Abstract><AbstractText>Full-length amyloid beta peptides (Abeta(1-40/42)) form neuritic amyloid plaques in Alzheimer's disease (AD) patients and are implicated in AD pathology. However, recent transgenic animal models cast doubt on their direct role in AD pathology. Nonamyloidogenic truncated amyloid-beta fragments (Abeta(11-42) and Abeta(17-42)) are also found in amyloid plaques of AD and in the preamyloid lesions of Down syndrome, a model system for early-onset AD study. Very little is known about the structure and activity of these smaller peptides, although they could be the primary AD and Down syndrome pathological agents. Using complementary techniques of molecular dynamics simulations, atomic force microscopy, channel conductance measurements, calcium imaging, neuritic degeneration, and cell death assays, we show that nonamyloidogenic Abeta(9-42) and Abeta(17-42) peptides form ion channels with loosely attached subunits and elicit single-channel conductances. The subunits appear mobile, suggesting insertion of small oligomers, followed by dynamic channel assembly and dissociation. These channels allow calcium uptake in amyloid precursor protein-deficient cells. The channel mediated calcium uptake induces neurite degeneration in human cortical neurons. Channel conductance, calcium uptake, and neurite degeneration are selectively inhibited by zinc, a blocker of amyloid ion channel activity. Thus, truncated Abeta fragments could account for undefined roles played by full length Abetas and provide a unique mechanism of AD and Down syndrome pathologies. The toxicity of nonamyloidogenic peptides via an ion channel mechanism necessitates a reevaluation of the current therapeutic approaches targeting the nonamyloidogenic pathway as avenue for AD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyunbum</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Cancer Research Nanobiology Program, SAIC-Frederick, Inc, National Cancer Institute, Frederick, MD 21702, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arce</LastName><ForeName>Fernando Teran</ForeName><Initials>FT</Initials></Author><Author ValidYN="Y"><LastName>Ramachandran</LastName><ForeName>Srinivasan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Capone</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Azimova</LastName><ForeName>Rushana</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kagan</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Nussinov</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Ratnesh</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN261200800001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C549047">amyloid beta-peptide (9-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605559">amyloid beta-protein (11-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>155178-13-5</RegistryNumber><NameOfSubstance UI="C086839">amyloid beta-protein (17-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20308552</ArticleId><ArticleId IdType="pmc">PMC2851998</ArticleId><ArticleId IdType="doi">10.1073/pnas.0914251107</ArticleId><ArticleId IdType="pii">0914251107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bucciantini M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, et al. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan BL. Amyloidosis and protein folding. Science. 2005;307:42&#x2013;43. author reply 42&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641174</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Zheng J, Lal R, Nussinov R. New structures help the modeling of toxic amyloidbeta ion channels. Trends Biochem Sci. 2008;33:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT., Jr Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002;418:291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Bhatia R, Lal R. Amyloid &#x3b2; protein forms ion channels: implications for Alzheimer&#x2019;s disease pathophysiology. FASEB J. 2001;15:2433&#x2013;2444.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689468</ArticleId></ArticleIdList></Reference><Reference><Citation>Quist A, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA. 2005;102:10427&#x2013;10432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180768</ArticleId><ArticleId IdType="pubmed">16020533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee SK, Quist AP, Lal R. Amyloid &#x3b2; protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J Biol Chem. 1998;273:13379&#x2013;13382.</Citation><ArticleIdList><ArticleId IdType="pubmed">9593665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Zhu YJ, Lal R. Amyloid &#x3b2; protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry. 1999;38:11189&#x2013;11196.</Citation><ArticleIdList><ArticleId IdType="pubmed">10460176</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Pollard HB, Rojas E. Zn2+ interaction with Alzheimer amyloid &#x3b2; protein calcium channels. Proc Natl Acad Sci USA. 1996;93:1710&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40007</ArticleId><ArticleId IdType="pubmed">8643694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer&#x2019;s &#x3b2;-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem. 2000;275:14077&#x2013;14083.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirakura Y, Lin MC, Kagan BL. Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red. J Neurosci Res. 1999;57:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirakura Y, Yiu WW, Yamamoto A, Kagan BL. Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block) Amyloid. 2000;7:194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11019860</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat Cell Biol. 2004;6:1054&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Motte J, Williams RS. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 1989;77:535&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">2524150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing E, et al. Chemical characterization of A &#x3b2; 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem. 1994;269:10987&#x2013;10990.</Citation><ArticleIdList><ArticleId IdType="pubmed">8157623</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins LS, Murphy GM, Jr, Forno LS, Catalano R, Cordell B. P3 &#x3b2;-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer&#x2019;s disease brain. Am J Pathol. 1996;149:585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865300</ArticleId><ArticleId IdType="pubmed">8701997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, et al. Amyloid &#x3b2; 1-42 deposits do not lead to Alzheimer&#x2019;s neuritic plaques in aged dogs. Biochem J. 1996;313:575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1216946</ArticleId><ArticleId IdType="pubmed">8573095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalowski M, et al. The &#x201c;nonamyloidogenic&#x201d; p3 fragment (amyloid &#x3b2;17-42) is a major constituent of Down&#x2019;s syndrome cerebellar preamyloid. J Biol Chem. 1996;271:33623&#x2013;33631.</Citation><ArticleIdList><ArticleId IdType="pubmed">8969231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Norton DD, Wang X, Kusiak JW. Abeta 17-42 in Alzheimer&#x2019;s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain. 2002;125:2036&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183349</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczepanik AM, Rampe D, Ringheim GE. Amyloid-&#x3b2; peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem. 2001;77:304&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279286</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of &#x3b2;-amyloid peptides in vitro. J Biol Chem. 1995;270:23895&#x2013;23898.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Zheng J, Nussinov R. Models of &#x3b2;-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process. Biophys J. 2007;93:1938&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1959551</ArticleId><ArticleId IdType="pubmed">17526580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B, Nussinov R. Stabilities and conformations of Alzheimer&#x2019;s &#x3b2; -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. Proc Natl Acad Sci USA. 2002;99:14126&#x2013;14131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137848</ArticleId><ArticleId IdType="pubmed">12391326</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-&#x3b2;(1-42) fibrils. Proc Natl Acad Sci USA. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata K, et al. 3D structure of amyloid protofilaments of &#x3b2;2-microglobulin fragment probed by solid-state NMR. Proc Natl Acad Sci USA. 2006;103:18119&#x2013;18124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838716</ArticleId><ArticleId IdType="pubmed">17108084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson N, et al. General structural motifs of amyloid protofilaments. Proc Natl Acad Sci USA. 2006;103:16248&#x2013;16253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1637568</ArticleId><ArticleId IdType="pubmed">17060612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MC, Mirzabekov T, Kagan BL. Channel formation by a neurotoxic prion protein fragment. J Biol Chem. 1997;272:44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirakura Y, Kagan BL. Pore formation by &#x3b2;-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. Amyloid. 2001;8:94&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409039</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx J. Alzheimer&#x2019;s disease. Fresh evidence points to an old suspect: calcium. Science. 2007;318:384&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">17947560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustata M, et al. K3 fragment of amyloidogenic beta(2)-microglobulin forms ion channels: implication for dialysis related amyloidosis. J Am Chem Soc. 2009;131:14938&#x2013;14945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782653</ArticleId><ArticleId IdType="pubmed">19824733</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, Ma B, Lal R, Nussinov R. Models of toxic &#x3b2;-sheet channels of protegrin-1 suggest a common subunit organization motif shared with toxic alzheimer &#x3b2;-amyloid ion channels. Biophys J. 2008;95:4631&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2576390</ArticleId><ArticleId IdType="pubmed">18708452</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulin F, et al. P3 peptide, a truncated form of A &#x3b2; devoid of synaptotoxic effect, does not assemble into soluble oligomers. FEBS Lett. 2008;582:1865&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474239</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, et al. A heparin-binding domain in the amyloid protein precursor of Alzheimer&#x2019;s disease is involved in the regulation of neurite outgrowth. J Neurosci. 1994;14:2117&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577125</ArticleId><ArticleId IdType="pubmed">8158260</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem. 1996;67:1882&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. Alzheimer&#x2019;s disease: channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun. 2005;331:375&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850769</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29:258&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112278</ArticleId><ArticleId IdType="pubmed">18762209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokjohn TA, Roher AE. Amyloid precursor protein transgenic mouse models and Alzheimer&#x2019;s disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement. 2009;5:340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704491</ArticleId><ArticleId IdType="pubmed">19560104</ArticleId></ArticleIdList></Reference><Reference><Citation>Brender JR, et al. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J Am Chem Soc. 2008;130:6424&#x2013;6429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163023</ArticleId><ArticleId IdType="pubmed">18444645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H, et al. Misfolded amyloid ion channels present mobile &#x3b2;-sheet subunits in contrast to conventional ion channels. Biophys J. 2009;97:3029&#x2013;3037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784570</ArticleId><ArticleId IdType="pubmed">19948133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller P, Rudin DO, Tien HT, Wescott WC. Reconstitution of cell membrane structure in vitro and its transformation into an excitable system. Nature. 1962;194:979&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14476933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzabekov TA, Silberstein AY, Kagan BL. Use of planar lipid bilayer membranes for rapid screening of membrane active compounds. Methods Enzymol. 1999;294:661&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9916254</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone R, Blake S, Restrepo MR, Yang J, Mayer M. Designing nanosensors based on charged derivatives of gramicidin A. J Am Chem Soc. 2007;129:9737&#x2013;9745.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625848</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone R, et al. Amyloid-&#x3b2;-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotox Res. 2009;16:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864106</ArticleId><ArticleId IdType="pubmed">19526294</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart OS, Goodfellow JM, Wallace BA. The pore dimensions of gramicidin A. Biophys J. 1993;65:2455&#x2013;2460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225986</ArticleId><ArticleId IdType="pubmed">7508762</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20335313</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-3704</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of internal medicine</Title><ISOAbbreviation>Ann Intern Med</ISOAbbreviation></Journal><ArticleTitle>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.</ArticleTitle><Pagination><StartPage>726</StartPage><EndPage>732</EndPage><MedlinePgn>726-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7326/0003-4819-152-11-201006010-00232</ELocationID><Abstract><AbstractText>The CONSORT (Consolidated Standards of Reporting Trials) statement is used worldwide to improve the reporting of randomized, controlled trials. Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Kenneth F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Family Health International, Research Triangle Park, North Carolina 27709, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altman</LastName><ForeName>Douglas G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Moher</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><CollectiveName>CONSORT Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016431">Guideline</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Intern Med</MedlineTA><NlmUniqueID>0372351</NlmUniqueID><ISSNLinking>0003-4819</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2011 Feb 15;154(4):290-1; author reply 291-2. doi: 10.7326/0003-4819-154-4-201102150-00016.</RefSource><PMID Version="1">21320945</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D011643" MajorTopicYN="N">Publishing</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Altman</LastName><ForeName>Douglas G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbour</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutron</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devereaux</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickersin</LastName><ForeName>Kay</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elbourne</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellenberg</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gebski</LastName><ForeName>Val</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf8;tzsche</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groves</LastName><ForeName>Trish</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grunberg</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haynes</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hopewell</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juhn</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Middleton</LastName><ForeName>Philippa</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minckler</LastName><ForeName>Don</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montori</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulrow</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pocock</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rennie</LastName><ForeName>Drummond</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schriger</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulz</LastName><ForeName>Kenneth F</ForeName><Initials>KF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simera</LastName><ForeName>Iveta</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wager</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guyatt</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20335313</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-152-11-201006010-00232</ArticleId><ArticleId IdType="pii">0003-4819-152-11-201006010-00232</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20335454</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo.</ArticleTitle><Pagination><StartPage>4190</StartPage><EndPage>4196</EndPage><MedlinePgn>4190-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6393-09.2010</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive neurological disorder that causes dementia and poses a major public health crisis as the population ages. Aberrant processing of the amyloid precursor protein (APP) is strongly implicated as a proximal event in AD pathophysiology, but the neurochemical signals that regulate APP processing in the brain are not completely understood. Activation of muscarinic acetylcholine receptors (mAChRs) has been shown to affect APP processing and AD pathology, but less is known about the roles of specific mAChR subtypes. In this study, we used M(1) mAChR knock-out mice (M(1)KO) to isolate the effects of the M(1) mAChR on APP processing in primary neurons and on the development of amyloid pathology in a transgenic mouse model of AD. We demonstrate that the loss of M(1) mAChRs increases amyloidogenic APP processing in neurons, as evidenced by decreased agonist-regulated shedding of the neuroprotective APP ectodomain APPsalpha and increased production of toxic Abeta peptides. Expression of M(1) mAChRs on the M(1)KO background rescued this phenotype, indicating that M(1) mAChRs are sufficient to modulate nonamyloidogenic APP processing. In APP(Swe/Ind) transgenic mice, the loss of M(1) mAChRs resulted in increased levels of brain Abeta and greater accumulation of amyloid plaque pathology. Analysis of APP metabolites in APP(Swe/Ind) brain tissue indicates that the loss of M(1) mAChRs increases amyloidogenic APP processing. These results indicate that the M(1) mAChR is an important regulator of amyloidogenesis in the brain and provide strong support for targeting the M(1) mAChR as a therapeutic candidate in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Albert A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease and Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritz</LastName><ForeName>Jason J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Wess</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 AG029731</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS030454</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008169</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS030454</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018679">Cholinergic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>8Y164V895Y</RegistryNumber><NameOfSubstance UI="D002217">Carbachol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491234">Adam10 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002217" MajorTopicYN="N">Carbachol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018679" MajorTopicYN="N">Cholinergic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20335454</ArticleId><ArticleId IdType="mid">NIHMS189509</ArticleId><ArticleId IdType="pmc">PMC2855655</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6393-09.2010</ArticleId><ArticleId IdType="pii">30/12/4190</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 2009;5:234&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483218</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Potter PE, Kuo YM, Emmerling MR, Durham RA, Webster SD, Walker DG, Sue LI, Scott S, Layne KJ, Roher AE. Cholinergic deafferentation of the rabbit cortex: a new animal model of Abeta deposition. Neurosci Lett. 2000;283:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10729621</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Kuo YM, Schwab C, Walker DG, Roher AE. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neurosci Lett. 2001a;310:21&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524148</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res. 2001b;905:220&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KF, Zheng L, Fahrenholz F, Cuello AC. ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging. 2008;29:554&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187903</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley NJ, Bonner TI, Brann MR. Localization of a family of muscarinic receptor mRNAs in rat brain. J Neurosci. 1988;8:4646&#x2013;4652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569562</ArticleId><ArticleId IdType="pubmed">3199198</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLapp N, Wu S, Belagaje R, Johnstone E, Little S, Shannon H, Bymaster F, Calligaro D, Mitch C, Whitesitt C, Ward J, Sheardown M, Fink-Jensen A, Jeppesen L, Thomsen C, Sauerberg P. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. Biochem Biophys Res Commun. 1998;244:156&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9514902</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci. 2008;28:12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber SA, Nitsch RM, Schulz JG, Wurtman RJ. Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci. 1995;15:7442&#x2013;7451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578089</ArticleId><ArticleId IdType="pubmed">7472496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralle M, Botelho MG, Wouters FS. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem. 2009;284:15016&#x2013;15025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685684</ArticleId><ArticleId IdType="pubmed">19336403</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, Wengier A, Meshulam H, Marciano D, Karton Y, Fisher A. Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun. 1994;203:652&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">8074717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Maddalena A, Raschig A, M&#xfc;ller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, M&#xfc;ller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid. 2003;10:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12762134</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. 2008;28:10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol. 1997;52:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">9281605</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, Racchi M. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. Chem Biol Interact. 2007;165:138&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196952</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11:3218&#x2013;3226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575445</ArticleId><ArticleId IdType="pubmed">1941081</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1&#x2013;m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15:4077&#x2013;4092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578239</ArticleId><ArticleId IdType="pubmed">7751967</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 1993;10:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci U S A. 1998;95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci. 2001;21:5239&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie H, Li Z, Lukas RJ, Shen Y, Song L, Wang X, Yin M. Construction of SH-EP1-alpha4beta2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells. Cell Mol Neurobiol. 2008;28:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11515028</ArticleId><ArticleId IdType="pubmed">17912626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">1411529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48:913&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117548</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol. 2003;54:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891676</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci. 1996;777:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615&#x2013;29619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans. 2005;33:1087&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246051</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff-Pak DS. Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis. 2008;15:507&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20339023</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.</ArticleTitle><Pagination><StartPage>2716</StartPage><EndPage>2726</EndPage><MedlinePgn>2716-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.09-150359</ELocationID><Abstract><AbstractText>There is accumulating evidence that soluble amyloid-beta (Abeta) oligomers, rather than amyloid fibrils, are the principal pathogenic species in Alzheimer disease (AD). Here, we have developed a novel enzyme-linked immunosorbent assay (ELISA) specific for high-molecular-weight (HMW) Abeta oligomers. Analysis of Abeta oligomers derived from synthetic Abeta 1-42, by size-exclusion chromatography (SEC), revealed that our ELISA specifically detected HMW Abeta oligomers of 40-200 kDa. Using this ELISA, we detected significantly higher (P&lt;0.0001) signals in cerebrospinal fluid (CSF) samples from 25 patients with AD or mild cognitive impairment (MCI), compared to 25 age-matched controls. As a test for discriminating between the AD/MCI and control groups, the area under the curve in receiver operating characteristic analysis for the CSF HMW Abeta oligomers was greater than that for CSF Abeta x-42. Furthermore, the CSF levels of HMW Abeta oligomers showed a negative correlation with Mini-Mental State Examination scores in the AD/MCI group. We conclude that the CSF HMW Abeta oligomers detected by our ELISA could be useful as a diagnostic marker for AD, and also as a potential surrogate marker for disease severity. Our results support the idea that soluble HMW Abeta oligomers play a critical role in the pathogenesis and progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukumoto</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharmacology Research Division, Takeda Pharmaceutical Company, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kasai</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ishigami</LastName><ForeName>Noriko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Hiroya</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Masaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Allsop</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20339023</ArticleId><ArticleId IdType="doi">10.1096/fj.09-150359</ArticleId><ArticleId IdType="pii">fj.09-150359</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20348957</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>392</StartPage><EndPage>399</EndPage><MedlinePgn>392-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.557</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of motor neurons. Using unbiased transcript profiling in an ALS mouse model, we identified a role for the co-stimulatory pathway, a key regulator of immune responses. Furthermore, we observed that this pathway is upregulated in the blood of 56% of human patients with ALS. A therapy using a monoclonal antibody to CD40L was developed that slows weight loss, delays paralysis and extends survival in an ALS mouse model. This work demonstrates that unbiased transcript profiling can identify cellular pathways responsive to therapeutic intervention in a preclinical model of human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lincecum</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>ALS Therapy Development Institute, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Fernando G</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Monica Z</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Zutter</LastName><ForeName>Gerald S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Carrion</LastName><ForeName>Isarelis J</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Al-Nakhala</LastName><ForeName>Bashar M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Shawn M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>147205-72-9</RegistryNumber><NameOfSubstance UI="D023201">CD40 Ligand</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023201" MajorTopicYN="N">CD40 Ligand</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20348957</ArticleId><ArticleId IdType="doi">10.1038/ng.557</ArticleId><ArticleId IdType="pii">ng.557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2008 Jul 23;3(7):e2740</Citation><ArticleIdList><ArticleId IdType="pubmed">18648532</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1992 Nov;13(11):431-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1282319</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1990 Oct;16(5):401-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2004 Aug;3(8):711-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15286737</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscle Nerve. 1992 May;15(5):568-75</Citation><ArticleIdList><ArticleId IdType="pubmed">1316554</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2000 Nov 1;165(9):4783-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11045999</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Aug 03;4(8):e6489</Citation><ArticleIdList><ArticleId IdType="pubmed">19649300</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1993 Sep 3;261(5126):1328-30</Citation><ArticleIdList><ArticleId IdType="pubmed">7689748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Clin Pract Urol. 2007 Dec;4(12):677-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18059348</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1999 Oct 15;286(5439):531-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10521349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2006 Sep 10;24(26):4236-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16896004</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropathol. 1989 Nov-Dec;8(6):289-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotroph Lateral Scler. 2008;9(1):4-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2008 Feb;118(2):659-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18219391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Jul 15;173(2):993-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15240687</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Mol Ther. 2004 Dec;6(6):600-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15663324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1993 Sep 1;151(5):2497-510</Citation><ArticleIdList><ArticleId IdType="pubmed">8103067</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8789-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9238056</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">8637903</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16492768</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Sep 27;273(5283):1864-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8791592</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6550-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1378631</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2164219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2001;10(1):9-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11243513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1997 Nov 1;159(9):4212-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9379015</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1995 Feb 1;154(3):1470-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7529804</ArticleId></ArticleIdList></Reference><Reference><Citation>Int MS J. 2008 Jun;15(2):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18782500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1993 Jan;50(1):30-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2007 Dec;8(12):1071-1078</Citation><ArticleIdList><ArticleId IdType="pubmed">18024211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2002 Dec;5(12):1288-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Oct;9(10):1275-80</Citation><ArticleIdList><ArticleId IdType="pubmed">14502279</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1992 Mar;140(3):691-707</Citation><ArticleIdList><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15558-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1996 Jul 1;157(1):417-26</Citation><ArticleIdList><ArticleId IdType="pubmed">8683147</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1993 Nov 5;262(5135):909-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7694363</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Mol Diagn. 2008 Mar;8(2):167-78</Citation><ArticleIdList><ArticleId IdType="pubmed">18366303</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2008;460:185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18449488</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1998 Mar;121 ( Pt 3):469-79</Citation><ArticleIdList><ArticleId IdType="pubmed">9549523</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16021-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2004 Jan 1;20(1):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14693814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2002;18 Suppl 1:S233-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12169552</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 1996 Jan 15;61(1):4-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8560571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1999 Nov 1;163(9):4805-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10528180</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20356829</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>15</Issue><PubDate><Year>2010</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Learning induces neurotrophin signaling at hippocampal synapses.</ArticleTitle><Pagination><StartPage>7030</StartPage><EndPage>7035</EndPage><MedlinePgn>7030-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0912973107</ELocationID><Abstract><AbstractText>Learning-induced trophic activity is thought to be critical for maintaining health of the aging brain. We report here that learning, acting through an unexpected pathway, activates synaptic receptors for one of the brain's primary trophic factors. Unsupervised learning, but not exploratory activity alone, robustly increased the number of postsynaptic densities associated with activated (phosphorylated) forms of BDNF's TrkB receptor in adult rat hippocampus; these increases were blocked by an NMDA receptor antagonist. Similarly, stimulation of hippocampal slices at the learning-related theta frequency increased synaptic TrkB phosphorylation in an NMDA receptor-dependent fashion. Theta burst stimulation, which was more effective in this regard than other stimulation patterns, preferentially engaged NMDA receptors that, in turn, activated Src kinases. Blocking the latter, or scavenging extracellular TrkB ligands, prevented theta-induced TrkB phosphorylation. Thus, synaptic TrkB activation was dependent upon both ligand presentation and postsynaptic signaling cascades. These results show that afferent activity patterns and cellular events involved in memory encoding initiate BDNF signaling through synaptic TrkB, thereby ensuring that learning will trigger neurotrophic support.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lulu Y</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, University of California, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rex</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Sanaiha</LastName><ForeName>Yas</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gall</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS045540</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS45620</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH083396</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH083396</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS045540</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="Y">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020813" MajorTopicYN="N">Receptor, trkB</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20356829</ArticleId><ArticleId IdType="pmc">PMC2872439</ArticleId><ArticleId IdType="doi">10.1073/pnas.0912973107</ArticleId><ArticleId IdType="pii">0912973107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Faherty CJ, Kerley D, Smeyne RJ. A Golgi-Cox morphological analysis of neuronal changes induced by environmental enrichment. Brain Res Dev Brain Res. 2003;141:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644248</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick KM, Stearns NA, Pan JY, Berger-Sweeney J. Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice. Learn Mem. 2003;10:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC202309</ArticleId><ArticleId IdType="pubmed">12773583</ArticleId></ArticleIdList></Reference><Reference><Citation>Segovia G, Del Arco A, de Blas M, Garrido P, Mora F. Effects of an enriched environment on the release of dopamine in the prefrontal cortex produced by stress and on working memory during aging in the awake rat. Behav Brain Res. 2008;187:304&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17977609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sando SB, et al. Risk-reducing effect of education in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23:1156&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">18484674</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini AM, Jiang H, Pan H, Wu X, Lipsky RH. Hormesis: A promising strategy to sustain endogenous neuronal survival pathways against neurodegenerative disorders. Ageing Res Rev. 2008;7:21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17889623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: Insulin/IGF-1, BDNF and serotonin. Ageing Res Rev. 2004;3:445&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol. 2009;215:153&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632603</ArticleId><ArticleId IdType="pubmed">19013154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LY, Rex CS, Casale MS, Gall CM, Lynch G. Changes in synaptic morphology accompany actin signaling during LTP. J Neurosci. 2007;27:5363&#x2013;5372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672340</ArticleId><ArticleId IdType="pubmed">17507558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedulov V, et al. Evidence that long-term potentiation occurs within individual hippocampal synapses during learning. J Neurosci. 2007;27:8031&#x2013;8039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672739</ArticleId><ArticleId IdType="pubmed">17652593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex CS, et al. Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J Cell Biol. 2009;186:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712993</ArticleId><ArticleId IdType="pubmed">19596849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gall CM, Lauterborn JC. Regulation of BDNF expression: Multifaceted, region-specific control of a neuronal survival factor in the adult CNS. In: Mocchetti I, editor. Neurobiology of the Neurotrophins. Johnson City, TN: FP Graham Publishing Co.; 2000. pp. 541&#x2013;579.</Citation></Reference><Reference><Citation>Schaaf MJ, et al. Correlation between hippocampal BDNF mRNA expression and memory performance in senescent rats. Brain Res. 2001;915:227&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">16062169</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: A review and analysis. Brain Res Brain Res Rev. 1999;29:169&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">10209231</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto T, Eichenbaum H, Wiener SI, Wible CG. Learning-related patterns of CA1 spike trains parallel stimulation parameters optimal for inducing hippocampal long-term potentiation. Hippocampus. 1991;1:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ar&#xe9;valo JC, et al. Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination. Neuron. 2006;50:549&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">16701206</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WC, Mason SE. Effects of the NMDA receptor/channel antagonists CPP and MK801 on hippocampal field potentials and long-term potentiation in anesthetized rats. Brain Res. 1988;462:40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">2846123</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G. Theta rhythm of navigation: Link between path integration and landmark navigation, episodic and semantic memory. Hippocampus. 2005;15:827&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">16149082</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. Control of excitatory synaptic transmission by C-terminal Src kinase. J Biol Chem. 2008;283:17503&#x2013;17514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427324</ArticleId><ArticleId IdType="pubmed">18445593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopal R, Chao MV. A role for Fyn in Trk receptor transactivation by G-protein-coupled receptor signaling. Mol Cell Neurosci. 2006;33:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16860569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Trifilo JA, et al. Integrin signaling cascades are operational in adult hippocampal synapses and modulate NMDA receptor physiology. J Neurochem. 2005;93:834&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857387</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake RA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000;20:9018&#x2013;9027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC86555</ArticleId><ArticleId IdType="pubmed">11074000</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron. 2008;57:546&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18304484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever C, Burgess N, Cacucci F, Hartley T, O'Keefe J. What can the hippocampal representation of environmental geometry tell us about Hebbian learning? Biol Cybern. 2002;87:356&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">12461626</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger R, Whitson J, Larson J, Lynch G. Non-Hebbian properties of long-term potentiation enable high-capacity encoding of temporal sequences. Proc Natl Acad Sci USA. 1994;91:10104&#x2013;10108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44966</ArticleId><ArticleId IdType="pubmed">7937845</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser E, Moser MB, Andersen P. Spatial learning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci. 1993;13:3916&#x2013;3925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576447</ArticleId><ArticleId IdType="pubmed">8366351</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson J, Lynch G. Induction of synaptic potentiation in hippocampus by patterned stimulation involves two events. Science. 1986;232:985&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">3704635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczewski N, et al. Backpropagating action potentials trigger dendritic release of BDNF during spontaneous network activity. J Neurosci. 2008;28:7013&#x2013;7023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670985</ArticleId><ArticleId IdType="pubmed">18596175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18708092</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bohlen und Halbach O, Minichiello L, Unsicker K. TrkB but not trkC receptors are necessary for postnatal maintenance of hippocampal spines. Neurobiol Aging. 2008;29:1247&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442456</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe Y, Toyosawa K. Age-related changes in rat hippocampal theta rhythms: a difference between type 1 and type 2 theta. J Vet Med Sci. 1999;61:543&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">10379948</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex CS, et al. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci. 2007;27:3017&#x2013;3029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672589</ArticleId><ArticleId IdType="pubmed">17360925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kram&#xe1;r EA, Lin B, Rex CS, Gall CM, Lynch G. Integrin-driven actin polymerization consolidates long-term potentiation. Proc Natl Acad Sci USA. 2006;103:5579&#x2013;5584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1459396</ArticleId><ArticleId IdType="pubmed">16567651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs RB, Pfaff DW. In situ hybridization detection of trkA mRNA in brain: distribution, colocalization with p75NGFR and up-regulation by nerve growth factor. J Comp Neurol. 1994;341:324&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">8195465</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder DK, Routbort MJ, McNamara JO. Immunohistochemical evidence of seizure-induced activation of trk receptors in the mossy fiber pathway of adult rat hippocampus. J Neurosci. 1999;19:4616&#x2013;4626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782602</ArticleId><ArticleId IdType="pubmed">10341259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20371462</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>13</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Modeling an anti-amyloid combination therapy for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>13ra1</StartPage><MedlinePgn>13ra1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3000337</ELocationID><Abstract><AbstractText>As only symptomatic treatments are now available for Alzheimer's disease (AD), safe and effective mechanism-based therapies remain a great unmet need for patients with this neurodegenerative disease. Although gamma-secretase and BACE1 [beta-site beta-amyloid (Abeta) precursor protein (APP) cleaving enzyme 1] are well-recognized therapeutic targets for AD, untoward side effects associated with strong inhibition or reductions in amounts of these aspartyl proteases have raised concerns regarding their therapeutic potential. Although moderate decreases of either gamma-secretase or BACE1 are not associated with mechanism-based toxicities, they provide only modest benefits in reducing Abeta in the brains of APPswe/PS1DeltaE9 mice. Because the processing of APP to generate Abeta requires both gamma-secretase and BACE1, it is possible that moderate reductions of both enzymes would provide additive and significant protection against Abeta amyloidosis. Here, we test this hypothesis and assess the value of this novel anti-amyloid combination therapy in mutant mice. We demonstrate that genetic reductions of both BACE1 and gamma-secretase additively attenuate the amyloid burden and ameliorate cognitive deficits occurring in aged APPswe/PS1DeltaE9 animals. No evidence of mechanism-based toxicities was associated with such decreases in amounts of both enzymes. Thus, we propose that targeting both gamma-secretase and BACE1 may be an effective and safe treatment strategy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Vivian W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, 558 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savonenko</LastName><ForeName>Alena V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Melnikova</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyunsu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tong</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS41438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS047308</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041438</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20371462</ArticleId><ArticleId IdType="mid">NIHMS173450</ArticleId><ArticleId IdType="pmc">PMC2852193</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3000337</ArticleId><ArticleId IdType="pii">2/13/13ra1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Cai H, Borchelt DR, Price DL. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 2002;5:633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">12085093</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active &#x3b3;-Secretase complex. Neuron. 2003;38:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wen H, Brayton C, Das P, Smithson LA, Fauq A, Fan X, Crain BJ, Price DL, Golde TE, Eberhart CG, Wong PC. Epidermal growth factor receptor and Notch pathways participate in the tumor suppressor function of &#x3b3;-secretase. J. Biol. Chem. 2007;282:32264&#x2013;32273.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827153</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, Price DL, Eberhart CG, Wong PC. Moderate reduction of &#x3b3;-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 2007;27:10849&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672827</ArticleId><ArticleId IdType="pubmed">17913918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U.S.A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejaegere T, Serneels L, Sch&#xe4;fer MK, Van Biervliet J, Horr&#xe9; K, Depboylu C, Alvarez-Fischer D, Herreman A, Willem M, Haass C, H&#xf6;glinger GU, D'Hooge R, De Strooper B. Deficiency of Aph1B/C-&#x3b3;-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc. Natl. Acad. Sci. U.S.A. 2008;105:9775&#x2013;9780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474502</ArticleId><ArticleId IdType="pubmed">18626010</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM. Chronic treatment with the &#x3b3;-secretase inhibitor LY-411, 575 inhibits &#x3b2;-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ. Modulation of Notch processing by &#x3b3;-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 2004;82:341&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319485</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM. Dynamics of &#x3b2;-amyloid reductions in brain, cerebrospinal fluid, and plasma of &#x3b2;-amyloid precursor protein transgenic mice treated with a &#x3b3;-secretase inhibitor. J. Pharmacol. Exp. Ther. 2005;312:635&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452193</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 2007;282:26326&#x2013;26334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horr&#xe9; K, Van Houtvin T, Esselmann H, Paul S, Sch&#xe4;fer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May PC, Karran E, Wiltfang J, D'Hooge R, De Strooper B. &#x3b3;-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer's disease. Science. 2009;324:639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat. Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J. Neurosci. 2005;25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A&#x3b2; modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem. 2007;282:22707&#x2013;22720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to &#x3b2;-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Zhang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J. Neurosci. 2001;21:8198&#x2013;8209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763862</ArticleId><ArticleId IdType="pubmed">11588192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouzet B, Zhang WN, Feldon J, Rawlins JN. Hippocampal lesioned rats are able to learn a spatial position using non-spatial strategies. Behav. Brain Res. 2002;133:279&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110461</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Long JM, Johnson CT, Olton DS. Variable-interval probe test as a tool for repeated measurements of spatial memory in the water maze. Behav. Neurosci. 1993;107:627&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Lipska BK, Weinberger DR. Genetic mouse models of schizophrenia: From hypothesis-based to susceptibility gene-based models. Biol. Psychiatry. 2006;59:1180&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631133</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 2001;11:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao J, Wolpowitz D, Role LW, Talmage DA. Back signaling by the Nrg-1 intracellular domain. J. Cell Biol. 2003;161:1133&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172983</ArticleId><ArticleId IdType="pubmed">12821646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 2002;26:91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 1987;92:180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">3110839</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 1991;148:1301&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654746</ArticleId></ArticleIdList></Reference><Reference><Citation>Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical anti-psychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol. Psychiatry. 2002;52:729&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372664</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid &#x3b2;-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat. Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. Oxidative stress activates a positive feedback between the &#x3b3;- and &#x3b2;-secretase cleavages of the &#x3b2;-amyloid precursor protein. J. Neurochem. 2008;104:683&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2220052</ArticleId><ArticleId IdType="pubmed">18005001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Osta A, Alberini CM. Amyloid &#x3b2; mediates memory formation. Learn. Mem. 2009;16:267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661754</ArticleId><ArticleId IdType="pubmed">19318468</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-&#x3b2; positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Konietzko U. Amyloid-&#x3b2; immunisation for Alzheimer'sdisease. Lancet Neurol. 2008;7:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752661</ArticleId><ArticleId IdType="pubmed">18667360</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat. Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in &#x3b3;-secretase complexes during embryonic development. J. Neurosci. 2005;25:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725209</ArticleId><ArticleId IdType="pubmed">15634781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: Evidence for augmentation of a 42-specific &#x3b3; secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A&#x3b2; modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem. 2007;282:22707&#x2013;22720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC. &#x3b2;-Amyloid peptide vaccination results in marked changes in serum and brain A&#x3b2; levels in APPswe/PS1&#x394;E9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol. 2001;20:713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">11788049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. A power primer. Psychol. Bull. 1992;112:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19565683</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Xu GM, Price DL, Borchelt DR, Markowska AL. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPSWE. Neurobiol. Dis. 2003;12:194&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742740</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland DJ. Effects of scopolamine, &#x3b4;-amphetamine, and apomorphine on alternation and position biases. Pharmacol. Biochem. Behav. 1989;32:723&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">2740425</ArticleId></ArticleIdList></Reference><Reference><Citation>Koek W, Woods JH, Winger GD. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 1988;245:969&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">2838610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Zou H, Strong JA, Yu J, Zhou X, Xie Q, Zhao G, Jin M, Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology. 2005;177:256&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290006</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Long JM, Johnson CT, Olton DS. Variable-interval probe test as a tool for repeated measurements of spatial memory in the water maze. Behav. Neurosci. 1993;107:627&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20371803</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>14</Issue><PubDate><Year>2010</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex.</ArticleTitle><Pagination><StartPage>4833</StartPage><EndPage>4844</EndPage><MedlinePgn>4833-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5221-09.2010</ELocationID><Abstract><AbstractText>The metalloproteinase and major amyloid precursor protein (APP) alpha-secretase candidate ADAM10 is responsible for the shedding of proteins important for brain development, such as cadherins, ephrins, and Notch receptors. Adam10(-/-) mice die at embryonic day 9.5, due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generated Adam10 conditional knock-out (cKO) mice using a Nestin-Cre promotor, limiting ADAM10 inactivation to neural progenitor cells (NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells. Premature neuronal differentiation is associated with aberrant neuronal migration and a disorganized laminar architecture in the neocortex. Neurospheres derived from Adam10 cKO mice have a disrupted sphere organization and segregated more neurons at the expense of astrocytes. We found that Notch-1 processing was affected, leading to downregulation of several Notch-regulated genes in Adam10 cKO brains, in accordance with the central role of ADAM10 in this signaling pathway and explaining the neurogenic phenotype. Finally, we found that alpha-secretase-mediated processing of APP was largely reduced in these neurons, demonstrating that ADAM10 represents the most important APP alpha-secretase in brain. Our study reveals that ADAM10 plays a central role in the developing brain by controlling mainly Notch-dependent pathways but likely also by reducing surface shedding of other neuronal membrane proteins including APP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jorissen</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Human Genetics, Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie (VIB), 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prox</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bernreuther</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Silvio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schwanbeck</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Lutgarde</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Snellinx</LastName><ForeName>An</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Craessaerts</LastName><ForeName>Katleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thathiah</LastName><ForeName>Amantha</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tesseur</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bartsch</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Weskamp</LastName><ForeName>Gisela</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Blobel</LastName><ForeName>Carl P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY015719</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM064750</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM64750</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY015719</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078201">Aplp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.81</RegistryNumber><NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20371803</ArticleId><ArticleId IdType="mid">NIHMS197834</ArticleId><ArticleId IdType="pmc">PMC2921981</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5221-09.2010</ArticleId><ArticleId IdType="pii">30/14/4833</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexson TO, Hitoshi S, Coles BL, Bernstein A, van der Kooy D. Notch signaling is required to maintain all neural stem cell populations&#x2013;irrespective of spatial or temporal niche. Dev Neurosci. 2006;28:34&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508302</ArticleId></ArticleIdList></Reference><Reference><Citation>Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res. 2003;74:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Angevine JB, Jr, Sidman RL. Autoradiographic study of cell migration during histogenesis of cerebral cortex in the mouse. Nature. 1961;192:766&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">17533671</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol. 1999;147:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221902</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai M, Hattori C, Szab&#xf3; B, Sasagawa N, Maruyama K, Tanuma S, Ishiura S. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun. 2003;301:231&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkulak EC, Weinmaster G. Selective use of Adam10 and Adam17 in activation of Notch1 signaling. Mol Cell Biol. 2009;29:5679&#x2013;5695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772745</ArticleId><ArticleId IdType="pubmed">19704010</ArticleId></ArticleIdList></Reference><Reference><Citation>Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Isra&#xeb;l A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882063</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765&#x2013;27767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Caill&#xe9; I, Allinquant B, Dupont E, Bouillot C, Langer A, M&#xfc;ller U, Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004;131:2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos LS, Leone DP, Relvas JB, Brakebusch C, F&#xe4;ssler R, Suter U, ffrench-Constant C. Beta1 integrins activate a MAPK signalling pathway in neural stem cells that contributes to their maintenance. Development. 2004;131:3433&#x2013;3444.</Citation><ArticleIdList><ArticleId IdType="pubmed">15226259</ArticleId></ArticleIdList></Reference><Reference><Citation>Caviness VS, Jr, Takahashi T, Nowakowski RS. Numbers, time and neocortical neuronogenesis: a general developmental and evolutionary model. Trends Neurosci. 1995;18:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">7482802</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbin JG, Gaiano N, Juliano SL, Poluch S, Stancik E, Haydar TF. Regulation of neural progenitor cell development in the nervous system. J Neurochem. 2008;106:2272&#x2013;2287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640107</ArticleId><ArticleId IdType="pubmed">18819190</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa RM, Honjo T, Silva AJ. Learning and memory deficits in Notch mutant mice. Curr Biol. 2003;13:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906797</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Barger SW, Blalock EM, Mattson MP. Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature. 1996;379:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8538744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiano N. Strange bedfellows: Reelin and Notch signaling interact to regulate cell migration in the developing neocortex. Neuron. 2008;60:189&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon WR, Arnett KL, Blacklow SC. The molecular logic of Notch signaling&#x2014;a structural and biochemical perspective. J Cell Sci. 2008;121:3109&#x2013;3119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696053</ArticleId><ArticleId IdType="pubmed">18799787</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus-Porta D, Blaess S, Senften M, Littlewood-Evans A, Damsky C, Huang Z, Orban P, Klein R, Schittny JC, M&#xfc;ller U. Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron. 2001;31:367&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M, Altevogt DP. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003;17:292&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, L&#xfc;bke T, Lena Illert A, von Figura K, Saftig P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002;11:2615&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">12354787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto-Torii K, Torii M, Sarkisian MR, Bartley CM, Shen J, Radtke F, Gridley T, Sestan N, Rakic P. Interaction between Reelin and Notch signaling regulates neuronal migration in the cerebral cortex. Neuron. 2008;60:273&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913541</ArticleId><ArticleId IdType="pubmed">18957219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatten ME. Riding the glial monorail: a common mechanism for glial-guided neuronal migration in different regions of the developing mammalian brain. Trends Neurosci. 1990;13:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">1693236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatten ME. The role of migration in central nervous system neuronal development. Curr Opin Neurobiol. 1993;3:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori M, Osterfield M, Flanagan JG. Regulated cleavage of a contact-mediated axon repellent. Science. 2000;289:1360&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkle CL, Diestel S, Lieberman J, Maness PF. Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM) J Neurobiol. 2006;66:1378&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, Conlon RA, Mak TW, Bernstein A, van der Kooy D. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 2002;16:846&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186324</ArticleId><ArticleId IdType="pubmed">11937492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper NM, Turner AJ. The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem. 2002;9:1107&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052175</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvin DK, Zurcher SD, Nguyen T, Weinmaster G, Kornblum HI. Expression patterns of Notch1, Notch2, and Notch3 suggest multiple functional roles for the Notch-DSL signaling system during brain development. J Comp Neurol. 2001;436:167&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi M, Ang SL, Shiota K, Nakanishi S, Kageyama R, Guillemot F. Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES-1) leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and severe neural tube defects. Genes Dev. 1995;9:3136&#x2013;3148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543157</ArticleId></ArticleIdList></Reference><Reference><Citation>Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell. 2005;123:291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WY, Shen J. Presenilins are required for maintenance of neural stem cells in the developing brain. Mol Neurodegener. 2008;3:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235867</ArticleId><ArticleId IdType="pubmed">18182109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber T, Kidd S, Young MW. Kuzbanian-mediated cleavage of Drosophila Notch. Genes Dev. 2002;16:209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC155326</ArticleId><ArticleId IdType="pubmed">11799064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Luo J, Redies C. Differential expression of five members of the ADAM family in the developing chicken brain. Neuroscience. 2008;157:360&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18832016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsell CE, Boulter J, diSibio G, Gossler A, Weinmaster G. Expression patterns of Jagged, Delta1, Notch1, Notch2, and Notch3 genes identify ligand-receptor pairs that may function in neural development. Mol Cell Neurosci. 1996;8:14&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923452</ArticleId></ArticleIdList></Reference><Reference><Citation>Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci. 2006;7:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16429119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol. 1994;25:439&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">7915758</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell SK. Constructing the cerebral cortex: neurogenesis and fate determination. Neuron. 1995;15:761&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mission JP, Takahashi T, Caviness VS., Jr Ontogeny of radial and other astroglial cells in murine cerebral cortex. Glia. 1991;4:138&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">1709615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani K, Saito T. Progenitors resume generating neurons after temporary inhibition of neurogenesis by Notch activation in the mammalian cerebral cortex. Development. 2005;132:1295&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15750183</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000;228:151&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11112321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell. 2000;5:197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell. 1997;90:271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">9244301</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812885</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R. A closer look at alpha-secretase. Curr Alzheimer Res. 2008;5:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393803</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113:1456&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P. Specification of cerebral cortical areas. Science. 1988;241:170&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">3291116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 2005;24:742&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549617</ArticleId><ArticleId IdType="pubmed">15692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 1996;175:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608856</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci. 1992;12:4565&#x2013;4574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575989</ArticleId><ArticleId IdType="pubmed">1432110</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M, Carlo AS, Breyhan H, Sporbert A, Militz D, Schmidt V, Wozny C, Harmeier A, Erdmann B, Bales KR, Wolf S, Kempermann G, Paul SM, Schmitz D, Bayer TA, Willnow TE, Andersen OM. Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem. 2008;283:14826&#x2013;14834.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362153</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, Kirkwood A, Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuurmans C, Guillemot F. Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol. 2002;12:26&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861161</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem. 2000;275:2568&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644715</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Sch&#xfc;tz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol. 1999;208:166&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075850</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M, Geraerts M, Pype S, Dillen L, Van Hove C, Mercken M. The functional gamma-secretase inhibitor prevents production of amyloid beta 1&#x2013;34 in human and murine cell lines. Neurosci Lett. 2001;315:145&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716984</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M. The metalloprotease ADAM10 is required for notch1 S2 cleavage. J Biol Chem. 2009;284:31018&#x2013;31027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781502</ArticleId><ArticleId IdType="pubmed">19726682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent B. ADAM proteases: protective role in Alzheimer's and prion diseases? Curr Alzheimer Res. 2004;1:165&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chan SL, Miele L, Yao PJ, Mackes J, Ingram DK, Mattson MP, Furukawa K. Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A. 2004;101:9458&#x2013;9462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC438998</ArticleId><ArticleId IdType="pubmed">15190179</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen C, Metzstein MM, Greenwald I. SUP-17, a Caenorhabditis elegans ADAM protein related to Drosophila KUZBANIAN, and its role in LIN-12/NOTCH signalling. Development. 1997;124:4759&#x2013;4767.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, R&#xfc;ther E, Kornhuber J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem. 2002;81:481&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065657</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Klein R, Tian X, Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004;269:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005;8:709&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917835</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon K, Nery S, Rutlin ML, Radtke F, Fishell G, Gaiano N. Fibroblast growth factor receptor signaling promotes radial glial identity and interacts with Notch1 signaling in telencephalic progenitors. J Neurosci. 2004;24:9497&#x2013;9506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730142</ArticleId><ArticleId IdType="pubmed">15509736</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B, Wilson MA, Younkin S, Kandel ER, Kirkwood A, Shen J. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 2001;31:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun K, Fischman S, Johnson J, Hrabe de Angelis M, Weinmaster G, Rubenstein JL. Modulation of the notch signaling by Mash1 and Dlx1/2 regulates sequential specification and differentiation of progenitor cell types in the subcortical telencephalon. Development. 2002;129:5029&#x2013;5040.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong W, Jiang MM, Weinmaster G, Jan LY, Jan YN. Differential expression of mammalian Numb, Numblike and Notch1 suggests distinct roles during mouse cortical neurogenesis. Development. 1997;124:1887&#x2013;1897.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman L, Parr B, Lendahl U, Cunningham M, McKay R, Gavin B, Mann J, Vassileva G, McMahon A. Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron. 1994;12:11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8292356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20403962</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>Pt 5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia.</ArticleTitle><Pagination><StartPage>1328</StartPage><EndPage>1341</EndPage><MedlinePgn>1328-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awq065</ELocationID><Abstract><AbstractText>The molecular pathways leading to Alzheimer-type dementia are not well understood, but the amyloid beta-protein is believed to be centrally involved. The quantity of amyloid beta-protein containing plaques does not correlate well with clinical status, suggesting that if amyloid beta-protein is pathogenic it involves soluble non-plaque material. Using 43 brains from the Newcastle cohort of the population-representative Medical Research Council Cognitive Function and Ageing Study, we examined the relationship between biochemically distinct forms of amyloid beta-protein and the presence of Alzheimer-type dementia. Cortical samples were serially extracted with Tris-buffered saline, Tris-buffered saline containing 1% TX-100 and with 88% formic acid and extracts analysed for amyloid beta-protein by immunoprecipitation/western blotting. The cohort was divisible into those with dementia at death with (n = 14) or without (n = 10) significant Alzheimer-type pathology, and those who were not demented (n = 19). Amyloid beta-protein monomer in extracts produced using Tris-buffered saline and Tris-buffered saline containing 1% TX-100 were strongly associated with Alzheimer type dementia (P &lt; 0.001) and sodium dodecyl sulphate-stable amyloid beta-protein dimer was detected specifically and sensitively in Tris-buffered saline, Tris-buffered saline containing 1% TX-100 and formic acid extracts of Alzheimer brain. Amyloid beta-protein monomer in the formic acid fraction closely correlated with diffuse and neuritic plaque burden, but was not specific for dementia. These findings support the hypothesis that soluble amyloid beta-protein is a major correlate of dementia associated with Alzheimer-type pathology and is likely to be intimately involved in the pathogenesis of cognitive failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mc Donald</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savva</LastName><ForeName>George M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Welzel</LastName><ForeName>Alfred T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Forster</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Ganesh M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Ince</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><CollectiveName>Medical Research Council Cognitive Function and Ageing Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0900582</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>867660</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>IR01AGO27443</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2010 May;133(Pt 5):1297-9. doi: 10.1093/brain/awq099.</RefSource><PMID Version="1">20418529</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20403962</ArticleId><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="doi">10.1093/brain/awq065</ArticleId><ArticleId IdType="pii">awq065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ball M, Braak H, Coleman P, Dickson D, Duyckaerts C, Gambetti P, et al. Consensus recommendations for the postmortem diagnosis of Alzheimers-disease. Neurobiol Aging. 1997;18:S12.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, McCracken C, Matthews FE. Medical Research Council Cognitive Function and Ageing Study (CFAS). Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS) Int J Epidemiol. 2006;35:1140&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980700</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland JRM, Dewey ME, Griffiths-Jones HM. Dementia and depression in elderly persons: AGECAT compared with DSM III and pervasive illness. Int J Geriatr Psychiatry. 1990;5:47&#x2013;51.</Citation></Reference><Reference><Citation>Dickson D, Crystal H, Mattiace L, Masur D, Blau A, Davis P, et al. Identification of normal and pathological aging in prospectively studied nondemeneted elderly individuals. Neurobiol Aging. 1991;13:179&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, et al. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol. 1999;154:271&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853431</ArticleId><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid &#x3b2;-protein in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol. 1999;155:23&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866667</ArticleId><ArticleId IdType="pubmed">10393832</ArticleId></ArticleIdList></Reference><Reference><Citation>Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, et al. Quantitation of amyloid beta-protein (A&#x3b2;) in the cortex during aging and in Alzheimer&#x2019;s-disease. Am J Pathol. 1998;152:1633&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858449</ArticleId><ArticleId IdType="pubmed">9626067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. 1991;12:383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert FABC, Gill C, Paykel ES, Beardsall L. CAMCOG-a concise neuropsychological test to assist dementia diagnosis: sociodemographic determinants in an elderly population sample. Br J Clin Psychol. 1995;34:529&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8563660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A&#xdf;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci. 1997;94:1550&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, Brown T, Davis P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia:a subgroup with preserved mentalk status and numerous neocortical plaques. Ann Neurol. 1988;23:138&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y-M, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble A&#x3b2; (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PloS Med. 2009;6:e1000180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765638</ArticleId><ArticleId IdType="pubmed">19901977</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownless L, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Ihara Y. The presence of amyloid &#xdf;-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry. 1998;37:15247&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9799484</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc. 2000;283:1571&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med. 1996;37:201&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667045</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. &#x3b2;-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. Proc Natl Acad Sci. 1993;90:10836&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva G, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, Neuropathology, and Dementia. N Eng J Med. 2009;360:2302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166:368&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2449095</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta dimers isolated directly from Alzheimer's disease brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, et al. Distinct pools of beta-amyloid in alzheimer disease-affected brain. Arch Neurol. 2008;65:906&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586606</ArticleId><ArticleId IdType="pubmed">18625856</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol. 2005;58:147&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15984012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K, et al. Biochemical evidence for the long-tail form (Abeta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun. 1994;205:834&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999120</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Hartley DM, Selkoe DJ. The many faces of A&#xdf;: Structures and activity. Curr Med Chem Immununol EndocrMetab Agent. 2003;3:277&#x2013;91.</Citation></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Abeta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. Detection of intracellular oligomers of amyloid &#xdf;-protein in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>